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ABSTRACT 
 
The Hepatitis C virus (HCV) NS3/4A protease inhibitors (PIs) have become a 
mainstay of newer all-oral combination therapies. Despite improvements in 
potency of this inhibitor class, drug resistance remains a problem with the rapid 
emergence of resistance-associated substitutions (RASs). In this thesis I 
elucidate the molecular mechanisms of drug resistance for PIs against a resistant 
variant and apply insights toward the design of inhibitors with improved 
resistance profiles using structural, biochemical and computational techniques. 
Newer generation PIs retain high potency against most single substitutions in the 
protease active site by stacking on the catalytic triad. I investigated the molecular 
mechanisms of resistance against the Y56H/D168A variant. My analysis 
revealed that the Y56H substitution disrupts these inhibitors’ favorable stacking 
interactions with the catalytic residue His57.  
 
To further address the impact of drug resistance, I designed new inhibitors that 
minimize contact with known drug resistance residues that are unessential in 
substrate recognition. The initially designed inhibitors exhibited flatter resistance 
profiles than the newer generation PIs but lost potency against the D168A 
variant. Finally, I designed inhibitors to extend into the substrate envelope (SE) 
and successfully regained potency against RAS variants maintaining a flat 
profile. These inhibitors both pack well in the enzyme and fit within the SE. 
Together these studies elucidate the molecular mechanisms of PI resistance and 
highlight the importance of substrate recognition in inhibitor design. The insights 
from this thesis provide strategies toward the development of diverse NS3/4A PIs 
that may one day lead to the eradication of HCV.  
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Chapter I 
Introduction  
 2 
1.1 Hepatitis C Virus Epidemiology  
Hepatitis C virus (HCV) is a global epidemic estimated to chronically infect 
over 71 million people worldwide.1 HCV is the leading cause of chronic liver 
disease, which often progresses to cirrhosis or becomes malignantly transformed 
to hepatocellular carcinoma (HCC).1 This virus has been termed “the silent killer” 
as a majority of patients are often asymptomatic and their infection goes decades 
without detection.2 In fact, over 80% of infected patients will develop chronic liver 
disease.3 HCV was primarily transmitted through contact with blood products.4 
However, injection drug use has become the principal form of transmission with 
the incidence of intravenous drug injection on a steep rise.5  
Patients infected with HCV have a heterogeneous population of viral species 
known as quasispecies due to low fidelity of the RNA-dependent RNA 
polymerase. In addition to quasispecies contributing to the viral genetic diversity, 
HCV can also be classified into seven known genotypes (GT1-7) and multiple 
subtypes (a, b, c etc.).6-8 Genotypes differ at the nucleotide level by greater than 
30% and subtypes differ by 20-25%.9 GT1 and GT3 are the most prevalent 
accounting for 46% and 30% of global infections, respectively.6,7 GT1 infections 
predominately occur in North America and Europe while GT3 infections are 
common in South-East Asia. Other genotypes, though less common, also have 
distinct global distributions. GT2 viruses predominate in sub-Saharan Africa while 
GT4 viruses account for infections in the Middle East, Egypt and Central Africa. 
GT5 viruses are endemic to South Africa, GT6 in Asia and GT7 in Central 
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Africa.10 Thus, the genetic and global diversity of HCV infection has presented a 
challenge toward the treatment of patients infected with HCV.  
1.2 Hepatitis C Viral Proteins and Life Cycle  
HCV is a hepacivirus of the Flaviviridae family with an enveloped positive 
single-stranded RNA genome that is approximately 9.6-kb in size. The genome is 
composed of an open reading frame that encodes a long polyprotein precursor 
consisting of ~3000 amino acids.11 The 5’ untranslated region of the HCV 
genome contains an internal ribosome entry site that provides access to the host 
replication machinery for viral protein synthesis.12,13 The polyprotein precursor is 
cleaved by cellular and viral proteases into structural (Core, E1, E2), p7 and non-
structural (NS2, NS3, NS4A, NS4B, NS5A, NS5B) proteins (Figure 1.1). These 
viral proteins are necessary for viral processes including entry, uncoating, 
translation, replication, viral assembly and release.  
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Figure 1.1: HCV genome and processing of the polyprotein.  
The HCV genome is 9.6 kb in length and consists of a 5’ IRES and 3’ UTR. The 
positive stranded RNA genome is translated into a long polyprotein that is 
cleaved by host and viral proteases into structural and functional components. 
Arrows above the polyprotein indicate cleavage by the NS2 and NS3/4A 
proteases. The structural proteins include the core, envelope and P7 proteins. 
NS3, NS4A, NS4B, NS5A and NS5B represent the functional proteins that 
perform integral steps in the viral lifecycle that are necessary for replication and 
viral maturation.14  
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The core protein is an RNA binding protein that forms the viral 
nucleocapsid.15 E1 and E2 are envelope glycoproteins that are responsible for 
viral entry into the hepatocyte. The elusive P7 protein is a 63 amino acid 
viroporin that forms a membrane ion channel implicated in viral particle formation 
and release.16 The non-structural proteins form the viral replication machinery. 
They also help assemble and release the virus for subsequent rounds of 
infection. NS2 is a cysteine protease responsible for cleaving the NS2/NS3 
junction. Though less understood, NS2 has also been implicated in viral 
assembly and release.11 NS3 is a multifunctional protein with both a protease 
and helicase domain that facilitates polyprotein cleavage, ATP-dependent RNA 
unwinding, and evasion of host innate immune function. NS4A is a small cofactor 
that contributes one beta strand to the N-terminal NS3 protease domain 
localizing and stabilizing NS3 to the ER membrane and enhancing proteolytic 
activity.11 NS4B serves as a membrane anchor through formation of the 
membranous web, which is a scaffold for the replication complex.11 The RNA 
binding protein, NS5A is a phosphoprotein that is responsible for viral assembly. 
NS5B is the RNA-dependent RNA polymerase (RdRp) which replicates the HCV 
genome.11  
 In the HCV viral lifecycle, circulating viral particles enter hepatocytes through 
interactions of envelope proteins E1 and E2 with cell surface receptors including 
Tetraspanin (CD81), and Scavenger receptor class B type I (SR-B1).17 Other 
factors also mediate fusion including LDL receptor, claudin-1 and occludin.14,18 
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Once a successful fusion event occurs, HCV enters the hepatocyte via clatherin-
mediated endocytosis and the RNA genome is released into the cytoplasm due 
to pH dependent membrane fusion.19 Host cell replication machinery then 
translates the positive sense RNA into the long polyprotein precursor. Cellular 
proteases and viral proteases NS2 and NS3/4A proteolytically cleave the 
polyprotein into functional components.20 Once translation of the essential 
proteins is complete, the viral replication complex forms consisting of viral 
proteins, cellular machinery and nascent RNA strands.14 Replication occurs in a 
two-step process: (1) Positive sense RNA template is used to synthesize 
negative sense RNA. (2) Negative sense RNA then serves as template for the 
production of positive-sense RNA that is used for RNA replication, translated into 
protein or packaged into new viral particles.21 Finally, the viral genome will be 
packaged into viral particles forming mature virions, which will be trafficked 
through the secretory pathway and released for subsequent rounds of infection.14 
These steps are crucial to HCV pathogenesis and pharmaceutical companies 
have developed inhibitors that target essential proteins in the viral life cycle.  
1.3 Direct-Acting Antivirals against Hepatitis C Virus  
In the last 5-7 years the advent of direct–acting antivirals (DAAs) against HCV 
proteins NS3/4A, NS5A and NS5B has remarkably improved therapeutic options 
and treatment outcomes for HCV-infected patients.22,23 Prior to their 
development, the standard of care (SOC) for HCV treatment was a combination 
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of peg-interferon α (Peg-IFN) and ribavirin (RBV). Interferons are a class of 
cytokines that are secreted by the host innate immune system in response to 
viral infection.24 Ribavirin, a purine analogue, though the mechanism of action is 
not well understood, is believed to promote hypermutation of the RNA genome 
and inhibit nucleoside biosynthesis as well as other processes that are necessary 
for viral replication.25 The Peg-IFN/RBV combination therapy only resulted in a 
sustained virological response (SVR: the standard indication of cure from 
infection), of less than 50% in GT1 and slightly higher in other genotypes.26 Peg-
IFN had to be administered via intravenous injection once a week over the 
course of up to 72 weeks. In addition to poor efficacy, treatment with Peg-IFN 
caused severe side effects resulting in low tolerability.27,28 Thus, pharmaceutical 
companies made a significant effort to develop robust small molecule DAAs 
against essential proteins in the HCV viral life cycle to overcome the challenges 
with this non-specific combination therapy. 
The first DAAs approved for triple combination therapy with peg-IFN and RBV 
were NS3/4A protease inhibitors (PIs) telaprevir and boceprevir.29,30 These 
inhibitors prevent cleavage of the HCV polyprotein, which is a crucial step in viral 
replication and maturation. The use of telaprevir and boceprevir to treat HCV 
infection was a major turning point in anti-HCV development as these drugs 
significantly increased the SVR to 60-75% in GT1 infected patients.31-37 However, 
these first generation DAAs lacked efficacy, tolerability due to severe side effects 
and required a long duration of treatment (approximately 48 weeks).38  
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We have recently moved toward an era of all-oral IFN-free combination 
therapy with shorter treatment duration. In fact, the U.S. FDA has approved six 
new all-oral combination therapies: (1) harvoni® (sofosbuvir/ledipasvir),39 (2) 
viekira pak™ (ombitasvir/paritaprevir/ritonavir/dasabuvir),40 (3) zepatier® 
(elbasvir/grazoprevir),41 and (4) epclusa® (sofosbuvir/velpatasvir),42 (5) vosevi®  
(sofosbuvir/velpatasvir/voxilaprevir)43 and (6) mavyret™ 
(glecaprevir/pibrentasvir).44,45 Each combination therapy includes small molecule 
inhibitors that target specific protein in the viral life cycle. Sofosbuvir is nucleotide 
NS5B inhibitor that gets incorporated into the nascent RNA chain, which induces 
a chain termination event that prevents active transcription.46 Dasabuvir is a non-
nucleotide NS5B inhibitor that allosterically binds to the polymerase preventing 
conformational changes that are necessary for viral RNA replication.47,48 NS5A 
inhibitors, ledipasvir, ombitasvir, elbasvir, velpatasvir, and pibrentasvir, block 
RNA replication and virion assembly/release.49 Paritaprevir, grazoprevir, 
voxilaprevir and glecaprevir are newer generation NS3/4A PIs. The use of DAA-
based combination therapies has increased SVR response to almost 100% in 
GT1 infections.50 Of note, the two most recent combinations have pan-genotypic 
activity, including against GT3, a major milestone in HCV therapeutics.51 Newer 
generation inhibitors and various combinations improved SVR rates across all 
genotypes to greater than 83%.52 For many patients the new DAA combination 
therapies have reduced the treatment duration from twenty-four to eight weeks. 
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Through all of these advances, the NS3/4A PIs have become a critical 
component in DAA-based combination therapy. 
1.4 NS3 Bifunctional Protein and Protease Architecture 
The 631 amino acid NS3 protein is a bifunctional enzyme consisting of an N-
terminal protease domain and a C-terminal super family II DEAD-box helicase 
domain (Figure 1.2).11,53 Each domain is essential for viral replication, 
responsible for a crucial step in the viral life cycle. The protease domain forms a 
heterodimer with NS4A, a 54-residue protein, which significantly improves 
catalytic efficiency.11,54 The NS3 protease is responsible for viral processing and 
escape from host immune system. The latter function is mediated via cleavage of 
TRIF or MAV adaptor proteins that play a role in the host’s virus-induced 
signaling pathways.55,56 The helicase domain unwinds RNA duplexes during viral 
replication. While both domains of the NS3 can function independently, studies 
have shown that two domains together are optimal for catalytic efficiency.57-59  
The first crystal structures of the NS3 protease domain were solved in 1996, 
providing insights on this target’s druggability.60,61 The protease domain is a 
chymotrypsin-like serine protease with the canonical catalytic triad residues 
Asp81, His57 and Ser139.14 The N-terminal domain is composed of 8 beta 
strands (one from the NS4A cofactor) and the C-terminal domain has a 
conventional six-stranded beta barrel, which together form a double barrel fold 
architecture.11,60,61 The C-terminal beta barrel domain contains a tetrahedrally 
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coordinated zinc ion that is necessary for the structural integrity of the 
protease.60,61 In fact, this metal ion is located over 20 angstroms away from the 
catalytic triad residues, which explains its structural role over a functional role in 
enzyme catalysis. In contrast to other proteases in the chymotrypsin family, the 
NS3 protease lacks several loops that are responsible for a well-defined 
substrate-binding pocket.11 Thus, the substrate-binding groove is quite shallow 
and solvent exposed62 (Figure 1.2) – a true challenge in early drug design 
efforts.  
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Figure 1.2: Structure of NS3/4A protein and substrate binding pocket.  
(a) The NS3/4A protease consists of an N-terminal protease domain (green) and 
a C-terminal helicase domain (purple). The protease domain is stabilized by the 
essential NS4A cofactor, which forms one of the N-terminal beta sheets (orange). 
(b) The NS3/4A is a serine protease with the canonical catalytic triad residues 
His57, Asp81 and Ser139, shown as yellow sticks. (c) Surface representation of 
the NS3/4A protease domain highlighting the shallow, solvent exposed binding 
groove (orange) which hampered early drug discovery efforts. The * indicates the 
catalytic residues (PDB ID: 3M5L).  
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1.5 Small Molecule Inhibition of HCV NS3/4A Protease 
A major turning point in HCV PI development occurred in 1998, when the N-
terminal cleavage product, DDIVPC-OH, of the NS3/4A substrate was identified 
as a weak competitive inhibitor.63,64 Pharmaceutical companies exploited this 
hexapeptide scaffold using structure-based drug design (SBDD)65-67, which led to 
the development of the first-in-class NS3/4A PI ciluprevir (BILN-2061) (Figure 
1.3). BILN-2061 is a macrocyclic inhibitor that exhibited subnanomolar activity 
against GT1 and an excellent pharmacokinetics profile.68 Given the excellent 
profile of this inhibitor, BILN-2061 was advanced to human clinical trials 
demonstrating the ability to reduce the HCV viral titer in infected patients by up to 
3 logs after a 1-2 day administration.69 Unfortunately, BILN-2061 was 
discontinued due to severe cardiotoxcity. Nevertheless, this proof-of-concept 
drug demonstrated that HCV NS3/4A PIs could be potent antivirals used toward 
the eradication of HCV infection.     
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Figure 1.3: Development of proof-of-concept drug ciluprevir.  
The N-terminal substrate cleavage product, hexapeptide DDIVPC-OH, was 
identified as a weak competitive inhibitor of the NS3/4A protease. Structure-
based drug design and extrapolation of the hexapeptide scaffold led to the 
discovery and development of ciluprevir – the first PI in the NS3/4A PI drug class. 
This drug was discontinued due to its cardiotoxicity.   
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Two different classes of NS3/4A PIs have been developed over the course of 
20 years including: (1) covalent, and (2) non-covalent inhibitors (Figure 1.4). 
Optimization of the scaffold and SBDD resulted in modified peptidomimetics that 
share a common scaffold spanning the P4–P1’ positions.70-77 All HCV NS3/4A 
peptidomimetics contain a P1’ ketoamide or sulfonamide, P1 cysteine mimic, a 
P2 proline, P3 moiety, and a P4 or P5 capping group. The first FDA approved PIs 
were linear inhibitors telaprevir and boceprevir with a ketoamide warhead that 
forms a reversible covalent bond with the catalytic residue Ser139. However, 
these inhibitors were not as potent as other inhibitors that were being developed 
in parallel by other pharmaceutical companies. Moreover, resistance was 
clinically observed within two weeks of administration with these drugs. In 
particular, resistance substitutions R155K/T and V36M/S were seen in patients 
as well as double substitution variants R155K/V36M.78,79 
More potent and promising inhibitors incorporated a similar scaffold as BILN-
2061, a P1–P3 macrocyclic inhibitor with a large P2 moiety. The introduction of a 
large heterocyclic moiety attached to the P2 proline, significantly improved the 
potency of the competitive inhibitors.67,80 The non-covalent competitive inhibitor 
class share a common P3–P1’ peptidic core, and are either linear or macrocyclic; 
the macrocycle is located either between P1–P3 or P2–P4 moieties. The linear 
competitive inhibitors include asunaprevir,81 sovaprevir,82 and faldaprevir.83 
Asunaprevir was recently approved in Japan as a treatment option for GT1 
infection.84 Simeprevir85 and danoprevir86 are P1–P3 macrocyclic inhibitors. 
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Simeprevir is U.S. FDA-approved to treat GT1 infections.87 The P2–P4 
macrocylic inhibitors include vaniprevir, which was developed by Merck and is 
also approved for treatment of GT1 in Japan.88 These inhibitors had improved 
activity profiles against wildtype GT1 but were highly susceptible to resistance 
substitutions at residues Arg155, Ala156, and Asp168 – the three most common 
resistance sites in the protease active site.89,90 Moreover, these inhibitors lacked 
activity against other HCV genotypes, a necessary benchmark to meet in anti-
HCV development.   
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Figure 1.4: 2D chemical structures of NS3/4A protease inhibitors.  
There are two inhibitor drugs classes, covalent and non-covalent. The covalent 
inhibitors are the linear ketoamide drug class. Non-covalent inhibitors can be 
subdivided into the two groups including linear and macrocyclic. The macrocycle 
is either located between the P1–P3 positions of the scaffold or P2–P4. The 
canonical nomenclature for drug moiety positioning is indicated using 
asunaprevir.   
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1.6 Development of Pan-genotypic Protease Inhibitors 
Toward the development of a pan-genotypic inhibitor, AbbVie introduced 
paritaprevir, a potent P1–P3 macrocyclic inhibitor with promising activity against 
the NS3/4A target. In a 3-day monotherapy study with co-administration of 
ritonavir, an average decrease of 4 log10 in HCV viral RNA was observed at the 
end of the dosing period.91 Paritaprevir also had cross-genotypic activity with 
inhibition observed against GTs 1, 4 and 6.91 However, paritaprevir exhibited 
reduced efficacy against the GT3 replicon. The most common single substitution 
variants selected for in patients were R155K and D168V.92 Double substitution 
variants including Y56H/D168A have been observed in clinical samples as 
well.93,94 Despite the emergence of resistance, paritaprevir was FDA-approved in 
2014 in combination with an NS5A and NS5B inhibitor for the treatment of GT1 
infection. 
At this time, Merck developed grazoprevir (MK-5172), a very potent P2–P4 
macrocyclic inhibitor. It was one of the first PIs to exhibit an excellent activity 
profile against some common single substitution variants as well as cross-
genotypic activity (excluding GT3 – a hard to treat variant).95,96 In 2016, 
grazoprevir gained FDA approval in combination with NS5A inhibitor elbasvir for 
the treatment of GT1 and GT4 infections. This was the first all-oral PI containing 
regimen with FDA-approval to treat a non GT1 HCV infection, marking a critical 
turning point in PI development. Grazoprevir demonstrated sub-nanomolar to 
single digit nanomolar activity against GTs 1, 2, 4, 5, and 6 in antiviral assays 
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(EC50 < 4 nM).97 However, like paritaprevir antiviral activity of grazoprevir against 
the GT3 variant was reduced by at least two orders of magnitude.97 Grazoprevir 
had improved activity against resistant variant R155K but was highly or 
moderately susceptible to A156T or D168A, respectively. Moreover, double 
substitution (Y56H/D168A) and triple substitution variants 
(Y56H/A156T/D168A/N) were observed in clinical studies.92,94,97,98  
The success of grazoprevir scaffold led to the development of PIs voxilaprevir 
and glecaprevir. In 2017, the first pan-genotypic combination therapies consisting 
of these inhibitors were FDA-approved for the treatment of GT1-6, a major 
milestone in anti-HCV research.99,100 Interestingly, voxilaprevir and glecaprevir 
are structurally similar to grazoprevir with minor modifications to the scaffold 
(Figure 1.5). These inhibitors showed excellent potency against all GTs and 
have activity against common resistance associated substitutions (RASs) 
including D168A and R155K. However, like grazoprevir, they are highly 
susceptible to the A156T variant. Additionally, though limited clinical data exist, 
double substitutions have been selected for in in vitro assays including 
A156V/D168V, Y56H/Q168R and other combinations of active and distal site 
substitutions.51  
All the aforementioned NS3/4A PIs exploit critical interactions within the 
protease active site that enhance the potency of these inhibitors. However, many 
of these interactions are not essential for substrate recognition, and substitutions 
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in the NS3/4A protein for most inhibitors are detrimental to potency resulting in 
drug resistance. Thus coupling our understanding of substrate recognition and 
the molecular underpinnings of drug resistance is necessary for the successful 
development of novel PIs with improved resistance profiles.  
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Figure 1.5: 2D chemical structure of grazoprevir and similar P2–P4 
macrocyclic inhibitors.  
Modifications of grazoprevir scaffold led to development of newer generation PIs 
voxilaprevir and glecaprevir. Differences in chemical structure are highlighted in 
red. These minor modifications led the identification of PIs with pan-genotypic 
activity and lower susceptibility to single site substitutions.   
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1.7 Substrate Recognition and Protease Inhibitor Resistance 
The NS3/4A viral substrates share little sequence homology except a 
cysteine at P1 and an acid at P6 (Table 1.1).101 Insights from HIV-1 protease, 
another viral protease with highly diverse substrates, revealed that substrates are 
recognized by the consensus volume that they occupy in the protease active site, 
termed the substrate envelope (SE) (Figure 1.6).102 High-resolution crystal 
structures of substrate-protease complexes showed that HCV substrates also 
occupy a similar volume in the protease active site.90,101 This consensus volume 
or SE is the basis of molecular recognition for the NS3/4A protease substrates. It 
is well established that in the NS3/4A protease, drug resistance substitutions 
occur where inhibitors protrude outside of the SE and contact residues 
unessential in substrate recognition.89 
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Figure 1.6: Superposition of NS3/4A substrates in the substrate envelope.  
The NS3/4A substrates (pink) occupy a consensus volume in the protease active 
site known as the substrate envelope (blue). The NS3/4A protease is shown as a 
smooth ribbon. The catalytic triad and residues that commonly mutate to confer 
resistance are shown as yellow and green sticks, respectively.  
  
H57
D81
S139
R155
A156
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P3 P5
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Table 1.1: Amino acid sequence of NS3/4A protease substrates for GT1 
 
Substrate 
Amino Acid at Position: 
P6 P5 P4 P3 P2 P1 P1’ P2’ P3’ P4' 
3-4A D L E V V T S T W L 
4A/4B D E M E E C S Q H S 
4B/5A E C T T P C S G S V 
5A/5B E D V V C C S M S L 
TRIF P(8)a S S T P C S A H W 
MAVS E R E V P C H R P Y 
aThe TRIF substrate has a polyproline sequence consisting of 8 proline residues.   
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Drug resistance results from a loss of inhibitor binding affinity while 
maintaining substrate processing. The NS5B RNA-dependent RNA polymerase 
has low fidelity resulting in one substitution per 103 – 107 nucleotides, which 
equates to one error per round of genome replication.103 Thus, due to the large 
error rate, patients infected with HCV develop a heterogeneous population of 
viral species known as quasispecies. The P2 moieties of most protease inhibitors 
protrude beyond the substrate envelope and contact the S2 subsite residues 
Arg155, Ala156 and Asp168 (Figure 1.7).89 The residues Arg155, Ala156, and 
Asp168, where the most common drug resistance substitutions occur, are 
located around the active site. In the inhibitor-bound state, HCV NS3/4A protease 
has an extensive active site electrostatic network that spans the catalytic triad 
residues His57 and Asp81 all the way to residues Arg155, Asp168 and Arg123. 
Residues Arg155 and Asp168, located beyond the substrate envelope, form a 
salt bridge that is critical to inhibitor binding and disrupted upon substitution at 
either residue (Figure 1.7).   
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Figure 1.7: Location of common resistance substitutions in the protease 
active site and the electrostatic network.  
The most common sites where substitutions occur that confer resistance to 
NS3/4A protease inhibitors are Arg155, Ala156 and Asp168 shown in blue, red 
and greens sticks, respectively. Arg123 is a residue that is variable in GT3 and 
forms part of the electrostatic network in GT1. The electrostatic network is 
highlighted by gray dashes. The catalytic triad residues His57, Asp81 and 
Ser139 are shown as yellow sticks.   
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1.8 Mechanisms of Resistance for Single Substitutions   
The NS3/4A protease inhibitors are highly effective drugs with the ability to 
rapidly reduce the HCV viral titer in infected patients.45,104,105 However, most 
NS3/4A protease inhibitors are highly susceptible to single site substitutions 
R155K, A156T and D168A. We have shown that the resistance profile of PIs 
largely depends on how the PIs protrude beyond the substrate envelope,89,90 
which is largely determined by the identity of their P2 moiety and macrocycle 
location.106 High-resolution crystal structures of protease inhibitors bound to WT 
and substituted proteases allowed us to elucidate the molecular basis of 
resistance against single substitution protease variants.89 Residues Arg155 and 
Asp168, located in the S2 subsite, form a critical salt bridge that provides 
additional hydrophobic surface necessary for inhibitor binding. This salt bridge 
stabilizes Arg155 in a conformation that allows efficient inhibitor binding. 
Disruption of this electrostatic network as a result of substitutions at Arg155 or 
Asp168 underlies the mechanism of resistance for most NS3/4A protease 
inhibitors.  
Residue Arg155 often mutates to a lysine (R155K) to confer resistance. 
Danoprevir, asunaprevir, and many older generation protease inhibitors have 
large P2 moieties that predominately bind on the S2 subsite residues (Figure 
1.8). The guanidinium group of Arg155 makes favorable cation−π interactions 
with the P2 heterocyclic moiety of these NS3/4A protease inhibitors. Thus, when 
Arg155 mutates to a lysine residue, inhibitors lose the ability to bind efficiently.  
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Substitutions at Asp168 cause resistance due to indirect structural effects and 
changes in electrostatics. Asp168 is a pivotal drug resistance residue as most 
PIs are susceptible to substitutions at Asp168, which are often present in patients 
who fail therapy.107 Notably, the polymorphism Gln168 at this position underlies 
reduced efficacy of PIs against GT3.108 We and others have shown structurally 
that loss in hydrophobic interactions and the hydrogen bond network with 
Arg155, as a result of substitutions at Asp168 are responsible for reduced 
inhibitor potency.89,109,110 However, the introduction of the quinoxaline moiety at 
the P2 position of the inhibitor scaffold, led to the development of grazoprevir, a 
compound with a distinct resistance profile relative to inhibitors that primarily 
interact with S2 subsite residues.  
The P2 quinoxaline of grazoprevir binds uniquely in the protease active site, 
making hydrophobic interactions with the catalytic triad residues His57 and 
Asp81 (Figure 1.8).89 In fact, the P2 quinoxaline moiety of grazoprevir avoids 
direct interactions with Arg155 and Asp168, minimizing susceptibility to 
resistance due to substitutions at these residues. In the case of grazoprevir, 
although the P2 moiety protrudes outside the substrate envelope,89 it stacks 
against the invariant catalytic triad, which is one strategy that can be used to 
avoid drug resistance.  
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Figure 1.8: The binding mode of NS3/4A PIs.  
Surface view of PIs bound to the NS3/4A active site. (a) asunaprevir, (b) 
danoprevir, and (c) grazoprevir. The catalytic triad is shown in yellow and drug 
resistance residues Ala156, Arg155, and Asp168 are shown in blue, red and 
green, respectively. Many of the current inhibitors in clinical development have 
large P2 groups that contact residues in the S2 subsite, which mutate to confer 
resistance. Structural analysis revealed that inhibitors have different binding 
modes underlying reduced inhibitor potency against resistant associated 
substitutions. The P2 isoindoline group of danoprevir occupies two conformations 
in the protease active site. (PDB IDs: 4WF8, 3M5L, and 3SUD, respectively).  
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Even with this unique binding mode, grazoprevir is not immune to resistance.  
Grazoprevir is highly susceptible to substitutions at Ala156 due to the location of 
the macrocycle – a major structural feature that impacts PI resistance profiles.106 
Inhibitors with a P2–P4 macrocycle like grazoprevir are susceptible to Ala156 
mutations as a change to a larger residue results in steric clash with the 
macrocycle.89,111 We rationalized that changing the macrocycle location could 
improve activity against the A156T variant.  Indeed, we have shown 5172-
mcP1P3, a P1–P3 macrocyclic analogue of grazoprevir, is less susceptible to 
Ala156 mutations and has an improved resistance profile.106 The unique binding 
mode of grazoprevir is conserved in the P1–P3 macrocyclic analogue (Figure 
1.9).111 5172-mcP1P3 is less susceptible to drug resistance because the P2 
group is less constrained than in grazoprevir. Thus, designing inhibitors with 
modified P2 quinoxalines similar to 5172-mcP1P3 is a strategy that can be 
employed to develop more robust NS3/4A inhibitors.  
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Figure 1.9: Binding conformation of grazoprevir and 5172-mcP1P3 in the 
active site of wild-type NS3/4A protease.  
(a) Grazoprevir and (b) P1–P3 analog 5172mc-P1P3 bind similarly in the 
protease active site whereby the P2 quinoxaline moiety makes strong 
interactions with the catalytic residues, minimizing contact with known residues 
that mutate to confer resistance. The catalytic triad is highlighted in yellow, and 
drug resistance residues Arg155, Ala156, and Asp168 are shown in blue, red, 
and green, respectively.  (PDB IDs: 3SUD and 5EPN, respectively). 
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1.9 Emergence of double substitution variants 
Newer generation PIs have significantly improved activity against single site 
substitutions in the protease. However the emergence of multi-substituted 
variants has become a new problem in PI advancement. Often times, double 
substitution variants include an Asp168 substitution, such as R155K/D168A, 
A156T/D168A, Y56H/D168A and Y56H/D168V proteases. Acquisition of an 
additional substitution may give rise to new viral variants with substitutions that 
are often not seen alone, as in the case with Y56 and A156 substitutions. One 
key clinically relevant protease variant is Y56H/D168A, often present in patients 
who fail therapy with the newer generation PIs.92,94,98 Grazoprevir and 
paritaprevir are highly susceptible to this signature variant and exhibit over 500-
fold loss in potency.92,97,112 While the molecular basis of drug resistance caused 
by single-site RASs has been well characterized, the impact of clinically relevant 
NS3/4A protease double substitutions on inhibitor binding and the mechanisms 
of drug resistance remain largely unexplored.89,90,111 Though the Y56H/D168A 
variant has been hypothesized to cause resistance due to reduced hydrophobic 
contacts of the inhibitor P2 moiety with the NS3/4A protease, this alone does not 
explain the significant loss in potency.97 Moreover, considering the similarity in 
the inhibitor scaffolds of the most recently FDA-approved PIs and modes of 
action, there is a danger that these newly emerging variants may be cross-drug 
resistant and patients may not respond to any current treatment option. Thus, 
elucidating the molecular mechanisms of resistance for PIs against these multi-
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substituted variants and diversifying our PI arsenal is necessary for the 
elaboration of next-generation PIs.  
1.10 Scope of Thesis   
This thesis attempts to understand mechanisms of drug resistance against 
NS3/4A PIs and develop design strategies to improve PI resistance profiles. It is 
paramount to elucidate mechanisms of drug resistance against HCV PIs as 
insights can provide new approaches toward the development of novel antivirals. 
The newest anti-HCV therapeutics available for the treatment of HCV infection 
are FDA-approved PIs voxilaprevir and glecaprevir. The development of these 
pan-genotypic inhibitors was a major achievement in anti-HCV therapeutics. 
However, one threat to the clinical effectiveness of HCV NS3/4A PIs is the 
emergence of double substitution variants that confer resistance to these new 
drugs. In Chapter II, I elucidate the structural and dynamic mechanisms of 
resistance of PIs against the highly resistant Y56H/D168A variant – identifying a 
novel mechanism of resistance.  
At the conception of this research, the current FDA-approved pan-genotypic 
NS3/4A PIs were in their infancy. A major goal in the field was to develop robust 
inhibitors with improved activity against resistance associated single substitutions 
in the protease active site, including D168A. Grazoprevir was a promising drug 
but still moderately susceptible to Asp168 and highly susceptible to Ala156 
substitutions. To further improve the resistance profile, I explored structure-
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activity relationship and used insights from previous structural studies to design 
novel inhibitors. Chapter III demonstrates that P1–P3 macrocyclic inhibitors 
based on the grazoprevir scaffold with modified quinoxaline moieties have 
improved activity against single RASs. Chapter IV highlights the importance of 
substrate recognition in inhibitor design by use of the substrate envelope to 
further improve resistance profiles. The designed inhibitors leveraged 
evolutionarily constrained locations in the protease active site, including the 
invariant catalytic triad and the substrate envelope. Together these studies 
highlight the importance of substrate recognition in inhibitor design, elucidate the 
molecular mechanism of resistance of PIs against multi-substituted variants and 
provide strategies toward the development of diverse NS3/4A PIs that may one 
day lead to the eradication of HCV.  
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Chapter II 
Clinical signature variant of HCV NS3/4A 
protease uses a new mechanism to confer 
resistance 
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2.1 Abstract 
The development of direct-acting antivirals is a major milestone in the 
treatment of hepatitis C virus (HCV) infections. The HCV NS3/4A protease 
inhibitors (PIs) are a mainstay of recent all-oral combination therapies. Despite 
significant progress, drug resistance remains a problem with the emergence of 
resistance-associated substitutions causing treatment failure. Newer generation 
PIs such as grazoprevir and paritaprevir retain high potency against most single 
substitutions in the protease in part by stacking on the invariant catalytic triad. 
The evolutionarily conserved catalytic residues cannot mutate without 
compromising enzymatic activity, an advantage exploited by all recent HCV PIs. 
Nevertheless, double substitution variants, notably Y56H/D168A have emerged 
in patients who fail therapy with a PI-containing regimen. The molecular 
mechanism by which Asp168 substitutions confer resistance has been 
extensively characterized. However, for this newly emerging clinically relevant 
variant with an additional mutation at Tyr56, mechanism of resistance is 
unknown. Here, we elucidate the molecular mechanism of resistance against the 
Y56H/D168A protease variant, for a series of PIs (grazoprevir and 4 analogs, 
paritaprevir, and danoprevir), through inhibition assays, co-complex crystal 
structures and molecular dynamics simulations. The PIs had varying degrees of 
susceptibility to Y56H/D168A, with those stacking on the catalytic His57 losing 
the most potency. Structural and dynamic analyses revealed that the Y56H 
substitution disrupts these inhibitors’ favorable stacking interactions with the 
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neighboring catalytic His57, while still maintaining substrate turnover. Thus we 
uncovered a new mechanism of resistance used by the Y56H/D168A variant 
where substitutions at neighboring residues disrupt interactions of the catalytic 
residue with inhibitors.  
2.2 Introduction 
Hepatitis C virus (HCV) is a global threat infecting over 150 million people 
worldwide.7 Over 80% of individuals infected with HCV develop chronic liver 
disease, which often progresses to cirrhosis or becomes malignantly transformed 
to hepatocellular carcinoma.1 Prior to the introduction of direct-acting antivirals 
(DAAs), the standard of care for HCV infection consisted of pegylated interferon 
alpha and ribavirin.113 This treatment resulted in a sustained virological response 
(SVR; the standard indication of cure from infection), of less than 50% against 
genotype 1 (GT1) and had low tolerability due to severe side effects.114 
Fortunately, in the last several years the advent of DAAs against essential viral 
proteins NS3/4A, NS5A and NS5B has significantly improved therapeutic options 
and treatment outcomes for patients infected with HCV.23,115 
HCV is a highly diverse virus with seven known genotypes (GT1–7) and 
multiple subtypes.6-8 Patients infected with HCV develop a heterogeneous 
population of viral species known as quasispecies due to low fidelity of the RNA-
dependent RNA polymerase.116,117 The genetic diversity both among genotypes 
and within a viral population presents a challenge in the treatment of HCV 
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infections. The six U.S. FDA approved all-oral combination therapies have varied 
effectiveness, and especially the earlier therapies can fail against certain 
genotypes.115 Newer generation inhibitors and various combinations have 
improved SVR rates across all genotypes to greater than 83%.52 The two most 
recent combination therapies approved in 2017 by the FDA, Vosevi and Mavyret, 
have pan-genotypic activity, a major milestone in HCV treatment.43,118 While the 
treatment options for HCV infection have significantly improved, one major threat 
to the clinical effectiveness of all anti-HCV drug classes is the emergence of 
resistance-associated substitutions (RASs) in target proteins.51,107,112,119  
RASs often weaken inhibitor binding resulting in reduced activity against the 
target enzyme. The HCV NS3/4A protease inhibitors (PIs) are highly effective 
drugs with the ability to rapidly reduce the HCV viral titer in infected patients but 
are susceptible to RASs around the protease active site.45,105 There are currently 
five FDA-approved protease inhibitors: simeprevir,85 paritaprevir (ABT-450),91 
grazoprevir (MK-5172),120 glecaprevir51 and voxilaprevir.121 All of these PIs 
incorporate large heterocyclic moieties at the P2 position to achieve high 
potency. However, this large P2 moiety often renders PIs susceptible to RASs, 
particularly at residues Arg155, Ala156, and Asp168. We have shown that the 
resistance profile of PIs largely depends on how the PIs protrude beyond the 
substrate envelope,89,90 which is largely determined by the identity of their P2 
moiety and macrocycle location.106 Substitutions typically occur at residues that 
interact with PIs beyond the substrate envelope, preserving substrate recognition 
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and turnover while disrupting inhibitor binding. Two such residues are Arg155 
and Asp168 located in the S2 subsite, which form a critical electronic network 
that provides a surface essential for inhibitor binding but not for substrate 
recognition. Our previous crystal structures revealed that disruption of this 
electrostatic network as a result of substitutions at either Arg155 or Asp168 
underlies the mechanism of resistance for earlier generation NS3/4A PIs.89,109 
Grazoprevir (MK-5172) is a highly potent P2–P4 macrocyclic inhibitor with 
cross-genotypic activity but reduced potency against GT3, a difficult to treat HCV 
variant.96 Grazoprevir was the first inhibitor with a unique binding mode whereby 
the P2 quinoxaline moiety, which still protrudes beyond the substrate envelope, 
stacks on the residues of the invariant catalytic triad. The catalytic residues 
cannot mutate without compromising substrate recognition and turnover, 
avoiding resistance. Robustness of grazoprevir against resistance prompted this 
binding mode to be exploited by all newer generation inhibitors including 
glecaprevir and voxilaprevir, which share a similar scaffold to grazoprevir. This 
binding mode also minimizes interactions with S2 subsite residues that typically 
mutate to confer resistance (Figure 2.1)89 and thus reduces grazoprevir’s 
susceptibility to substitutions at residue Arg155. However, grazoprevir is still 
moderately susceptible to substitutions at Asp168 due to the packing of the P2–
P4 macrocycle.  
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Figure 2.1: The binding mode of NS3/4A protease inhibitors, location of 
residues that mutate to confer resistance and 2D chemical structure of 
NS3/4A protease inhibitors.    
Surface view of NS3/4A protease inhibitors (a) grazoprevir and (b) danoprevir 
bound to the active site. Danoprevir’s P2 isoindoline moiety occupies two 
conformations in the protease active site. The catalytic triad is shown in yellow 
and drug resistance residues Tyr56, Arg155, Ala156, and Asp168 are shown in 
magenta, blue, red and green, respectively. Residues Tyr56 and Asp168 are 
located almost 15 Å apart in the protease active site. (c) Grazoprevir, 
voxilaprevir, glecaprevir and paritaprevir are approved by the FDA. Danoprevir 
was in clinical development. All other inhibitors were synthesized in house as 
P1–P3 macrocyclic analogs of grazoprevir. 
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In fact, most PIs are susceptible to substitutions at Asp168, which are often 
present in patients who fail therapy.107 Notably, the polymorphism Gln168 at this 
position underlies reduced efficacy of PIs against GT3.122 Glecaprevir and 
voxilaprevir have improved resistance profiles against D168A and are active 
against GT3, but like grazoprevir are highly susceptible to substitutions at 
Ala15651 due to van der Waals clashes with their P2–P4 macrocycles.106,111 
Unfortunately, even with the newest combinations some patients still fail therapy, 
with more than one RAS detected in the infecting viral population.41 The 
emergence of such double and sometimes triple-site RAS variants in clinic is 
threatening the effectiveness of current anti-HCV therapies.98 
While the molecular basis of drug resistance caused by single-site RASs has 
been well characterized,89,90,111,123 the impact of clinically relevant NS3/4A 
protease double substitutions on inhibitor binding and the mechanisms of drug 
resistance remain largely unexplored. One key clinically relevant protease variant 
is Y56H/D168A, often present in patients who fail therapy with the newer 
generation PIs. Grazoprevir and paritaprevir are highly susceptible to this 
signature variant and exhibit over 500-fold loss in potency.92,97,112 Substitutions at 
Tyr56 rarely occur alone, but are becoming common in combination with 
substitutions at Asp168. These residues are not in physical contact, with Tyr56 
located next to the catalytic His57, approximately 15 Å away from residue 
Asp168. Nevertheless, co-evolution of these two sites results in a detrimental 
loss of potency for all PIs. The molecular mechanism underlying high-level 
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resistance of PIs against the Y56H/D168A double substitution variant is 
unknown.  
To elucidate the molecular mechanism of resistance for PIs against the 
Y56H/D168A NS3/4A protease variant, we used a multi-disciplinary approach 
involving enzyme inhibition and antiviral assays, co-crystal structures, and 
molecular dynamics simulations. A panel of 7 NS3/4A PIs (grazoprevir and 4 
analogs, paritaprevir, and danoprevir) with varying macrocycle locations and P2 
binding modes were tested for enzyme inhibition and antiviral potency. To tease 
out the impact of individual substitutions, the double substitution variant was 
compared to both single substitutions and wild-type GT1a NS3/4A protease. 
While all inhibitors were 3–10 orders of magnitude less active against the 
Y56H/D168A NS3/4A protease variant, the potency loss was exacerbated for PIs 
that stack on the catalytic triad, including grazoprevir. Crystal structures and 
dynamic analysis of grazoprevir bound to protease variants revealed that this 
resistance is largely due to the Y56H substitution disrupting the favorable 
stacking interactions with the neighboring catalytic residue His57. Thus, in 
addition to the loss of the ionic network due to D168A substitution,89,109 
decreased direct interactions with catalytic His57 underlie resistance against this 
double substitution variant. To prevent such mechanisms of clinically relevant 
resistance a novel strategy of inhibitor design limiting interactions with Tyr56 
while still maintaining stacking against the catalytic residues is warranted. 
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2.3 Results 
2.3.1 Inhibitors are highly susceptible to the Y56H/D168A 
NS3/4A variant 
Enzyme inhibition and replicon potency of HCV NS3/4A PIs correlate closely 
with efficacy in the clinic, as does loss of potency due to site-specific 
substitutions. As Y56H and D168A substitutions have been selected in clinic 
together under the selective pressure of PIs, these two substitutions may have 
interdependent effects in conferring resistance. Thus to determine the impact of 
Y56H/D168A and potential interdependency of these substitutions, enzyme 
inhibition and replicon assays were performed against WT (GT-1a), Y56H, 
D168A and the double substitution variant for a panel of diverse NS3/4A PIs 
(Figure 2.1 and Tables 2.1, 2.2). This panel included FDA-approved inhibitors 
(grazoprevir, paritaprevir), P1–P3 macrocyclic analogs of grazoprevir (5172-
mcP1P3, JZ01-15, AM-07, MG-28) and danoprevir (Figure 2.1). The inhibitors 
were selected to test the role of the macrocycle (P1–P3 versus P2–P4) and the 
packing of the P2 moiety on susceptibility to these substitutions.   
All seven inhibitors were potent against WT with inhibition constants (Ki) 
ranging from 0.2–7.2 nM, (Figure 2.2A and Table 2.1), in agreement with 
previous reports.124 Similarly, in replicon assays, all inhibitors exhibited sub-
nanomolar to 1.4 nM potency against WT HCV (Figure 2.2B and Table 2.2). 
Relative to WT protease, all PIs lost potency against the D168A variant, as has 
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been observed for NS3/4A inhibitors.96,108 However, the potency losses varied 
significantly from 14- to 1800-fold, with the thiophene substituted P1–P3 
macrocyclic analog AM-07 losing the most potency and danoprevir exhibiting a 
200-fold reduction in potency in enzyme inhibition assays. As we previously 
reported,124 grazoprevir exhibited > 200-fold lower potency against the D168A 
variant in enzyme inhibition assays but was still one of the most potent inhibitors 
against this drug resistant protease variant (Ki =49.1 nM). The P1–P3 
macrocyclic inhibitors JZ01-15 and 5172-mcP1P3 (with a methyl and ethyl 
substituted quinoxaline, respectively) exhibited lower potency against WT 
protease compared to grazoprevir but were less susceptible to the D168A 
variant, resulting in an inhibition constant similar to grazoprevir (Ki = 52 and 82.4 
nM, respectively). Similar trends were observed in replicon assays with inhibitors 
losing 10- to 124-fold in potency compared to WT. Grazoprevir was over 100-fold 
less potent against the D168A variant (EC50 = 26.8 nM). Interestingly, JZ01-15 
exhibited the best activity against the D168A variant in replicon assays with EC50 
below 5 nM (EC50 = 4.8 nM). Thus the P1–P3 macrocyclic inhibitor with a small 
methyl substitution on the P2 quinoxaline showed a much flatter resistance 
profile and was less susceptible to D168A substitution.  
The impact of Y56H on inhibition by NS3/4A PIs has not been well 
characterized, as this substitution is rarely observed alone. Enzyme inhibition 
assays on our panel of PIs showed that all inhibitors except danoprevir were 
susceptible to the Y56H substitution, exhibiting reduced potency ranging from 
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29–177 fold. The antiviral activities closely correlated with enzyme inhibition 
assays with inhibitors losing 51–138 fold in potency. In contrast, danoprevir, 
whose P2 isoindoline moiety does not stack on the catalytic triad,89 maintained 
potency similar to WT  (Ki = 1 nM, EC50 = 0.57 nM) against the Y56H variant (Ki = 
3 nM, EC50 = 6.2 nM).  
The potency loss of PIs against Y56H variant could be due to disruption of 
Tyr56 residue’s direct interactions with the P2 quinoxaline. To isolate the effect of 
direct hydrophobic interactions of the methoxy group at the 7-position of the P2 
quinoxaline with the Tyr56 residue, we tested MG-28, which lacks this 
substituent. MG-28 is an analog of 5172-mcP1P3 and differs only at this position. 
MG-28 was more susceptible to the Y56H substitution compared to 5172-
mcP1P3 (Ki = 205 nM compared with 101 nM). While 5172-mcP1P3 was more 
potent against WT protease, fold-changes against Y56H variant were 
comparable regardless of the presence of this group (31 and 29 fold), also for a 
very close analog (JZ01-15, 30-fold). Thus loss of direct hydrophobic interactions 
with Tyr56 does not underlie susceptibility to the Y56H substitution, suggesting 
another mechanism of resistance.  
All inhibitors were highly susceptible to the Y56H/D168A variant with enzyme 
inhibition constants in the mid-nanomolar to micromolar range (Ki = 500 nM – 2 
µM). In fact, all inhibitors exhibited a greater than 200-fold loss in potency relative 
to WT protease. Danoprevir was 500-fold less potent against the Y56H/D168A 
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protease (Ki = 520 nM). However, most of this potency loss is due to the D168A 
substitution (Ki = 199 nM) with only an additional 2.5-fold reduction in potency 
with Y56H. The same trend was observed for danoprevir in replicon assays 
(D168A EC50 = 50.6 nM, Y56H/D168A EC50 = 136 nM). In contrast, grazoprevir 
and paritaprevir were highly susceptible to the Y56H/D168A protease showing 
2500-fold and 8500-fold lower potency, respectively compared to WT. The 
replicon assays correlated with enzyme potency, with grazoprevir and 
paritaprevir exhibiting 1923- and 2941-fold lower potency against the 
Y56H/D168A variant. JZ01-15 and 5172-mcP1P3 exhibited a relatively flatter 
resistance profile, losing 200-400 fold in enzyme inhibition assays. In fact, of the 
inhibitors with a P2 quinoxaline moiety, JZ01-15 was the only compound with 
measurable activity against the double substitution variant in replicon assays 
(EC50 = 231 nM). Thus, although the extent of the loss of potency was dependent 
on the particular inhibitor, the Y56H/D168A variant was detrimental to potency 
against all the inhibitors. 
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Figure 2.2: In vitro resistance profile of NS3/4A protease inhibitors.  
(a) Enzyme inhibition constants (against protease domain) and (b) replicon-
based half maximal effective concentrations for WT HCV NS3/4A and drug-
resistant variants Y56H, D168A and Y56H/D168A. All inhibitors lost activity 
against the Y56H/D168A protease variant. * Indicates EC50 value greater than 
500 nM.  
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Table 2.1: Inhibitory activity against GT1a HCV NS3/4A protease and drug 
resistant variants with fold changes with respect to GT1a wild-type, and the 
Michaelis-Menten constants (Km) of the protease variants. 
 
Inhibitor 
Ki (nM) (Fold change)  
GT1a WT Y56H D168A Y56H/D168A 
Grazoprevir 0.21 ± 0.03 11.9 ± 1.1   (57) 
49.1 ± 1.6 
 (234) 
531.7 ± 29.7 
(2532) 
Paritaprevir 0.35 ± 0.04 61.8 ± 13.1  (177) 
297 ± 23 
(849) 
2974 ± 230 
(8497) 
5172-mcP1P3 3.29 ± 0.52 101 ± 17  (31) 
82.4 ± 4.4 
(25) 
1179 ± 73 
(358) 
JZ01-15 3.60 ± 0.44 109 ± 19  (30) 
52.0 ± 2.4 
(14) 
784 ± 50 
(218) 
AM-07 1.0 ± 0.1 29.7 ± 4.2  (29) 
1823 ± 347 
(1770) 
2375 ± 1200 
(2306) 
MG-28 7.18 ± 1.02  205 ± 33 (29) 
190 ± 13 
(26)  
1773 ± 394 
(247) 
Danoprevir 1.0 ± 0.1 2.9 ± 0.3  (3) 
199 ± 64 
(199) 
520.3 ± 58.0 
(520) 
  Km (µM)  
 7.9 ± 1.2 5.3 ± 0.5 1.3 ± 0.1 3.2 ± 0.4 
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Table 2.2: Antiviral activity against wild-type GT1a HCV and drug resistant 
variants, with fold changes with respect to wild-type. 
 
Inhibitor 
Replicon EC50 (nM) (Fold change)  
GT1a  Y56H  D168A  Y56H/D168A  
Grazoprevir 0.26 35.8  (138) 26.8 (103) >500 (1923) 
Paritaprevir 0.17 23.5  (138) 17.9 (105) >500 (2941) 
5172-mcP1P3 0.56 28.7  (51) 12.9 (23) >500 (893) 
JZ01-15 0.47 24.6  (52) 4.8 (10) 231 (491) 
AM-07 1.43 90.6  (63) 177.7 (124) >500 (350) 
Danoprevir 0.57 6.2  (11) 50.6 (89) 136 (239) 
 
 50 
2.3.2 Double mutant cycle analysis reveals interdependency 
of Tyr56 and Asp168 for most PIs 
To delineate whether or not there is an interdependency between the two 
sites of mutation on the loss of inhibitor potency against the double substitution 
variant Y56H/D168A, the free energy of binding, ΔG (Table 2.3), was calculated 
for each inhibitor from the experimentally measured inhibition constants (Table 
2.1). If the change in binding free energy (ΔΔG) to the double mutant relative to 
WT is equal to the sum of the free energy changes to each single mutant, then 
the substitutions are additive. If not, then the substitutions are coupled or 
interdependent in conferring resistance. This type of analysis is referred to as a 
double mutant cycle.125 The double mutant cycle analysis revealed that the 
substitutions were not additive but coupled for most of the inhibitors with the 
exception of danoprevir (difference in ΔΔG only ~0.06 kcal/mol) (Figure 2.3), 
which does not stack on the catalytic residues. The interdependency was most 
pronounced in other inhibitors with differences in ΔΔG for the double mutant 
compared to sum of the single mutants of 0.45 kcal/mol for 5172-mcP1P3 and 
JZ01-15, and 1–2 kcals/mol for grazoprevir, paritaprevir and AM-07. Surprisingly, 
the substitutions were negatively coupled, with the two changes together having 
less impact on inhibitor binding than what would be predicted by the simple 
addition of each independently.  
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Table 2.3: Gibbs free energy of binding against HCV NS3/4A protease and drug 
resistant variants, calculated from the enzyme inhibition constants in Table S1. 
 
Inhibitor 
ΔG (kcal/mol)  
GT1a  Y56H  D168A  Y56H/D168A  
Grazoprevir -12.97 ± 0.08 -10.62 ± 0.05 -9.79 ± 0.02 -8.41 ± 0.03 
Paritaprevir -12.67 ± 0.07 -9.66 ± 0.12 -8.75 ± 0.05 -7.40 ± 0.05 
5172-mcP1P3 -11.37 ± 0.09 -9.37 ± 0.10 -9.49 ± 0.03 -7.94 ± 0.04 
JZ01-15 -11.31 ± 0.07 -9.33 ± 0.10 -9.76 ± 0.03 -8.18 ± 0.04 
AM-07 -12.04 ± 0.07 -10.08 ± 0.08 -7.69 ± 0.11 -7.54 ± 0.29 
Danoprevir -12.06 ± 0.06 -11.44 ± 0.06 -8.98 ± 0.19 -8.42 ± 0.06 
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Figure 2.3: Double mutant cycle analysis of NS3/4A protease inhibitors.  
ΔΔG for each inhibitor used in the enzyme inhibition assay against the 
Y56H/D168A double substitution (black) and the sum of each single substitution 
(green). The substitutions Y56H and D168A show a coupled effect for 
grazoprevir, paritaprevir and AM-07. However, these substitutions are additive for 
danoprevir and to a lesser extent for 5172-mcP1P3 and JZ01-15. 
 
 
  
Gr
az
op
rev
ir
Pa
rit
ap
rev
ir
51
72
-m
cP
1P
3
JZ
01
-15
AM
-07
Da
no
pr
ev
ir
0
2
4
6
8 ΔΔG	Y56H/D168A ΔΔG	Y56H	+	ΔΔG	D168A
ΔΔ
G	
kc
al
/m
ol
 53 
2.3.3 Crystal structures of protease-inhibitor complexes 
As danoprevir and grazoprevir represent the extremes of whether or not the 
impact of Y56H and D168A are additive or coupled, high-resolution crystal 
structures were determined of these inhibitors bound to Y56H/D168A and Y56H 
protease variants. The structures had resolutions ranging from 1.2–1.9 Å, and 
complemented our previously determined structures of danoprevir (PDB ID: 
3M5L and 3SU1 for WT, and D168A respectively) and grazoprevir (3SUD and 
3SUF for WT and D168A respectively).89 In total three new structures of 
danoprevir–Y56H, danoprevir–Y56H/D168A and grazoprevir–Y56H were 
determined, but the grazoprevir–Y56H/D168A complex failed to crystalize 
despite extensive crystallization efforts (Table 2.4). These are the first co-crystal 
structures of NS3/4A PIs bound to either Y56H or the double substitution 
Y56H/D168A variant. These high-resolution structures afforded us atomic level 
details of protein-inhibitor interactions to elucidate the structural mechanism of 
resistance for NS3/4A PIs against the Y56H/D168A protease variant.  
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Table 2.4. X-ray data collection and crystallographic refinement statistics. 
 
Y56H-
grazoprevir 
Y56H-
danoprevir 
Y56H/D168A-
danoprevir 
PDB code 6C2M 6C2O 6C2N 
Resolution 1.86 Å 1.18 Å 1.80 Å 
Space group P21 P212121 P212121 
Twin Law h,-k,-h-l   
Twin Fraction 0.26   
Molecules in AUa 4 1 1 
Cell dimensions:    
a (Å) 56.6 55.4 60 
b (Å) 103.3 59.0 55.4 
c (Å) 74.0 60.0 58.9 
β (°) 90 90 90 
Completeness (%) 96.0 99.8 96.4 
Total reflections 208132 528153 139059 
Unique reflections 63506 65383 18030 
Average I/σ 11.4 18.5 17.8 
Redundancy 3.3 8.1 7.7 
Rsym (%)b 6.6 (28.1) 6.9 (41.1) 9.8 (29.9) 
RMSDc in:     
Bond lengths (Å) 0.005 0.015 0.009 
Bond angles (°) 0.9 1.9 1.3 
Rfactor (%)d 18.1 12.3 16.2 
Rfree (%)e 22.4 14.4 19.0 
aAU, asymmetric unit. 
bRsym = Σ | I − <I>|/ Σ I, where I = observed intensity, <I> = average intensity over 
symmetry equivalent; values in parentheses are for the highest resolution shell. 
cRMSD, root mean square deviation. 
dRfactor = Σ || Fo| − |Fc||/ Σ|Fo|.   
eRfree was calculated from 5% of reflections, chosen randomly, which were 
omitted from the refinement process. 
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2.3.4 Danoprevir resistance to the Y56H/D168A variant is 
solely due to the D168A substitution 
Danoprevir is a P1–P3 macrocyclic NS3/4A inhibitor with an isoindoline P2 
group. We previously elucidated the resistance mechanisms of this inhibitor 
against RASs by analyzing high-resolution crystal structures of danoprevir bound 
to WT and mutant proteases.25 Comparing the structures of danoprevir bound to 
WT and Y56H proteases revealed that the binding mode and active site residues 
Arg155 and Asp168 are unchanged (Figure 2.4A). These results reinforced the 
inhibition data indicating danoprevir is not susceptible to Y56H, likely because 
the molecular contacts needed for efficient inhibitor binding are unaltered. In 
contrast, D168A substitution (Figure 2.5) resulted in a 0.8 Å shift of the Arg155 
side chain away from residue Asp168, disrupting the cation-π interaction critical 
for danoprevir binding. Superposition of the D168A- and Y56H/D168A-protease 
structures showed that the active sites are almost identical (Figure 2.4B), in 
agreement with no further significant loss due to addition of Y56H and lack of 
coupling between the two substitutions for this inhibitor. Thus the D168A 
substitution alone underlies danoprevir resistance against the Y56H/D168A 
protease variant.  
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Figure 2.4: Crystal structures of danoprevir and grazoprevir bound to WT 
and mutant proteases.  
Superposition of danoprevir bound to (a) WT (blue) and Y56H (red) and (b) 
D168A (orange) and Y56H/D168A (purple) proteases. Superposition of 
grazoprevir bound to (c) WT (blue) and Y56H (red) and (d) D168A (orange) 
proteases. Danoprevir’s P2 isoindoline moiety occupies two conformations in the 
protease active site. Drug resistance residues and the catalytic triad residues 
His57, Asp81 and S139A are shown in sticks. 
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Figure 2.5: Crystal structure of danoprevir bound to WT and D168A HCV 
NS3/4A proteases.  
Superposition of danoprevir bound to WT (blue) and D168A (orange) proteases. 
Danoprevir’s P2 isoindoline moiety occupies two conformations in the protease 
active site. Drug resistance residues and the catalytic triad residues (His57, 
Asp81 and S139A) are shown as sticks.   
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A156 S139A
D81
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To assess the molecular details of inhibitor packing, van der Waals (vdW) 
contact energies were calculated for danoprevir and protease active site for each 
crystal structure. Total vdW contact energies were conserved between WT and 
Y56H proteases (–83.6 and –82.6 kcal/mol, respectively) as well as D168A and 
Y56H/D168A proteases (–81.0 and –81.7 kcal/mol, respectively). Compared to 
WT protease, Y56H contact energy landscape was highly conserved (Figure 
2.6), but disrupted in the D168A and Y56H/D168A complexes with reduced 
interactions in the S2-subsite around residue Asp168. Thus, structural changes 
due to substitution at residue Asp168 underlie resistance to the Y56H/D168A 
variant for danoprevir, which is expected to be valid for other inhibitors that 
primarily interact with S2 subsite residues.  
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Figure 2.6: Packing of danoprevir in the active site of HCV NS3/4A protease 
variants. 
The van der Waals (vdW) contact energies of danoprevir from crystal structures 
mapped onto the protease surface in (a) WT, (b) Y56H, (c) D168A and (d) 
Y56H/D168A proteases. The warmer (red) and cooler (blue) colors indicate more 
and less contacts with the inhibitor, respectively. Residues with substitutions 
among the variants are labeled in red.  
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2.3.5 Resistance mechanism of grazoprevir and analogs 
against single and double mutants   
Grazoprevir is a P2–P4 macrocyclic inhibitor with a P2 quinoxaline moiety. 
Given that grazoprevir and analogs share a binding mode whereby the P2 
quinoxaline moiety predominately interacts with the catalytic residues (His57 and 
Asp81), the mechanism of resistance against Y56H/D168A resistant protease 
was expected to differ from danoprevir.  
The P1–P3 macrocyclic analogs of grazoprevir, JZ01-15, 5172-mcP1P3 and 
AM-07, exhibited resistance profiles similar to grazoprevir against the single and 
double substitution variants. JZ01-15 exhibited the best profile with similar 
activity against the D168A substitution as grazoprevir. We recently showed that 
P1–P3 macrocyclic inhibitors with small substitutions at the 3-position of the P2 
quinoxaline, such as JZ01-15 and 5172-mcP1P2, maintain potency against 
single RASs.124 In contrast, AM-07 has a larger thiophene-substituted 
quinoxaline that makes cation-π interactions with Arg155 and hydrophobic 
interactions with Tyr56. As a result of this binding mode, this inhibitor is highly 
susceptible to D168A, resulting in a higher loss in potency against the double 
substitution variant compared to grazoprevir and the other two analogs. Thus, 
structural features of the inhibitor, especially the identity of the P2 heterocyclic 
moiety, determine susceptibility to the Y56H/D168A protease variant.  
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To investigate the molecular basis of resistance conferred by Y56H 
substitution, grazoprevir crystal structures bound to WT and mutant protease 
were analyzed and compared. The comparative structural analysis revealed 
significant changes in inhibitor packing at the P2 quinoxaline and P2–P4 
macrocycle region due to Y56H substitution. The P2 quinoxaline moiety moved 
away from the catalytic residue His57 toward the S2 subsite residues, weakening 
the critical π-π interactions between the quinoxaline and His57 ring (Figure 
2.4C). His57 side chain adopted an alternate confirmation relative to WT, further 
affecting the stacking interactions with the P2 moiety. Moreover, Asp168 shifted 
closer to the Arg155 residue, exhibiting a conformation similar to other inhibitor-
protease co-complexes.89 Thus unlike danoprevir, the active site of protease and 
stacking of grazoprevir were perturbed by the Y56H substitution.  
Compared to WT protease, the structure and binding mode of grazoprevir to 
D168A variant was minimally altered (Figure 2.4D). However, as we previously 
reported, grazoprevir resistance against the D168A variant is due to disruption of 
the ionic network between Arg155 and Asp168.89 As indicated by the structural 
analysis, the individual Y56H and D168A substitutions have different 
mechanisms in conferring resistance, and combination of these substitutions 
cause a significant reduction in grazoprevir potency. However, whether Y56H 
and D168A substitutions together further alter inhibitor packing, or exacerbate 
the loss of critical interactions with the His57 ring observed in the Y56H co-
complex is unclear. 
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2.3.6 Altered dynamics correlate with structural 
mechanisms of resistance 
To interrogate the resistance mechanism against the double substitution 
variant further and complement our experimental data we turned to 
computational methods. Molecular dynamics simulations also augmented our 
structural analysis, as extensive crystallization efforts failed to result in a co-
complex structure of grazoprevir bound to the Y56H/D168A protease, possibly 
due to the significant loss in binding affinity. Molecular dynamics simulations 
were performed to investigate the dynamic mechanism of resistance for both 
danoprevir and grazoprevir, as we have previously shown that changes in HCV 
protease dynamics underlie susceptibility to resistance.111 
To assess inhibitor packing against the protease active site, inter-molecular 
vdW interactions were assessed over the MD trajectories for each residue at the 
active site (Figures 2.7, 2.8). Both single substitution and the double substitution 
variants showed an overall decrease in total vdW contact energies (5 kcal/mol 
and 10 kcal/mol, respectively) relative to WT protease for grazoprevir and 
danoprevir, consistent with the experimental loss in binding affinity. As expected, 
D168A substitution decreased contacts of this residue with grazoprevir in both 
the single and double substitution proteases (Figures 2.7A-D, 2.8A). 
Interestingly, the Y56H substitution not only decreased grazoprevir interactions at 
this position but also at other binding site residues, especially at the catalytic 
His57. This loss was compounded when D168A was combined with Y56H, with 
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considerable loss of contacts not only locally at the site of mutation but 
distributed throughout the binding site, including at residues Thr42, Gly58, and 
Gly137. There was a striking ~2.5 kcal/mol loss in vdW interactions of 
grazoprevir with His57 relative to WT protease, indicating that the addition of 
Y56H substitution to the D168A background causes severe loss of interactions 
with the neighboring catalytic His57 residue.  
In contrast to grazoprevir, danoprevir binding to the active site was similar to 
WT when bound to each single and double substitution variant, with more 
localized loss of interactions due to the substitutions (Figures 2.7E–5H, 2.8B). 
While the D168A substitution caused decreased interactions with both this 
residue and the catalytic His57, the addition of Y56H alleviated this loss in the 
double substitution variant, in direct contrast to the case of grazoprevir. Overall, 
the binding landscape of danoprevir was relatively unaltered in the variants 
relative to WT protease in the dynamic analysis (Figure 2.7), similar to what was 
seen in the crystal structures (Figure 2.6). 
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Figure 2.7: Packing of inhibitors in the NS3/4A protease active site during 
MD trajectories.  
The van der Waals (vdW) contact potentials averaged from MD simulations of 
protease active site residues for grazoprevir bound to (a) WT1a, (b) Y56H, (c) 
D168A, (d) Y56H/D168A and danoprevir bound to (e) WT1a, (f) Y56H, (g) 
D168A, (h) and Y56H/D168A proteases, respectively.  The warmer (red) and 
cooler (blue) colors indicate more and less contacts with the inhibitor, 
respectively. Drug resistance residues are highlighted in red. 
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Figure 2.8: Inhibitor interactions with wildtype HCV NS3/4A protease and 
variants by residue.  
The van der Waals (vdW) contact energies and change in vdW (ΔvdW) relative 
to wildtype for (a) grazoprevir, and (b) danoprevir bound to protease variants, 
calculated from MD trajectories. These vdW values are mapped onto the 
protease surface in Figure 2.7.  
(a)
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Grazoprevir
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The loss of correlation of motions between the inhibitor and protease can be 
an indicator of resistance, as we have previously shown for GT3 HCV NS3/4A 
protease.108 To examine the coupling of atomic fluctuations between the inhibitor 
and protease, the correlation coefficients between the inhibitor and the protease 
backbone were calculated (Figure 2.9). In the WT complex, the dynamics of 
grazoprevir were highly correlated with the motions of the residues in the active 
site (Figure 2.9A). This coupling was the most pronounced for active site 
residues 134–136 and 156–157, displaying correlations with all inhibitor moieties. 
The dynamics of the P1 and P1’ moieties of grazoprevir were highly coupled to 
the dynamics of residue His57. Additionally, the dynamics of P2 quinoxaline, and 
P1 and P1’ moieties were coupled with catalytic residue Asp81, and Leu82. 
Neither of these correlations was present when the Tyr56 was mutated to a 
histidine. Apart from this loss of correlations, Y56H substitution had only little 
effect on intra-molecular dynamics. 
In contrast, the D168A substitution severely reduced the dynamic coupling of 
grazoprevir with the protease active site. In addition to the loss of P1 and P1’ 
coupling with catalytic residues His57 and Asp81, correlation between the P2 
quinoxaline and residues 132–138 were severely reduced. In the Y56H/D168A 
protease, the correlation of motions between grazoprevir and residues 132–138 
was completely lost, in addition to severe weakening of the coupled dynamics 
between residue 157 and the inhibitor moieties. Thus, the loss of coupling 
between inhibitor and protease dynamics correlated with reduced inhibitor 
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potency against both the single mutant and the Y56H/D168A double substitution 
variant. 
The dynamics of danoprevir–protease complexes were also in agreement 
with the structural mechanisms of resistance revealed from crystal structures 
(Figure 2.9B). In the WT complex, danoprevir dynamic coupling with active site 
residues were most pronounced at residues 56–58, 135–136 and 156–157. The 
correlations of danoprevir with the Y56H protease were essentially unaltered 
relative to WT complex. This similarity is in agreement with structural analysis, as 
the Tyr56 substitution does not impact the binding of danoprevir (Figure 2.4). In 
the D168A complex, correlations of the P1’ moiety with residues 55–58 were 
reduced, while P2+ isoindoline moiety had increased correlations with residue 
K136, in agreement with increased intermolecular vdW contacts (Figure 2.7). In 
the Y56H/D168A variant, the correlations of motions were similar to those seen 
in the D168A variant. Thus, for inhibitors with binding modes similar to 
danoprevir, substitutions at Asp168 are the primary cause of resistance to the 
double substitution variant Y56H/D168A.  
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Figure 2.9: Cross-correlation coefficients of inhibitors and atomic 
fluctuations of active site residues mapped onto protease surface.  
Protease-inhibitor dynamic coupling of (a) grazoprevir and (b) danoprevir bound 
to GT1a, Y56H, D168A, and Y56H/D168A proteases. Warm colors in the 
matrices indicate increased correlations. Residues are colored on the surface to 
indicate their location in the active site. 
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2.4 Discussion 
Although drug resistance has been a major problem in the efficacy of anti-
HCV therapeutics, especially for NS3/4A PIs, newer generation inhibitors are 
robust against single-site substitutions that were once detrimental to PI clinical 
viability. More importantly, there are currently two all-oral regimens that have 
pan-genotypic HCV activity including against the evasive GT3.51 Though much 
progress has been made in anti-HCV therapeutics, a new challenge that may 
threaten the success of PIs is the emergence of viral variants with more than one 
substitution in the protease.51,98 In this study we reveal the structural and 
dynamic mechanisms of drug resistance for the Y56H/D168A protease, a double-
site RAS variant that has been identified in patients who failed therapy with PI-
containing regimens.  
The Y56H/D168A variant was resistant to all tested PIs, and the inhibitor 
binding mode determined the molecular mechanism of resistance. Prior to the 
development of grazoprevir, PIs typically contained large heterocyclic P2 
moieties that strongly interacted with S2 subsite residues.89,106 This binding mode 
resulted in detrimental loss of potency against single-site RASs in the protease 
active site, especially at residues Arg155 and Asp168.89,106 In the inhibitor-bound 
state, HCV NS3/4A protease has an extensive active site electrostatic network 
that spans the catalytic triad residues His57 and Asp81 all the way to S2 subsite 
residues Arg155, Asp168 and Arg123. Residues Arg155 and Asp168, located 
beyond the substrate envelope, form a salt bridge that is critical to inhibitor 
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binding and disrupted upon substitution at either residue.90 For inhibitors with a 
binding mode similar to danoprevir, disruption of this electrostatic network due to 
an Asp168 substitution causes rearrangement of the Arg155 side chain, resulting 
in the loss of favorable cation-π interactions between the P2 isoindoline and 
Arg155 guanidinium group.89,109 For such inhibitors that do not stack on the 
catalytic residues and have no physical interactions with Tyr56, resistance to the 
double substitution is predominantly due to the D168A change.  Thus the 
addition of Y56H substitution to D168A protease does not cause any further 
active site changes or loss in potency, and the individual Asp168 substitution is 
responsible for the decreased inhibitor binding affinity.  
Grazoprevir and newer generation inhibitors have a P2 quinoxaline moiety 
that makes extensive interactions with the catalytic triad residues, reducing 
susceptibility to single-site RASs at the S2 subsite.111 However, this binding 
mode causes vulnerability for grazoprevir and inhibitors with a similar binding 
mode to substitutions that result in loss of critical π-π stacking interactions with 
the catalytic residue His57. The crystal structure of grazoprevir bound to the 
Y56H protease determined here, reveals that this interaction is weakened when 
neighboring Tyr56 mutates to a smaller His residue. This loss is compounded in 
the double substitution Y56H/D168A variant, thereby destabilizing the binding of 
grazoprevir. The alterations due to the Y56H substitution and the double 
substitution Y56H/D168A are unlikely to impact the recognition and processing of 
the viral substrates (Table S1), as unlike grazoprevir the substrates do not stack 
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on the aromatic surface of the catalytic His57.89,90,101 The substrates also make 
no direct contact with Tyr56, so substitutions at Tyr56 are unlikely to either 
directly or indirectly impact substrate turnover. As a general rule, the reliance of 
an inhibitor on interactions with the target that are not essential for biological 
function creates an opportunity for resistance causing substitutions.89,111,126 
When these interactions are within the substrate envelope or with catalytic 
residues, the chances of resistance emerging is minimized. Nevertheless, in this 
study we observe a new indirect mechanism of resistance to packing at the 
active site, that disrupts interactions with the catalytic residue through 
substitution in a neighboring residue not involved in substrate recognition. 
Robustness of grazoprevir against single-site RASs has led to drug design 
efforts by pharmaceutical companies to pursue PIs with similar scaffolds to 
grazoprevir. Pan-genotypic PIs voxilaprevir and glecaprevir have a P2 
quinoxaline and P2–P4 macrocycle as in grazoprevir. Considering the high 
similarity in the scaffolds of these latest-generation inhibitors, there is a danger 
that all PIs currently in clinic might be susceptible to the same resistant variants, 
including Y56H/D168A. While these inhibitors have low susceptibility to single-
site substitutions at residues Arg155 and Asp168, they have selected for double 
substitution variants in in vitro studies.51 In fact, in vitro resistance testing of 
glecaprevir selected for resistance against GT3 double substitution variant 
Y56H/Q168R losing almost 1400-fold in potency.15 This suggests that double 
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substitution variants containing Y56H may emerge in other genotypes and 
reduce the clinical effectiveness of PIs.    
Under increased drug pressure, more protease variants with more than one 
substitution will likely become clinically relevant. The accumulation of additional 
substitutions can allow RAS variants to emerge that alone are not viable, but in 
combination can rescue the viral fitness. We previously demonstrated that 
inhibitors with a P2–P4 macrocycle are highly susceptible to substitutions at 
Ala156, as a change to a larger side chain results in steric clashes with the 
inhibitor’s macrocycle. Ala156 substitutions cause low replicative capacity, but 
additional changes at other positions in the NS3/4A protease can improve 
enzymatic activity and thus viral fitness, leading to clinically relevant variants. 
Voxilaprevir and glecaprevir also select for substitutions at Ala156 in vitro, which 
causes a large fold shift in inhibitor potency. Moreover, Ala156-Asp168 double 
substitutions have been selected in vitro, which improve fitness. Although not yet 
observed clinically, the A156T substitution if coupled with such a fitness-rescuing 
second substitution could cause resistance to all P2–P4 macrocyclic PIs with a 
P2 quinoxaline moiety. In fact, the additional substitution does not have to occur 
at the active site. We have shown in HIV-1 protease that active site and distal 
substitutions often occur in combination to confer resistance.127 Similarly, 
glecaprevir selected substitutions at Ala156 in combination with Gln/Pro89 in GT 
1a/b, which is located outside of the active site. This additional substitution at 
position 89 appears to have improved replicative efficiency to 100%.51 
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Understanding the molecular mechanisms of resistance and enzymatic fitness of 
these multi-substituted variants will be necessary to improve potency of PIs 
against emerging resistant variants.  
One strategy used in rational drug design of PIs to avoid drug resistance is 
exploiting interactions with the catalytic triad residues. The catalytic triad residues 
are critical for the biological function of the protease and thus almost always 
invariant. However, we find that even though the catalytic residues themselves 
cannot mutate to confer resistance, this drug design strategy can be 
circumvented by selecting substitutions at other locations that disrupt critical 
inhibitor interactions of these residues. The Y56H substitution severely disrupts 
the favorable interactions of grazoprevir’s P2 moiety with catalytic His57 residue. 
While exploiting interactions with evolutionarily constrained residues is still one of 
the best strategies for inhibitor design, diverse PIs need to be considered, 
preferably with enhanced interactions with the catalytic residues that cannot be 
disrupted by nearby changes in the protease active site. As new drugs and 
combinations are developed, drug resistance needs to be considered at the 
outset of inhibitor design to minimize the emergence of resistance. Additionally, 
the arsenal of PIs needs to be diversified, as the similarity in scaffold is likely to 
lead to cross-resistance and susceptibility to multi-substituted variants. 
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2.5 Methods 
2.5.1 Inhibitor Synthesis 
Grazoprevir, paritaprevir, danoprevir and grazoprevir analogs were 
synthesized in-house using previously reported methods. Grazoprevir was 
prepared following a reported synthetic method.120 Paritaprevir, danoprevir, and 
grazoprevir analogs were synthesized similarly using our convergent reaction 
sequence as previously described, with minor modifications.106  
2.5.2 Expression and Purification of NS3/4A Constructs  
The HCV GT1a NS3/4A protease gene described in the Bristol Myers Squibb 
patent was synthesized by GenScript and cloned into a PET28a expression 
vector.128 The D168A, Y56H and Y56H/D168A genes were engineered using the 
site-directed mutagenesis protocol from Stratagene. Protein expression and 
purification were carried out as previously described with minor modifications.89 
Briefly, transformed Escherichia coli BL21(DE3) cells were grown in TB media 
containing 30 µg/mL of kanamycin antibiotic at 37 °C. After reaching an OD600 of 
0.8, cultures were induced with 1 mM IPTG and harvested after 3 h of 
expression. Cells were pelleted by centrifugation, resuspended in Resuspension 
buffer (RB) [50 mM phosphate buffer, 500 mM NaCl, 10% glycerol, 2 mM β-ME, 
pH 7.5] and frozen at −80 °C for storage. 
Cell pellets were thawed and lysed via cell disruptor (Microfluidics Inc.) two 
times to ensure sufficient DNA shearing. Lysate was centrifuged at 19,000 rpm, 
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for 25 min at 4 °C. The soluble fraction was applied to a nickel column (Qiagen) 
pre-equilibrated with RB. The beads and soluble fraction were incubated at 4 °C 
for 1.5 h and the lysate was allowed to flow through. Beads were washed with 
RB supplemented with 20 mM imidazole and eluted with RB supplemented with 
200 mM imidazole. The eluent was dialyzed overnight (MWCO 10 kD) to remove 
the imidazole, and the His-tag was simultaneously removed with thrombin 
treatment. The eluate was judged >90% pure by polyacrylamide gel 
electrophoresis, concentrated, flash frozen, and stored at −80 °C. 
2.5.3 Determination of the Inner Filter Effect 
The inner filter effect (IFE) for the NS3/4A protease substrate was determined 
using a previously described method.129 Briefly, fluorescence end-point readings 
were taken for substrate concentrations between 0 µM and 20 µM. Afterward, 
free 5-FAM fluorophore was added to a final concentration of 25 µM to each 
substrate concentration and a second round of fluorescence end-point readings 
was taken. The fluorescence of free 5-FAM was determined by subtracting the 
first fluorescence end point reading from the second round of readings. IFE 
corrections were then calculated by dividing the free 5-FAM florescence at each 
substrate concentration by the free 5-FAM florescence at zero substrate.  
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2.5.4 Determination of Michaelis–Menten  (Km) Constant 
Km constants for GT1 and D168A protease were previously determined.106 
The Km of Y56H and Y56H/D168A proteases were determined using the following 
method. A 20 µM concentration of substrate [Ac-DE-Dap(QXL520)- EE-Abu-γ-
[COO]AS-C(5-FAMsp)-NH2] (AnaSpec) was serially diluted into assay buffer [50 
mM Tris, 5% glycerol, 10 mM DTT, 0.6 mM LDAO, and 4% dimethyl sulfoxide] 
and proteolysis was initiated by rapid injection of 10 µL protease (final 
concentration 20 nM) in a reaction volume of 60 µL. The fluorescence output 
from the substrate cleavage product was measured kinetically using an EnVision 
plate reader (Perkin-Elmer) with excitation wavelength at 485 nm and emission at 
530 nm. Inner filter effect corrections were applied to the initial velocities (Vo) at 
each substrate concentration. Vo versus substrate concentration graphs were 
globally fit to the Michaelis–Menten equation to obtain the Km value. 
2.5.5 Enzyme Inhibition Assays 
For each assay, 2 nM of NS3/4A protease (GT1a, Y56H, D168A and 
Y56H/D168A) was pre-incubated at room temperature for 1 h with increasing 
concentration of inhibitors in assay buffer (50 mM Tris, 5% glycerol, 10 mM DTT, 
0.6 mM LDAO, and 4% dimethyl sulfoxide, pH 7.5). Inhibition assays were 
performed in non-binding surface 96-well black half-area plates (Corning) in a 
reaction volume of 60 µL. The proteolytic reaction was initiated by the injection of 
5 µL of HCV NS3/4A protease substrate (AnaSpec), to a final concentration of 
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200 nM and kinetically monitored using a Perkin Elmer EnVision plate reader 
(excitation at 485 nm, emission at 530 nm). Three independent data sets were 
collected for each inhibitor with each protease construct. Each inhibitor titration 
included at least 12 inhibitor concentration points, which were globally fit to the 
Morrison equation to obtain the Ki value. Gibbs free energy of binding was 
calculated using the following equation: ΔG = RTlnKi 
2.5.6 Cell-Based Drug Susceptibility Assays 
Mutations (Y56H, D168A, and Y56H/D168A) were constructed by site-
directed mutagenesis using a Con1 (genotype 1b) luciferase reporter 
replicon containing the H77 (genotype 1a) NS3 sequence.130 Replicon RNA of 
each protease variant was introduced into Huh7 cells by electroporation. 
Replication was then assessed in the presence of increasing concentrations of 
protease inhibitors by measuring luciferase activity (relative light units) 96 h after 
electroporation. The drug concentrations required to inhibit replicon replication by 
50% (EC50) were calculated directly from the drug inhibition curves.  
2.5.7 Crystallization and structure determination 
Protein expression and purification were carried out as previously 
described.89 The Ni-NTA purified WT1a protein was thawed, concentrated to 3 
mg/mL, and loaded on a HiLoad Superdex75 16/60 column equilibrated with gel 
filtration buffer (25 mM MES, 500 mM NaCl, 10% glycerol, and 2 mM DTT, pH 
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6.5). The protease fractions were pooled and concentrated to 25 mg/mL with an 
Amicon Ultra-15 10 kDa filter unit (Millipore). The concentrated samples were 
incubated for 1 h with 3:1 molar excess of inhibitor. Diffraction-quality crystals 
were obtained overnight by mixing equal volumes of concentrated protein 
solution with precipitant solution (20–26% PEG-3350, 0.1 M sodium MES buffer, 
4% ammonium sulfate, pH 6.5) at RT or 15 °C in 24-well VDX hanging drop 
trays. Crystals were harvested and data was collected at 100 K. Cryogenic 
conditions contained the precipitant solution supplemented with 15% glycerol or 
ethylene glycol.   
X-ray diffraction data were collected at Advance Photon Source beamline 23-
ID-B or our in-house Rigaku X-ray system with a Saturn 944 detector. All 
datasets were processed using HKL-3000.131 Structures were solved by 
molecular replacement using PHASER.132 Model building and refinement were 
performed using Coot133 and PHENIX,134 respectively. The final structures were 
evaluated with MolProbity135 prior to deposition in the PDB. To limit the possibility 
of model bias throughout the refinement process, 5% of the data were reserved 
for the free R-value calculation.136 Structure analysis, superposition and figure 
generation were done using PyMOL.137 X-ray data collection and crystallographic 
refinement statistics are presented above (Table 2.4).  
2.5.8 System Preparation for Molecular Dynamics 
Simulations 
 
 79 
Crystal structures of HCV protease bound to grazoprevir were taken from the 
Protein Databank (PDB IDs 3SUD and 3SUF).89 When there were multiple 
copies of the protease–inhibitor complex in the crystallographic unit, the complex 
with the lowest overall B-Factors was chosen. In the case of the double 
substitution variant, the complex was modeled in silico using the Prime structure 
prediction wizard.138 Protein structures were then prepared for simulation using 
the Protein Preparation Wizard from the Schrodinger Suite,139 keeping all co-
crystallized water molecules. Missing atom were added using Prime.140 The 
protonation state of the protein side chains at pH 7.0 was determined using 
PROPKA.141,142 The hydrogen bond network was optimized by exhaustive 
sampling of the orientation of crystallographic waters and side chains of polar 
amino acids. Finally, the structure was subjected to gradient minimization with 
convergence criterion 0.5 Å using Impref.143 
2.5.9 Molecular Dynamics Simulations 
Molecular dynamic simulations of protein-inhibitor complexes were carried out 
as previously described.127 The protein-inhibitor complex was placed in a cubic 
solvent box maintaining at least 1.5 nm spacing between any solute atom and 
the box boundaries. The system’s net charge was neutralized by adding chloride 
ions; additionally, sodium and chloride ions were added to a total salt 
concentration of 0.15 M. 
 80 
MD simulations were carried out using the Desmond software suite.144 Protein 
and ligand were parameterized using the OPLS3 force field.145 For the water 
molecules, TIP3P force field parameters were used.146 During simulations, long-
range electrostatic forces were calculated using the Particle Mesh Ewald 
method.147 Short-range non-bonded forces were truncated smoothly at 1.2 nm. 
The RESPA integrator was used with a 2 fs time step for bonded and short-range 
non-bonded forces and a 6 fs time step for long-range electrostatic forces.148 
Before running MD simulations, the solvated system was energy minimized 
using a stepwise protocol. In the first iteration, all solvent molecules were 
minimized using 10 steepest decent steps followed by up to 5000 L-BSFG 
minimization steps. The convergence criterion was an energy gradient of 0.5 kcal 
mol-1 Å-1 while applying solute heavy atoms a force constant of 1000 kcal mol-1 Å-
2. In the second iteration only the backbone restraints were kept and the system 
was subjected to the same minimization procedure as in the first iteration. In the 
third step, the restraints on the backbone heavy atoms were lowered to 5 kcal 
mol-1 Å-2. For the final minimization step, all restraints were removed and the 
system was minimized using the L-BFSG method until an energy gradient of 0.05 
kcal mol-1 Å-1 was reached. 
Following minimization, a number of short MD simulations were performed to 
equilibrate the system. Initially a 12 ps simulation in the NVT ensemble using the 
Berendsen thermostat at 10 K was performed. The backbone position was 
restrained using a force constant of 50 kcal mol-1 Å-2. This was followed by a 24 
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ps simulation in the NPT ensemble maintaining the restraints on the protein 
backbone. Subsequently a 50 ps unrestrained NPT simulation was run during 
which the temperature was increased from 10 K to the target temperature of 300 
K. This was followed by a 500 ps NPT simulation at 300 K allowing the system to 
thermalize. The final production stage consisted of a 100 ns simulation in the 
NPT ensemble at 300 K and 1bar. Atomic coordinates were recorded every 5 ps. 
All simulations were run in triplicate using the aforementioned protocol.  
2.5.10 Correlated Motions 
To measure both linear and non-linear correlated protein dynamics, the 
Linear Mutual Information between atom pairs was calculated. This is based on 
the approach proposed by Lange and Grubmueller.149 Briefly, correlated 
dynamics were measured by calculating their mutual information  𝐼[𝑥;𝑦] = !(!;!)! ! !(!)!;!   where x and y are two sets of atomic coordinates, p(x) and p(y) are 
there marginal probability distributions and p(x;y) is the joint probability 
distribution. If the two atoms x and y are fully independent the joint probability 
distribution p(x;y) equals the sum of its marginal probability distributions, thus 
I[x;y] becomes 0. If the two atoms are not completely independent I[x;y] assumes 
a positive value. To improve interpretability the mutual information I(x;y) is 
subsequently transformed into the generalized correlation coefficient 𝑟!" 𝑥;𝑦 = {1− exp (−2𝐼[𝑥;𝑦]/𝑑)}  with d=3 since x and y are Euclidean coordinates. 𝑟!"[𝑥;𝑦] has a value of 0 for fully independent motions and a value of 1 for fully 
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coupled dynamics.  To calculate the generalized correlation coefficient, 
snapshots were taken from a trajectory at 5ps intervals. Global, translational and 
rotational motions were minimized by aligning all snapshots to the first frame of 
the trajectory. Pairwise and marginal probability distribution were estimated by a 
Gaussian distribution. This approach has the advantage to capture both linear 
and non-linear correlated motions while avoiding computationally more 
demanding density estimates. 
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Chapter III 
Hepatitis C Virus NS3/4A Protease Inhibitors 
Incorporating Flexible P2 Quinoxalines 
Target Drug Resistant Viral Variants 
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3.1 Abstract 
A substrate envelope-guided design strategy is reported for improving the 
resistance profile of HCV NS3/4A protease inhibitors. Analogues of 5172-
mcP1P3 were designed by incorporating diverse quinoxalines at the P2 position 
that predominantly interact with the invariant catalytic triad of the protease. 
Exploration of structure-activity relationships showed that inhibitors with small 
hydrophobic substituents at the 3-position of P2 quinoxaline maintain better 
potency against drug resistant variants, likely due to reduced interactions with 
residues in the S2 subsite. In contrast, inhibitors with larger groups at this 
position were highly susceptible to mutations at Arg155, Ala156 and Asp168. 
Excitingly, several inhibitors exhibited exceptional potency profiles with EC50 
values ≤ 5 nM against major drug resistant HCV variants. These findings support 
that inhibitors designed to interact with evolutionarily constrained regions of the 
protease, while avoiding interactions with residues not essential for substrate 
recognition, are less likely to be susceptible to drug resistance. 
3.2 Introduction 
Hepatitis C virus (HCV) infects over 130 million people globally and is the 
leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma.1 
HCV is known as a “silent killer” as a majority of affected patients remain 
unaware of their infection, and over time the acute infection progresses to 
chronic liver disease.150 The rate of cirrhosis is estimated to increase from 16% 
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to 32% by the year 2020 due to the high number of untreated patients.151 Thus, 
there is an urgent need to ensure that patients infected with HCV receive proper 
treatment. However, HCV infection is difficult to treat, as the virus is genetically 
diverse with six known genotypes (genotype 1–6), each of which is further sub-
divided into numerous subtypes.6 Genotype 1 (GT1) and genotype 3 (GT3) are 
the most prevalent accounting for 46% and 30% of global infections, 
respectively.6,7 Therapeutic regimen and viral response are largely genotype 
dependent with most treatments being efficacious only against GT1.22  
The recent advent of direct-acting antivirals (DAAs) targeting essential viral 
proteins NS3/4A, NS5A, and NS5B has remarkably improved therapeutic options 
and treatment outcomes for HCV infected patients.22,23 Four new all-oral 
combination treatments have been approved by the US FDA: (1) 
sofosbuvir/ledipasvir,152 (2) ombitasvir/paritaprevir/ritonavir/dasabuvir,40 (3) 
elbasvir/grazoprevir,41 and (4) sofosbuvir/velpatasvir.42 The DAA-based therapies 
are highly effective against GT1 with sustained virological response (SVR) rates 
greater than 90%.22,23 However, most of the FDA approved treatments and those 
in clinical development are not efficacious against other genotypes, especially 
GT3.23 Moreover, except for sofosbuvir, all current DAAs are susceptible to drug 
resistance.107 Therefore, more robust DAAs need to be developed with higher 
barriers to drug resistance and a broad spectrum of activity against different HCV 
genotypes. 
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The HCV NS3/4A protease is a major therapeutic target for the development 
of pan-genotypic HCV inhibitors.153,154 The NS3/4A protease inhibitors (PIs) 
telaprevir155 and boceprevir156 were the first DAAs approved for the treatment of 
HCV GT1 infection in combination therapy with pegylated-interferon and 
ribavirin.31,33 Three recently approved PIs, simeprevir,85 paritaprevir91 and 
grazoprevir120 are integral components of various combination therapies currently 
used as the standard of care for HCV infected patients.22,23,154 Two other NS3/4A 
PIs, asunaprevir81 and vaniprevir,88 have been approved in Japan. In addition, a 
number of next generation NS3/4A PIs are in clinical development including 
glecaprevir45 and voxilaprevir121 (Figure 3.1). 
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Figure 3.1: Chemical structures of HCV NS3/4A protease inhibitors. 
Simeprevir, paritaprevir and grazoprevir are approved by the FDA; voxilaprevir 
and glecaprevir are in clinical development. 
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All NS3/4A PIs share a common peptidomimetic scaffold and are either linear 
or macrocyclic; the macrocycle is located either between P1–P3 or P2–P4 
moieties.154 In addition, these inhibitors contain a large heterocyclic moiety 
attached to the P2 proline, which significantly improves inhibitor potency against 
wild-type (WT) NS3/4A protease.80,157 However, all NS3/4A PIs are susceptible to 
drug resistance, especially due to single site mutations at protease residues 
Arg155, Ala156 and Asp168.92,158 Notably, D168A/V mutations are present in 
nearly all patients who fail treatment with PIs.107 Moreover, natural 
polymorphisms at this position are responsible for significantly reduced inhibitor 
potency against GT3.122 We previously determined the molecular mechanisms of 
drug resistance due to single site mutations by solving high-resolution crystal 
structures of PIs bound to WT and mutant proteases.89,90,108,123 These crystal 
structures revealed that the large heterocyclic P2 moieties of PIs bind outside the 
substrate binding region, defined as the substrate envelope, and make extensive 
interactions with residues Arg155, Ala156 and Asp168.89,123 The inhibitor P2 
moiety induces an extended S2 subsite by forcing the Arg155 side chain to rotate 
nearly 180° relative to its conformation in substrate complexes.90 This altered 
Arg155 conformation is stabilized by electrostatic interactions with Asp168, 
providing additional hydrophobic surface that is critical for efficient inhibitor 
binding. Disruption of electrostatic interactions between Arg155 and Asp168 due 
to mutations underlies drug resistance against NS3/4A PIs.89,90,109,123 Moreover, 
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we have shown that structural differences at the P2 moiety largely determine the 
resistance profile of these inhibitors.106 
Grazoprevir (MK-5172, 1), one of the most potent HCV NS3/4A PIs, has a 
unique binding mode where the P2 quinoxaline moiety interacts with residues of 
the catalytic triad, avoiding direct interactions with Arg155 and Asp168 (Figure 
3.2).89 As a result, 1 has an excellent potency profile across different genotypes 
and relatively low susceptibility to drug resistance due to mutations at Arg155 
and Asp168.96,120 However, 1 is highly susceptible to mutations at Ala156, mainly 
due to steric clashes of larger side chains with the P2–P4 macrocycle. We have 
shown that the P1–P3 macrocyclic analogue 5172-mcP1P3 (2) avoids this steric 
clash while still maintaining the unique binding mode of 1 (Figure 3.2).111 
Compound 2, though slightly less potent than 1 against WT HCV, has an 
excellent potency profile with EC50 values in the single digit nanomolar range 
against drug resistant variants including A156T. Similar to 1, the P2 quinoxaline 
moiety in 2 stacks against the catalytic residues His57 and Asp81 and largely 
avoids direct interactions with residues around the S2 subsite.111 But unlike 1, the 
flexible P2 quinoxaline moiety in 2 better accommodates mutations at Ala156, 
resulting in an overall improved resistance profile.106,111 Thus, the P1–P3 
macrocyclic analogue 2 is a promising lead compound for structure-activity 
relationship (SAR) studies to further improve potency against drug resistant 
variants and other genotypes.  
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Figure 3.2: Chemical structures and binding modes of grazoprevir (1) and 
analogue 2.  
(a) Compound 2 was designed by replacing the P2–P4 macrocycle in 1 with a 
P1–P3 macrocycle. (b) The binding conformation of 1 (PDB code: 3SUD) and 2 
(PDB code: 5EPN) in the active site of wild-type NS3/4A protease. Compound 2 
maintains the unique binding mode of 1 whereby the P2 quinoxaline makes 
strong interactions with the catalytic residues avoiding contacts with known drug 
resistance residues. The catalytic triad is highlighted in yellow and drug 
resistance residues Arg155, Ala156, and Asp168 are shown in blue, red and 
green, respectively. The canonical nomenclature for drug moiety positioning is 
indicated using grazoprevir. 
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The substrate envelope model provides a rational approach to design NS3/4A 
PIs with improved resistance profiles by exploiting interactions with the protease 
residues essential for function and avoiding direct contacts with residues that can 
mutate to confer drug resistance.159-161 Another approach applied to design PIs 
with improved resistant profiles involves incorporation of conformational flexibility 
that can allow the inhibitor to adapt to structural changes in the protease active 
site due to mutations.109 Here, we describe a structure-guided strategy that 
combines these two approaches and, together with our understanding of the 
mechanisms of drug resistance, led to the design of NS3/4A PIs with exceptional 
potency profiles against major drug resistant HCV variants. Based on the lead 
compound 2, a series of analogues were designed and synthesized with diverse 
substituents at the 3-position of P2 quinoxaline moiety. Investigation of SARs 
identified P2 quinoxaline derivatives that predominantly interact with the invariant 
catalytic triad and avoid contacts with the S2 subsite residues. The results 
indicate that combining the substrate envelope model with optimal 
conformational flexibility provides a general strategy for the rational design of 
NS3/4A PIs with improved resistance profiles. 
3.3 Chemistry 
The NS3/4A PIs with diverse P2 quinoxaline moieties were synthesized using 
the reaction sequence outlined in Scheme 3.1. A Cs2CO3-mediated SN2 reaction 
of 3-substituted quinoxalin-2-ones 8a-g with the activated proline derivative 3 
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provided the key P2 intermediates 9a-g in 75–90% yield. The alternate SNAr 
reaction between activated quinoxaline derivatives and Boc-protected hydroxy-
proline resulted in lower yields, and purification of the resulting P2 acid products 
was significantly more challenging. The 3-substituted 7-methoxy-quinoxalin-2-
ones 8a-b and 8d-e were prepared by condensation reactions of 4-
methoxybenzene-1,2-diamine with the corresponding ethyl glyoxylates. The 3-
chloro-7-methoxyquinoxalin-2-one 8c was prepared according to a reported 
method.120 
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Scheme 3.1: Synthesis of HCV NS3/4A protease inhibitors. Reagents and 
conditions: (a) Cs2CO3, NMP, 55 °C, 6 h; (b) 4 N HCl in dioxane, CH2Cl2, RT, 3 
h; (c) HATU, DIEA, DMF, RT, 4 h; (d) LiOH.H2O, THF, H2O, RT, 24 h; (e) HATU, 
DIEA, DMF, RT, 2 h; (f) Zhan 1B catalyst, 1,2-DCE, 70 °C, 6 h; (g) 4 N HCl, 
dioxane, RT, 3 h; (h) N-(cyclopentyloxycarbonyloxy)-succinimide, DIEA, CH3CN, 
RT, 36 h. 
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The P1–P3 macrocyclic PIs were assembled from the P2 intermediates 9a-g 
using a sequence of deprotection and peptide coupling steps followed by the 
ring-closing metathesis (RCM) reaction (Method A). Removal of the Boc group in 
9a-g using 4 N HCl provided the amine salts 10a-g, which were coupled with the 
amino acid 11 in the presence of HATU and DIEA to yield the P2–P3 ester 
intermediates 12a-g. Hydrolysis of these esters with LiOH and reaction of the 
resulting carboxylic acids 13a-g with the P1–P1’ fragments 14162 and 15163 under 
HATU/DIEA coupling conditions provided the bis-olefin intermediates 16a-g and 
17a-e. Finally, cyclization of the bis-olefin intermediates was accomplished using 
a highly efficient RCM catalyst Zhan 1B, and provided the inhibitors 18b-g and 
19a-e in 45–80% yield. Interestingly, RCM reactions of bis-olefins 17a-e bearing 
the 1-methylcyclopropylsulfonamide provided higher yield than the corresponding 
cyclopropylsulfonamide analogues 16a-g. Finally, removal of the Boc group and 
reaction of the resulting amine salts 20a-g and 21a-e with the N-
(cyclopentyloxycarbonyloxy)-succinimide in the presence of DIEA afforded the 
inhibitors 22a-g and 23a-e with the N-terminal cyclopentyl P4 moiety. 
A subset of inhibitors was synthesized using an alternate reaction sequence 
that allowed late-stage modification at both the P1’ and P4 positions as illustrated 
in Scheme 3.2 (Method B). The P2–P3 acid intermediates 13a-d were reacted 
with the commercially available amine salt 24 under HATU/DIEA coupling 
conditions to afford the bis-olefin intermediates 25a-d. RCM reaction in the 
presence of Zhan 1B catalyst provided the macrocyclic intermediates 26a-d in 
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75–90% yield, which was better than that obtained in the presence of the P1’ 
acylsulfonamide. The P1–P3 macrocyclic core intermediates 26a-d can be 
modified in either direction after removing the C- or N-terminal protecting groups. 
Thus, hydrolysis of the C-terminal ethyl ester with LiOH provided the acids 27a-d, 
which were then reacted with either cyclopropylsulfonamide 28 or 1-
methylcyclopropylsulfonamide 29 in the presence of CDI and DBU to afford the 
final inhibitors 18b-d and 19a-d. The N-terminal tert-butyl capping group was 
replaced with the cyclopentyl moiety as described earlier to provide the target 
inhibitors 22a-d and 23a-d. 
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Scheme 3.2: Alternate synthesis of HCV NS3/4A protease inhibitors. 
Reagents and conditions: (a) HATU, DIEA, DMF, RT, 2 h; (b) Zhan 1B catalyst, 
1,2-DCE, 70 °C, 5 h; (c) LiOH.H2O, THF, MeOH, H2O, RT, 24 h; (d) CDI, THF, 
DBU, reflux, 1.5 h, RT, 36 h. 
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3.4 Results and Discussion 
Our goal was to develop a structure-guided design strategy to improve the 
resistance profile of HCV NS3/4A PIs based on the substrate envelope 
model.159,160 Compound 2 is an attractive scaffold for exploring this strategy due 
to the unique structural features: (1) the P2 quinoxaline moiety that 
predominantly interacts with the highly conserved catalytic residues Asp81 and 
His57 and (2) the conformational flexibility that allows the inhibitor to efficiently 
accommodate structural changes in the S2 subsite due to resistance mutations. 
Despite these promising features, optimization of substituents at the P2 
quinoxaline and the N-terminal capping may be key to discovering analogues 
with improved potency and resistance profiles. Therefore, efforts were focused 
on exploration of SARs at the P2 quinoxaline moiety in 2, specifically substituting 
the ethyl group at the 3-position that directly interacts with protease S2 subsite 
residues Arg155 and Ala156. The SAR strategy was based on insights from 
detailed structural analysis of 1 and 2 bound to wild-type NS3/4A protease and 
drug resistant variants.89,111 Based on these insights, we hypothesized that small 
hydrophobic groups at the 3-position of the quinoxaline would be preferred for 
retaining inhibitor potency against drug resistant variants, but larger groups that 
make extensive interactions with Arg155, Ala156 and Asp168 would result in 
inhibitors highly susceptible to mutations at these positions. To test this 
hypothesis, a series of inhibitors with diverse substituents at the 3-position of P2 
quinoxaline were designed and synthesized. 
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The potency and resistance profiles of NS3/4A PIs were assessed using 
biochemical and replicon assays. The enzyme inhibition constants (Ki) were 
determined against wild-type GT1a NS3/4A protease, drug-resistant variant 
D168A, and GT3a NS3/4A protease (Table 3.1). The cellular antiviral potencies 
(EC50) were determined using replicon-based antiviral assays against wild-type 
HCV and drug-resistant variants R155K, A156T, D168A, and D168V (Table 3.2). 
Grazoprevir (GZR, 1) was used as a control in all assays. The observed antiviral 
potencies are generally higher than protease inhibitory potencies, likely because 
biochemical assays were performed using the protease domain alone rather then 
the full-length NS3/4A.  
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Table 3.1: Inhibitory activity against wild-type NS3/4A protease and drug 
resistant variants 
 
Inhibitor R1 R2 R3 
Ki (nM) 
GT1a WT 
Protease 
GT1a D168A 
Protease 
GT3a 
Protease 
2 OMe Et H 3.29 ± 0.52 82.4 ± 4.4 204 ± 19 
19a OMe Et Me 1.82 ± 0.38 55.2 ± 5.3 171 ± 23 
22a OMe Et H 1.24 ± 0.14 52.3 ± 3.2 211 ± 18 
23a OMe Et Me 1.37 ± 0.34 55.2 ± 5.3 186 ± 30 
18b OMe Me H 3.40 ± 0.47 50.9 ± 3.7 152 ± 18 
19b OMe Me Me 3.60 ± 0.44 52.0 ± 2.4 119 ± 18 
22b OMe Me H 0.93 ± 0.15 31.9 ± 2.5 147 ± 20 
23b OMe Me Me 1.13 ± 0.22 36.3 ± 1.8 121 ± 16 
18c OMe Cl H 1.07 ± 0.17 39.8 ± 3.4 67.5 ± 8.0 
19c OMe Cl Me 1.11 ± 0.38 77.7 ± 6.1 53.6 ± 5.9 
22c OMe Cl H 0.49 ± 0.15 30.6 ± 2.6 85.6 ± 11 
23c OMe Cl Me 0.44 ± 0.15 25.7 ± 1.8 61.0 ± 12 
18d OMe CF3 H 13.3 ± 3.9 157 ± 12 344 ± 141 
19d OMe CF3 Me 5.77 ± 1.78 118 ± 13 231 ± 74 
22d OMe CF3 H 7.55 ± 2.39 115 ± 12 757 ± 334 
23d OMe CF3 Me 8.14 ± 2.37 110 ± 14 433 ± 206 
18e OMe i-Pr H 4.27 ± 1.34 239 ± 20 NT 
19e OMe i-Pr Me 0.58 ± 0.08 211 ± 19 NT 
22e OMe i-Pr H 1.44 ± 0.46 161 ± 11 NT 
23e OMe i-Pr Me 1.34 ± 0.48 156 ± 17 NT 
18f H 2-thiophene H 1.03 ± 0.13 1823 ± 347 NT 
22f H 2-thiophene H 1.59 ± 0.56 900 ± 81 NT 
18g H Et H 7.18 ± 1.02 190 ± 13 NT 
22g H Et H 1.99 ± 0.48 107 ± 7.0 NT 
GZR (1)    0.21 ± 0.03 49.1 ± 1.6 30.3 ± 1.9 
NT: not tested 
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Table 3.2: Antiviral activity against wild-type HCV and drug resistant variants. 
 
Inhibitor R1 R2 R3 
Replicon EC50 (nM) 
WT R155K A156T D168A D168V 
2 OMe Et H 0.33 1.75 9.65 6.31 9.10 
19a OMe Et Me 0.43 1.80 4.52 4.97 6.42 
22a OMe Et H 0.14 2.08 11.8 3.60 11.9 
23a OMe Et Me 0.16 2.07 10.6 3.45 7.08 
18b OMe Me H 0.39 1.17 5.95 4.24 3.17 
19b OMe Me Me 0.30 0.80 1.57 2.37 1.60 
22b OMe Me H 0.11 0.89 2.88 2.63 4.32 
23b OMe Me Me 0.13 1.09 3.99 2.16 2.85 
18c OMe Cl H 0.16 0.44 16.2 1.42 0.73 
19c OMe Cl Me 0.18 0.40 8.86 1.07 0.49 
22c OMe Cl H 0.15 0.59 3.55 1.32 1.55 
23c OMe Cl Me 0.15 0.56 4.32 0.97 1.09 
18d OMe CF3 H 1.98 3.45 36.2 16.8 17.1 
19d OMe CF3 Me 1.52 2.30 20.5 8.64 8.31 
22d OMe CF3 H 4.86 7.97 117 15.1 24.0 
23d OMe CF3 Me 4.04 6.90 75.9 8.46 11.4 
18e OMe i-Pr H 1.43 5.02 25.7 15.3 23.7 
19e OMe i-Pr Me 1.86 4.14 21.2 11.9 18.1 
22e OMe i-Pr H 0.48 7.63 32.1 7.96 30.1 
23e OMe i-Pr Me 0.59 6.83 27.6 7.91 18.2 
18f H 2-thiophene H 0.98 21.7 256 111 193 
22f H 2-thiophene H 0.40 19.2 183 42.2 70.0 
18g H Et H 0.46 1.81 10.6 8.55 14.0 
22g H Et H 0.24 4.28 24.6 7.50 19.3 
GZR (1)                 0.14 1.89 238 9.69 5.41 
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Compound 1 showed sub-nanomolar inhibitory potency against WT NS3/4A 
protease and maintained nanomolar activity against drug resistant variant D168A 
and GT3a protease. Similarly, in replicon assays 1 exhibited an excellent potency 
profile with sub-nanomolar activity against WT HCV (EC50 = 0.14 nM) and low 
nanomolar activity against drug resistant variants R155K, D168A, and D168V. 
However, in line with previous reports,106 1 was highly susceptible to the A156T 
mutation (EC50 = 238 nM), losing over 1000-fold potency against this variant. 
Compared to 1, the P1–P3 macrocyclic analogue 2 exhibited lower inhibitory 
potency against WT protease and the D168A variant. Also, the inhibitory activity 
of 2 against the GT3a protease was considerably lower than that of 1. However, 
as we have previously shown,106 2 displayed a superior potency profile in 
replicon assays with sub-nanomolar activity against WT HCV (EC50 = 0.33 nM) 
and maintained single digit nanomolar potency against all drug-resistant variants 
tested. Notably, unlike 1, compound 2 maintained low nanomolar potency against 
the A156T variant (EC50 = 9.65 nM). Thus, with an improved resistance profile 
compared to 1, the P1–P3 macrocyclic analogue 2 is an attractive lead 
compound for further optimization. 
3.4.1 Modifications of P1’ and P4 Capping Groups  
Initial SAR efforts to optimize lead compound 2 focused on exploring changes 
at the P1’ position and N-terminal capping group. Recent SAR studies of diverse 
NS3/4A PIs indicate that replacement of the cyclopropylsulfonamide moiety at 
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the P1’ position with a slightly more hydrophobic 1-methylcyclopropylsulfonamide 
improves inhibitor potency in replicon assays.163,164 Moreover, changes at the P4 
position have been shown to significantly affect inhibitor potency against drug 
resistant variants, as these groups bind in close proximity to the pivotal drug 
resistance site Asp168.165 For carbamate-linked P4 capping groups, generally 
bulky hydrophobic moieties are preferred but the size of the group appears to be 
dependent on the heterocyclic moiety present at the P2 position.109 
First, replacing the cyclopropylsulfonamide at the P1’ position in 2 with 1-
methylcyclopropylsulfonamide provided the analogue 19a. Compared to the 
parent compound 2, 19a showed slightly better Ki values against WT, D168A and 
GT3a proteases and exhibited similar or slightly better antiviral potency against 
WT and drug resistant variants. Next, the tert-butyl P4 capping group in both 2 
and 19a was replaced with a larger cyclopentyl moiety, resulting in analogues 
22a and 23a. Unlike the change at the P1’ position, the P4 cyclopentyl 
modification provided mixed results. Compound 22a afforded a 2-fold increase in 
potency than 2 in biochemical assays against WT protease and a slight 
improvement against the D168A variant, but was equipotent to 2 against GT3a 
protease. Similarly, in replicon assays 22a exhibited 2-fold enhanced potency 
against WT HCV and D168A variant, but showed similar potency as 2 against the 
R155K and D168V variants. Compound 23a, with a 1-
methylcyclopropylsulfonamide moiety at the P1’ position and a cyclopentyl group 
at the P4 position, exhibited potency profile largely similar to 22a. Surprisingly, a 
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slight loss in potency was observed against the A156T variant for compounds 
with a cyclopentyl versus tert-butyl capping group. Overall, these minor 
modifications at the P1’ and N-terminal capping regions of inhibitor 2 were 
tolerated and provided analogues with improved potency profiles.    
3.4.2 SAR Exploration of P2 Quinoxaline 
Next, SARs at the P2 quinoxaline in compound 2 were explored. Efforts 
mainly focused on replacing the 3-position ethyl group with diverse functional 
groups with respect to size and electronic properties. Replacement of the ethyl 
group in 2 with a smaller methyl group provided analogue 18b. As expected, 
reducing the size of the hydrophobic group at this position resulted in improved 
potency profile. Compound 18b showed slightly enhanced potency against drug 
resistant variants in biochemical and antiviral assays, with a notable ~2-fold 
improvement against the D168V variant (EC50 = 3.17 nM). The introduction of 1-
methylcyclopropylsulfonamide moiety at the P1’ position afforded inhibitor 19b 
with protease inhibitory activity comparable to the parent compound 18b. 
However, similar to the 3-ethylquinoxaline analogue (19a), compound 19b 
demonstrated significant gain in potency in replicon assays. In fact, compared to 
2, 19b exhibited 2- to 6-fold enhancement in potency against drug resistant 
variants R155K (EC50 = 0.80 nM), A156T (EC50 = 1.57 nM), D168A (EC50 = 2.37 
nM), and D168V (EC50 = 1.6 nM). Replacement of the tert-butyl P4 capping in 
18b and 19b with a cyclopentyl group, providing 22b and 23b, resulted in an 
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increase in WT and D168A inhibitory activity as well as 2- to 3-fold increase in 
WT replicon potency. Unlike the corresponding 3-ethylquinoxaline analogues 
(22a and 23a), the 3-methyquinoxaline compounds 22b and 23b maintained the 
excellent potency profile observed for the corresponding tert-butyl analogues. 
Remarkably, with the exception of 18b (A156T EC50 = 5.95 nM), all compounds 
in the 3-methylquinoxaline series display exceptional potency profiles with EC50 
values below 5 nM against WT and clinically relevant drug resistant variants. 
To gain insights into the excellent potency profile observed for the 3-
methyquinoxaline series, we determined the X-ray crystal structure of inhibitor 
19b in complex with the WT NS3/4A protease at a resolution of 1.8 Å (Figure 
3.3, Table 3.3, PDB code: 5VOJ). The WT-19b complex structure was compared 
with the previously reported structures of compound 2 in complex with WT 
protease and the A156T variant (PDB codes: 5EPN and 5EPY).111 The two WT 
structures overlap very well, with only minor differences in the S1 and S2 
subsites because of modifications in the inhibitor structure. In the WT-2 crystal 
structure, the 3-ethyl group at the P2 quinoxaline makes hydrophobic interactions 
with the hydrocarbon portion of the Arg155 side-chain, while the methylene 
portion of this group interacts with the side-chain of Ala156. The smaller methyl 
group at this position in the WT-19b structure maintains hydrophobic interactions 
with Ala156, while minimizing chances of steric clash with a larger side-chain, 
such as in A156T.   
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Figure 3.3: Binding mode of 19b in the HCV NS3/4A protease active site.  
(a) X-ray crystal structure of WT1a HCV NS3/4A protease in complex with 
inhibitor 19b (b) and superposition of WT-2 and WT-19a complexes. The 
protease active site is shown as a surface with inhibitor 19b shown in orange and 
2 shown in blue. The catalytic triad is highlighted in yellow and drug resistance 
residues Arg155, Ala156, and Asp168 are shown as sticks. 
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Table 3.3: X-ray data collection and crystallographic refinement statistics. 
 WT1a-19b WT1a-18f 
PDB code 5VOJ 5VP9 
Resolution 1.80 Å 1.86 Å 
Space group P212121 P212121 
Molecules in AUa 1 1 
Cell dimensions   
a (Å) 55.4 54.8 
b (Å) 58.6 58.4 
c (Å) 59.9 60.4 
β (°) 90 90 
Completeness (%) 94.1 99.9 
Total reflections 120670 111301 
Unique reflections 17608 16852 
Average I/σ 7.8 15.7 
Redundancy 6.9 6.6 
Rsym (%)b 5.0 (15.9) 6.0 (31.7) 
RMSDc in    
Bond lengths (Å) 0.005 0.005 
Bond angles (°) 1.1 0.9 
Rfactor (%)d 16.0 16.8 
Rfree (%)e 19.3 20.8 
aAU, asymmetric unit. 
bRsym = Σ | I − <I>|/ Σ I, where I = observed intensity, <I> = average intensity over 
symmetry equivalent; values in parentheses are for the highest resolution shell. 
cRMSD, root mean square deviation. 
dRfactor = Σ || Fo| − |Fc||/ Σ|Fo|.   
eRfree was calculated from 5% of reflections, chosen randomly, which were 
omitted from the refinement process. 
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Unlike inhibitor 1, the P1–P3 macrocyclic analogues retain potency against 
the A156T variant. Comparison of the WT-2 and A156T-2 (PDB code: 5EPY) 
structures shows subtle changes in inhibitor interactions with the mutant 
protease.111 In the A156T-2 structure the P2 quinoxaline largely maintains 
interactions with the catalytic residues, but the ethyl group is shifted away from 
Arg155 side chain toward A156T. Moreover, to accommodate a larger Thr side-
chain, the Asp168 side chain adopts another conformation, moving away from 
Arg155. These changes underlie reduced inhibitor potency against the A156T 
variant, but unlike 1, inhibitor 2 is able to better accommodate these changes due 
to a flexible P2 moiety. The 3-methylquinoxaline analogues are more potent 
against the A156T variant than the corresponding 3-ethylquinoxaline compounds 
likely due the reduced interactions of the smaller methyl group with the Thr side-
chain. Replacing the methyl group with hydrogen at the 3-position of quinoxaline 
would further reduce interactions with the S2 subsite residues, but could result in 
a highly flexible P2 moiety, likely destabilizing interactions with the catalytic 
residues. Thus, a small hydrophobic group at the 3-position of P2 quinoxaline is 
preferred to maintain favorable interactions with Ala156 and avoid steric clashes 
with the Thr side-chain in the A156T variant. 
The improved potency profile of 3-methyquinoxaline compounds led to 
exploration of bioisosteric replacements of the 3-methyl group with varied size 
and electronic properties. To that end, analogues 18c and 19c bearing the 3-
chloro-7-methoxyquinoxaline at the P2 position were prepared. The protease 
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inhibitory potency profiles of these compounds were excellent and showed 
improvement against WT, D168A and GT3a over 2. These potency gains were 
not only maintained in replicon assays but were more significant, with the only 
exception of A156T variant. Both compounds 18c and 19c were more active than 
the corresponding 3-methylquinoxaline analogues (18b and 19b) with EC50 
values less than 1 nM against WT, R155K and D168V and less than 2 nM 
against the D168A variant, but experienced about 3- to 6-fold reduction in 
potency against the A156T variant. However, potency losses against the A156T 
variant were largely reversed when the P4 tert-butyl group in 18c and 19c was 
replaced with a larger cyclopentyl moiety to afford 22c and 23c. Similar to the 3-
methylquinoxaline compounds, the 3-chloroquinoxaline analogues displayed 
exceptional potency profiles with EC50 values of less than 5 nM against all drug 
resistant variants including A156T. These results clearly demonstrate that small 
hydrophobic groups with weak electron-donating properties at the 3-position of 
P2 quinoxaline can be replaced with weak electron-withdrawing groups without 
affecting the overall potency profile. 
Next, a larger and strongly electron-withdrawing trifluoromethyl moiety was 
explored at the 3-position of P2 quinoxaline, leading to inhibitors 18d and 19d. 
This modification, however, resulted in significant potency losses in both 
biochemical and replicon assays. Compound 18d was about 2- to 4-fold less 
active than 2 against WT protease and variants. Analogue 19d with the 1-
methylcyclopropylsulfonamide moiety at the P1’ position showed similar trends 
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when compared to the corresponding 19a. In line with biochemical data, both 
18d and 19d suffered 2- to 6-fold decrease in replicon potency against WT and 
drug resistant variants, though 19d maintained relatively good potency profile. In 
contrast to the results in previous series, the introduction of the larger cyclopentyl 
P4 capping group, as in 22d and 23d, was detrimental to replicon potency, 
particularly against the A156T variant. Moreover, compounds in the 3-
(trifluoromethyl)quinoxaline series were among the least active against the GT3a 
protease in biochemical assays. These results indicate that strong electron-
withdrawing groups at the 3-position of the P2 quinoxaline may be detrimental to 
potency. However, a recent SAR study indicates that PIs incorporating the 3-
(trifluoromethyl)quinoxaline can be optimized with modifications at the 7-position 
of quinoxaline in combination with changes at the P1–P3 macrocycle and P4 
capping group.166  
In the absence of a co-crystal structure, the lower inhibitory potencies of 
compounds in the 3-(trifluoromethyl)quinoxaline series against WT protease 
could not be explained by molecular modeling, which suggested a similar binding 
conformation of the P2 quinoxaline in 18d as observed for 2 (Figure 3.4A). 
Perhaps there are repulsive interactions between trifluoromethyl moiety and the 
side chain of Asp168, and/or the strong electron-withdrawing effect may weaken 
the overall interactions of the P2 quinoxaline with the catalytic residues. Potency 
losses against resistant variants may also result from the larger size of the 
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trifluoromethyl moiety, which is comparable to that of an ethyl group, though both 
have different topographical shapes.167 
To isolate the effects of larger size versus electronic properties on potency, 
inhibitors 18e and 19e with the larger isopropyl group at the 3-position of the P2 
quinoxaline were designed and evaluated. These compounds showed WT 
protease inhibitory activity similar to the corresponding 3-ethylquinoxaline 
analogues (2 and 19a), but experienced 2- to 4-fold reduced activity against the 
D168A variant. A broader reduction in potency was observed for both 18e and 
19e in replicon assays against WT and drug resistant variants. The cyclopentyl 
P4 group in analogues 22e and 23e slightly improved biochemical and replicon 
potency against WT and D168A variants, but was largely unfavorable to replicon 
potency against R155K and A156T variants. This trend is broadly similar to the 
results observed with the 3-(trifluoromethyl)quinoxaline series, indicating that 
both electronic properties and size of the group at the 3-position of P2 
quinoxaline are important for maintaining potency against drug resistant variants. 
Modeling indicated that compared to 2 the P2 quinoxaline moiety in 18e has to 
shift away from the catalytic triad in order to accommodate the larger isopropyl 
group thereby weakening critical stacking interactions with His57 (Figure 3.4B). 
Overall, SAR data from the 3-isopropyl- and 3-(trifluoromethyl)-quinoxaline series 
supports the hypothesis that large substituents at the 3-position of P2 quinoxaline 
have detrimental effect on inhibitor potency against drug resistant variants.  
 112 
 
 
Figure 3.4: Comparison of lead compound 2 with analogues (a) 18d, and (b) 
18e, modeled in the active site of WT HCV NS3/4A protease.  
Compound 2 is shown in salmon and modified inhibitors are in green. The 
catalytic triad is highlighted in yellow and drug resistance residues Arg155, 
Ala156, and Asp168 are in sticks. 
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These findings were further reinforced by the results obtained for the 3-
(thiophen-2-yl)quinoxaline analogues 18f and 22f. Based on molecular modeling, 
the large thiophene moiety in these compounds was expected to make extensive 
interactions with the residues Arg155 and Ala156, resulting in improved potency 
against WT protease. However, mutations at these positions as well as at 
Asp168 would cause significant potency losses, as these residues are crucial for 
efficient inhibitor binding. As expected, compound 18f (a previously reported 
NS3/4A PI incorrectly labeled as ABT-450)85,168 showed a 3-fold enhancement in 
WT biochemical potency but was dramatically less active against the D168A 
variant, losing over 1800-fold potency. Similarly, in replicon assays analogue 18f 
showed considerably reduced potency against all drug resistant variants with 
losses ranging from 20- to 250-fold compared to WT (Tables 3.4 and 3.5). The 
cyclopentyl P4 analogue 22f also experienced large potency losses against the 
variants, albeit to a lesser extent than 18f. Thus inhibitors with large groups at 
the 3-position of P2 quinoxaline are highly susceptible to mutations at residues 
Arg155, Ala156 and Asp168, leading to poor resistance profiles. 
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Table 3.4: Fold change in inhibitory activity against wild-type GT3 NS3/4A 
protease and drug resistant variants relative to WT 
 
Inhibitor R1 R2 R3 
Fold change relative to WT 
GT1a D168A Protease GT3a Protease 
2 OMe Et H 25 62 
19a OMe Et Me 30 94 
22a OMe Et H 42 170 
23a OMe Et Me 40 136 
18b OMe Me H 15 45 
19b OMe Me Me 14 33 
22b OMe Me H 34 158 
23b OMe Me Me 32 107 
18c OMe Cl H 37 63 
19c OMe Cl Me 70 48 
22c OMe Cl H 62 175 
23c OMe Cl Me 58 139 
18d OMe CF3 H 12 26 
19d OMe CF3 Me 20 40 
22d OMe CF3 H 15 100 
23d OMe CF3 Me 14 53 
18e OMe i-Pr H 56 NT 
19e OMe i-Pr Me 364 NT 
22e OMe i-Pr H 112 NT 
23e OMe i-Pr Me 116 NT 
18f H 2-thiophene H 1770 NT 
22f H 2-thiophene H 566 NT 
18g H Et H 26 NT 
22g H Et H 54 NT 
GZR (1)    234 144 
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Table 3.5: Fold change in antiviral activity against drug resistant variants relative 
to WT  
 
Inhibitor R1 R2 R3 
Replicon EC50 (nM) (Fold change) 
R155K A156T D168A D168V 
2 OMe Et H (5) (29) (19) (28) 
19a OMe Et Me (4) (11) (12) (15) 
22a OMe Et H (15) (84) (26) (85) 
23a OMe Et Me (13) (66) (22) (44) 
18b OMe Me H (3) (15) (11) (8) 
19b OMe Me Me (3) (5) (8) (5) 
22b OMe Me H (8) (26) (24) (39) 
23b OMe Me Me (8) (31) (17) (22) 
18c OMe Cl H (3) (101) (9) (5) 
19c OMe Cl Me (2) (49) (6) (3) 
22c OMe Cl H (4) (24) (9) (10) 
23c OMe Cl Me (4) (29) (6) (7) 
18d OMe CF3 H (2) (18) (8) (9) 
19d OMe CF3 Me (2) (13) (6) (5) 
22d OMe CF3 H (2) (24) (3) (5) 
23d OMe CF3 Me (2) (19) (2) (3) 
18e OMe i-Pr H (4) (18) (11) (17) 
19e OMe i-Pr Me (2) (11) (6) (10) 
22e OMe i-Pr H (16) (67) (17) (63) 
23e OMe i-Pr Me (12) (47) (13) (31) 
18f H 2-thiophene H (22) (261) (113) (197) 
22f H 2-thiophene H (48) (458) (106) (175) 
18g H Et H (4) (23) (19) (30) 
22g H Et H (18) (103) (31) (80) 
GZR (1)    (14) (1700) (69) (39) 
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The X-ray crystal structure of inhibitor 18f in complex with WT NS3/4A 
protease was determined at a resolution of 1.9 Å, providing insights into the 
binding modes of P2 quinoxaline with a larger thiophene substituent at the 3-
position (Figure 3.5, Table 3.3, PDB code: 5VP9). Comparison of the WT-18f 
and WT-2 crystal structures showed significant differences in the interactions of 
quinoxaline moieties with the catalytic triad and S2 subsite residues. As 
predicted, the quinoxaline moiety in WT-18f structure is shifted toward the active 
site to accommodate the larger thiophene substituent. The thiophene ring makes 
extensive interactions with residues in the S2 subsite, including cation-π 
interactions with Arg155, likely contributing to the improved potency against the 
WT protease. As this Arg155 conformation is stabilized by electrostatic 
interactions with Asp168, mutations at either residue would disrupt inhibitor 
binding by loss of direct interactions as well as indirect structural effects. In 
addition, the A156T mutation would result in a steric clash with the thiophene 
ring, as reflected in the antiviral data for this variant. These biochemical and 
structural findings are in line with previous studies that show inhibitors that are 
dependent on extensive interactions with the S2 subsite residues for potency are 
highly susceptible to mutations at residues Arg155, Ala156 and Asp168. 
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Figure 3.5: X-ray crystal structure of WT1a HCV NS3/4A protease in 
complex with inhibitor 18f (a) and superposition of WT-2 and WT-18f 
complexes (b).  
The protease active site is shown as a surface with inhibitor 18f shown in orange 
and 2 shown in blue. The catalytic triad is highlighted in yellow and drug 
resistance residues Arg155, Ala156, and Asp168 are shown as sticks. 
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As compounds 18f and 22f lacked the C-7 substituent at the P2 quinoxaline, 
analogues 18g and 22g were prepared to investigate the effect of this group on 
inhibitor potency. Compared to 2, analogue 18g experienced about 2-fold 
decrease in biochemical potency and only minor loss in replicon potency against 
WT and drug resistant variants. The P4 cyclopentyl analogue 22g resulted in 
about 2-fold reduced potency compared to the corresponding compound 22a. 
Thus removal of the C-7 methoxy group has minimal effect on inhibitor potency. 
The slightly reduced potency of 18g and 22g is likely due to the reduced 
hydrophobic interactions with the aromatic ring of Tyr56 and the methylene 
portion of His57 of the catalytic triad. In contrast, the observed potency losses 
against resistant variants for the 3-(thiophen-2-yl)quinoxaline compounds most 
likely result from loss of interactions of the 2-thiophene moiety with the S2 
subsite residues of the protease. 
3.4.3 Effects of P2 Substituent Size and Flexibility  
Taken together, our SAR results indicate that resistance profiles of compound 
2 and analogues are strongly influenced by the substituent at the 3-position of P2 
quinoxaline and N-terminal capping group. While all PIs showed reduced potency 
against drug resistance variants in both enzyme inhibition and replicon assays, 
fold potency losses varied significantly depending on the substituents at the 3-
position of P2 quinoxaline. To evaluate susceptibility to the clinically important 
D168A variant, to which all current NS3/4A PIs are susceptible, potencies were 
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normalized to WT for PIs with the same P4 capping groups (Figure 3.6). Fold 
changes in Ki against the D168A protease variant for PIs with the same P1’ and 
P4 capping groups largely trended with the size of the substituent at the 3-
position of P2 quinoxaline, with the exception of trifluoromethyl compounds. 
Losses in potency were significantly higher for compounds with the larger 2-
thiophene substituent at the P2 quinoxaline. These results strongly support using 
the substrate envelope model to reduce direct inhibitor interactions in the S2 
subsite, thereby reducing inhibitor susceptibility to drug resistance. 
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Figure 3.6: Resistance profiles of protease inhibitors in enzyme inhibition 
and antiviral assays for PIs with (a) tert-butyl and (b) cyclopentyl P4 
capping groups.  
Enzyme inhibitory (blue bars) and antiviral (orange bars) activities against the 
D168A variant were normalized with respect to the wild-type NS3/4A protease 
domain or wild-type HCV replicon. *Indicates value higher than 1000.  
*
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As we and others have shown,89,90,109,123 the reduced potencies of NS3/4A 
PIs against drug resistant variants R155K, A156T, and D168A/V mainly result 
from disruption of the electrostatic interactions between Arg155 and Asp168. 
Compared to 1, compound 2 and most analogues incorporating flexible P2 
quinoxaline showed lower fold-changes in potency against these variants 
(Tables 3.4 and 3.5). In these P1–P3 macrocyclic PIs the conformational 
flexibility of the P2 allows this moiety to adapt to the structural changes caused 
by mutations at Arg155, Ala156 and Asp168, resulting in better resistance 
profiles. Potency losses were higher for compound 1 because constraint imposed 
by the macrocycle does not allow the P2 moiety to adapt to the structural 
changes resulting from these mutations. Compound 1 and similar P2–P4 
macrocyclic PIs, such as voxilaprevir and glecaprevir, are likely to be more 
susceptible to mutations that cause significant structural changes in the protease 
active site. However, the P1–P3 macrocyclic compounds reported here, as well 
as those reported in patent literature that incorporate similar flexible P2 
quinoxaline moieties,169 are likely to be more effective against clinically relevant 
drug resistant variants. More broadly, combining the substrate envelope model 
with optimal conformational flexibility provides a rational approach to design 
NS3/4A PIs with improved resistance profiles. 
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3.5 Conclusions 
Drug resistance is a major problem across all DAA classes targeting HCV. As 
new therapies are developed the potential for drug resistance must be minimized 
at the outset of inhibitor design. The substrate envelope model provides a 
rational approach to design robust NS3/4A PIs with improved resistance profiles. 
Our SAR findings support the hypothesis that reducing PI interactions with 
residues in the S2 subsite leads to inhibitors with exceptional potency and 
resistance profiles. Specifically, the P1–P3 macrocyclic inhibitors incorporating 
flexible P2 quinoxaline moieties bearing small hydrophobic groups at the 3-
position maintain excellent potency in both enzymatic and antiviral assays 
against drug resistant variants. While these inhibitors protrude from the substrate 
envelope, they leverage interactions with the essential catalytic triad residues 
and avoid direct contacts with residues that can mutate to confer resistance. 
Moreover, conformational flexibility at the P2 moiety is essential to efficiently 
accommodate structural changes due to mutations in the S2 pocket in order to 
avoid resistance. These insights provide strategies for iterative rounds of inhibitor 
design with the paradigm that designing inhibitors with flexible P2 quinoxalines, 
leveraging evolutionarily constrained areas in the protease active site and 
expanding into the substrate envelope may provide inhibitors that are robust 
against drug resistant variants. 
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3.6 Methods 
3.6.1 General 
All reactions were performed in oven-dried round bottomed or modified 
Schlenk flasks fitted with rubber septa under argon atmosphere, unless 
otherwise noted. All reagents and solvents, including anhydrous solvents, were 
purchased from commercial sources and used as received. Flash column 
chromatography was performed using silica gel (230–400 mesh, EMD Millipore). 
Thin-layer chromatography (TLC) was performed using silica gel (60 F-254) 
coated aluminum plates (EMD Millipore), and spots were visualized by exposure 
to ultraviolet light (UV), exposure to iodine adsorbed on silica gel, and/ or 
exposure to an acidic solution of p-anisaldehyde (anisaldehyde) followed by brief 
heating. 1H NMR and 13C NMR spectra were acquired on Varian Mercury 400 
MHz and Bruker Avance III HD 500 MHz NMR instruments. Chemical shifts are 
reported in ppm (δ scale) with the residual solvent signal used as reference and 
coupling constant (J) values are reported in hertz (Hz). Data are presented as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, dd = doublet of 
doublet, t = triplet, q = quartet, m = multiplet, br s = broad singlet), coupling 
constant in Hz, and integration. High-resolution mass spectra (HRMS) were 
recorded on a Thermo Scientific Orbitrap Velos Pro mass spectrometer coupled 
with a Thermo Scientific Accela 1250 UPLC and an autosampler using 
electrospray ionization (ESI) in the positive mode. The purity of final compounds 
was determined by analytical HPLC and was found to be ≥95% pure. HPLC was 
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performed on a Waters Alliance 2690 system equipped with a Waters 2996 
photodiode array detector and an autosampler under the following conditions: 
column, Phenomenex Luna-2 RP-C18 (5 µm, 4.6 × 250 mm, 120 Å, Torrance, 
CA); solvent A, H2O containing 0.1% formic acid (FA), solvent B, CH3CN 
containing 0.1% FA; gradient, 50% B to 100% B over 15 min followed by 100% B 
over 5 min; injection volume, 10 µL; flow rate, 1 mL/ min. Retention times and 
purity data for each target compound are provided in the experimental section. 
(For additional synthesis of macrocyclic final compounds and intermediates 
please see Appendix C).  
3.6.2 Typical procedures for the synthesis of protease 
inhibitors using Method A: 
 
1-(tert-Butyl) 2-methyl (2S,4R)-4-((3-ethyl-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidine-1,2-dicarboxylate (9a). A solution of 3-ethyl-7-
methoxyquinoxalin-2-one 8a (3.0 g, 14.7 mmol) in anhydrous NMP (45 mL) was 
treated with Cs2CO3 (7.40 g, 22.7 mmol). After stirring the reaction mixture at 
room temperature for 15 min, proline derivative 3 (6.20 g, 13.3 mmol) was added 
in one portion. The reaction mixture was heated to 55 °C, stirred for 4 h, and then 
another portion of proline derivative 3 (0.48 g, 1.0 mmol) was added. The 
resulting reaction mixture was stirred at 55 °C for an additional 2 h, cooled to 
room temperature, quenched with aqueous 1 N HCl solution (150 mL), and 
extracted with EtOAc (300 mL). The organic fraction was washed successively 
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with saturated aqueous NaHCO3 and NaCl (150 mL each), dried (Na2SO4), 
filtered, and evaporated under reduced pressure. The residue was purified by 
flash column chromatography using 15–30% EtOAc/hexanes as the eluent to 
provide 9a (5.50 g, 87%) as a white foamy solid. 1H NMR (400 MHz, CDCl3) 
(mixture of rotamers, major rotamer) δ 7.85 (d, J = 9.0 Hz, 1 H), 7.18 (m, 1H), 
7.11 (d, J = 2.8 Hz, 1 H), 5.73 (br s, 1 H), 4.47 (t, J = 8.0 Hz, 1 H), 3.98–3.86 (m, 
5 H), 3.78 (s, 3 H), 2.92 (q, J = 7.2 Hz, 2 H), 2.68–2.60 (m, 1 H), 2.43–2.36 (m, 1 
H), 1.43 (s, 9 H), 1.31 (t, J = 7.2 Hz, 3 H) ppm; 13C NMR (100 MHz, CDCl3) δ 
173.56, 160.59, 155.38, 154.02, 148.95, 141.26, 134.12, 129.07, 119.02, 106.11, 
80.76, 73.81, 58.43, 55.93, 52.73, 52.40, 36.88, 28.47, 26.68, 11.97 ppm; HRMS 
(ESI) m/z: [M + H]+ calcd for C22H30N3O6, 432.2129; found 432.2135. 
1-(tert-Butyl) 2-methyl (2S,4R)-4-((7-methoxy-3-
(trifluoromethyl)quinoxalin-2-yl)oxy)pyrrolidine-1,2-dicarboxylate (9d). The 
same procedure was used as described above for compound 9a. 7-methoxy-3-
(trifluoromethyl)quinoxalin-2(1H)-one 8d (4.76 g, 19.5 mmol) in NMP (65 mL) 
was treated with Cs2CO3 (9.80 g, 30.0 mmol) and proline derivative 3 (9.0 g, 19.3 
mmol) to provide 9d (6.50 g, 71%) as a pale yellow foamy solid. 1H NMR (500 
MHz, CDCl3) (mixture of rotamers, major rotamer) δ 7.77 (d, J = 9.0 Hz, 1 H), 
7.48–7.43 (m, 2 H), 5.76 (br s, 1 H), 4.50 (t, J = 8.0 Hz, 1 H), 3.97–3.91 (m, 5 H), 
3.78 (s, 3 H), 2.69–2.64 (m, 1 H), 2.41–2.34 (m, 1 H), 1.42 (s, 9 H) ppm; 13C 
NMR (125 MHz, CDCl3) δ 173.43, 159.58, 153.98, 152.11, 138.39, 137.22, 
127.99, 125.73, 120.70 (q, J = 273.4 Hz), 107.64, 80.69, 74.62, 58.27, 56.02, 
 126 
52.32, 52.11, 36.70, 28.34 ppm; 19F NMR (470 MHz, CDCl3); −67.73 ppm; HRMS 
(ESI) m/z: [M + H]+ calcd for C21H25F3N3O6, 472.1690; found 472.1689. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)non-8-enoyl)-4-((3-
ethyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (12a). A 
solution of ester 9a (4.80 g, 11.1 mmol) in anhydrous CH2Cl2 (30 mL) was treated 
with a solution of 4 N HCl in 1,4-dioxane (30 mL). After stirring the reaction 
mixture at room temperature for 3 h, solvents were evaporated under reduced 
pressure, and the residue was dried under high vacuum. The pale yellow solid 
was triturated with diethyl ether (3 × 30 mL) and dried under high vacuum to yield 
the amine salt 10a (4.0 g, 98%) as an off-white powder. 
A mixture of amine salt 10a (4.0 g, 10.9 mmol) and (S)-2-((tert-
butoxycarbonyl)amino)non-8-enoic acid 11 (3.0 g, 11.1 mmol) in anhydrous DMF 
(60 mL) was treated with DIEA (7.30 mL, 44.2 mmol) and HATU (6.35 g, 16.7 
mmol). The resulting reaction mixture was stirred at room temperature for 4 h, 
then diluted with EtOAc (400 mL), and washed successively with aqueous 0.5 N 
HCl, saturated aqueous NaHCO3, and saturated aqueous NaCl (250 mL each). 
The organic portion was dried (Na2SO4), filtered, and evaporated under reduced 
pressure. The residue was purified by flash chromatography using 20–30% 
EtOAc/hexanes as the eluent to provide 12a (5.50 g, 86%) as a white foamy 
solid. 1H NMR (400 MHz, CDCl3) (mixture of rotamers, major rotamer) δ 7.86 (d, 
J = 8.8 Hz, 1 H), 7.20 (dd, J = 9.2, 2.8 Hz, 1 H), 7.12 (d, J = 2.8 Hz, 1 H), 5.87–
5.75 (m, 2 H), 5.20 (d, J = 8.4 Hz, 1 H), 5.02–4.92 (m, 2 H), 4.73 (t, J = 8.4 Hz, 1 
 127 
H), 4.38 (q, J = 7.2 Hz, 1 H), 4.17 (d, J = 12.0 Hz, 1 H), 4.06 (dd, J = 11.6, 4.4 
Hz, 1 H), 3.94 (s, 3 H), 3.78 (s, 3 H), 2.90 (q, J = 7.6 Hz, 2 H), 2.69–2.64 (m, 1 
H), 2.41–2.34 (m, 1 H), 2.05 (app q, J = 6.8 Hz, 2 H), 1.82–1.74 (m, 1 H), 1.63–
1.56 (m, 1 H), 1.45–1.25 (m, 18 H) ppm; 13C NMR (100 MHz, CDCl3) δ 172.34, 
171.96, 160.61, 155.61, 155.13, 148.95, 141.08, 139.18, 129.22, 119.08, 114.58, 
106.14, 79.84, 74.48, 58.19, 55.91, 52.88, 52.67, 52.05, 35.16, 33.88, 32.88, 
29.14, 28.96, 28.46, 26.52, 24.92, 11.86 ppm; HRMS (ESI) m/z: [M + H]+ calcd 
for C31H45N4O7 585.3283; found 585.3286. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)non-8-enoyl)-4-((7-
methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate 
(12d). The same procedure was used as described above for compound 12a. 
Compound 9d (6.0 g, 12.7 mmol) was treated with 4 N HCl (40 mL) to afford 
amine salt 10d (5.10 g, 12.5 mmol), which was coupled with acid 11 (3.80 g, 14.0 
mmol) using DIEA (9.25 mL, 56.0 mmol) and HATU (7.60 g, 20.0 mmol) to 
provide 12d (6.40 g, 81%) as a pale yellow foamy solid. 1H NMR (500 MHz, 
CDCl3) (mixture of rotamers, major rotamer) δ 7.78 (d, J = 9.0 Hz, 1 H), 7.48 (dd, 
J = 9.0, 2.5 Hz, 1 H), 7.44 (d, J = 2.5 Hz, 1 H), 5.86 (br s, 1 H), 5.84–5.78 (m, 1 
H), 5.18 (d, J = 9.0 Hz, 1 H), 5.01–4.92 (m, 2 H), 4.75 (t, J = 8.0 Hz, 1 H), 4.35 
(q, J = 7.5 Hz, 1 H), 4.19 (d, J = 12.0 Hz, 1 H), 4.08 (dd, J = 11.5, 4.5 Hz, 1 H), 
3.95 (s, 3 H), 3.78 (s, 3 H), 2.70–2.65 (m, 1 H), 2.41–2.35 (m, 1 H), 2.04 (app q, 
J = 7.0 Hz, 2 H), 1.80–1.75 (m, 1 H), 1.60–1.54 (m, 1 H), 1.45–1.28 (m, 15 H) 
ppm; 13C NMR (125 MHz, CDCl3) δ 172.10, 171.60, 159.99, 155.37, 151.78, 
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138.98, 138.41, 136.93, 134.40 (q, J = 36.3 Hz), 127.85, 125.66, 120.53 (q, J = 
273.4 Hz), 114.33, 107.54, 79.58, 75.05, 57.83, 55.91, 52.44, 52.33, 51.75, 
34.77, 33.65, 32.70, 28.91, 28.73, 28.18, 24.70 ppm; 19F NMR (470 MHz, 
CDCl3); −67.73 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C30H40F3N4O7, 
625.2844; found 625.2844. 
tert-Butyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-
2-vinylcyclopropyl)carbamoyl)-4-((3-ethyl-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate (16a). A solution of 
ester 12a (5.86 g, 10.0 mmol) in THF-H2O mixture (1:1, 140 mL) was treated with 
LiOH.H2O (1.40 g, 33.4 mmol). The resulting reaction mixture was stirred at room 
temperature for 24 h. The reaction mixture was cooled to ~5 °C, acidified to a pH 
of 2.0 by slow addition of aqueous 0.25 N HCl (~ 200 mL), and extracted with 
EtOAc (2 × 400 mL). The organic portions were washed separately with 
saturated aqueous NaCl (200 ml), dried (Na2SO4), filtered, and evaporated under 
reduced pressure. The gummy residue was dissolved in CHCl3 (50 mL), 
concentrated under reduced pressure, and the residue was dried under high 
vacuum overnight to yield the acid 13a (5.70 g, 100%) as a white foamy solid. 
A mixture of acid 13a (2.10 g, 3.7 mmol) and amine salt 14162 (1.20 g, 4.5 
mmol) in anhydrous DMF (35 mL) was treated with DIEA (2.43 mL, 14.7 mmol) 
and HATU (2.1 g, 5.5 mmol). The resulting reaction mixture was stirred at room 
temperature for 2.5 h, then diluted with EtOAc (300 mL) and washed 
successively with aqueous 0.5 N HCl, saturated aqueous NaHCO3, and 
 129 
saturated aqueous NaCl (200 mL each). The organic portion was dried (Na2SO4), 
filtered, and evaporated under reduced pressure. The residue was purified by 
flash chromatography using 50–70% EtOAc/hexanes as the eluent to provide the 
bis-olefin compound 16a (2.50 g, 86%) as a white solid. 1H NMR (400 MHz, 
CDCl3) δ 10.24 (s, 1 H), 7.84 (d, J = 8.8 Hz, 1 H), 7.18 (dd, J = 8.8, 2.4 Hz, 1 H), 
7.13 (d, J = 2.8 Hz, 1 H), 7.04 (s, 1 H), 5.91 (br s, 1 H), 5.85–5.73 (m, 2 H), 5.32 
(d, J = 8.4 Hz, 1 H), 5.27 (d, J = 17.2 Hz, 1 H), 5.14 (d, J = 11.2 Hz, 1 H), 5.01–
4.90 (m, 2 H), 4.47 (t, J = 7.6 Hz, 1 H), 4.38–4.33 (m, 1 H), 4.20 (d, J = 11.6 Hz, 
1 H), 4.02 (dd, J = 11.2, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.96–2.84 (m, 3 H), 2.56–
2.51 (m, 2 H), 2.11 (q, J = 8.8 Hz, 1 H), 2.05–1.99 (m, 3 H), 1.74–1.54 (m, 2 H), 
1.47–1.10 (m, 21 H), 1.08–1.03 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 
174.09, 172.58, 168.69, 160.54, 155.89, 154.99, 148.88, 140.95, 139.07, 134.69, 
132.71, 129.45, 119.02, 118.77, 114.67, 106.13, 80.0, 74.66, 60.61, 55.91, 
53.42, 52.62, 41.83, 35.46, 34.47, 33.89, 32.40, 31.39, 28.98, 28.89, 28.47, 
26.68, 25.47, 23.83, 11.85, 6.68, 6.26 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C39H55N6O9S, 783.3746; found 783.3734. 
tert-Butyl ((S)-1-((2S,4R)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate 
(17a). The same procedure was used as described above for compound 16a. 
Acid 13a (1.50 g, 2.6 mmol) was coupled with amine salt 15163 (0.90 g, 3.2 mmol) 
using DIEA (1.75 mL, 10.6 mmol) and HATU (1.50 g, 3.9 mmol) to provide the 
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bis-olefin compound 17a (1.75 g, 84%) as a white solid. 1H NMR (400 MHz, 
CDCl3) δ 10.02 (s, 1 H), 7.84 (d, J = 9.2 Hz, 1 H), 7.19 (dd, J = 8.8, 2.8 Hz, 1 H), 
7.13 (d, J = 2.8 Hz, 1 H), 7.06 (s, 1 H), 5.90 (br s, 1 H), 5.83–5.73 (m, 2 H), 5.37 
(d, J = 9.2 Hz, 1 H), 5.27 (d, J = 17.2 Hz, 1 H), 5.14 (d, J = 10.8 Hz, 1 H), 5.98 
(dd, J = 17.2, 1.6 Hz, 1 H), 4.92 (dd, J = 10.4, 1.2 Hz, 1 H), 4.48 (t, J = 8.0 Hz, 1 
H), 4.39–4.33 (m, 1 H), 4.16 (d, J = 12.0 Hz, 1 H), 4.02 (dd, J = 11.6, 4.0 Hz, 1 
H), 3.94 (s, 3 H), 2.89 (q, J = 7.6 Hz, 2 H), 2.57–2.50 (m, 2 H), 2.12 (q, J = 8.8 
Hz, 1 H), 2.05–1.99 (m, 3 H), 1.75–1.58 (m, 4 H), 1.49 (s, 3 H), 1.45–1.18 (m, 19 
H), 0.93–0.79 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 173.79, 172.41, 
167.51, 160.31, 155.71, 154.76, 148.63, 140.73, 138.85, 134.41, 132.60, 129.18, 
118.80, 118.54, 114.41, 105.89, 79.74, 74.42, 60.36, 55.68, 53.17, 52.43, 41.71, 
36.56, 35.23, 34.22, 33.64, 32.19, 28.70, 28.67, 28.25, 26.43, 25.35, 23.49, 
18.37, 14.27, 13.29, 11.64 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C40H57N6O9S, 797.3902; found 797.3887. 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-14a-
((cyclopropylsulfonyl)carbamoyl)-2-((3-ethyl-7-methoxyquinoxalin-2-
yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (2). A degassed solution of bis-olefin 16a (1.40 g, 1.8 mmol) in 
1,2-DCE (300 mL) was heated to 50 °C under argon, then Zhan 1b catalyst 
(0.150 g, 0.20 mmol) was added in two portions over 10 min. The resulting 
reaction mixture was heated to 70 °C and stirred for 6 h. The reaction mixture 
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was cooled to room temperature and concentrated under reduced pressure. The 
residue was purified by flash chromatography using 50–80% EtOAc/hexanes as 
the eluent to yield the P1–P3 macrocyclic product 2 (0.72 g, 53%) as an off-white 
solid. 1H NMR (400 MHz, CDCl3) δ 10.28 (s, 1 H), 7.84 (d, J = 9.6 Hz, 1 H), 7.20–
7.15 (m, 2 H), 6.91 (s, 1 H), 5.90 (br s, 1 H), 5.69 (q, J = 8.8 Hz, 1 H), 5.14 (d, J = 
7.6 Hz, 1 H), 4.96 (t, J = 9.2 Hz, 1 H), 4.59 (t, J = 7.6 Hz, 1 H), 4.49 (d, J = 11.6 
Hz, 1 H), 4.30–4.24 (m, 1 H), 4.02 (dd, J = 10.8, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.94–
2.85 (m, 3 H), 2.70–2.51 (m, 3 H), 2.31 (q, J = 8.8 Hz, 1 H), 1.93–1.64 (m, 2 H), 
1.60–1.05 (m, 24 H), 0.95–0.89 (m, 1 H) ppm; 13C NMR (100 MHz, CDCl3) δ 
177.15, 173.28, 168.02, 160.29, 155.00, 154.90, 148.66, 140.88, 136.31, 134.28, 
128.90, 124.47, 118.82, 105.91, 79.84, 74.68, 59.45, 55.72, 53.08, 51.92, 44.57, 
34.65, 32.81, 31.01, 29.70, 28.14, 27.11, 27.16, 26.31, 26.06, 22.16, 20.92, 
11.56, 6.67, 6.12 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C37H51N6O9S, 
755.3433; found 755.3410. Anal. HPLC: tR 14.23 min, purity 97%. 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-2-((3-ethyl-7-methoxyquinoxalin-2-
yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (19a). The same procedure was used as described above for 
compound 2. Bis-olefin 17a (1.45 g, 1.8 mmol) was treated with Zhan 1b catalyst 
(0.150 g, 0.20 mmol) in 1,2-DCE (300 mL) to afford the P1–P3 macrocyclic 
product 19a (1.0 g, 71%) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 
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10.16 (s, 1 H), 7.82 (d, J = 10.0 Hz, 1 H), 7.18–7.15 (m, 2 H), 6.94 (s, 1 H), 5.90 
(br s, 1 H), 5.69 (q, J = 9.2 Hz, 1 H), 5.16 (d, J = 8.0 Hz, 1 H), 4.99 (t, J = 9.2 Hz, 
1 H), 4.59 (t, J = 8.0 Hz, 1 H), 4.49 (d, J = 11.6 Hz, 1 H), 4.30–4.25 (m, 1 H), 4.04 
(dd, J = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.87 (q, J = 7.6 Hz, 2 H), 2.70–2.51 (m, 
3 H), 2.33 (q, J = 8.0 Hz, 1 H), 1.92–1.68 (m, 4 H), 1.60–1.15 (m, 24 H), 0.85–
0.78 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 177.19, 173.24, 167.0, 160.23, 
154.99, 154.88, 148.73, 140.84, 136.26, 134.25, 129.03, 124.89, 118.72, 105.92, 
79.84, 74.67, 59.48, 55.72, 53.11, 51.92, 44.71, 36.43, 34.68, 32.80, 29.62, 
28.14, 27.09, 26.38, 26.12, 22.19, 20.93, 18.17, 14.51, 12.50, 11.54 ppm; HRMS 
(ESI) m/z: [M + H]+ calcd for C38H53N6O9S, 769.3589; found 769.3561. Anal. 
HPLC: tR 15.01 min, purity 99%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-14a-
((cyclopropylsulfonyl)carbamoyl)-2-((3-ethyl-7-methoxyquinoxalin-2-
yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (22a). Compound 2 (0.40 g, 0.53 mmol) was treated with a 
solution of 4 N HCl in 1,4-dioxane (10 mL). The reaction mixture was stirred at 
room temperature for 3 h, then concentrated under reduced pressure, and the 
residue was dried under high vacuum. The off-white solid was triturated with 
diethyl ether (3 × 10 mL) and dried under high vacuum to yield the amine salt 20a 
(0.37 g, 100%) as a white powder. 
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A solution of the above amine salt 20a (0.37 g, 0.53 mmol) in anhydrous 
CH3CN (15 mL) was treated with DIEA (0.35 mL, 2.1 mmol) and N-
(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol). The reaction 
mixture was stirred at room temperature for 36 h, then concentrated under 
reduced pressure and dried under high vacuum. The residue was purified by 
flash chromatography using 50–90% EtOAc/hexanes as the eluent to provide the 
target compound 22a (0.32 g, 79%) as a white solid. 1H NMR (400 MHz, CDCl3) 
δ 10.29 (s, 1 H), 7.83 (d, J = 9.6 Hz, 1 H), 7.21–7.16 (m, 2 H), 6.94 (s, 1 H), 5.93 
(br s, 1 H), 5.70 (q, J = 8.8 Hz, 1 H), 5.26 (d, J = 8.0 Hz, 1 H), 4.96 (t, J = 8.4 Hz, 
1 H), 4.86–4.82 (m, 1 H), 4.60 (t, J = 7.6 Hz, 1 H), 4.45 (d, J = 11.2 Hz, 1 H), 
4.34–4.28 (m, 1 H), 4.03 (dd, J = 11.2, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.93–2.85 (m, 
3 H), 2.70–2.48 (m, 3 H), 2.30 (q, J = 8.8 Hz, 1 H), 1.93–1.23 (m, 23 H), 1.15–
1.06 (m, 2 H), 0.96–0.88 (m, 1 H) ppm; 13C NMR (100 MHz, CDCl3) δ 177.18, 
173.03, 168.04, 160.28, 155.65, 154.93, 148.78, 140.90, 136.27, 134.20, 128.92, 
124.46, 118.80, 105.92, 77.87, 74.55, 59.47, 55.72, 53.01, 52.17, 44.54, 34.58, 
32.72, 32.63, 32.59, 31.01, 29.70, 27.14, 27.05, 26.40, 26.05, 23.56, 22.16, 
20.90, 11.61, 6.67, 6.12 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C38H51N6O9S, 
767.3433; found 767.3408. Anal. HPLC: tR 14.50 min, purity 98%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-2-((3-ethyl-7-methoxyquinoxalin-
2-yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
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yl)carbamate (23a). The same procedure was used as described above for 
compound 22a. Compound 19a (0.40 g, 0.52 mmol) was treated with 4 N HCl in 
1,4-dioxane (10 mL) to yield the amine salt 21a, which was treated with DIEA 
(0.35 mL, 2.1 mmol) and N-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 
0.66 mmol) to provide the target compound 23a (0.30 g, 74%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 10.17 (s, 1 H), 7.81 (d, J = 9.6 Hz, 1 H), 7.21–7.16 
(m, 2 H), 6.93 (s, 1 H), 5.92 (br s, 1 H), 5.70 (q, J = 9.2 Hz, 1 H), 5.26 (d, J = 7.6 
Hz, 1 H), 4.99 (t, J = 9.6 Hz, 1 H), 4.86–4.81 (m, 1 H), 4.59 (t, J = 7.6 Hz, 1 H), 
4.45 (d, J = 11.2 Hz, 1 H), 4.34–4.28 (m, 1 H), 4.04 (dd, J = 11.6, 4.0 Hz, 1 H), 
3.94 (s, 3 H), 2.87 (q, J = 7.2 Hz, 2 H), 2.70–2.48 (m, 3 H), 2.32 (q, J = 8.8 Hz, 1 
H), 1.92–1.23 (m, 27 H), 0.85–0.78 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 
177.21, 172.99, 166.98, 160.22, 155.63, 154.90, 148.84, 140.85, 136.22, 134.36, 
129.05, 124.88, 118.70, 105.93, 77.86, 74.54, 59.51, 55.71, 53.05, 52.16, 44.70, 
36.43, 34.61, 32.72, 32.64, 32.58, 29.63, 27.13, 27.06, 26.47, 26.12, 23.56, 
22.18, 20.94, 18.17, 14.49, 12.50, 11.59 ppm; HRMS (ESI) m/z: [M + H]+ calcd 
for C39H53N6O9S, 781.3589; found 781.3561. Anal. HPLC: tR 15.25 min, purity 
99%. 
3.6.3 Typical procedures for the synthesis of protease 
inhibitors using Method B: 
 
Ethyl (1R,2S)-1-((2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)non-8-
enoyl)-4-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)pyrrolidine-2-
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carboxamido)-2-vinylcyclopropane-1-carboxylate (25d). A solution of ester 
12d (6.40 g, 10.25 mmol) in THF-H2O (1:1 mixture, 140 mL) was treated with 
LiOH.H2O (1.38 g, 32.0 mmol). The resulting reaction mixture was stirred at room 
temperature for 24 h, then cooled to ~5 °C, acidified to a pH of 2.0 by slow 
addition of aqueous 0.25 N HCl (~ 200 mL), and extracted with EtOAc (2 × 500 
mL). The organic portions were washed separately with saturated aqueous NaCl 
(250 ml), dried (Na2SO4), filtered, and evaporated under reduced pressure. The 
gummy residue was dissolved in CHCl3 (50 mL), concentrated under reduced 
pressure, and the residue was dried under high vacuum to yield the acid 13d 
(6.12 g, 98%) as a pale yellow foamy solid. 
A solution of acid 13d (6.12 g, 10.0 mmol) and amine salt 24 (2.50 g, 13.0 
mmol) in anhydrous CH2Cl2 (100 mL) was treated with DIEA (9.10 mL, 55.0 
mmol), HATU (5.30 g, 14.0 mmol) and DMAP (0.60 g, 4.9 mmol). The resulting 
reaction mixture was stirred at room temperature for 14 h, then diluted with 
EtOAc (500 mL), and washed successively with aqueous 1.0 N HCl, saturated 
aqueous NaHCO3, and saturated aqueous NaCl (250 mL each). The organic 
portion was dried (Na2SO4), filtered, and evaporated under reduced pressure. 
The residue was purified by flash chromatography using 25–35% EtOAc/hexanes 
as the eluent to provide the bis-olefin compound 25d (6.54 g, 87%) as a pale 
yellow foamy solid. 1H NMR (500 MHz, CDCl3) (mixture of rotamers, major 
rotamer) δ 7.78 (d, J = 9.2 Hz, 1 H), 7.53 (br s, 1 H), 7.47 (dd, J = 9.2, 2.8 Hz, 1 
H), 7.43 (d, J = 2.4 Hz, 1 H), 5.88 (br s, 1 H), 5.81–5.70 (m, 2 H), 5.30 (dd, J = 
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16.8, 0.8 Hz, 1 H), 5.14–5.10 (m, 2 H), 5.01–4.89 (m, 2 H), 4.79 (dd, J = 14.0, 5.6 
Hz, 1 H), 4.35–4.29 (m, 1 H), 4.21–4.08 (m, 3 H), 3.94 (s, 3 H), 2.90–2.82 (m, 1 
H), 2.48–2.38 (m, 1 H), 2.16 (q, J = 9.0 Hz, 1 H), 2.04–1.98 (m, 2 H), 1.86 (dd, J 
= 8.0, 5.2 Hz, 1 H), 1.66–1.52 (m, 2 H), 1.46 (dd, J = 9.6, 5.6 Hz, 1 H), 1.43–1.21 
(m, 19 H) ppm; 13C NMR (125 MHz, CDCl3) δ 173.02, 171.00, 169.87, 159.62, 
155.52, 152.03, 138.92, 138.48, 137.16, 133.66, 128.02, 125.73, 120.72 (q, J = 
273.6 Hz), 118.08, 114.52, 107.66, 79.98, 75.26, 61.40, 58.41, 56.02, 52.58, 
52.43, 40.14, 33.89, 33.77, 32.76, 32.62, 28.97, 28.78, 28.31, 25.18, 23.11, 
14.48 ppm; 19F NMR (470 MHz, CDCl3); −67.77 ppm; HRMS (ESI) m/z: [M + H]+ 
calcd for C37H49F3N5O8, 748.3528; found 748.3514. 
Ethyl (2R,6S,13aS,14aR,16aS,Z)-6-((tert-butoxycarbonyl)amino)-2-((7-
methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)-5,16-dioxo-
1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-
tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-
14a(5H)-carboxylate (26d). A degassed solution of bis-olefin 25d (1.50 g, 2.0 
mmol) in 1,2-DCE (300 mL) was heated to 50 °C under argon, then Zhan 1b 
catalyst (0.150 g, 0.20 mmol) was added in two portions over 10 min. The 
resulting mixture was heated to 70 °C and stirred for 5 h. The reaction mixture 
was cooled to room temperature and concentrated under reduced pressure. The 
residue was purified by flash chromatography using 25–35% EtOAc/hexanes as 
the eluent to yield the P1–P3 macrocyclic product 26d (1.0 g, 70%) as an off-
white foamy solid. 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.8 Hz, 1 H), 7.47 
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(dd, J = 8.8, 2.8 Hz, 1 H), 7.44 (d, J = 2.4 Hz, 1 H), 7.03 (br s, 1 H), 5.84–5.80 
(m, 1 H), 5.56–5.49 (m, 1 H), 5.32–5.22 (m, 2 H), 4.92 (q, J = 4.4 Hz, 1 H), 4.49 
(t, J = 7.6 Hz, 1 H), 4.24–4.05 (m, 4 H), 3.95 (s, 3 H), 3.05–2.99 (m, 1 H), 2.41–
2.35 (m, 1 H), 2.24–2.14 (m, 3 H), 1.93–1.86 (m, 2 H), 1.66–1.60 (m, 1 H), 1.55 
(dd, J = 96, 5.2 Hz, 1 H), 1.46–1.20 (m, 18 H) ppm; 13C NMR (100 MHz, CDCl3) δ 
172.81, 171.95, 169.74, 159.69, 155.21, 152.20, 138.56, 137.25, 134.50, 128.08, 
125.91, 125.84, 120.80 (q, J = 276 Hz), 107.73, 80.04, 75.42, 61.50, 58.08, 
56.13, 52.21, 51.39, 41.36, 32.16, 31.77, 28.45, 28.10, 28.02, 26.37, 25.74, 
23.70, 22.57, 14.72 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C35H45F3N5O8, 
720.3215; found 720.3203. 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-14a-
((cyclopropylsulfonyl)carbamoyl)-2-((7-methoxy-3-
(trifluoromethyl)quinoxalin-2-yl)oxy)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (18d). A solution of ester 26d (1.0 g, 1.4 mmol) in THF-MeOH-H2O 
(1:1:1 mixture, 20 mL) was treated with LiOH.H2O (0.18 g, 4.2 mmol). The 
resulting reaction mixture was stirred at room temperature for 24 h, then cooled 
to ~5 °C, acidified to a pH of 2.0 by slow addition of aqueous 0.25 N HCl, and 
extracted with EtOAc (2 × 150 mL). The organic portions were washed 
separately with saturated aqueous NaCl (100 ml), dried (Na2SO4), filtered, and 
evaporated under reduced pressure. The gummy residue was dissolved in CHCl3 
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(10 mL), concentrated under reduced pressure, and the residue was dried under 
high vacuum to yield the acid 27d (0.95 g, 98%) as a pale yellow foamy solid. 
A mixture of acid 27d (0.40 g, 0.58 mmol) and CDI (0.131 g, 0.81 mmol) in 
anhydrous THF (8 mL) was heated at reflux for 1.5 h. The solution was cooled to 
room temperature and slowly added to a solution of cyclopropanesulfonamide 28 
(0.10 g, 0.82 mmol) in anhydrous THF (4 mL) followed by DBU (0.12 mL, 0.81 
mmol). The resulting reaction mixture was stirred at room temperature for 24 h, 
then quenched with aqueous 0.5 N HCl to pH ~2. Solvents were partially 
evaporated under reduced pressure, and the residue was extracted with EtOAc 
(2 × 100 mL). The combined organic portions were washed with saturated 
aqueous NaCl (100 mL), dried (Na2SO4), filtered, and evaporated under reduced 
pressure. The residue was purified by flash chromatography using 40–70% 
EtOAc/hexanes as the eluent to afford the title compound 18d (0.28 g, 60%) as a 
white solid. 1H NMR (400 MHz, CDCl3) δ 10.28 (s, 1 H), 7.83 (d, J = 9.2 Hz, 1 H), 
7.49 (dd, J = 8.8, 2.8 Hz, 1 H), 7.42 (d, J = 2.8 Hz, 1 H), 6.87 (s, 1 H), 5.92 (br s, 
1 H), 5.70 (q, J = 8.8 Hz, 1 H), 5.13 (d, J = 7.6 Hz, 1 H), 4.97 (t, J = 8.4 Hz, 1 H), 
4.62–4.56 (m, 2 H), 4.23–4.17 (m, 1 H), 4.01 (dd, J = 11.6, 3.2 Hz, 1 H), 3.94 (s, 
3 H), 2.93–2.87 (m, 1 H), 2.68–2.50 (m, 3 H), 2.31 (q, J = 8.8 Hz, 1 H), 1.95–1.54 
(m, 2 H), 1.53–1.02 (m, 21 H), 0.96–0.88 (m, 1 H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 176.99, 173.31, 167.91, 159.45, 154.93, 151.76, 138.27, 136.99, 
136.32, 134.56 (q, J = 36.2 Hz), 127.99, 125.57, 124.53, 120.8 (q, J = 274.0 Hz), 
107.40, 79.76, 75.54, 59.44, 55.89, 52.72, 51.86, 44.65, 34.61, 32.82, 31.02, 
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29.61, 28.02, 27.04, 25.99, 22.21, 20.93, 6.67, 6.12 ppm; HRMS (ESI) m/z: [M + 
H]+ calcd for C36H46F3N6O9S, 795.2994; found 795.2974. Anal. HPLC: tR 14.59 
min, purity 100%. 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-2-((7-methoxy-3-
(trifluoromethyl)quinoxalin-2-yl)oxy)-14a-(((1-
methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (19d). The same procedure was used as described above for 
compound 18d. Acid 27d (0.43 g, 0.62 mmol) was treated with CDI (0.141 g, 
0.87 mmol), 1-methylcyclopropanesulfonamide 29 (0.118 g, 0.87 mmol) and DBU 
(0.13 mL, 0.87 mmol) to afford the title compound 19d (0.34 g, 68%) as a white 
solid. 1H NMR (400 MHz, CDCl3) δ 10.15 (s, 1 H), 7.83 (d, J = 9.2 Hz, 1 H), 7.48 
(dd, J = 9.2, 2.8 Hz, 1 H), 7.42 (d, J = 2.8 Hz, 1 H), 6.90 (s, 1 H), 5.91 (s, 1 H), 
5.70 (q, J = 9.2 Hz, 1 H), 5.14 (d, J = 7.6 Hz, 1 H), 5.00 (t, J = 9.2 Hz, 1 H), 4.62–
4.55 (m, 2 H), 4.24–4.18 (m, 1 H), 4.02 (dd, J = 11.6, 3.6 Hz, 1 H), 3.94 (s, 3 H), 
2.71–2.51 (m, 3 H), 2.33 (q, J = 8.4 Hz, 1 H), 1.93–1.75 (m, 4 H), 1.56–1.18 (m, 
21 H), 0.85–0.78 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 177.30, 173.46, 
167.15, 159.68, 155.16, 152.01, 138.50, 137.23, 136.50, 134.60 (q, J = 36.0 Hz), 
128.23, 125.79, 125.19, 120.83 (d, J = 274.0 Hz), 107.65, 80.01, 75.79, 59.70, 
56.12, 52.97, 52.08, 45.03, 36.65, 34.86, 33.06, 29.81, 28.26, 27.31, 27.24, 
26.32, 22.47, 21.21, 18.42, 14.73, 12.77 ppm; HRMS (ESI) m/z: [M + H]+ calcd 
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for C37H48F3N6O9S, 809.3150; found 809.3129. Anal. HPLC: tR 15.23 min, purity 
99%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-14a-
((cyclopropylsulfonyl)carbamoyl)-2-((7-methoxy-3-
(trifluoromethyl)quinoxalin-2-yl)oxy)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (22d). Compound 18d (0.40 g, 0.52 mmol) was treated with a 
solution of 4 N HCl in 1,4-dioxane (10 mL). The reaction mixture was stirred at 
room temperature for 3 h, concentrated under reduced pressure, and the residue 
was dried under high vacuum. The pale yellow solid was triturated with diethyl 
ether (3 × 10 mL) and dried under high vacuum to yield the amine salt 20d (0.37 
g, 100%) as a white powder. 
A solution of the above amine salt 20d (0.37 g, 0.52 mmol) in anhydrous 
CH3CN (15 mL) was treated with DIEA (0.35 mL, 2.1 mmol) and N-
(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol). The reaction 
mixture was stirred at room temperature for 24 h, then concentrated under 
reduced pressure and dried under high vacuum. The residue was purified by 
flash chromatography using 50–90% EtOAc/hexanes as the eluent to provide the 
target compound 22d (0.30 g, 74%) as a white solid. 1H NMR (400 MHz, CDCl3) 
δ 10.27 (s, 1 H), 7.82 (d, J = 9.2 Hz, 1 H), 7.48 (dd, J = 9.2, 2.8 Hz, 1 H), 7.42 (d, 
J = 2.8 Hz, 1 H), 6.78 (s, 1 H), 5.95 (s, 1 H), 5.70 (q, J = 9.6 Hz, 1 H), 5.23 (d, J = 
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8.0 Hz, 1 H), 4.98 (t, J = 8.8 Hz, 1 H), 4.74–4.69 (m, 1 H), 4.60 (t, J = 7.6, 1 H), 
4.54 (d, J = 11.6, 1 H), 4.25–4.19 (m, 1 H), 3.99 (dd, J = 11.6, 4.0 Hz, 1 H), 3.94 
(s, 3 H), 2.94–2.88 (m, 1 H), 2.68–2.50 (m, 3 H), 2.31 (q, J = 8.8 Hz, 1 H), 1.94–
1.24 (m, 21 H), 1.20–1.07 (m, 2 H), 0.96–0.89 (m, 1 H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 177.33, 173.29, 168.27, 159.68, 155.87, 152.08, 138.56, 137.24, 
136.47, 134.74 (q, J = 36.0 Hz), 128.24, 125.75, 124.79, 120.87 (d, J = 273.2 
Hz), 107.62, 78.02, 75.70, 59.68, 56.11, 52.90, 52.35, 44.83, 34.71, 32.92, 
32.81, 32.64, 31.26, 29.87, 27.27, 26.24, 23.81, 23.75, 22.49, 21.11, 6.89, 6.34 
ppm; HRMS (ESI) m/z: [M + H]+ calcd for C37H46F3N6O9S, 807.2994; found 
807.2976. Anal. HPLC: tR 14.98 min, purity 99%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-2-((7-methoxy-3-
(trifluoromethyl)quinoxalin-2-yl)oxy)-14a-(((1-
methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (23d). The same procedure was used as described above for 
compound 22d. Compound 19d (0.40 g, 0.52 mmol) was treated with 4 N HCl in 
1,4-dioxane (10 mL) to yield the amine salt 21d, which was treated with DIEA 
(0.35 mL, 2.1 mmol) and N-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 
0.66 mmol) to provide the target compound 23d (0.30 g, 74%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 10.18 (s, 1 H), 7.83 (d, J = 9.6 Hz, 1 H), 7.48 (dd, J 
= 8.8, 2.8 Hz, 1 H), 7.41 (d, J = 2.8 Hz, 1 H), 6.94 (s, 1 H), 5.94 (s, 1 H), 5.70 (q, 
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J = 8.8 Hz, 1 H), 5.28 (d, J = 7.6 Hz, 1 H), 5.00 (t, J = 8.8 Hz, 1 H), 4.74–4.69 (m, 
1 H), 4.60 (t, J = 7.6, 1 H), 4.54 (d, J = 12.0, 1 H), 4.25–4.19 (m, 1 H), 4.00 (dd, J 
= 11.6, 3.6 Hz, 1 H), 3.94 (s, 3 H), 2.68–2.50 (m, 3 H), 2.31 (q, J = 8.4 Hz, 1 H), 
1.92–1.20 (m, 24 H), 0.85–0.78 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 
177.33, 173.25, 167.13, 159.68, 155.84, 152.08, 138.56, 137.24, 136.44, 134.75 
(q, J = 35.2 Hz), 128.25, 125.74, 125.21, 120.86 (d, J = 274.0 Hz), 107.62, 78.02, 
75.71, 59.73, 56.12, 52.89, 52.34, 45.03, 36.65, 34.73, 32.93, 32.82, 32.64, 
29.83, 27.26, 27.21, 26.29, 23.81, 23.75, 22.52, 21.23, 18.42, 14.73, 12.76 ppm. 
HRMS (ESI) m/z: [M + H]+ calcd for C38H48F3N6O9S, 821.3150; found 821.3133. 
Anal. HPLC: tR 15.65 min, purity 97%. 
3.6.4 Expression and Purification of NS3/4A Constructs 
The HCV GT1a NS3/4A protease gene described in the Bristol Myers Squibb 
patent128 was synthesized by GenScript and cloned into a PET28a expression 
vector. The D168A gene was engineered using the site-directed mutagenesis 
protocol from Stratagene. Protein expression and purification were carried out as 
previously described.89 Briefly, transformed Escherichia coli BL21(DE3) cells 
were grown in LB media containing 30 µg/mL of kanamycin antibiotic at 37 °C. 
After reaching an OD600 of 0.8, cultures were induced with 1 mM IPTG and 
harvested after 4 h of expression. Cells were pelleted by centrifugation, 
resuspended in Resuspension buffer [50 mM phosphate buffer, 500 mM NaCl, 
10% glycerol, 2 mM β-ME, pH 7.5] and frozen at −80 °C for storage. 
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Cell pellets were thawed and lysed via cell disruptor (Microfluidics Inc.) two 
times to ensure sufficient DNA shearing. Lysate was centrifuged at 19,000 rpm, 
for 25 min at 4 °C. The soluble fraction was applied to a nickel column (Qiagen) 
pre-equilibrated with Resuspension buffer. The beads and soluble fraction were 
incubated at 4 °C for 1.5 h and the lysate was allowed to flow through. Beads 
were washed with Resuspension buffer supplemented with 20 mM imidazole and 
eluted with Resuspension buffer supplemented with 200 mM imidazole. The 
eluent was dialyzed overnight (MWCO 10 kD) to remove the imidazole, and the 
His-tag was simultaneously removed with thrombin treatment. The eluate was 
judged >90% pure by polyacrylamide gel electrophoresis, concentrated, flash 
frozen, and stored at −80 °C. 
The HCV GT3a NS3/4A protease gene was synthesized by GenScript. 
Transformed Escherichia coli BL21(DE3) cells were grown in LB media 
containing 30 µg/mL of kanamycin antibiotic at 37 °C. After reaching an OD600 
0.7, cultures were incubated at 4 °C for 20 min before being induced with 1 mM 
IPTG and placed at 18 °C for overnight expression. Cells were pelleted by 
centrifugation, resuspended in Resuspension buffer and frozen at –80 °C for 
storage. 
Cell pellets were thawed and lysed via cell disruptor (Microfluidics Inc.) two 
times to ensure sufficient DNA shearing and treated with DNaseI. The lysate was 
treated and purified using a nickel column as above, with an additional wash with 
1 M NaCl prior to elution. The protein was further purified using a HiLoad 
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Superdex75 16/60 column equilibrated with Resuspension buffer. The eluate was 
judged >90% pure by polyacrylamide gel electrophoresis, concentrated, flash 
frozen, and stored at −80 °C . 
3.6.5 Determination of the Inner Filter Effect 
The inner filter effect (IFE) for the NS3/4A protease substrate was determined 
using a previously described method.129 Briefly, fluorescence end-point readings 
were taken for substrate concentrations between 0 µM and 20 µM. Afterward, 
free 5-FAM fluorophore was added to a final concentration of 25 µM to each 
substrate concentration and a second round of fluorescence end-point readings 
was taken. The fluorescence of free 5-FAM was determined by subtracting the 
first fluorescence end point reading from the second round of readings. IFE 
corrections were then calculated by dividing the free 5-FAM florescence at each 
substrate concentration by the free 5-FAM florescence at zero substrate.  
3.6.6 Determination of Michaelis–Menten  (Km) Constant 
Km constants for GT1 and D168A protease were previously determined.106 
The Km of GT3 protease was determined using the following method. A 20 µM 
concentration of substrate [Ac-DE-Dap(QXL520)- EE-Abu-γ-[COO]AS-C(5-
FAMsp)-NH2] (AnaSpec) was serially diluted into assay buffer [50 mM Tris, 5% 
glycerol, 10 mM DTT, 0.6 mM LDAO, and 4% dimethyl sulfoxide] and proteolysis 
was initiated by rapid injection of 10 µL GT3 protease (final concentration 20 nM) 
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in a reaction volume of 60 µL. The fluorescence output from the substrate 
cleavage product was measured kinetically using an EnVision plate reader 
(Perkin-Elmer) with excitation wavelength at 485 nm and emission at 530 nm. 
Inner filter effect corrections were applied to the initial velocities (Vo) at each 
substrate concentration. Vo versus substrate concentration graphs were globally 
fit to the Michaelis–Menten equation to obtain the Km value. 
3.6.7 Enzyme Inhibition Assays 
For each assay, 2 nM of NS3/4A protease (GT1a, D168A and GT3a) was 
pre-incubated at room temperature for 1 h with increasing concentration of 
inhibitors in assay buffer [50 mM Tris, 5% glycerol, 10 mM DTT, 0.6 mM LDAO, 
and 4% dimethyl sulfoxide]. Inhibition assays were performed in nonbinding 
surface 96-well black half-area plates (Corning) in a reaction volume of 60 µL. 
The proteolytic reaction was initiated by the injection of 5 µL of HCV NS3/4A 
protease substrate (AnaSpec), to a final concentration of 200 nM and kinetically 
monitored using a Perkin Elmer EnVision plate reader (excitation at 485 nm, 
emission at 530 nm). Three independent data sets were collected for each 
inhibitor with each protease construct. Each inhibitor titration included at least 12 
inhibitor concentration points, which were globally fit to the Morrison equation to 
obtain the Ki value.  
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3.6.8 Cell-Based Drug Susceptibility Assays 
Mutations (R155K, A516T, D168A and D168V) were constructed by site-
directed mutagenesis using a Con1 (genotype 1b) luciferase reporter 
replicon containing the H77 (genotype 1a) NS3 sequence.130 Replicon RNA of 
each protease variant was introduced into Huh7 cells by electroporation. 
Replication was then assessed in the presence of increasing concentrations of 
protease inhibitors by measuring luciferase activity (relative light units) 96 h after 
electroporation. The drug concentrations required to inhibit replicon replication by 
50% (EC50) were calculated directly from the drug inhibition curves.  
3.6.9 Crystallization and Structure Determination 
Protein expression and purification were carried out as previously 
described.89 The Ni-NTA purified WT1a protein was thawed, concentrated to 3 
mg/mL, and loaded on a HiLoad Superdex75 16/ 60 column equilibrated with gel 
filtration buffer (25 mM MES, 500 mM NaCl, 10% glycerol, and 2 mM DTT, pH 
6.5). The protease fractions were pooled and concentrated to 25 mg/mL with an 
Amicon Ultra-15 10 kDa filter unit (Millipore). The concentrated samples were 
incubated for 1 h with 3:1 molar excess of inhibitor. Diffraction-quality crystals 
were obtained overnight by mixing equal volumes of concentrated protein 
solution with precipitant solution (20–26% PEG-3350, 0.1 M sodium MES buffer, 
4% ammonium sulfate, pH 6.5) at RT or 15 °C in 24-well VDX hanging drop 
trays. Crystals were harvested and data was collected at 100 K. Cryogenic 
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conditions contained the precipitant solution supplemented with 15% glycerol or 
ethylene glycol.  
Diffraction data were collected using an in-house Rigaku X-ray system with a 
Saturn 944 detector. All datasets were processed using HKL-3000.131 Structures 
were solved by molecular replacement using PHASER.132 The WT-2 complex 
structure (PDB code: 5EPN)111 was used as the starting structure for all structure 
solutions. Model building and refinement were performed using Coot133 and 
PHENIX,134 respectively. The final structures were evaluated with MolProbity135 
prior to deposition in the PDB. To limit the possibility of model bias throughout 
the refinement process, 5% of the data were reserved for the free R-value 
calculation.136 Structure analysis, superposition and figure generation were done 
using PyMOL.137 X-ray data collection and crystallographic refinement statistics 
are presented above (Table 3.3).  
3.6.10 Molecular Modeling 
Molecular modeling was carried out using MacroModel (Schrödinger, LLC, 
New York, NY).170 Briefly, inhibitors were modeled into the active site of WT1a 
and A156T proteases using the WT-2 and A156T-2 co-complex structures (PDB 
code: 5EPN and 5EPY).111 Structures were prepared using the Protein 
Preparation tool in Maestro 11. 2D chemical structures were modified with the 
appropriate changes using the Build tool in Maestro. Once modeled, molecular 
energy minimizations were performed for each inhibitor–protease complex using 
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the PRCG method with 2500 maximum iterations and 0.05 gradient convergence 
threshold. PDB files of modeled complexes were generated in Maestro for 
structural analysis.  
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Chapter IV 
Design of HCV NS3/4A PIs leveraging 
untapped regions of the substrate envelope 
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4.1 Abstract 
 In HCV, rapid selection of resistance-associated variants often leads to 
reduced efficacy of NS3/4A protease inhibitors (PIs). One strategy to combat 
resistance is to constrain inhibitors within evolutionarily conserved regions in the 
protease active site. The substrate envelope provides a rational drug design 
strategy to exploit evolutionary constraints that mimic substrate interactions to 
limit susceptibility to resistance. We designed HCV NS3/4A PIs with modified P4 
capping groups or modified P4 amino acids with P5 capping groups that extend 
in the P4 direction, leveraging unexploited areas in the substrate envelope. 
Inhibition assays revealed that inhibitors have flatter resistant profiles and higher 
affinity over FDA-approved NS3/4A PI grazoprevir and parent compound JZ01-
15 against resistant variants. Crystal structures confirmed that inhibitors fit within 
the substrate envelope and that extending into the S4 pocket of the substrate 
envelope improve both resistance profile and inhibitor potency. Thus, the HCV 
substrate envelope is a powerful tool for the design of robust PIs and further 
modification of the P4 position on the inhibitor scaffold may lead to more 
efficacious PIs toward the eradication of HCV infection.   
4.2 Introduction  
Drug resistance is a major threat to the treatment of patients infected with 
Hepatitis C virus (HCV). The clinical sequelae of HCV infection include chronic 
liver disease, cirrhosis from prolonged inflammation and hepatocellular 
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carcinoma.1 The severe liver damage caused by the insidious progression of 
HCV infection has made this virus the leading cause of liver transplantation in 
most countries.171 Despite advancements in treatment options and outcomes 
with the development of direct-acting antivirals (DAAs) against essential viral 
proteins encoded by the HCV genome, drug resistance remains a problem with 
the rapid emergence of resistance–associated substitutions (RASs) affecting all 
viral targets.22,23,51,107,112,119 This rapid selection of RASs is in part due to the high 
replication rate of HCV and the low fidelity of the RNA-dependent RNA 
polymerase (RdRp).116,117 At baseline, patients can be infected with a diverse 
viral population known as quasispecies.172 At the start of antiviral therapy, the 
selective drug pressure often leads to the rise of additional resistant viral species 
that are not effectively inhibited by the administered drug.173 Thus, drugs with 
increased efficacy and minimized susceptibility to resistance are needed to 
effectively eradicate HCV infection.  
The NS3/4A protease is an excellent target for the development of novel and 
robust DAAs. This essential protease proteolytically cleaves the HCV polyprotein 
precursor into functional components necessary for viral replication and 
maturation.174 The NS3/4A viral substrates share little sequence homology 
except a cysteine at P1 and an acid at P6 positions.101 The diversity of the 
NS3/4A cleavage sites implies that a specific sequence motif is not the basis of 
substrate specificity. However, when the substrates are bound to the protease 
active site, they occupy a similar consensus volume termed the substrate 
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envelope (SE).90 This consensus volume is the basis of molecular recognition for 
the NS3/4A protease substrates. Drug resistance is loss of inhibitor binding 
affinity while maintaining substrate processing. In the NS3/4A protease, 
resistance substitutions occur where inhibitors protrude outside the substrate 
envelope and contact residues of the enzyme that are unessential in substrate 
recognition.89  
The FDA has approved five protease inhibitors (PIs) for the treatment of HCV: 
simeprevir,85 paritaprevir,91 grazoprevir,120 glecaprevir51 and voxilaprevir.121 All 
protease inhibitors (PIs) have large heterocyclic P2 moieties that significantly 
improve potency.80 However, the identity of the P2 moiety strongly influences the 
inhibitor resistance profile. The P2 moiety of older generation PIs protrudes 
beyond the substrate envelope and contacts the S2 subsite residues Arg155, 
Ala156 and Asp168.89 These residues are where the most common drug 
resistance substitutions occur. Notably, Asp168 RASs are present in nearly all 
patients who fail therapy with a PI-containing regimen.107 Arg155 and Asp168 are 
critical residues that contribute to an electrostatic network necessary for efficient 
inhibitor binding. High-resolution crystal structures of PIs bound to wildtype and 
resistant proteases revealed that disruption of this electrostatic network due to 
substitutions at Arg155 or Asp168 underlie the mechanism of resistance for older 
NS3/4A PIs.89,109  
While protrusion beyond the substrate envelope at the P2 position on the 
inhibitor scaffold is inevitable without compromising potency, utilization of 
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evolutionarily constrained residues in the protease active site may still enable 
circumvention of resistance. In the case of grazoprevir, although the P2 
quinoxaline protrudes outside of the substrate envelope, this moiety stacks 
against the invariant catalytic triad and minimizes contact with the S2 subsite 
residues.89,111 Grazoprevir is a P2–P4 macrocyclic inhibitor with a P2 quinoxaline 
moiety that predominantly binds on catalytic triad residues His57 and Asp81. 
Substitution of any of the catalytic triad residues would disrupt enzymatic activity, 
preventing the likelihood of viable resistance. However, grazoprevir is still highly 
susceptible to the A156T substitution as the larger threonine side chain clashes 
with the inhibitor macrocycle, and is moderately susceptible to Asp168 
substitutions.111 Nevertheless, given the relatively improved resistance profile of 
grazoprevir, drug companies have exploited this inhibitor scaffold leading to the 
development of newer generation P2–P4 macrocyclic inhibitors glecaprevir and 
voxilaprevir.  
Macrocyclization status also plays a critical role in inhibitor susceptibility to 
resistance substitutions. Design of 5172-mcP1P3, a P1–P3 macrocyclic analog 
of grazoprevir, led to an inhibitor with an improved resistance profile that was 
less susceptible to single site substitutions in the protease active site, particularly 
A156T.106 Moreover, change of the macrocycle from the P2–P4 to the P1–P3 
position maintained the binding mode of the parent compound grazoprevir.111 
Further modifications of the P2 quinoxaline moiety of the 5172-mcP1P3 scaffold 
revealed that small substituents at the 3-position such as the methyl group in 
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JZ01-15, are better at maintaining activity against drug resistant variants due to 
limited contact with S2 subsite residues.124  
An additional strategy that can be employed to thwart resistance is to design 
inhibitors to fit within the substrate envelope. Previous studies with HIV-1 
protease demonstrate that the substrate envelope can successfully be used as a 
drug design constraint. Ten inhibitors based on the FDA-approved drug darunavir 
were designed to better fit in the substrate envelope and exhibited robust activity 
against multi-drug resistant HIV-1 variants.175 The scaffold of all current HCV PIs 
only spans the P4–P1’ positions with a small P4 capping group. In fact, the 
volume remaining in the substrate envelope is almost equal to the volume of the 
inhibitor that protrudes outside the envelope.160 Thus, current protease inhibitors 
can be extended into the P4–P5 pockets of the HCV substrate envelope. 
Analysis of the dynamic substrate envelope revealed that the P1–P5 positions 
are quite conserved with the P6 position being the most dynamic.160 Therefore, 
further elaboration to the inhibitor scaffold may benefit by modifications at the P4 
and P5 positions. To design more robust inhibitors, our design incorporated the 
following strategies: fit within the substrate envelope, leverage interactions 
unexploited by current inhibitors, and incorporate moieties that interact with the 
invariant catalytic triad minimizing contacts with unessential residues. Thus, 
leveraging our knowledge of the binding modes of current inhibitors and 
substrates, and the mechanisms of drug resistance, the aim was to design 
inhibitors that are less susceptible to resistance.  
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We used the substrate envelope strategy to optimize HCV PIs based on the 
JZ01-15 scaffold by incorporating modifications at the P4–P5 positions that fit 
within the substrate envelope. The modifications extend toward the region of the 
HCV NS3/4A substrate envelope that is not utilized by current inhibitors. A panel 
of 9 inhibitors was designed, synthesized, and assayed, and a select subset was 
co-crystallized bound to wildtype and D168A protease. Biochemical analysis 
revealed that all inhibitors designed to fit within the substrate envelope exhibited 
flatter resistance profiles than FDA-approved drug grazoprevir. Crystal structures 
of 5 of the PIs bound to wildtype and D168A protease have been determined, 
and confirmed that these inhibitors fit within the substrate envelope as designed. 
Structural analysis of the carbamate-linked P4 compounds revealed that the 
improved activity observed against the D168A variant is due to enhanced filling 
of the S4 pocket, utilization of additional space in the substrate envelope, and 
optimization of interactions in the substrate binding site. Thus use of the 
substrate envelope in NS3/4A PI design can be successfully incorporated at the 
outset of inhibitor design providing inhibitors with improved potency and 
resistance profiles against drug resistant variants.  
4.3 Results 
Substitutions in the protease active site can result in detrimental loss of 
potency for many PIs. Specifically, Asp168 is a pivotal residue as substitutions at 
this position often weaken the ability of inhibitors to bind efficiently.89,106 Though 
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newer generation inhibitors glecaprevir and voxilaprevir are not susceptible to 
Asp168 substitutions, they are still highly susceptible to Ala156 substitutions due 
their P2–P4 macrocycle.51 Thus the P1–P3 macrocyclic JZ01-15 scaffold (Figure 
4.1) was targeted to elaborate as this is an inhibitor not susceptible to the A156T 
substitution; this strategy may lead to inhibitors that fit within the substrate 
envelope and that are less susceptible to resistance. Moreover, polymorphisms 
at the Asp168 position, which is Gln168 in genotype 3, underlie reduced efficacy 
of most PIs.108 Thus, designing novel inhibitors using the substrate envelope 
approach to have better activity against Asp168 substitutions in genotype 1 may 
give rise to improved activity against other genotypes.  
Modifications to the JZ01-15 scaffold were made at the P4–P5 positions to 
utilize unexploited space in the substrate envelope. Hydrophobic moieties at the 
P4 position were used to mimic substrate interactions, as HCV substrates across 
genotypes have hydrophobic residues at this position.11 Our goal was to extend 
toward the S4 substrate-binding pocket and leverage specific interactions 
common to substrates including backbone hydrogen bonds to residues in this 
binding groove. We used two general approaches to sample the chemical space 
in the substrate envelope by synthesizing a set of 9 inhibitors with either a 
modified carbamate linked P4-cap (P4–cap inhibitors) or a modified P4 amino 
acid with a small P5 capping group (P4–P5-cap inhibitors) (Figure 4.1). 
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Figure 4.1: Chemical structures of designed HCV NS3/4A protease 
inhibitors.  
Grazoprevir is an FDA-approved PI. Change of the macrocycle location and 
modification of the P2 quinoxaline moiety of 5172-mcP1P3 led to the 
development of JZ01-15. The designed inhibitors (a) P4–P5-cap and (b) P4–cap 
were based on the JZ01-15 scaffold with modifications at the P4 and P4–P5 
regions. The canonical nomenclature for drug moiety positioning is indicated for 
WK-23.  
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4.3.1 Designed compounds inhibit wildtype protease 
The enzyme inhibition constants (Ki values) of the designed inhibitors were 
determined against wildtype protease and the D168A drug resistant variant. All 9 
inhibitors were potent against wildtype protease with Ki values ranging from 1.13 
– 29.5 nM (Figure 4.2A). Overall inhibitors with a modified P4 capping group 
were more potent than inhibitors with a modified P4 amino acid and small P5 
capping group. WK-23, a P4–P5-cap inhibitor with a t-butyl P4 moiety and small 
carbamate-linked P5 methoxy capping group, exhibited reduced potency against 
wildtype protease (Ki = 29.5 nM) relative to parent compound JZ01-15 (Ki = 3.6 
nM). To test the effect of the capping group, we designed AJ-67, which is 
identical to WK-23 except for the N-acetyl capping group. Both AJ-67 and WK-23 
showed similar activity against wildtype protease. This trend was also observed 
with AJ-66 and AJ-73, two P4 isopropyl inhibitors that differ only at the P5 
position, suggesting that the capping change tested here does not affect inhibitor 
potency.  
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Figure 4.2: Resistance profile of NS3/4A protease inhibitors.  
a) Enzyme inhibition constants against wildtype (blue) and D168A (orange) 
protease and b) fold change of enzyme inhibitory activity against the D168A 
variant normalized with respect to the wild-type NS3/4A protease.  
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The P4–cap inhibitors (AJ-71, JZ01-19 and AJ-74) overall had improved 
potency against wildtype protease relative to both P4–P5-cap inhibitors and 
parent compound JZ01-15. The Ki values of these compounds ranged from 
1.13–2.56 nM. JZ01-19 was 3-fold more potent than parent compound JZ01-15 
and only 5 fold less potent than grazoprevir. While no inhibitor exhibited sub-
nanomolar activity against wildtype protease as the FDA-approved P2–P4 
macrocyclic grazoprevir (Ki = 0.21 nM), we were able to modify the P4–cap of 
inhibitors and gain potency. Thus modification at the P4 position using a 
substrate envelope guided approach yielded inhibitors with improved potency 
relative to the parent compound. 
4.3.2 Designed inhibitors have improved resistance profile 
against the D168A variant 
To understand if the substrate envelope as a constraint in inhibitor design 
results in compounds that are less susceptible to resistance, we tested the 
pivotal D168A variant. All PIs tested lost considerable activity against the D168A 
variant including grazoprevir, as has previously been reported.106,124 P4–P5-cap 
inhibitors were less potent against the D168A variant than the P4–cap inhibitors, 
similar to wildtype protease. All P4–cap inhibitors had improved activity against 
the D168A variant (Ki range: 16 – 39 nM) relative to parent compound JZ01-15 
(Ki = 52 nM). Remarkably, AJ-74, a P4–cap inhibitor with a methylcyclopentyl 
capping group exhibited 3-fold improved potency against the D168A variant 
compared to grazoprevir (Ki = 16 and 49 nM, respectively). 
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While all PIs showed reduced potency against the D168A variant relative to 
WT protease in the enzyme inhibition assay, the fold change losses were much 
smaller for all 9 designed inhibitors (Figure 4.2B). Grazoprevir is highly 
susceptible to the D168A variant exhibiting over a 230-fold reduction in potency. 
All inhibitors designed to fit within the substrate envelope exhibited between 9- to 
32-fold reductions in potency, much smaller than observed for grazoprevir. Thus 
inhibitors designed using the substrate envelope have flatter resistance profiles 
and suggest that substrate envelope guided design can produce compounds with 
low nanomolar potency and reduced susceptibility to drug resistance.  
4.3.3 Structure determination of protease-inhibitor 
complexes 
To understand the molecular basis for the observed resistance profiles of the 
inhibitors as well as to determine if the inhibitors fit within the substrate envelope 
as designed, crystal structures of select inhibitors bound to wildtype and D168A 
proteases were determined (Table 4.1). A total of seven new crystal structures 
with resolutions ranging from 1.6 – 1.9 Å were determined for this study. Five 
crystal structures of WK-23, AJ-67, AJ-71, JZ01-19, and AJ-74 were determined 
in complex with wildtype protease. Crystallization efforts with drug resistant 
variant D168A were successful with inhibitors AJ-67 and AJ-71. All structures 
were analyzed in comparison with previously determined crystal structures of 
parent compound JZ01-15 (PDB ID: 5VOJ for wildtype) and grazoprevir (PDB 
IDs: 3SUD for wildtype and 3SUF for D168A, respectively).89,124    
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Table 4.1: X-ray data collection and crystallographic refinement statistics. 
 
WT- 
WK-23 
WT- 
AJ-67 
WT- 
AJ-71  
WT- 
JZ01-19 
WT- 
AJ-74 
D168A- 
AJ-67 
D168A-
AJ-71 
Resolution 1.58 Å 1.75 Å 1.92 Å 1.79 Å 1.87 Å 1.83Å 1.80Å 
Space group P212121 P212121 P212121 P212121 P212121 P212121 P212121 
Molecules in AUa 1 1 1 1 1 1 1 
Cell dimensions:        
a (Å) 55.5 55.1 55.6 55.3 55.1 55.5 55.7 
b (Å) 58.5 59.8 58.6 58.6 59.6 58.7 58.6 
c (Å) 59.9 58.5 60.0 59.8 58.5 60.0 60.1 
β (°) 90 90 90 90 90 90 90 
Completeness (%) 91.3 97.0 96.7 98.1 97.4 98.1 92.6 
Total reflections 250177 119548 106822 118729 110776 115996 120162 
Unique reflections 25037 19508 14999 18610 16126 17556 17476 
Average I/σ 7.9 8.8 19.8 14.5 12.7 12.8 6.3 
Redundancy 10 6.1 7.1 6.4 6.9 6.6 6.9 
Rsym (%)b 5.7 (15.2) 4.3 (18.3) 10.6 (45.8) 7.1 (28.4) 6.3 (19.6) 7.0 (21.6) 3.9 (11.7) 
RMSDc in:         
  Bond lengths (Å) 0.007 0.009 0.01 0.004 0.02 0.006 0.01 
  Bond angles (°) 1.0 1.3 1.0 0.8 0.6 1.1 1.5 
Rfactor (%)d 15.1 14.6 18.7 18.2 18.3 16.1 13.8 
Rfree (%)e 18.3 19.3 22.7 22.9 23.3 19.4 18.0 
aAU, asymmetric unit. 
bRsym = Σ | I − <I>|/ Σ I, where I = observed intensity, <I> = average intensity over symmetry 
equivalent; values in parentheses are for the highest resolution shell. 
cRMSD, root mean square deviation. 
dRfactor = Σ || Fo| − |Fc||/ Σ|Fo|.   
eRfree was calculated from 5% of reflections, chosen randomly, which were omitted from the 
refinement process. 
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The binding mode of all of the designed inhibitors was very similar to parent 
compound JZ01-15 and grazoprevir. The P2 quinoxaline maintained the π-π 
stacking interaction with catalytic His57 residue irrespective of modifications at 
the P4 and P5 positions as expected (Figure 4.3). In fact, changes in the binding 
mode occurred only at the positions that were modified, with the P3–P1’ positions 
of the ligand relatively unchanged. In all structures, inhibitors formed conserved 
hydrogen bonds with backbone atoms in the protease including: 1) P1 amide 
nitrogen with the backbone carbonyl of Arg155, 2) P3 amide nitrogen with the 
backbone carbonyl of Ala157, 3) P3 cabonyl with the backbone nitrogen of 
Ala157 and 4) the P1’ acylsulfonamide moiety with backbone atoms of residues 
137–139 in the oxyanion hole. Additionally, the Nε nitrogen of His57 made a 
hydrogen bond with the sulfonamide nitrogen in all inhibitor complexes. 
Differences in hydrogen bonding were observed in the S4 pocket where 
modifications to the inhibitor were made. 
4.3.4 Inhibitors with the P4–P5 modifications fit within the 
substrate envelope and gain substrate-like interactions 
Grazoprevir, although potent, protrudes from the substrate envelope making 
this inhibitor highly susceptible to drug resistance mutations especially at Ala156 
and Asp168 due to the positioning of the P2–P4 macrocycle and P4 moiety 
(Figure 4.3A).  Modification of the macrocycle location and the P2 position led to 
JZ01-15, which fits better in the substrate envelope (Figure 4.3B). The crystal 
structures of parent compound JZ01-15 bound to wildtype protease and the 
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additional 5 inhibitor-wildtype protease structures superimpose extremely well. 
Moreover, the designed inhibitors fit within the substrate envelope, utilizing 
unexplored space and leveraging substrate-like contacts (Figure 4.3C). Thus, 
crystal structures confirm that inhibitors fit within the substrate envelope as they 
were designed.  
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Figure 4.3: Fit of NS3/4A protease inhibitors within the substrate envelope.  
Inhibitors a) grazoprevir, b) JZ01-15 and c) designed inhibitors WK-23, AJ-67, 
AJ-71, JZ01-19 and AJ-74 shown as sticks (orange) in the substrate envelope 
(blue). The side chains of the catalytic triad and common drug resistance 
residues are shown as yellow and green sticks, respectively. A side view and top 
view of the inhibitors in the substrate envelope are shown with the P1–P6 
positions of the envelope labeled.  
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4.3.5 Active site hydrogen bond network is conserved for 
inhibitors  
WK-23 is a P4–P5-cap inhibitor with a t-butyl moiety at the P4 position and a 
carbamate-linked P5 methoxy capping group. Crystal structures of this inhibitor 
bound to wildtype protease revealed that the carbonyl group of the P5 cap gains 
hydrogen bonds with the backbone nitrogen and side chain of Ser159 (Figure 
4.4A). This interaction is reminiscent of the protease-substrate complexes as this 
backbone hydrogen bond to Ser159 is conserved in all structures of bound 
substrates. Alteration of the P5 capping group to an N-acetyl cap did not change 
the binding mode of this inhibitor relative to WK-23 (Figure 4.4B). In fact, the 
hydrogen bonds to the backbone and side chain of Ser159 are maintained in the 
presence of a different capping group (Figure 4.5). This is in agreement with our 
biochemical data as both inhibitors had similar potency against wildtype 
protease. Interestingly, WK-23 and AJ-67 bind very similarly to viral substrates 
(Figure 4.4C, D). Although these inhibitors are not as potent as parent 
compound JZ01-15, they demonstrate that the substrate envelope can be utilized 
to design inhibitors that mimic substrate binding.  
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Figure 4.4: Binding modes of P4–P5-cap inhibitors.  
(a) Surface representation of (a) WK-23 (orange) and (b) AJ-67 (purple) bound to 
the active site of wildtype NS3/4A protease. Superposition of viral substrates 
(gray) and (c) WK-23 and (d) AJ-67. Substrate hydrogen bonds to Ser159 are 
shown in panel (c) and (d). Catalytic triad residues are highlighted in yellow and 
drug resistance residues Arg155, Ala156, Asp168 and Ser159 are shown as 
purple, red, green and blue sticks, respectively.  
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4.3.6 Loss of hydrogen bond with Ser159 side chain 
underlies reduced efficacy of P4–P5-cap inhibitors to 
the D168A variant 
To investigate the molecular basis of reduced potency for the P4–P5-cap 
modified inhibitors against the D168A resistant variant, crystal structures of AJ-
67 bound to wildtype protease and the mutant protease were comparatively 
analyzed. Similar to grazoprevir, loss in potency is likely due to loss of the 
electrostatic network as a result the D168A substitution (Figure 4.5A).89 The 
overall structure of AJ-67 bound to the D168A is very similar to this inhibitor 
bound to wildtype protease. However, the major change occurs at residue 
Ser159. This residue adopts an altered confirmation of the side chain where the 
hydroxyl group is pointed away from the inhibitor (Figure 4.5B, 4.6). As a result, 
the hydrogen bond of AJ-67 with the Ser159 side chain that is present in the 
wildtype structure is lost. Additionally, the P5 capping group of AJ-67 shifts by 0.5 
Å (Figure 4.6). This results in reduced interactions with the S4 subsite. It is likely 
that this mechanism for reduced potency against D168A variant is the same for 
all inhibitors that bind similar to AJ-67 including WK-23 and other P4–P5-cap 
inhibitors.  
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Figure 4.5: Hydrogen bond network in the protease active site of 
grazoprevir and designed PIs.  
Cartoon representation of (a) grazoprevir, (b) AJ-67 and (c) AJ-71 bound to 
wildtype (blue) and D168A (orange) proteases. The catalytic triad and S4 subsite 
residues are shown as sticks. Water molecules are shown as non-bonded 
spheres (red) and dash lines represent hydrogen bonds (black).   
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Figure 4.6: Crystal structure of AJ-67 bound to wildtype and mutant 
proteases.  
Superposition of AJ-67 bound to (a) wildtype (blue) and (b) D168A (orange) 
proteases. S4 subsite residues and catalytic triad residues His57, Asp81 and 
S139 are shown as sticks. Inset shows a zoomed-in view of the P4–P5 moieties. 
Atoms that differ by .2 Å are displayed with a black arrow. The greatest deviation 
occurs at the P5 capping group.  
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4.3.7 Electronegative moieties at the P4 position allow for 
additional hydrogen bonds to S4 pocket residues 
The P4–cap inhibitors had an improved potency profile than the P4–P5-cap 
inhibitors. The crystal structure of AJ-71 showed that this inhibitor when bound to 
wildtype protease has an extensive hydrogen bond network including the 
conserved hydrogen bond between Arg155 and Asp168 (Figure 4.5C). 
Additionally there is water-bridge between the ether oxygen of the carbamate 
group and backbone nitrogen of Ser159 mimicking the substrate-protease 
interaction also observed in the P4–P5-cap inhibitors. The trifluoro-2,2-
dimethylpropane moiety can make a hydrogen bond with the NH2 group Arg123, 
an additional interaction that is not present in parent compound JZ01-15 or 
grazoprevir. Thus, the addition of this electronegative P4 group allows for 
enhanced interaction with the S4 pocket of the protease.  
4.3.8 Hydrogen bond network of P4–cap inhibitor is 
conserved when bound to D168A protease 
The P4–cap inhibitors were more potent than the P4–P5 extended inhibitors 
against D168A protease. Unlike the P4–P5-cap inhibitors, the hydrogen bond 
network is unaltered in D168A relative to wildtype protease. AJ-71 adopts two 
different conformations in the protease active site when bound to the D168A 
protease. One conformation (Figure 4.5C) is stabilized by a water-bridge 
hydrogen bond between the fluoro group and NH1 hydrogen of Arg155. 
Interestingly, Arg155 adopts two unique conformations that are stabilized by the 
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presence of a sulfate ion. A phosphate ion, which is present in the buffer in which 
our biochemical assays were performed, could also stabilize the Arg155 residue 
in these conformations for AJ-71 to bind. The alternate conformation of AJ-71 in 
complex with D168A protease retains the flouro-mediated hydrogen bond with 
Arg123 present when bound to wildtype protease. Although the potency of this 
inhibitor is reduced against the D168A variant, this inhibitor likely maintains 
potency better than the JZ01-15 or grazoprevir due to the conserved hydrogen 
bond network.  
4.3.9 Packing of the designed inhibitors differs at the S4 
pocket of the wildtype NS3/4A protease  
To assess the molecular details of inhibitor packing at the S4 pocket, van der 
Waals (vdW) contact energies were calculated for each protease-inhibitor 
structure. Total vdW energies ranged from -90 to -87 kcal/mol. Most designed 
inhibitors had increased vdW contacts with the protease relative to parent 
compound JZ01-15 and grazoprevir (total vdW = -85 and -88 respectively). While 
the overall vdW profiles of each inhibitor class (P4 vs P4–P5-cap) were relatively 
the same in the areas of the inhibitor scaffold that are common (P1’–P3), most 
changes occurred at the S4 subsite (Figure 4.7). The P4–P5 inhibitors WK-23 
and AJ-67, which are larger in size than the P4–cap inhibitors, had between a 1-
3 kcal/mol increase in vdW contact energy relative to JZ01-15 with S4 subsite 
residues Ala157, Val158 and Ser159 when bound to wildtype protease (Figure 
4.7A). Residues Ala157 and Val158 form the base of the S4 pocket whereas 
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Ser159 is located right outside of the S4 pocket. Relative to JZ01-15 and 
grazoprevir, WK-23 and AJ-67 had fewer interactions with Asp168, a residue that 
forms one wall of the S4 pocket. This suggests that P4–P5-cap inhibitors bind 
more outside of the pocket rather than extending into the pocket.  
This is not the case for the P4–cap inhibitors. Relative to JZ01-15, all 3 P4–
cap inhibitors had increased hydrophobic contacts with Arg123, Val158 and 
Asp168 especially JZ01-19 and AJ-74 with the cyclopentyl and methycyclopentyl 
capping group, respectively (Figure 4.7B). The P4–cap inhibitors actually fit 
better in the S4 pocket than the P4–P5-cap inhibitors that override the pocket 
similar to grazoprevir (Figure 4.8). The P4 cyclopropyl capping group of 
grazoprevir and the t-butyl P4 moiety of AJ-67 are positioned over the S4 pocket 
unlike AJ-71. Moreover, P4–cap inhibitors JZ01-19 and AJ-74 with hydrophobic 
cyclic rings pack well against the aliphatic portion of the Arg155 and Asp168 side 
chains and also interact with the nonpolar residue Ala156 (Figure 4.9). AJ-71 
with the electronegative CF3 group also utilizes the space in the S4 pocket 
similarly to JZ01-19 and AJ-74 (Figure 4.8). Thus, the enhanced potency of 
these inhibitors against wildtype protease compared to the P4–P5-capping 
inhibitors likely stems from more efficient filling of the S4 pocket. 
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Figure 4.7: Inhibitor vdW interactions with wildtype HCV NS3/4A protease.  
(a) The van der Waals (vdW) contact energies for P4–P5-cap inhibitors and (b) 
change in vdW (Δ vdW) relative to parent compound JZ01-15. (c) vdW contact 
energies for P4–cap inhibitors AJ-71, JZ01-19 and AJ-74 and (d) Δ vdW relative 
to JZ01-15. These vdW values were calculated from the wildtype crystal 
structures of each inhibitor complex. Catalytic residues and S4 subsite residues 
are highlighted with a yellow and black star, respectively. Residues with the 
largest changes in vdW contact energies for both inhibitors classes are 
underlined.   
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Figure 4.8: Packing of inhibitors at S4 pocket of wildtype and D168A 
protease.  
Surface view of grazoprevir, AJ-67 and AJ71 bound to wildtype (blue) and D168A 
(orange) proteases. AJ-71 occupies two conformations in the protease active site 
when bound to D168A protease. The S4 pocket  is outlined using a dashed line. 
Catalytic triad residues and S4 subsite residues are shown as sticks.     
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Figure 4.9: Packing of P4–cap inhibitors at the S4 pocket of wildtype 
protease.  
(a) Front view and (b) side view of AJ-74 bound to wildtype protease. (c) Front 
view and (d) side view of JZ01-19 bound to wildtype protease. The protease is 
shown in surface representation. Inhibitors, S4 subsite residues and catalytic 
triad residues are shown as sticks.   
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4.3.10 D168A substitution alters the packing of P4–P5-cap 
inhibitors at the S4 pocket  
The substitution of Asp168 to a nonpolar alanine residue results in an 
approximately 2 kcal/mol reduction of vdW contact energies for P4–P5-cap 
inhibitor AJ-67 (total vdW -90 and -89 kcal/mol wildtype and D168A protease, 
respectively). The largest reductions in contacts occur at residues 168 and 159 
(Figure 4.10). This inhibitor relies on interactions with Ser159 as observed in 
hydrogen bond analysis. The P4–cap inhibitor AJ-71, which is more potent 
against D168A protease compared to AJ-67, has a more conserved vdW profile 
against the D168A variant losing about 1 kcal/mol in contacts (total vdW -87 and 
-86 kcal/mol wildtype and D168A respectively). AJ-71 loses the most contact with 
Asp168. However, the crystal structure shows that AJ-71 can adopt multiple 
conformations that gain other interactions including hydrogen bonds in the 
protease active site to accommodate the D168A substitution.  
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Figure 4.10: Changes in vdW interactions in D168A variant relative to 
wildtype protease.  
Changes for inhibitors AJ-67 and AJ-71 are shown in blue and red, respectively. 
vdW interactions were calculated from crystal structures of inhibitors bound to 
wildtype and D168A proteases. 
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4.4 Discussion 
A major obstacle in the design of inhibitors that remain active against rapidly 
evolving disease targets is drug resistance. As is the case with HCV, the 
emergence of resistance due to low fidelity of the NS5B RdRp leads to a 
heterogeneous population of viral species in the infected patient. Thus, to combat 
resistance, exploiting evolutionarily conserved regions in the protease active site 
is one strategy that may provide more “resistance-proof” inhibitors. The substrate 
envelope offers an added constraint in structure-based drug design allowing 
inhibitors to mimic substrates and avoid interactions with residues that are 
unessential in substrate processing. In this study, we demonstrate that the 
substrate envelope can successfully guide the design of inhibitors with improved 
resistance profiles against the pivotal D168A drug resistant variant in HCV 
protease.  
While in this study we focused on the D168A variant, other common single-
site substitutions to older generation inhibitors include R155K and A156T.101 
Grazoprevir, a drug with a P2 quinoxaline that binds on the catalytic residues 
His57 and Asp81, provides an inhibitor scaffold that is not susceptible to R155K 
substitutions due to limited interactions with this residue.89,106 However, 
grazoprevir is highly susceptible to A156T due to steric clash with the inhibitor’s 
P2–P4 macrocycle.111 The most recent FDA-approved HCV PIs voxilaprevir and 
glecaprevir share a very similar scaffold to grazoprevir including the P2–P4 
macrocycle, and both are susceptible to the A156T resistance substitution.51 
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Modification of grazoprevir’s P2–P4 macrocycle to the P1–P3 position led to the 
development of analogs with the P2 quinoxaline moieties such as JZ01-15 that 
have reduced susceptibility to R155K and A156T substitutions.124 It is necessary 
to identify such new inhibitor scaffolds to diversity our arsenal of PIs to limit 
cross-resistance. Further alteration of the P1–P3 macrocyclic inhibitor scaffold in 
conserved regions of the substrate envelope, especially the P4 region, proved to 
be a viable strategy to improve resistance profiles by use of substrate mimicry.  
Toward that end, two approaches were used to design novel PIs with either a 
P4–cap or a P4 modified amino acid and P5 capping group to explore 
unleveraged space in the substrate envelope. The P4–P5-cap inhibitors were 
less potent against both wildtype and D168A compared to parent compound 
JZ01-15 and FDA-approved inhibitor grazoprevir. However, these inhibitors 
exhibited flatter resistance profiles against the D168A substitution with an overall 
fold change in potency relative to wildtype less than 15 compared to 234 for 
grazoprevir. Although this scaffold allowed for additional backbone hydrogen 
bonds similar to those observed in viral substrates and side chain interactions 
with residues in the S4 subsite, these additional interactions were lost upon 
substitution at Asp168.  
In contrast to the P4–P5-cap inhibitors, the P4–cap inhibitors adequately 
utilize space in the substrate envelope gaining hydrogen bonds and vdW 
interactions that enhance the potency of these inhibitors, while maintaining 
improved resistance profiles. The P4–P5-cap inhibitors have flatter resistance 
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profiles but the P4 moiety does not adequately fill the S4 pocket. Like 
grazoprevir, these inhibitors have P4 groups that simply override the pocket 
instead of targeting the S4 space directly. The t-butyl P4 group of parent 
compound JZ01-15, somewhat extends into the S4 pocket but additional 
modifications to this scaffold here significantly improved filling of the S4 pocket 
and the potency. Our results demonstrate that the fit of the inhibitor in the 
substrate envelope and optimal filling of the S4 pocket is necessary to improve 
potency. 
Our findings suggest that additional alterations of the P4 moiety that fit within 
the substrate envelope may lead to inhibitors with improved potency against 
wildtype and mutant proteases. Structure activity relationship of P4 capping 
groups on other scaffolds have led to the development of more potent NS3/4A 
PIs with improved pharmacokinetic profiles.176,177 However, these inhibitors were 
not designed in the context of the substrate envelope and were only tested for 
activity against wildtype protease. Inhibitors designed without evolutionary 
constraints may be susceptible to resistance due to interactions with residues 
that are functionally unimportant in substrate processing. The exploration of other 
hydrophobic moieties that pack well in the S4 pocket may further improve vdW 
interactions. In addition, as in AJ-71, other hydrogen bond acceptors at the P4 
position of the inhibitors scaffold could improve interactions with Arg123 as the 
conformation of this residue is highly conserved in substrate and inhibitor 
complexes. Therefore, the combination of the substrate envelope constraint, P1–
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P3 macrocycle and exploration of additional of diverse P4 groups may identify 
PIs with further improved resistance profiles.  
In a quickly evolving disease target having an inhibitor that binds with high 
potency against the wildtype enzyme of interest is not sufficient. Instead, 
leveraging evolutionarily conserved regions of the target is critical, especially the 
substrate-binding pocket when designing competitive inhibitors. Substrate 
mimicry should be utilized at the outset of drug design to avoid resistance, as 
substitutions that disrupt inhibitor binding will then likely affect substrate 
processing as well. The substrate envelope provides a rational design strategy 
toward this goal, for the identification of inhibitors that are more robust against 
drug resistant variants. Use of the substrate envelope in conjunction with design 
of novel inhibitors with diverse P4 moieties may give rise to next-generation P1–
P3 macrocyclic inhibitors that have broad activity against multi-substituted 
protease variants and low susceptibility to cross-resistance.  
4.5 Methods  
4.5.1 Inhibitor Synthesis 
Grazoprevir, JZ01-15 and substrate envelope designed analogs were 
synthesized in-house using previously reported methods. Grazoprevir was 
prepared following a reported synthetic method.120 JZ01-15 and analogs were 
synthesized using our convergent reaction sequence as previously described, 
with minor modifications.106  
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4.5.2 Expression and Purification of NS3/4A Constructs  
The HCV GT1a NS3/4A protease gene described in the Bristol Myers Squibb 
patent was synthesized by GenScript and cloned into a PET28a expression 
vector.128 Cys159 was mutated to a serine residue to prevent disulfide bond 
formation and facilitate crystallization. The D168A gene were engineered using 
the site-directed mutagenesis protocol from Stratagene. Protein expression and 
purification were carried out as previously described.89 Briefly, transformed 
Escherichia coli BL21(DE3) cells were grown in TB media containing 30 µg/mL of 
kanamycin antibiotic at 37 °C. After reaching an OD600 of 0.7, cultures were 
induced with 1 mM IPTG and harvested after 3 h of expression. Cells were 
pelleted by centrifugation, resuspended in Resuspension buffer (RB) [50 mM 
phosphate buffer, 500 mM NaCl, 10% glycerol, 2 mM β-ME, pH 7.5] and frozen 
at −80 °C for storage. 
Cell pellets were thawed and lysed via cell disruptor (Microfluidics Inc.) two 
times to ensure sufficient DNA shearing. Lysate was centrifuged at 19,000 rpm, 
for 25 min at 4 °C. The soluble fraction was applied to a nickel column (Qiagen) 
pre-equilibrated with RB. The beads and soluble fraction were incubated at 4 °C 
for 1.5 h and the lysate was allowed to flow through. Beads were washed with 
RB supplemented with 20 mM imidazole and eluted with RB supplemented with 
200 mM imidazole. The eluent was dialyzed overnight (MWCO 10 kD) to remove 
the imidazole, and the His-tag was simultaneously removed with thrombin 
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treatment. The eluate was judged >90% pure by polyacrylamide gel 
electrophoresis, concentrated, flash frozen, and stored at −80 °C. 
4.5.3 Correction for the Inner Filter Effect 
The inner filter effect (IFE) for the NS3/4A protease substrate was determined 
using a previously described method.129 Briefly, fluorescence end-point readings 
were taken for substrate concentrations between 0 µM and 20 µM. Afterward, 
free 5-FAM fluorophore was added to a final concentration of 25 µM to each 
substrate concentration and a second round of fluorescence end-point readings 
was taken. The fluorescence of free 5-FAM was determined by subtracting the 
first fluorescence end point reading from the second round of readings. IFE 
corrections were then calculated by dividing the free 5-FAM florescence at each 
substrate concentration by the free 5-FAM florescence at zero substrate.  
4.5.4 Determination of Michaelis–Menten  (Km) Constant 
Km constants for GT1 and D168A protease were previously determined.106 
Briefly, a 20 µM concentration of substrate [Ac-DE-Dap(QXL520)- EE-Abu-γ-
[COO]AS-C(5-FAMsp)-NH2] (AnaSpec) was serially diluted into assay buffer [50 
mM Tris, 5% glycerol, 10 mM DTT, 0.6 mM LDAO, and 4% dimethyl sulfoxide] 
and proteolysis was initiated by rapid injection of 10 µL protease (final 
concentration 20 nM) in a reaction volume of 60 µL. The fluorescence output 
from the substrate cleavage product was measured kinetically using an EnVision 
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plate reader (Perkin-Elmer) with excitation wavelength at 485 nm and emission at 
530 nm. Inner filter effect corrections were applied to the initial velocities (Vo) at 
each substrate concentration. Vo versus substrate concentration graphs were 
globally fit to the Michaelis–Menten equation to obtain the Km value. 
4.5.5 Enzyme Inhibition Assays 
For each assay, 2 nM of NS3/4A protease (GT1a and D168A) was pre-
incubated at room temperature for 1 h with increasing concentration of inhibitors 
in assay buffer (50 mM Tris, 5% glycerol, 10 mM DTT, 0.6 mM LDAO, and 4% 
dimethyl sulfoxide, pH 7.5). Inhibition assays were performed in non-binding 
surface 96-well black half-area plates (Corning) in a reaction volume of 60 µL. 
The proteolytic reaction was initiated by the injection of 5 µL of HCV NS3/4A 
protease substrate (AnaSpec), to a final concentration of 200 nM and kinetically 
monitored using a Perkin Elmer EnVision plate reader (excitation at 485 nm, 
emission at 530 nm). Three independent data sets were collected for each 
inhibitor with each protease construct. Each inhibitor titration included at least 12 
inhibitor concentration points, which were globally fit to the Morrison equation to 
obtain the Ki value.  
4.5.6 Crystallization and Structure Determination 
Protein expression and purification were carried out as previously 
described.89 Briefly, the Ni-NTA purified WT1a protein was thawed, concentrated 
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to 3 mg/mL, and loaded on a HiLoad Superdex75 16/60 column equilibrated with 
gel filtration buffer (25 mM MES, 500 mM NaCl, 10% glycerol, and 2 mM DTT, 
pH 6.5). The protease fractions were pooled and concentrated to 25 mg/mL with 
an Amicon Ultra-15 10 kDa filter unit (Millipore). The concentrated samples were 
incubated for 1 h with 3:1 molar excess of inhibitor. Diffraction-quality crystals 
were obtained overnight by mixing equal volumes of concentrated protein 
solution with precipitant solution (20–26% PEG-3350, 0.1 M sodium MES buffer, 
4% ammonium sulfate, pH 6.5) at RT or 15 °C in 24-well VDX hanging drop 
trays. Crystals were harvested and data was collected at 100 K. Cryogenic 
conditions contained the precipitant solution supplemented with 15% glycerol or 
ethylene glycol.   
X-ray diffraction data were collected in-house using our Rigaku X-ray system 
with a Saturn 944 detector. All datasets were processed using HKL-3000.131 
Structures were solved by molecular replacement using PHASER.132 Model 
building and refinement were performed using Coot133 and PHENIX,134 
respectively. The final structures were evaluated with MolProbity135 prior to 
deposition in the PDB. To limit the possibility of model bias throughout the 
refinement process, 5% of the data were reserved for the free R-value 
calculation.136 Structure analysis, superposition and figure generation were done 
using PyMOL.137 X-ray data collection and crystallographic refinement statistics 
are presented above (Table 4.1). 
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4.5.7 Construction of HCV Substrate Envelope 
The HCV substrate envelope was computed using a method previously 
described.89 The HCV viral substrates representing the product complex 3-4A 
(residues 626–631 of full-length HCV PDB ID: 1CU1), 4A/4B (chain B, PDB ID: 
3M5M), 4B/5A (chain D, PDB ID: 3M5N) and 5A/5B (chain A, PDB ID: 3M5O) 
were used to construct the envelope. All structure were aligned in PyMOL using 
the Cα atoms of protease residues 137–139 and 154–160. Following 
superposition of all structures, Gaussian object maps at a contour of 0.5 were 
generated for each cleavage product in PyMOL.53,89 Four consensus maps were 
generated representing the minimum volume occupied by any 3 viral substrates. 
The four consensus maps were summed together to generate the final substrate 
envelope representing the shared van der Waals volume of the viral substrates.  
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Chapter V 
Discussion 
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5.1 Elucidation of mechanisms of resistance is paramount 
to the design of novel antivirals  
 
In rapidly evolving disease targets, the acquisition of drug resistance is almost 
inevitable. Though many argue that use of combination therapies to treat HCV 
including drugs against multiple viral proteins essential in the viral life cycle can 
potentially prevent resistance, there are other factors that need to be considered. 
Patient compliance, adherence to the drug regimen and taking the medicine 
correctly, is an important factor that is preventable. Differences in host genes 
from patient to patient can lead to variations of drug absorption, distribution, 
metabolism, and excretion (ADME) properties which can affect the effective 
dosing. Moreover, cost of the drugs can be a huge barrier to patients completing 
a course of treatment. All of these factors can lead to sub-optimal dosing, which 
is a nidus for the rise of resistant viral species. 
 Resistance is a change in the molecular recognition of the target for the drug, 
usually due to mutation, with minimal effect on substrate processing. The most 
optimal drug design approach is one that incorporates strategies to evade 
resistance at the outset of inhibitor design. However, evidence that a drug may 
become resistant is not always available a priori. Thus, when resistance does 
occur, it is paramount to understand the particular mechanisms of resistance at 
play and use those insights toward iterative rounds of drug design. In Chapter II 
of this thesis, I elucidated the mechanisms of resistance for highly potent 
inhibitors including grazoprevir against the Y56H/D168A protease variant. This 
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chapter demonstrated that even with the most potent inhibitors against the 
NS3/4A protease, HCV can incorporate multiple substitutions that disrupt 
inhibitor binding while still maintaining substrate processing. Chapters III and IV 
demonstrated that the use of insights from mechanisms of resistance determined 
prior to the start of this thesis research can be used to successfully design novel 
inhibitors that are more robust against resistance associated substitutions. 
Therefore, it is my hope that the mechanisms I have discovered will be used to 
design a diverse arsenal of HCV PIs with improved resistance profiles and 
effectiveness against highly mutated viral species. 
5.2 Implications for other multi-substituted protease 
variants  
Throughout this thesis, I have highlighted the importance of elucidating the 
mechanisms of drug resistance to inform drug design and development. Though I 
elucidated the resistance mechanisms of PIs against the Y56H/D168A variant, 
other double and even triple substitution variants consisting of Y56H, A156T, and 
D168A/N have been observed in patients who fail therapy with grazoprevir.98 In 
fact, resistance selection assays with glecaprevir selected double substitutions 
including A156T.51 This substitution has never been a threat as Ala156 
substitutions cause low replicative capacity. However, an additional substitution 
may improve enzymatic fitness by restoring substrate turnover, and allow viral 
variants to emerge that are detrimental to inhibitor potency. The aforementioned 
primary substitutions are located in the protease active site where the inhibitor 
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binds. However, additional substitutions do not have to occur at the active site. In 
HIV-1 protease, active site and distal substitutions often occur in combination to 
confer resistance.127 A recent study with glecaprevir selected substitutions at 
Ala156 in combination with Gln/Pro89 in GT 1a/b, which is located outside of the 
active site. This additional substitution at position 89 appears to have improved 
replicative efficiency to 100%.51 It is necessary to understand the molecular 
underpinning of resistance to these multi-substituted proteases, as there is a high 
likelihood of cross-resistance to glecaprevir and voxilaprevir given the structural 
similarity of these drugs. Understanding the molecular mechanisms of resistance 
and enzymatic fitness of these multi-substituted proteases will be necessary to 
improve potency of PIs against emerging resistant viral variants.  
In Chapter II, double mutant cycle analysis provided insights into how 
mutations may work together or independently to confer resistance. This analysis 
is a powerful tool to study the coupling of amino acids substitutions in double-
substitution variants. However, to fully understand the scope of resistance, we 
must also study the single substitution proteins individually. This may not always 
be feasible structurally, so I cannot overstate the value of computational 
techniques, especially molecular dynamics simulations, to understand how 
mutations change protein flexibility and dynamics on the atomistic scale. To 
further elucidate why two or three particular substitutions occur together, 
experimental techniques should be used to investigate changes protein stability, 
substrate turnover, and replicative capacity in single and multi-substituted 
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variants. These experiments may shed light on viral evolution and why particular 
substitutions occur together to confer resistance.  
5.3 Exploiting evolutionarily constrained regions in the 
protease active site to avoid resistance 
Evolutionarily constrained regions in the protease active site are comprised of 
residues that are critical to substrate turnover. The NS3/4A protease is a serine 
protease with the canonical catalytic triad consisting of residues His57, Asp81, 
and Ser139.53 Substitution of any one of these residues would be detrimental to 
the protease function. Thus, designing inhibitors that strongly interact with 
conserved residues such as the catalytic triad in the target protein is one strategy 
that can reduce the susceptibility to resistance, as substitutions will affect both 
inhibitor and substrate binding. 
 The P2 quinoxaline moiety of grazoprevir utilizes interactions with catalytic 
triad residues His57 and Asp81.89,111 Crystal structures solved in Chapter III–IV 
as well as Appendix A of inhibitors with modified P2 quinoxaline moieties 
demonstrate that regardless of location of the inhibitor macrocycle and 
substituents on the P2 quinoxaline, this binding mode is conserved for all 
inhibitors. Moreover, newer generation inhibitors voxilaprevir and glecaprevir 
designed based on the grazoprevir scaffold have a P2 quinoxaline. Although 
there are no crystal structures of these inhibitors bound to wildtype protease, in 
my opinion, they likely have a binding mode similar to grazoprevir. This binding 
mode was once thought to be “resistance proof.” However, Chapter II 
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demonstrates that substitution of neighboring residue Tyr56 to a smaller histidine 
residue actually impacts the binding of the quinoxaline moiety, weakening the 
critical π–π interactions with the heterocyclic ring of His57.  
To maintain strong interactions with the catalytic triad even in the presence of 
such mutations, rational design of other P2 candidate moieties that have the 
propensity to bind similarly to the P2 quinoxaline should be considered. 
Additionally, other strategies to strengthen the stacking interactions of the 
pyrazine ring of the quinoxaline with His57 may provide new inhibitors that are 
less susceptible to the Y56H/D168A double mutant. Some studies suggest that 
replacement of a CH group with a nitrogen atom may improve inhibitor binding 
and pharmacokinetic properties.178 Thus, the addition of a pyridopyrazine moiety 
at the P2 position of the inhibitor scaffold may yield antivirals with enhanced 
interactions with the His57 ring.  
In addition to optimizing inhibitor interactions with the catalytic triad residues, 
the substrate envelope can be used as an added constraint in novel PI design. 
Drugs designed to stay within the volume of the substrate envelope should be 
less susceptible to resistance. This has been demonstrated in HIV-1 protease 
where inhibitor pairs were synthesized that either intentionally extended beyond 
or were contained within the substrate envelope.179 Inhibitors that respected the 
substrate envelope constraint were more robust against drug resistant variants. 
In Chapter IV, crystal structure analysis and biochemical data showed that HCV 
PIs that fit within the substrate envelope have flatter resistance profiles. 
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Moreover, inhibitors that exploit the S4 pocket of the substrate envelope are not 
only less resistant, but also gain potency against the D168A variant.  
Our lab has an extensive history in exploring structure-activity relationships of 
different PI scaffolds for both HIV-1 and HCV protease.124,180-184 The substrate 
envelopes in HIV-1 protease and now HCV protease have successfully provided 
inhibitors that have improved resistance profiles against some of the most 
resistant variants.175,183 Thus, future SAR studies at the P4 position of the 
NS3/4A PI scaffold should incorporate the substrate envelope at the outset of 
novel inhibitor design. Diverse P4 moieties can be incorporated to interact with 
residues of the S4 pocket that are important in substrate recognition. Inhibitors 
should be biochemically characterized against wildtype GT1, other genotypes 
and resistant variants. Crystal structures should confirm fit with the envelope as 
well as evaluate new interactions that are gained or potentially lost with 
alterations at the P4 position. Hopefully, future SAR studies will generate a new 
arsenal of PIs that are more robust against common and emerging resistant 
variants.  
5.4 Role of macrocycle location in resistance 
The location of the inhibitor macrocycle greatly impacts the potency and 
resistance profile of HCV PIs. Our lab has demonstrated that the addition of a 
macrocycle to the inhibitor scaffold often improves the potency by 1 to 4 orders of 
magnitude.106 Inhibitors with a P2–P4 macrocycle, which connects the P2 moiety 
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to the P4 moiety, are often times more potent than the P1–P3 inhibitors. 
However, where P1–P3 macrocyclic inhibitor lack in potency, they make up the 
difference in their resistance profile. P1–P3 macrocyclic inhibitors have flatter 
resistance profiles likely due to their inherent flexibility. P2–P4 macrocyclic 
inhibitors are more susceptible to drug resistance substitutions because their P2 
and P4 groups are more constrained, restricting the ability to adapt to 
substitutions that change the binding site.106,124 Chapter III confirms this finding 
as well, as our P1–P3 macrocyclic analogs of grazoprevir although some were 
less potent had flatter resistance profiles. 
Voxilaprevir and glecaprevir, as aforementioned, are pan-genotypic P2–P4 
macrocyclic inhibitors with little susceptibility to most single substitutions in the 
NS3/4A protease. All P2–P4 macrocyclic inhibitors are highly susceptible to the 
A156T substitution, as the macrocycle will sterically clash with the larger 
threonine residue.106,111 These drugs, like grazoprevir, the FDA-approved 
inhibitor they are most similar to, select for substitutions at Ala156 in vitro, which 
causes a large fold shift in inhibitor potency. Moreover, Ala156-Asp168 double 
substitutions have been selected in vitro, which improve fitness. Although not yet 
observed clinically, the A156T substitution if coupled with such a fitness-rescuing 
second substitution could cause resistance to all P2–P4 macrocyclic PIs with a 
P2 quinoxaline moiety.  
Therefore, it is necessary to structurally analyze glecaprevir and voxilaprevir 
and design P1–P3 macrocyclic inhibitors that can obtain the same potency with 
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little susceptibility to RASs. Crystal structures of these inhibitors bound to 
wildtype, D168A, and other double substitution proteases could be determined 
and comparatively analyzed with grazoprevir, and P1–P3 macrocyclic analogs 
bound to the same variants. Structural analysis would provide mechanistic 
information about how subtle modifications to an inhibitor scaffold result in little 
change in activity against the most elusive resistant variants that were once 
detrimental to inhibitor potency. These insights can then be incorporated into the 
design of better P1–P3 macrocyclic inhibitors. This would lessen the threat of 
multi-mutant variants with the A156T substitution as P1–P3 macrocyclic inhibitors 
are not susceptible to this substitution. Moreover, incorporating inhibitor features 
of glecaprevir and voxilaprevir into P1–P3 macrocyclic inhibitor design may give 
rise to the first P1–P3 macrocyclic inhibitors with excellent potency and pan-
genotypic activity.  
5.5 Exploration of other genotypes  
At the conception of this thesis, one of my goals was to explore other GTs of 
HCV. Although I did assay compounds against GT3a protease in Chapter III, my 
thesis work primarily focused on GT1a. Rational drug design approaches for 
HCV PIs use GT1 as a surrogate for efficacy across genotypes. There is an 
abundance of structural data for GT1 protease, but limited structural data for 
other GTs has hampered drug design efforts. Although pan-genotypic PIs have 
 198 
received FDA-approval, their mechanism for potency against other genotypes or 
mutations they may select in other genotypes remains unknown.  
Globally, HCV genotypes differ at the nucleotide level by greater than 30% 
and subtypes differ by 20-25%.9 Interestingly, the active site of GT1 and GTs 4–6 
are 100% identical. GT2 and GT3 differ by 1 and 2 polymorphisms compared to 
GT1, respectively. In GT2, Thr160 is replaced by a smaller nonpolar residue 
alanine. GT3 has the polymorphisms D168Q and R123T.108 Protein engineering 
studies performed in our lab led to the design of a GT3 chimera consisting of a 
construct with a GT1 background and the active site polymorphism found in GT3 
as well as the additional mutation I132T. Crystal structures and MD simulations 
revealed that the differential efficacy of PIs observed against GT3 is due to 
changes in the protease hydrogen bond network and dynamic fluctuations as a 
result of the D168Q substitution.108 Crystal structures of glecaprevir and 
voxilaprevir bound to GT3 chimera may allow us to obtain mechanistic insights 
into the improved potency of these inhibitors against GT3.  
Although this chimera is amenable to crystallization and has led to valuable 
knowledge about GT3 protease, the differential efficacy of PIs against other non-
GT1 proteases where the active site is unchanged remains to be explained. 
Potentially, global changes outside of the active site might play a role in inhibitor 
efficacy against various GTs. As others and myself have performed extensive 
crystallization efforts with other non-GT1 proteases without any hits, novel 
techniques and approaches may be necessary to glean structural differences of 
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non-GT1-PI complexes. Even apo structures might afford structural information 
that can be used to investigate the mechanism of differential efficacy of PIs 
against non-GT1 protease variants. These findings can then be used in the 
design of optimal P1–P3 macrocyclic inhibitors that have pan-genotypic activity.  
Recent advances in single-particle cryoelectron microscopy (cryo-EM), 
another structural technique, may facilitate structure determination of non-GT1 
proteases.185-187 Full-length HCV NS3/4A protease is approximately 70 kDa. One 
limitation of this approach is that cryo-EM is more amenable to structure 
determination of large complexes (>150 kDa).187 However, a structure of 
isocitrate dehydrogenase (93 kDa) was solved to near-atomic resolution, 
demonstrating that with recent developments, cryo-EM may be applicable to 
smaller proteins.187 The difficulty with smaller proteins is that the alignment error 
of individual projections becomes higher as the size of the protein decreases due 
to decreased signal to noise ratio. Nevertheless, advance in microscopes, 
cameras and contrast via volta phase plates have led to improvement that may 
enable structure determination of smaller proteins.188,189 Additionally, the use of 
1-2 fragment antibodies (Fabs), which are about 50 kDa, allows one to increase 
the size of the molecule. Fabs also have the added benefit of helping with 
orientation determination.190  
A major focus in our lab is elucidating how small molecule inhibitors bind to 
wildtype and mutant proteins of different genotypes and exhibit differential 
efficacy. Studies have shown that cryo-EM can resolve density for small 
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molecule inhibitors bound to proteins.187,191 Thus, this technique may allow us to 
understand how inhibitors differentially bind to non-GT1 or mutant proteases in 
the context of full-length protease, which is currently not known in the field. 
Although cryo-EM can now reach resolutions similar to that of crystallography, a 
common opinion that others and I share, is that these two techniques should be 
used to complement one another. Both techniques have their own set of 
advantages in disadvantages. However the extensive crystal structure database 
of GT1a protease in our lab should be used in the analysis of future structures 
determined by cryo-EM as each could potentially represent different biological 
states that may be important in iterative rounds of inhibitor design.  
5.6 Design of PIs that target the helicase domain 
In the full-length NS3/4A protein, the C-terminus consists of the helicase 
domain. Although this thesis focused on the protease domain, there are many 
reasons why the full-length protein should be considered in future drug design 
strategies. The helicase domain enhances the proteolytic activity of the protease 
domain.192 Additionally, drug resistance mutations to protease inhibitors can 
occur in the helicase domain.193 Hence, substrate and inhibitor recognition may 
be influenced by the presence of the helicase domain. Structures of full-length 
NS3/4A bound to substrate and PIs will be necessary to interrogate the 
interactions of the helicase domain in substrate and inhibitor complexes.  
Helicase-protease inhibitors (HPIs) have the ability to block both helicase 
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unwinding and protease substrate processing via binding to an allosteric site 
located between the interfaces of the domains.194,195 These inhibitors have 
demonstrated activity against multiple genotypes and PI resistant variants. One 
group showed that HPIs and PIs actually work synergistically and that potentially 
HPIs stabilize the full-length protein in a conformation that facilitates PI 
binding.195 Thus, one strategy for future drug design would be to elaborate our 
P1–P3 PI scaffold to design inhibitors that can also disrupt helicase activity. The 
quinoxaline moiety, which interacts with conserved residues of the catalytic triad, 
binds close to the helicase-protease interface. Elaboration of the methoxy group 
at the 7-position of the P2 quinoxaline may provide inhibitors that can destabilize 
helicase activity while simultaneously blocking protease activity. This approach 
may reduce the susceptibility of HPIs to resistance, as inhibitors that bind in 
allosteric sites are likely to evolve resistance more rapidly because the allosteric 
site may be less conserved and not necessary for substrate recognition.   
5.7 Viral proteases of other rapidly evolving disease targets 
HCV is a member of the Flavividae family of positive stranded RNA viruses. 
Other closely related members of this family include Yellow Fever, Dengue, West 
Nile Virus (WNV) and Zika viruses to name a few.18,196-198 All of these viruses like 
HCV encode a protease that cleaves the viral polyprotein into functional and 
structural elements, which is a crucial step in the life cycle. HCV PIs are a 
success story in the treatment of HCV and in absence of treatment options for 
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other flaviviruses, a lot of effort in the field has been the development of DAAs 
against the viral protease in these viruses.199-202 To date, there are no FDA-
approved PIs against any of these viral proteases.  
Dengue and Zika NS2B-NS3 protease are closely related to HCV NS3/4A 
protease.203 Each virus like HCV encodes an RdRp with low fidelity, which 
implies that these viruses must recognize diverse substrates. Therefore, it is 
feasible that these viruses have their own unique substrate envelope that may be 
used in inhibitor design. In the absence of the selective pressure of a drug, it is 
difficult to predict residues that are likely to evolve resistance. However, one 
study provides strong evidence that resistance to a Dengue PIs can develop 
readily.204 The substrate envelope model has demonstrated benefit in improving 
or reducing susceptibility to resistance in two independent systems (HCV and 
HIV-1).183 Throughout this thesis, I have demonstrated that exploiting 
evolutionarily conserved regions in the protease and substrate mimicry are viable 
strategies to circumvent resistance. Substrate-protease structures of these and 
other viral proteases will be needed to construct the substrate envelope, which 
can then be very beneficial at the outset of inhibitor design.  
Zika and Dengue NS2B-NS3 proteases are serine proteases that share the 
canonical catalytic triad.203 In Chapter II and throughout this thesis, I have shown 
that a critical interaction of grazoprevir and HCV PIs that have been developed in 
the Schiffer laboratory is the stacking interactions between the P2 quinoxaline 
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and the His57 ring. Is it possible to develop Dengue or Zika PIs that leverage this 
same interaction? Could other heterocyclic rings be employed in inhibitor design 
and evaluated using the substrate envelope, with computational and biophysical 
techniques? One recent study demonstrated that repurposing HCV PIs that were 
discovered in high-throughput screens could yield promising Zika PIs.201 
Incorporation of HCV PI pharmacophores that predominantly interact with 
catalytic residues at the outset of DAA design may limit evolution of resistance 
and result in robust inhibitors against other viral proteases.   
5.8 Concluding Remarks  
In the duration of this thesis research, the treatment options and outcomes for 
HCV infection have truly transformed. However, even with these improvements, 
drug resistance still remains a problem with many people failing therapy. This 
thesis elucidates the mechanisms of drug resistance for PIs against a highly 
resistant variant and uses previously determined mechanistic resistance 
knowledge in iterative rounds of drug design with the goal of improving 
resistance profiles. My studies have shed light on a novel mechanism of drug 
resistance that may affect all newly FDA-approved PIs due to cross-resistance. 
In addition, I demonstrated that minimized contact with known residues that 
mutate to confer resistance and use of evolutionarily constrained regions in the 
protease active site are strategies that can successfully be employed to design 
inhibitors with better or maintained activity against resistance associated 
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variants. Future studies for following up on this work would be to determine the 
mechanisms of resistance for other relevant multi-substituted protease variants, 
and interrogate why particular substitutions occur together. Moreover, elucidating 
the differential potency of PIs against other genotypes, possibly using cryo-EM, 
may help design diverse inhibitors that are pan-genotypic, less susceptible to 
cross-resistance and more robust against resistance associated variants. My 
hope is that this work will guide future drug design efforts that will one day lead to 
the eradication of HCV infection. Although there are other public health factors 
including access to treatment, IV drug use, patient non-adherence that must also 
be addressed, my hope is that this thesis contributes to solving the drug 
resistance problem and providing cure for each and every HCV-infected patient.  
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Appendix A 
Quinoxaline-Based Linear HCV NS3/4A 
Protease Inhibitors Exhibit Potent Activity 
and Reduced Susceptibility to Drug 
Resistant Variants 
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Preface 
Appendix A is a collaborative study that is in preparation.   
Rusere, L. N.; Matthew, A. N.; Lockbuam, G. J.; Jahangir, M.; Newton, A.; 
Petropoulos, C. J.; Huang, W.; Kurt Yilmaz, N.; Schiffer, C. A.; Ali, A. 
Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent 
Activity and Reduced Susceptibility to Drug Resistant Variants. 
 
Contributions from Ashley N. Matthew:  
I expressed and purified all wildtype and mutant proteins used in this study. I 
performed a subset of the enzyme inhibition assays. I solved all the protease-
inhibitor crystal structures and interpreted the data. I also wrote part of the 
manuscript and made all the figures of solved crystal structures. 
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A.1 Abstract 
A series of linear HCV NS3/4A protease inhibitors was designed by 
eliminating the P2–P4 macrocyclic linker in grazoprevir, which in addition to 
conferring conformational flexibility allowed SAR exploration of diverse 
quinoxalines at the P2 position. Biochemical and replicon data indicated 
preference for small hydrophobic groups at the 3-position of P2 quinoxaline for 
maintaining potency against drug resistant variants R155K, A156T and D168A/V. 
The linear inhibitors, though generally less potent than the corresponding 
macrocyclic analogues, were relatively easier to synthesize and less susceptible 
to drug resistance. X-ray crystal structures of three inhibitors bound to wild-type 
NS3/4A protease revealed slightly different binding conformation of the P2 
quinoxaline depending on the substituent at the 3-position, which significantly 
impacted inhibitor potency and resistance profile. The SAR and structural 
analysis highlight inhibitor features that strengthen interactions of the P2 moiety 
with the catalytic triad residues, providing valuable insights to improve potency 
and resistance profile.  
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A.2 Introduction 
Hepatitis C virus (HCV) is a serious global health problem. The most recent 
estimates indicate that at least 70 million people worldwide have chronic HCV 
infection, and about 1.75 million new cases are recorded each year.1 HCV is the 
leading cause of liver diseases such as cirrhosis, fibrosis and liver cancer, and 
more than 50% of liver transplant cases result from chronic HCV infection. The 
treatment of HCV infection has been challenging due to high genetic diversity of 
the virus and a lack of antiviral drugs that effectively target all HCV genotypes.2 
Fortunately, recent advances in direct-acting antivirals (DAAs) targeting the HCV 
NS3/4A, NS5A and NS5B proteins have significantly improved sustained 
virological response (SVR) in patients across HCV genotypes.3 However, the 
high genetic diversity of HCV and the rapid emergence of drug resistance 
necessitate the use of combination therapies with two or three drugs from 
different classes to effectively treat infected patients. 
The HCV NS3/4A protease inhibitors (PIs) are a key component of new all-
oral combination therapies.3 The five FDA approved PIs are all macrocyclic 
acylsulfonamides with different heterocyclic moieties at the P2 position.4 Of 
these, paritaprevir and grazoprevir are active against most HCV genotypes,5,6 
while recently approved drugs glecaprevir and voxilaprevir exhibit pan-genotypic 
activity.7,8 These new PIs are also significantly more active against most 
polymorphic and drug resistant HCV variants.9 The development of NS3/4A PIs 
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with pan-genotypic activity and improved resistance profiles marks a major 
milestone in anti-HCV drug discovery. 
Despite remarkable improvements in potency and resistance profiles, the 
current NS3/4A PIs are still susceptible to drug resistance due to substitutions at 
one or more amino acid positions in the target protein.10,11 The most common 
resistance-associated substitutions (RASs) in the NS3/4A protease occur at 
residues Arg155, Ala156, and Asp168. Inhibitors show varying susceptibility to 
RASs at these and other positions depending on the heterocyclic moiety at the 
P2 position and the location of the macrocycle.12,13 Grazoprevir (1) (Figure A.1) 
was the first NS3/4A PI to show activity against most HCV genotypes and RASs 
due to its unique binding conformation.12,14 The P2 quinoxaline moiety in 1 
largely avoids direct interactions with residues Arg155 and Asp168, but instead 
interacts with the catalytic His57 and Asp81.12 As a result, 1 maintains potency 
against substitutions at Arg155 and is only moderately susceptible to 
substitutions at Asp168. However, the P2–P4 macrocycle in 1 causes steric 
clashes with larger substitutions at Ala156, resulting in drastically reduced 
potency.12 Both glecaprevir and voxilaprevir are also P2–P4 macrocyclic 
compounds structurally similar to grazoprevir and are expected to bind in similar 
conformations, as indicated by their particularly high susceptibility to substitutions 
at Ala156.9,15 These three PIs currently in clinical use indeed exhibit similar 
resistance profiles and thus are prone to cross-resistance. Therefore, more 
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robust NS3/4A PIs need to be developed, preferably incorporating diverse 
structural features.  
We have shown that the unique binding conformation of 1 does not depend 
on the P2–P4 macrocycle, as the P1−P3 macrocyclic and linear analogues, 
5172-mcP1P3 (2) and 5172-linear (3) (Figure A.1), still bind in a similar 
conformation as the parent compound.16 In the absence of the P2–P4 
macrocyclic constraint, the conformationally flexible P2 quinoxaline moiety can 
help the inhibitor better adapt to structural changes in the protease active site 
due to RASs, particularly at Ala156. Accordingly, compared to 1, the P1–P3 
macrocyclic analogue 2 exhibits similar potency against RASs at Arg155 and 
Asp168 but is significantly less susceptible to substitutions at Ala156, resulting in 
an overall improved resistance profile.13 
In addition to conferring conformational flexibility, elimination of the P2–P4 
macrocycle in 1 provides opportunities to further improve potency and resistance 
profiles by exploring structure-activity relationship (SAR) at the 3-position of P2 
quinoxaline in both the P1–P3 macrocyclic (2) and linear (3) analogues. Toward 
this end, we recently developed a substrate envelope guided design strategy that 
aims to exploit interactions with the invariant catalytic triad, minimize interactions 
with the S2 subsite residues and incorporate conformational flexibility at the P2 
moiety, which led to the identification of P1–P3 macrocyclic analogues of 2 with 
exceptional potency and resistance profiles.17 These exciting findings 
encouraged us to explore SAR of linear compound 3 to identify analogues with 
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improved potency against drug resistance HCV variants. In this letter, we report 
the structure-guided design, synthesis, and SAR studies of a series of 
quinoxaline-based linear NS3/4A PIs. In addition, we report co-crystal structures 
of three linear inhibitors with different P2 quinoxaline moieties bound to NS3/4A 
protease, providing valuable structural insights to further optimize potency and 
resistance profiles. 
A.3 Chemistry 
The synthesis of linear NS3/4A PI with diverse P2 quinoxaline moieties is 
outlined in Scheme A.1. The key Boc-protected P2 intermediates 4a-e were 
prepared from the corresponding 3-substituted 7-methoxy-quinoxalin-2-ones by 
an SN2 displacement reaction with the activated cis-hydroxyproline derivative as 
described previously.17 The P2 intermediates 4a-e were treated with 4N HCl to 
provide the proline derivatives 5a-e, which were subsequently reacted with N-
Boc-L-tert-leucine using HATU and DIEA to afford the P2–P3 intermediates 6a-e. 
The proline methyl ester intermediates were then hydrolyzed with LiOH to afford 
the acid intermediates 7a-e. Finally, the P2–P3 acids 7a-e were coupled with the 
P1–P1' acylsulfonamide intermediates 8 and 9, which were prepared following 
reported methods,18,19 to afford the target inhibitors 3, 10b-e and 11a-e. The tert-
butyl-capped compounds were converted to the corresponding cyclopentyl-
capped derivatives by removal of the Boc protecting group followed by reaction 
of the resulting amine salts with the N-(cyclopentyloxycarbonyloxy)-succinimide 
 212 
carbonate using DIEA as a base to furnish the desired compounds 14a-e and 
15a-e. (For synthesis of linear final compounds and intermediates please see 
Appendix C). 
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Scheme A.1: Synthesis of HCV NS3/4A protease inhibitors.  
Reagents and conditions: (a) 4 N HCl in dioxane, CH2Cl2, RT, 3 h; (b) Boc-Tle-
OH, HATU, DIEA, DMF, RT, 4 h; (c) LiOH.H2O, THF, H2O, RT, 24 h; (d) HATU, 
DIEA, DMF, RT, 2 h; (e) 4 N HCl in dioxane, RT, 3 h; (f) N-
(cyclopentyloxycarbonyloxy)-succinimide, DIEA, CH3CN, RT, 36 h.   
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A.4 Results and Discussion 
Although linear NS3/4A PIs are generally less potent compared to the 
corresponding macrocyclic analogues, they offer noteworthy advantages over the 
latter, including conformational flexibility that permits adaptability to RASs. 
Moreover, facile synthesis enables rapid sampling of inhibitor chemical space to 
optimize potency and pharmacokinetic properties. While all the current FDA 
approved NS3/4A PIs are macrocyclic, a number of linear inhibitors have been 
successfully developed including asunaprevir,20 which has been approved in 
Japan. Thus, despite reduced potency, linear inhibitors can serve as potential 
lead compounds to develop cheaper alternatives to complex, synthetically 
challenging macrocyclic drugs. 
We employed a structure-guided design strategy to identify analogues of the 
linear inhibitor 3 with improved potency and reduced susceptibility to clinically 
relevant HCV variants. The SAR exploration was focused on optimizing 
interactions of the P2 quinoxaline moiety and minimizing direct interactions with 
S2 subsite residues. In addition to exploring SAR at the 3-position of the P2 
quinoxaline, modifications at the P1′ and the N-terminal capping groups were 
also investigated (Figure A.1). The potency and resistance profiles of the 
resulting linear PIs were evaluated using biochemical and replicon assays. The 
enzyme inhibition constants (Ki) were determined against WT GT1a NS3/4A 
protease and drug-resistant variants R155K and D168A (Table A.1). For a 
subset of compounds, cellular antiviral potencies (EC50) were determined using 
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replicon-based antiviral assays against WT HCV and drug-resistant variants 
R155K, A156T, D168A, and D168V (Table A.2). Grazoprevir (1) was used as a 
control in all assays. 
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Figure A.1: Structures of the HCV NS3/4A protease inhibitors. 
Grazoprevir (1), P1–P3 macrocyclic analogue 5172-mcP1P3 (2), linear analogue 
5172-linear (3), and SAR compounds. 
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Table A.1: Inhibitory activity against wild-type NS3/4A protease and drug 
resistant variants 
 
Inhibitor R1 R2 
GT1a NS3/4A Protease Ki (nM) (fold change) 
WT R155K D168A 
3  Et H 19 ± 2.7 17 ± 2.3 (0.9) 642 ± 101 (34) 
11a  Et Me 16 ± 1.3  14 ± 1.1 (0.9)  385 ± 31 (24)  
14a  Et H 9.8 ± 2.0 15 ± 2.2 (1.5) 350 ± 30 (36) 
15a  Et Me 6.9 ± 0.5 13 ± 2.7 (1.9) 145 ± 14 (21)  
10b  Me H 18 ± 1.6 8.5 ± 2.1 (0.5) 290 ± 24 (16) 
11b  Me Me 14 ± 2.1 14 ± 1.7 (1.0) 265 ± 26 (19) 
14b  Me H 9.2 ± 0.9 9.6 ± 0.9 (1.0) 144 ± 23 (16) 
15b Me Me 7.1 ± 1.1 10 ± 1.3 (1.4) 140 ± 13 (20) 
10c  i-Pr H 32 ± 5.1 49 ± 11 (1.5) 1086 ± 137 (34) 
11c  i-Pr Me 29 ± 9.4 27 ± 5.6 (0.9) 1179 ± 170 (41) 
14c  i-Pr H 17 ± 3.2 55 ± 11 (3) 985 ± 106 (58) 
15c  i-Pr Me 21 ± 2.6 43 ± 11 (2.0) 1000 ± 80 (48) 
10d  Cl H 7.8 ± 1.1 2.2 ± 0.4 (0.3) 128 ± 16 (16) 
11d  Cl Me 6.1 ± 1.1 3.8 ± 0.6 (0.7) 119 ± 16 (31) 
14d  Cl H 3.8 ± 0.6 4.1 ± 0.5 (1.1) 99 ± 10 (26) 
15d  Cl Me 3.9 ± 0.7 5.2 ± 0.8 (1.3) 51 ± 6.0 (13) 
10e CF3 H 87 ± 18 24 ± 3.3 (0.3) 723 ± 80 (8) 
11e  CF3 Me 46 ± 9.6 12 ± 1.7 (0.3) 513 ± 50 (11) 
14e  CF3 H 34 ± 8.3 26 ± 7.7 (0.8) 703 ± 63 (21) 
15e  CF3 Me 22 ± 3.4 22 ± 6.9 (1.0) 516 ± 61 (24) 
5172-mcP1P3   2.0 ± 0.1 3.1 ± 0.34 (1.6) 91 ± 10 (46) 
Grazoprevir   0.20 ± 0.1 0.80 ± 0.3 (4) 40 ± 5.0 (200) 
 
N
O
H
NO
O
O
HN
O
N
H
O
S
O O
N
N
R1
OMe
R2
N
O
H
NO
O
O
HN
O
N
H
O
S
O O
N
N
R1
OMe
R2
3, 10b-e; 11a-e 14a-e; 15a-e
 218 
Table A.2: Antiviral activity against wild-type HCV and drug resistant variants 
 
Inhibitor R1 R2 
Replicon EC50 (nM) (fold change) 
WT R155K A156T D168A D168V 
3  Et H 24 50 (2.1) 73 (3.0) >500 (>21) >500 (>21) 
11a  Et Me      
14a  Et H      
15a  Et Me      
10b  Me H      
11b  Me Me      
14b  Me H 10 48 (4.8) 164 (16) 101 (10) 150 (15) 
15b  Me Me 4.5 28 (6.2) 87 (19) 45 (10) 59 (13) 
10c  i-Pr H      
11c  i-Pr Me      
14c  i-Pr H      
15c i-Pr Me      
10d  Cl H 6.6 10 (1.5) 107 (16) 38 (5.8) 12 (1.8) 
11d  Cl Me 6.3 10 (1.6) 100 (16) 30 (4.8) 12 (1.9) 
14d  Cl H 7.4 40 (5.4) 292 (40) 50 (6.8) 54 (7.3) 
15d  Cl Me 3.1 27 (8.7) 163 (53) 25 (8.1) 23 (7.4) 
10e  CF3 H      
11e  CF3 Me      
14e  CF3 H      
15e  CF3 Me      
5172-mcP1P3   0.33 1.8 (5.5) 9.7 (29) 6.3 (19) 9.1 (28) 
Grazoprevir   0.12 1.9 (16) 200 (1667) 11 (92) 5.3 (44) 
 
  
N
O
H
NO
O
O
HN
O
N
H
O
S
O O
N
N
R1
OMe
R2
N
O
H
NO
O
O
HN
O
N
H
O
S
O O
N
N
R1
OMe
R2
3, 10b-e; 11a-e 14a-e; 15a-e
 219 
Compared to the macrocyclic PIs 1 and 2, the linear analogue 3 exhibited 
significantly lower potency against WT protease (Ki = 19 nM) and experienced an 
even larger reduction in antiviral potency (EC50 = 24 nM), which is in line with our 
previous reports.13 Compound 3 was also less potent than 1 and 2 against drug-
resistant variants R155K, D168A and D168V in both enzyme inhibition and 
replicon assays. The significant potency losses for the linear compound 3 are 
likely due to the increase in conformational flexibility and associated entropic 
penalty of binding to the protease. However, close examination of the overall 
resistance profile revealed that fold losses in potency were generally lower for 
compound 3 than 1 in both enzyme inhibition and replicon assays. Moreover, 
while 1 was highly susceptible to the A156T variant (EC50 = 200 nM), with >1600-
fold loss in potency compared to WT, compound 3 showed better antiviral 
potency against this variant (EC50 = 73 nM). The reduced susceptibility to RAS 
variants, particularly at residue Ala156, observed for 3 demonstrates that 
removal of the macrocyclic linker and the resulting conformational flexibility 
allows the inhibitor to adapt to substitutions in the S2 subsite.  
To improve the potency profile of inhibitor 3, analogues with modifications at 
the P1' and P4 capping regions were prepared and tested. Replacement of the 
P1' cyclopropylsulfonamide with a more hydrophobic 1-
methylcyclopropylsulfonamide moiety generally improved potency of the resulting 
analogues. Thus, compared to 3, analogue 11a afforded a slight increase in 
enzyme potency against WT protease and RAS variants R155K and D168A. 
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Similarly, replacing the tert-butyl P4 capping group with a bulkier cyclopentyl 
moiety in 14a provided compounds with improved potency. Analogue 15a with 
the 1-methyl-cyclopropylsulfonamide moiety at P1’ and cyclopentyl P4 capping 
group was 2- and 4-fold more potent than 3 against WT (Ki = 6.9 nM) and D168A 
(Ki = 145 nM) but showed similar potency against the R155K protease. Thus, 
minor modifications at the P1' and P4 moieties of inhibitor 3 provided analogues 
with improved potency against WT protease and the D168A variant. 
We have shown that minimizing inhibitor interactions in the S2 subsite 
resulted in an overall improvement in potency and resistance profiles.17 Although 
the P2 quinoxaline in 3 largely avoids direct interactions with residues in the S2 
subsite, the ethyl group at the 3-position of this moiety makes hydrophobic 
interactions with the hydrocarbon portion of the Arg155 side chain as well as with 
Ala156. Thus, in an effort to optimize interactions with these residues, we 
explored changes at the 3-position of P2 quinoxaline moiety. Based on the co-
crystal structures and SAR results from the P1–P3 macrocyclic series,17 we 
expected that replacing the ethyl group with a smaller methyl group at this 
position, while reducing overall inhibitor interactions in the S2 subsite, would 
maintain important hydrophobic interactions with side chains of Arg155 and 
Ala156. As expected, compound 10b incorporating the 3-methylquinoxaline was 
2-fold more potent than 3 against the R155K and D168A protease variants in 
enzyme inhibition assays. However, analogue 11b with the 1-
methylcyclopropylsulfonamide moiety at P1' position did not show much 
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improvement in enzyme potency compared to 10b. Compounds 14b and 15b 
with the cyclopentyl P4 capping group were slightly more potent than the 
corresponding tert-butyl analogues 10b and 11b against WT and D168A. 
Furthermore, compounds 14b and 15b showed nanomolar potency in replicon 
assays against WT HCV, and despite losing about 5–20-fold potency, 15b 
maintained significant potency against all variants tested. Although both the 3-
ethyl and 3-methyl-quinoxaline compounds showed similar potencies against WT 
and R155K protease variants, PIs with the smaller methyl substituent were 
generally more potent against the D168A variant. Together, the enzyme inhibition 
and replicon data indicate a preference for smaller substituents at the 3-position 
of the P2 quinoxaline to maintain potency against RAS variants. 
Next, a larger isopropyl group was incorporated in compounds 10c and 11c to 
further explore the optimal size of the substituent at the 3-position of P2 
quinoxaline that can be accommodated in the S2 subsite without causing 
unfavorable interactions. These compounds displayed considerably lower 
potency compared to the 3-methyl- and 3-ethyl-quinoxaline compounds across 
all variants in enzyme inhibition assays. Moreover, compounds with a larger 
isopropyl group at this position were highly susceptible to RAS variants at 
residues Arg155 and Asp168 with Ki values in the millimolar range against the 
D168A protease. Analogues 14c and 15c, with a cyclopentyl P4 capping group, 
showed similar trends to the corresponding tert-butyl analogues across all 
protease variants tested. These findings further support our hypothesis that large 
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substituents at the 3-position of the P2 quinoxaline are detrimental to potency 
against the RAS variants. 
After determining optimal size of the substituent at the 3-position of the P2 
quinoxaline, we next focused our efforts on identifying isosteric replacements 
with variant electronic properties. Thus, a set of compounds bearing a 3-
chloroquinoxaline P2 moiety, with comparable spatial size to the 3-
methylquinoxaline, was analyzed by enzyme inhibition and antiviral assays. In 
general, compounds with the 3-chloroquinoxaline were significantly more potent 
than the corresponding 3-ethyl- and 3-methyl-quinoxaline analogues. 
Compounds 10d and 11d, with a tert-butyl P4 capping group, showed about 2-
fold better potency than the corresponding 3-methylquinoxaline analogues 10b 
and 11b against WT, R155K and D168A proteases. Similarly, the cyclopentyl-
capped compounds 14d and 15d (WT Ki = 3.8 and 3.9 nM, respectively) were 
more potent than the corresponding 14b and 15b, showing excellent potency 
against WT protease and RAS variants. In fact, both 14d and 15d exhibited Ki 
values against WT and RAS protease variants in the same range as the 
macrocyclic inhibitor 2 (WT Ki = 2.0 nM), indicating that potency of the 
quinoxaline-based linear PIs could be improved significantly by SAR exploration. 
In replicon assays, the 3-chloroquinoxaline compounds exhibited the best overall 
potency profile among the linear compounds, with PIs 10d, 11d and 15d showing 
significant improvement in replicon potency against the multidrug resistant HCV 
variants D168A/V (EC50 = 12–38 nM). However, these compounds were more 
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susceptible to the A156T substitution than the corresponding macrocyclic 
analogues.17 The improved potency profiles of the 3-chloroquinoxaline 
compounds compared to the corresponding 3-methylquinoxaline analogues 
indicate that the chloro group likely renders more favorable electronic properties 
to the P2 quinoxaline moiety, which improves the critical π-π stacking 
interactions with the catalytic residue His57. 
To further investigate the effect of electron-withdrawing groups on the activity 
of the inhibitors, derivatives with a more electronegative, although relatively 
larger, 3-trifluoromethylquinoxaline were examined. In contrast to the 3-
chloroquinoxaline inhibitors, compounds 10e and 11e showed considerable loss 
in potency against WT protease. However, despite relatively lower potency 
against WT, the 3-trifluoromethylquinoxaline analogues were slightly more potent 
than the corresponding 3-isopropylquinoxaline PIs against RAS variants R155K 
and D168A. Similar trends were observed for inhibitors 14e and 15e with the 
cyclopentyl P4 capping groups. While it is difficult to separate the effects of 
electronic properties of the chloro- and trifluoromethyl-quinoxaline moieties, it is 
likely that size played a more important role in determining the overall potency 
profile of these inhibitors. 
We determined crystal structures of three linear HCV NS3/4A PIs in complex 
with WT NS3/4A protease (Table A.3) in an effort to explain the observed 
potency and resistance profiles. The x-ray crystal structures of WT-15b, -15c and 
-15d co-complexes with PIs incorporating different P2 quinoxaline moieties were 
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compared with our previously determined structures of 1 and 3 (PDB IDs 3SUD 
and 5EQQ, respectively).12,16 These high-resolution structures provided details of 
protein-inhibitor interactions to elucidate the structural differences that underlie 
varied potency and susceptibility to RAS variants. 
  
 225 
Table A.3: X-ray data collection and crystallographic refinement statistics. 
 WT1a-15b WT1a-15c WT1a-15d 
PDB code 6CVW 6CVX 6CVY 
Resolution 1.78 Å 1.78 Å 1.80 Å 
Space group P212121 P212121 P212121 
Molecules in AUa 1 1 1 
Cell dimensions    
a (Å) 55.2 55.3 55.5 
b (Å) 58.5 58.5 58.5 
c (Å) 59.9 59.8 59.7 
β (°) 90 90 90 
Completeness (%) 98.3 99.1 96.4 
Total reflections 70790 119454 116526 
Unique reflections 18870 19054 17991 
Average I/σ 18.5 15.1 15.2 
Redundancy 3.8 6.3 6.5 
Rsym (%)b 7.8 (25.6) 7.1 (27.3) 8.5 (30.7) 
RMSDc in     
Bond lengths (Å) 0.014 0.019 0.009 
Bond angles (°) 1.4 1.5 1.1 
Rfactor (%)d 14.9 15.6 14.7 
Rfree (%)e 18.5 19.4 18.4 
aAU, asymmetric unit. 
bRsym = Σ | I − <I>|/ Σ I, where I = observed intensity, <I> = average intensity over 
symmetry equivalent; values in parentheses are for the highest resolution shell. 
cRMSD, root mean square deviation. 
dRfactor = Σ || Fo| − |Fc||/ Σ|Fo|.   
eRfree was calculated from 5% of reflections, chosen randomly, which were omitted from 
the refinement process. 
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The overall binding mode of linear inhibitors 15b-d is similar to that of 
macrocyclic inhibitors 1–2 and the parent compound 3, where the P2 quinoxaline 
predominately interacts with the catalytic triad residues (Figure A.2). These 
structures confirm that the quinoxaline moiety maintains this unique binding 
conformation irrespective of macrocyclization and the substituent at the 3-
position. The inhibitors 15b-d span the S1’–S4 pockets in the active site with a 
conserved hydrogen bond network present in all WT NS3/4A protease structures. 
Specifically, hydrogen bonds with the backbone carbonyl of Arg155 and nitrogen 
of Ala157 are maintained, and the P1’ acylsulfonamide moiety is positioned in the 
oxyanion hole, stabilized by hydrogen bonds with residues His57, Gly137, 
Ser138 and Ser139. Although the overall binding mode of linear analogues is 
similar to that of compound 1, there are subtle changes in the binding of P2 
quinoxaline that appear to impact inhibitor potency considerably. 
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Figure A.2: X-ray crystal structures of WT1a HCV NS3/4A protease in 
complex with linear inhibitors (a) 15b, (b) 15c, and (c) 15d.  
The protease active site is presented as a light grey surface with bound inhibitors 
depicted as orange sticks. The catalytic triad is highlighted in yellow, and drug 
resistance residues Arg155, Ala156, and Asp168 are shown as sticks. 
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The differences between the WT-1 and the 3-methylquinoxaline inhibitor 15b 
structures occur predominantly in the S2 subsite (Figure A.3A). Relative to WT-
1, the Asp168 side chain in the WT-15b structure is shifted to allow additional 
hydrogen bonding with the side chain of Arg155. This confirmation of Asp168, 
which allows the P4 cyclopentyl capping group to occupy the S4 pocket, is 
observed in all of the linear inhibitor structures and other WT protease-inhibitor 
complexes.12,17 The 3-methylquinoxaline moiety is shifted away from the catalytic 
residues toward the S2 subsite relative to the conformation of P2 quinoxaline in 
WT-1 structure. This shift was also observed in the parent compound 3, though 
to a lesser extent, likely to accommodate the larger ethyl group at the 3-position 
of quinoxaline (Figure A.4). However, despite larger shift of the 3-
methylquinoxaline moiety, inhibitor 15b has an improved potency profile against 
RAS variants compared to 3, likely due to weaker contacts of the smaller methyl 
group with residues in the S2 subsite that mutate to confer resistance. Thus, 
while a slight shift of the P2 quinoxaline toward the S2 subsite does not appear to 
affect the overall potency profile, the substituent at the 3-position of this moiety 
significantly impacts inhibitor potency against RAS variants.  
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Figure A.3: Superposition of WT-1 and (a) WT-15b, (b) WT-15c, and (c) WT-
15d complexes, focusing on the differences at the P2 quinoxaline.  
The protease is in ribbon representation (light grey), with bound inhibitors 1 
(blue) and 15b-d (orange) depicted as sticks. The side chains of catalytic triad 
and drug resistance residues Arg155, Ala156, and Asp168 are shown as sticks. 
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Figure A.4: Superposition of WT-1 and WT-3 complexes, focusing on the 
differences at the P2 quinoxaline.  
The protease is in ribbon representation (light grey), with bound inhibitors 1 
(blue) and 3 (orange) depicted as sticks. The side chains of catalytic triad and 
drug resistance residues Arg155, Ala156, and Asp168 are shown as sticks. 
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The shift of the quinoxaline moiety toward the S2 subsite residues was also 
observed in the WT-15c and WT-15d complexes (Figure A.3B–C), as well as in 
2 and other structures of the P1–P3 macrocyclic analogues.17 However, the 
crystal structure of inhibitor 15c with the 3-isopropyl substituted quinoxaline 
revealed an additional rearrangement of the P2 moiety. Compared to 1, the P2 
quinoxaline in 15c, with a larger isopropyl substituent, packs less against the 
catalytic His57 residue and instead moves toward the solvent exposed surface of 
the binding pocket (Figure A.3B). This movement of the quinoxaline away from 
the catalytic His57 is not observed in the inhibitor complexes with smaller 
substituents at the 3-position (Figure A.3A and 3C). Interestingly, this binding 
conformation is reminiscent of the conformation of 1 when bound to the A156T 
protease variant (PDB ID 3SUG) (Figure A.5), where the larger threonine 
residue causes steric clash with the P2–P4 macrocycle (cite).12,16 To 
accommodate the larger side chain in the A156T protease inhibitor 1 undergoes 
a rearrangement resulting in the shift of the P2 quinoxaline moiety toward the 
solvent exposed binding surface, weakening the critical π–π interactions with the 
catalytic His57 (Figure A.5A). This altered binding conformation of 1 results in 
dramatic potency losses against the RAS variants at Ala156.12 
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Figure A.5: (a) Superposition of WT-1 and A156T-1 and (b) A156T-1 and WT-
15d complexes, focusing on the differences at the P2 quinoxaline. 
The protease is in ribbon representation (light grey) with bound inhibitor 1 
depicted as sticks in blue (WT) and red (A156T), and inhibitor 15d (WT) in 
orange. The side chains of catalytic triad and drug resistance residues Arg155, 
Ala156, and Asp168 are shown as sticks. 
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Comparison of the A156T-1 and the WT-15c structures shows complete 
superposition of the inhibitors’ P2 quinoxaline moieties (Figure A.5B). The 
binding conformation of inhibitor 15c is altered relative to other linear compounds 
with smaller groups at the P2 quinoxaline to accommodate the bulky isopropyl 
substituent in the S2 subsite. This altered conformation of the 3-
isopropylquinoxaline results in significantly reduced interactions with the catalytic 
His57 residue. Any perturbation to the protease active site via substitution of the 
S2 subsite residues may further reduce interactions with the catalytic His57 
residue. These results reinforce the inhibition data, which shows that the 3-
isopropylquinoxaline compounds exhibit reduced potency against WT relative to 
the parent compound 3 and are the most susceptible to RAS variants. Moreover, 
these crystal structures highlight an important feature of inhibitor binding, 
suggesting that modifications of the inhibitor scaffold that cause movement of the 
quinoxaline away from the His57 toward the solvent exposed binding pocket are 
highly detrimental to potency. Whereas, movement of the quinoxaline away from 
His57 toward the S2 subsite residues has less of an effect on inhibitor potency 
when a smaller substituent is present at the 3-position of P2 quinoxaline. 
The 3-chloroquinoxaline series exhibited an excellent potency profile against 
WT and RAS variants even with a shift of the P2 quinoxaline moiety toward the 
S2 subsite. Interestingly, comparison of the WT-15b and WT-15d structures 
(Figure A.3C) did not reveal any noticeable difference in binding poses for the 3-
methyl- and 3-chloro-quinoxaline analogues that could explain the disparity in 
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inhibitory activity. The electronic effects of the chloro group appear to improve 
stacking interactions of the quinoxaline moiety with the catalytic residue His57, 
which are crucial for the binding of inhibitors with a P2 quinoxaline moiety. Thus, 
enhancing interactions with the catalytic triad residues by modifying the inhibitor 
P2 quinoxaline moiety is likely to improve overall binding energy and potency 
profiles. 
Interestingly, most of the linear PIs did not show any notable differences 
between potencies against the WT and R155K proteases. In fact, elevation in 
potency was observed for inhibitors with the 3-chloro- and 3-trifluoromethyl-
quinoxaline P2 moieties. Molecular modeling studies revealed that lysine side 
chain in R155K protease forms a salt bridge with Asp168 and another water 
mediated hydrogen bond with the backbone carbonyl of Lys80, while Asp168 
carboxylate forms two hydrogen bonds with the guanidinium group of Arg123 
(Figure A.6). This extensive network of interactions provides the hydrophobic 
surface that adequately accommodates the substituents at the 3-position of P2 
quinoxaline and hydrophobic groups at the P4 capping. This binding surface 
mimics the hydrophobic surface maintained by electrostatic interactions between 
Arg155 guanidinium and Asp168 carboxylate groups in WT protease and is likely 
responsible for the retention of potency by most of the linear analogues against 
the R155K variant. The additional water mediated hydrogen bonds between the 
quinoxaline ring nitrogen and Asp79 backbone carbonyl and Lys155 might be 
responsible for the enhancement in potency observed for some of the inhibitors. 
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Figure A.6: Energy minimized models of inhibitor 3 in the active site of (a) 
WT NS3/4A protease (5EQQ) and (b) drug resistant variant R155K (3SUE). 
The R155K mutation is shown underlined. Yellow and magenta dashed lines 
indicate hydrogen bonds or salt bridges, respectively. Catalytic triad residues are 
highlighted with an *.   
(a) (b)
K80
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A.5 Conclusion 
In summary, we have investigated the SAR of quinoxaline-based linear HCV 
NS3/4A PIs using a structure-guided design strategy to improve potency against 
drug resistant variants. X-ray crystal structures of three inhibitors with different 
P2 moieties bound to WT protease revealed the structural basis for the observed 
potency and resistance profiles. Inhibitors with small substituents at the 3-
position of the P2 quinoxaline were preferred for maintaining potency against 
drug resistant protease variants due to decreased interactions with the S2 
subsite residues. Compounds with larger groups at this position cause the P2 
quinoxaline moiety to shift out of the active site, weakening critical stacking 
interactions with the catalytic His57. These findings further support our 
hypothesis that optimizing inhibitor interactions with the S2 subsite residues in 
the protease active site results in improved potency and resistance profiles. 
Moreover, in the absence of a macrocycle, the quinoxaline-based linear PIs 
could be optimized by SAR exploration to provide compounds with high potency 
and improved resistance profiles.   
A.6 Methods  
A.6.1 Expression and Purification of NS3/4A Protease    
Constructs  
The HCV GT1a NS3/4A protease gene described in the Bristol Myers Squibb 
patent21 was synthesized by GenScript and cloned into a PET28a expression 
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vector. The D168A and R155K genes were engineered using the site-directed 
mutagenesis protocol from Stratagene. Protein expression and purification were 
carried out as previously described. Briefly, transformed Escherichia coli 
BL21(DE3) cells were grown in LB media containing 30 µg/mL of kanamycin 
antibiotic at 37 °C. After reaching an OD600 of 0.8, cultures were induced with 
1 mM IPTG and harvested after 4 h of expression. Cells were pelleted by 
centrifugation, resuspended in Resuspension buffer [50 mM phosphate buffer, 
500 mM NaCl, 10% glycerol, 2 mM β-ME, pH 7.5] and frozen at −80 °C for 
storage. 
Cell pellets were thawed and lysed via cell disruptor (Microfluidics Inc.) two 
times to ensure sufficient DNA shearing. Lysate was centrifuged at 19,000 rpm, 
for 25 min at 4 °C. The soluble fraction was applied to a nickel column (Qiagen) 
pre-equilibrated with Resuspension buffer. The beads and soluble fraction were 
incubated at 4 °C for 1.5 h and the lysate was allowed to flow through. Beads 
were washed with Resuspension buffer supplemented with 20 mM imidazole and 
eluted with Resuspension buffer supplemented with 200 mM imidazole. The 
eluent was dialyzed overnight (MWCO 10 kD) to remove the imidazole, and the 
His-tag was simultaneously removed with thrombin treatment. The eluate was 
judged >90% pure by polyacrylamide gel electrophoresis, concentrated, flash 
and stored at −80 °C. 
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A.6.2 Enzyme Inhibition Assays 
For each assay, 2 nM of NS3/4A protease (GT1a, R155K and D168A) was 
pre-incubated at room temperature for 1 h with increasing concentration of 
inhibitors in assay buffer (50 mM Tris, 5% glycerol, 10 mM DTT, 0.6 mM LDAO, 
and 4% dimethyl sulfoxide, pH 7.5). Inhibition assays were performed in non-
binding surface 96-well black half-area plates (Corning) in a reaction volume of 
60 µL. The proteolytic reaction was initiated by the injection of 5 µL of HCV 
NS3/4A protease substrate (AnaSpec), to a final concentration of 200 nM and 
kinetically monitored using a Perkin Elmer EnVision plate reader (excitation at 
485 nm, emission at 530 nm). Three independent data sets were collected for 
each inhibitor with each protease construct. Each inhibitor titration included at 
least 12 inhibitor concentration points, which were globally fit to the Morrison 
equation to obtain the Ki value.  
A.6.3 Cell-Based Drug Susceptibility Assays 
Mutations (R155K, D168A and A156T) were constructed by site-directed 
mutagenesis using a Con1 (genotype 1b) luciferase reporter replicon containing 
the H77 (genotype 1a) NS3 sequence.22 Replicon RNA of each protease variant 
was introduced into Huh7 cells by electroporation. Replication was then 
assessed in the presence of increasing concentrations of protease inhibitors by 
measuring luciferase activity (relative light units) 96 h after electroporation. The 
 239 
drug concentrations required to inhibit replicon replication by 50% (EC50) were 
calculated directly from the drug inhibition curves.  
A.6.4 Crystallization and Structure Determination 
Protein expression and purification were carried out as previously described. 
The Ni-NTA purified WT1a protein was thawed, concentrated to 3 mg/mL, and 
loaded on a HiLoad Superdex75 16/60 column equilibrated with gel filtration 
buffer (25 mM MES, 500 mM NaCl, 10% glycerol, and 2 mM DTT, pH 6.5). The 
protease fractions were pooled and concentrated to 25 mg/mL with an Amicon 
Ultra-15 10 kDa filter unit (Millipore). The concentrated samples were incubated 
for 1 h with 3:1 molar excess of inhibitor. Diffraction-quality crystals were 
obtained overnight by mixing equal volumes of concentrated protein solution with 
precipitant solution (20–26% PEG-3350, 0.1 M sodium MES buffer, 4% 
ammonium sulfate, pH 6.5) at RT in 24-well VDX hanging drop trays. Crystals 
were harvested and data was collected at 100 K. Cryogenic conditions contained 
the precipitant solution supplemented with 15% glycerol or ethylene glycol.   
 X-ray diffraction data were collected in-house using our Rigaku X-ray system 
with a Saturn 944 detector. All datasets were processed using HKL-3000.23 
Structures were solved by molecular replacement using PHASER.24 Model 
building and refinement were performed using Coot25 and PHENIX,26 
respectively. The final structures were evaluated with MolProbity27 prior to 
deposition in the PDB. To limit the possibility of model bias throughout the 
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refinement process, 5% of the data were reserved for the free R-value 
calculation.28 Structure analysis, superposition and figure generation were done 
using PyMOL.29 X-ray data collection and crystallographic refinement statistics 
are presented in Table A.3.  
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Hepatitis C virus (HCV), a virus that infects more than 180 million people 
worldwide, is the causative agent of chronic liver disease, which often progresses 
to fibrosis, liver cirrhosis, and hepatocellular carcinoma (HCC). According to the 
World Health Organization, almost half a million patients infected with HCV die 
each year from cirrhosis and HCC alone. In the last several years, treatment of 
HCV infections has been revolutionized by the development of small molecular 
inhibitors that target essential proteins encoded by the viral genome. These 
inhibitors, known as direct-acting antivirals (DAAs), have improved treatment 
option and outcomes and eliminated the need for interferon injections. However, 
the emergence of resistance-associated variants (RAVs) and high genetic 
variation among the six distinct genotypes of the virus have been presenting 
challenges, even leading to treatment failure.  
Newer all-oral DAA combination regimens for HCV infection consist of 
inhibitors that target the NS3/4A, NS5A, and NS5B viral proteins. Of note, 
NS3/4A protease inhibitors have become a mainstay of treatment as most new 
therapies contain an inhibitor from this class. While highly effective against other 
genotypes, treatment of genotype 3 infections has been the most challenging, 
especially in patients who failed previous therapy or have cirrhosis. Recently, 
AbbVie received Food and Drug Administration (FDA) approval for one of the first 
pan-genotypic combination therapies, Mavyret, consisting of glecaprevir and 
pibrentasvir, an NS3/4A protease and an NS5A inhibitor, respectively (Figure 
B.1). Given the excellent pan-genotypic response and safety profile in patients, 
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Mavyret was approved for the treatment of genotypes 1−6 in patients without 
cirrhosis, or with compensated cirrhosis. In patients with noncirrhotic chronic 
HCV who were treatment-naiv̈e or had previously been treated with pegylated 
interferon or ribavirin, the sustained virological response (SVR) rate was 
83−100%across all genotypes.
1 In treatment-naiv̈e patients with compensated 
liver disease, 99% of patients achieved SVR with a 12-week course.
2 Mavyret 
was approved as an 8-week course for treatment-naiv̈e patients without cirrhosis, 
shortening the previous standard of care by an additional 4 weeks.  
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Figure B.1: 2D chemical structure of MavyretTM combination inhibitors, 
Glecaprevir (ABT-493) and Pibrentasvir (ABT-530).  
Glecaprevir and pibrentasvir are an NS3/4A protease and an NS5A inhibitor, 
respectively with pan-genotypic activity. This combination therapy has resulted in 
a sustained virological response of 83%-100% across genotypes and was 
approved by the FDA as an 8-week course shortening the standard of care by 16 
weeks.  
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One component of the Mavyret combination, pibrentasvir (ABT-530), has 
excellent potency across all HCV genotypes and retains potency against 
common RAVs. Pibrentasvir had EC50 values across genotypes ranging from 
1.4 to 5 pM against the HCV replicon in antiviral assays.
3 Under the selective 
pressure of inhibitors, RAVs emerge at positions 28, 30, 31, and 93 in the NS5A 
protein. In fact, all current NS5A inhibitors are susceptible to mutations at Tyr93. 
In vitro studies indicate pibrentasvir also selects these mutations, including 
Y93H, that confer resistance to other NS5A inhibitors.
3 However, pibrentasvir 
maintained good potency against many single-site NS5A mutations, suggesting 
double or triple mutants need to emerge to confer high levels of resistance 
against this inhibitor.  
The other component of Mavyret, glecaprevir (ABT-493), is a P2−P4 
macrocyclic NS3/4A protease inhibitor with subnanomolar to low nanomolar 
activity against all genotypes, including genotype 3.
4 NS3/4A protease inhibitors 
are often susceptible to single-site mutations at residues Arg155, Ala156, and 
Asp168. Most if not all protease inhibitors are susceptible to mutations at 
Asp168, which are often present in patients who fail therapy with a protease 
inhibitor. Notably, this active site residue is not conserved in genotype 3 and is 
Gln168 instead, contributing to the natural resistance of genotype 3 to most 
treatments. While potent against 168 variations, including genotype 3, 
glecaprevir is highly susceptible to A156T and A156V mutations. We have shown 
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that inhibitors containing P2−P4 macrocycles, as in glecaprevir, are susceptible 
to changes at Ala156, as substitutions with a larger side chain result in steric 
clash with the inhibitor’s macrocycle.5 Luckily, mutations at Ala156 do not occur 
alone because of reduced replicative capacity; however, additional mutations 
could restore the enzymatic fitness, which can lead to clinically viable multi-
mutant resistant variants.  
Thus, both components of Mavyret have good resistance profiles against wild 
type genotypes and single-mutant variants of HCV. What needs to be considered 
is the emergence of double, triple, or other multi-mutant variants that may have 
high levels of resistance to one or both components of this combination. Such 
multi-mutant variants potentially pose a threat to the longevity and success of 
HCV treatment. There are already double- and triple-mutant variants that have 
been isolated from patients who failed therapy with previously FDA- approved 
combination therapies. Considering the similarity in the inhibitor scaffolds and 
modes of action, there is a danger that these variants may be cross-drug 
resistant and not respond to any current treatment option, including Mavyret. As 
new drugs and combinations are developed, it will be important to understand the 
mechanisms of resistance for these multi- mutant variants and incorporate those 
insights into drug design. Rather than concentrating all effort into inhibitors from 
the same class with highly similar scaffolds, diversifying the arsenal of DAAs and 
considering triple-combination therapy may be required to avoid cases of 
incurable HCV infection.  
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The approval of Mavyret dual-combination therapy marks another milestone 
in the treatment of HCV infections. There had been a major effort to develop an 
all-oral combination therapy with activity against all genotypes. With the approval 
of Mavyret, this goal has been met. The newer-generation inhibitors and various 
combinations provide treatment options for patients and improve SVR rates 
across all genotypes. For many cases, Mavyret has decreased the standard of 
care from 24 to 8 weeks. More importantly, treatment options for patients with 
compensated liver disease are now available. One major remaining concern is 
the possible emergence of drug resistance. The newer inhibitors have better 
activity against single-site RAVs, but highly resistant multi-mutant strains may 
become clinically relevant. Preventing the emergence and spread of cross-
resistant variants and developing inhibitors with improved potency against such 
variants may be the next challenge.  
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Appendix C 
Synthesis of macrocyclic and linear final 
compounds and intermediates 
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Preface 
The following appendix contains additional information on the synthesis of 
macrocyclic and linear final compounds as well as intermediates from Chapter III 
and Appendix A.    
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Synthesis of Intermediates and Macrocyclic Final 
Compounds 
 
Scheme C.1: Synthesis of quinoxalines.  
Reagents and conditions: (a) AcOH, rt, overnight, 50 °C, 2 h; (b) aq. H2SO4 (1.8 
M), rt, 24 h; (c) MeOH, rt, 24 h; (d) Et3N, 150 °C, 2 h; (e) SOCl2, DMF, 110 °C, 
1.5 h. 
3-Ethyl-7-methoxyquinoxalin-2(1H)-one (8a). 
 
A mixture of 4-methoxy-1,2-diaminobenzene 4 (5.0 g, 36.2 mmol) and ethyl 2-
oxobutanoate 6a (5.70 g, 43.8 mmol) in AcOH (25 mL) was stirred at room 
temperature overnight and then heated at 50 °C for 2 h. AcOH was removed 
under reduced pressure, and the reside was extracted with CH2Cl2 (2 × 150 mL). 
The combined organic portions were washed with H2O and 10% aqueous 
Na2CO3 solution, dried (Na2SO4), and evaporated under reduced pressure. The 
residue was triturated with hexanes and filtered. The solid was mixed with EtOAc 
(25 mL), stirred at room temperature for 30 min, filtered, and dried under high 
vacuum to provide the 3-ethyl-7-methoxyquinoxaline 8a (6.0 g, 81%) as a light 
purple solid. 1H NMR (500 MHz, DMSO-d6) δ 12.17 (s, 1 H), 7.61 (d, J = 8.5 Hz, 
1 H), 6.85 (dd, J = 9.0, 2.5 Hz, 1 H), 6.73 (d, J = 2.5 Hz, 1 H), 3.80 (s, 3 H), 2.74 
(q, J = 7.5 Hz, 3 H), 1.19 (t, J = 7.5 Hz, 3 H) ppm; 13C NMR (125 MHz, DMSO-d6) 
δ 160.30, 159.35, 155.26, 133.63, 129.78, 127.01, 111.78, 98.26, 55.97, 26.17, 
10.08 ppm; MS (ESI) m/z: [M + H]+ calcd for C11H13N2O2, 205.24; found 205.90. 
7-Methoxy-3-methylquinoxalin-2(1H)-one (8b).  
8a  R1 = OMe; R2 = Et
8b  R1 = OMe; R2 = Me
8d  R1 = OMe; R2 = CF3 
8e  R1 = OMe; R2 = i-Pr  
8f   R1 = H; R2 = 2-thiophene
4  R1 = OMe
5  R1 = H
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4-Methoxy-1,2-diaminobenzene 4 (130 g, 0.94 mol) was added to an aqueous 
solution of sulfuric acid (1.8 M, 1300 mL) and the mixture was treated with ethyl 
pyruvate 6b (132 g, 1.14 mol). The resulting reaction mixture was stirred at room 
temperature for 24 h, then treated with an aqueous solution of 3 N NaOH till pH 
7. After stirring the mixture for 30 min, the solid precipitate was filtered, washed 
with water and dried. The solid product was mixed with EtOAc (1000 mL), heated 
to 60 °C, and vigorously stirred for 1 h. The solid was filtered, washed with EtOAc 
and dried under high vacuum to provide the 3-methyl-7-methoxyquinoxaline 8b 
(135 g, 75%) as a light purple solid.1H NMR (500 MHz, DMSO-d6) δ 12.18 (s, 1 
H), 7.59 (d, J = 9.0 Hz, 1 H), 6.86 (dd, J = 9.0, 3.0 Hz, 1 H), 6.73 (d, J = 2.5 Hz, 1 
H), 3.81 (s, 3H), 2.34 (s, 3H) ppm; 13C NMR (125 MHz, DMSO-d6) δ 160.30, 
155.85, 155.62, 133.82, 129.58, 127.02, 111.82, 98.29, 55.97, 20.63 ppm; MS 
(ESI) m/z: [M + H]+ calcd for C10H11N2O2, 191.21; found 191.30. 
3-Chloro-7-methoxyquinoxalin-2(1H)-one (8c) 
 
The title compound was prepared according to the method described by Harper 
et al.1 1H NMR (500 MHz, DMSO-d6) δ 7.35 (d, J = 8.5 Hz, 1 H), 6.65 (d, J = 2.5 
Hz, 1 H), 6.62 (dd, J = 8.5, 2.5 Hz, 1 H), 3.77 (s, 3 H), 3.71 (br s, 1 H) ppm; 13C 
NMR (125 MHz, DMSO-d6) δ 159.79, 159.30, 145.76, 145.62, 128.88, 128.02, 
110.57, 103.48, 55.56 ppm; MS (ESI) m/z: [M + H]+ calcd for C9H8ClN2O2, 
211.62; found 211.60. 
7-Methoxy-3-(trifluoromethyl)quinoxalin-2(1H)-one (8d).  
 
A solution of ethyl trifluoropyruvate 6d (20.4 g, 120 mmol) in MeOH (50 mL) was 
slowly added to 4-methoxy-1,2-diaminobenzene 4 (15.0 g, 108 mmol). The 
resulting reaction mixture was stirred at room temperature for 24 h. The solid 
precipitate was filtered, washed with cold MeOH and dried. The solid residue was 
mixed with MeOH (60 mL), stirred at 50 °C for 30 min, cooled to 5 °C, filtered, 
and dried under high vacuum to provide the 7-methoxy-3-
(trifluoromethyl)quinoxalin-2(1H)-one 8d (12 g, 47%) as a mustard solid.1H NMR 
(500 MHz, DMSO-d6) δ 13.01 (s, 1 H), 7.41 (d, J = 2.5 Hz, 1 H), 7.37 (dd, J = 9.0, 
2.5 Hz, 1 H), 7.32 (d, J = 9.0 Hz, 1 H), 3.84 (s, 3H) ppm; 13C NMR (125 MHz, 
DMSO-d6) δ 156.33, 151.77, 144.50 (q, J = 36.4 Hz), 131.04, 128.59, 124.08, 
120.66 (d, J = 274.4 Hz), 117.23, 110.88, 56.26 ppm;19F NMR (470 MHz, DMSO-
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d6); −68.45 ppm; MS (ESI) m/z: [M + Na]+ calcd for C10H7F3N2O2Na, 267.16; 
found 267.40. 
3-Isopropyl-7-methoxyquinoxalin-2(1H)-one (8e). 
 
A mixture of 4-methoxy-1,2-diaminobenzene 4 (130 g, 0.94 mol) and ethyl 3-
methyl-2-oxobutanoate 6e (162 g, 1.12 mol) in AcOH (650 mL) was stirred at 
room temperature overnight, and then heated at 50 °C for 2 h. AcOH was 
removed under reduced pressure. The residue was diluted with H2O (650 mL) 
and CH2Cl2 (800 mL) and the pH of the mixture was adjusted to pH ~ 10 by slow 
addition of 10% aqueous NaOH solution. The resulting precipitate was filtered, 
washed with CH2Cl2 (100 mL) and dried under vacuum to provide the 3-
isopropyl-7-methoxyquinoxaline 8e (91 g, 45%) as a light brown solid. 1H NMR 
(500 MHz, DMSO-d6) δ 12.22 (s, 1 H), 7.62 (d, J = 9.0 Hz, 1 H), 6.86 (dd, J = 9.0, 
3.0 Hz, 1 H), 6.75 (d, J = 2.5 Hz, 1 H), 3.81 (s, 3H), 3.43–3.37 (m, 1H), 1.19 (d, J 
= 7.0 Hz, 6 H) ppm; 13C NMR (125 MHz, DMSO-d6) δ 162.35, 160.36, 154.91, 
133.64, 129.90, 126.91, 111.80, 98.24, 55.97, 30.08, 20.57 ppm; MS (ESI) m/z: 
[M + H]+ calcd for C12H15N2O2, 219.26; found 219.50. 
3-(Thiophen-2-yl)quinoxalin-2(1H)-one (8f). 
 
A mixture of 1,2-diaminobenzene 5 (5.41 g, 50 mmol) and ethyl 2-oxo-2-
(thiophen-2-yl)acetate 6f (9.2 g, 50 mmol) was stirred in ethanol (100 ml) at reflux 
for 18 h. The reaction mixture was cooled to 10 °C and stirred for 1 h. The solid 
precipitate was filtered, washed with ethanol (20 mL) and dried under high 
vacuum to give the title compound 8f (6.0 g, 53%) as a yellow solid. 1H NMR 
(500 MHz, DMSO-d6) δ 12.69 (s, 1 H), 8.41 (dd, J = 4.0, 1.5 Hz, 1 H), 7.83 (dd, J 
= 5.0, 1.0 Hz, 1 H), 7.77 (d, J = 8.0 Hz, 1 H), 7.51 (dt, J = 8.0, 1.5 Hz, 1 H), 7.35–
7.30 (m, 2 H), 7.23 (dd, J = 5.0, 3.5 Hz, 1 H) ppm; 13C NMR (125 MHz, DMSO-
d6) δ 153.42, 148.88, 138.92, 132.07, 131.89, 131.41, 131.36, 129.78, 128.11, 
128.0, 123.65, 115.28 ppm; MS (ESI) m/z: [M + H]+ calcd for C12H9N2OS, 229.28; 
found 229.50. 
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1-(tert-Butyl) 2-methyl (2S,4R)-4-((7-methoxy-3-methylquinoxalin-2-
yl)oxy)pyrrolidine-1,2-dicarboxylate (9b). 
 
 
A solution of 3-ethyl-7-methoxyquinoxalin-2-one 8b (4.0 g, 21 mmol) in 
anhydrous NMP (65 mL) was treated with Cs2CO3 (10.30 g, 31.6 mmol). After 
stirring the reaction mixture at room temperature for 15 min, proline derivative 3 
(8.82 g, 19.0 mmol) was added in one portion. The reaction mixture was heated 
to 55 °C, stirred for 4 h, and then another portion of proline derivative 3 (0.68 g, 
1.5 mmol) was added. The resulting reaction mixture was stirred at 55 °C for 
additional 2 h, cooled to room temperature, quenched with aqueous 1 N HCl 
solution (250 mL), and extracted with EtOAc (400 mL). The organic fraction was 
washed successively with saturated aqueous NaHCO3 and NaCl (250 mL each), 
dried (Na2SO4), filtered, and evaporated under reduced pressure. The residue 
was purified by flash column chromatography using 15–30% EtOAc/hexanes as 
the eluent to provide 9b (6.60 g, 75%) as a colorless gummy solid. 1H NMR (500 
MHz, CDCl3) (mixture of rotamers, major rotamer) δ 7.80 (d, J = 9.0 Hz, 1 H), 
7.17 (dd, J = 9.0, 3.0 Hz, 1 H), 7.11 (d, J = 2.5 Hz, 1 H), 5.71 (br s, 1 H), 4.48 (t, 
J = 8.0 Hz, 1 H), 3.99–3.91 (m, 4 H), 3.87 (d, J = 12.5 Hz, 1H), 3.78 (s, 3 H), 
2.67–2.58 (m, 1 H), 2.56 (s, 3 H), 2.43–2.37 (m, 1 H), 1.43 (s, 9 H) ppm; 13C 
NMR (125 MHz, CDCl3) δ 173.36, 160.24, 155.51, 153.81, 144.60, 141.04, 
134.22, 128.95, 118.63, 105.95, 80.54, 73.59, 58.20, 55.68, 52.48, 52.20, 36.70, 
28.26, 19.93 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C21H28N3O6, 418.1973; 
found 418.1976. 
1-(tert-butyl) 2-methyl (2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidine-1,2-dicarboxylate (9c). 
 
The same procedure was used as described above for compound 9b. 3-Chloro-
7-methoxyquinoxalin-2(1H)-one 8c (4.0 g, 19.0 mmol) in NMP (60 mL) was 
treated with Cs2CO3 (9.30 g, 28.6 mmol) and proline derivative 3 (8.40 g, 18.1 
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mmol) to provide 9c (6.30 g, 76%) as an off-white foamy solid. 1H NMR (400 
MHz, CDCl3) (mixture of rotamers, major rotamer) δ 7.80 (d, J = 8.8 Hz, 1 H), 
7.21 (dd, J = 8.8, 2.8 Hz, 1 H), 7.12 (d, J = 2.8 Hz, 1 H), 5.69 (br s, 1 H), 4.52 (t, 
J = 7.6 Hz, 1 H), 4.0–3.94 (s, 4 H), 3.88 (d, J = 12.8 Hz, 1 H), 3.78 (s, 3 H), 2.72–
2.62 (m, 1 H), 2.45–2.37 (m, 1 H), 1.43 (s, 9 H) ppm; 13C NMR (400 MHz, CDCl3) 
δ 173.32, 162.35, 153.84, 152.48, 141.03, 136.11, 134.06, 129.97, 119.95, 
105.83, 80.60, 75.02, 58.10, 55.81, 52.36 , 52.10, 36.64, 28.27 ppm; HRMS 
(ESI) m/z: [M + H]+ calcd for C20H25ClN3O6, 438.1426; found 438.1438. 
1-(tert-Butyl) 2-methyl (2S,4R)-4-((3-isopropyl-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidine-1,2-dicarboxylate (9e). 
 
The same procedure was used as described above for compound 9b. 3-
Isopropyl-7-methoxyquinoxalin-2(1H)-one 8e (4.0 g, 18.3 mmol) in NMP (65 mL) 
was treated with Cs2CO3 (9.0 g, 27.6 mmol) and proline derivative 3 (8.30 g, 17.9 
mmol) to provide 9e (7.30 g, 90%) as a colorless gummy solid. 1H NMR (500 
MHz, CDCl3) (mixture of rotamers, major rotamer) δ 7.83 (d, J = 8.0 Hz, 1 H), 
7.16 (d, J = 8.4 Hz, 1 H), 7.10 (s, 1 H) 5.74 (br s, 1 H), 4.48 (t, J = 7.5 Hz, 1 H), 
3.92–3.87 (m, 5 H), 3.78 (s, 3 H), 3.41–3.36 (m, 1 H), 2.68–2.59 (m, 1 H), 2.42–
2.35 (m, 1 H), 1.43 (s, 9 H), 1.31 (t, J = 7.0 Hz, 6 H) ppm; 13C NMR (125 MHz, 
CDCl3) δ 173.37, 160.19, 154.62, 153.82, 152.00, 140.68, 134.31, 129.39, 
118.41, 105.80, 80.49, 73.36, 58.28, 55.67, 52.58, 52.19, 36.68, 30.81, 28.25, 
20.43, 20.38 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C23H32N3O6, 446.2286; 
found 446.2287. 
1-(tert-Butyl) 2-methyl (2S,4R)-4-((3-(thiophen-2-yl)quinoxalin-2-
yl)oxy)pyrrolidine-1,2-dicarboxylate (9f). 
 
The same procedure was used as described above for compound 9b. 3-
(Thiophen-2-yl)quinoxalin-2(1H)-one 8f (3.0 g, 13.1 mmol) in NMP (40 mL) was 
treated with Cs2CO3 (6.62 g, 20.3 mmol) and proline derivative 3 (6.0 g, 12.9 
mmol) to provide 9f (4.90 g, 82%) as an off-white foamy solid. 1H NMR (400 
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MHz, CDCl3) (mixture of rotamers, major rotamer) δ 8.13 (t, J = 4.0 Hz, 1 H), 
8.01 (d, J = 7.6 Hz, 1H), 7.79 (t, J = 8.0 Hz, 1 H), 7.66–7.55 (m, 2 H), 7.53 (dd, J 
= 5.2, 1.2 Hz, 1 H), 7.20–7.14 (m, 1 H), 5.91 (br s, 1 H), 4.56 (t, J = 8.0 Hz, 1 H), 
4.08 (d, J = 12.8 Hz, 1 H), 4.0–3.95 (m, 1 H), 3.79 (s, 3 H), 2.81–2.72 (m, 1 H), 
2.49–2.41 (m, 1 H), 1.44 (s, 9 H) ppm; 13C NMR (100 MHz, CDCl3) δ 173.30, 
153.80, 152.45, 140.48, 139.83, 138.93, 138.81, 130.35, 130.20, 129.45, 128.56, 
128.09, 127.33, 126.72, 80.56, 74.51, 58.27, 52.66, 52.26, 36.69, 28.27 ppm; 
HRMS (ESI) m/z: [M + H]+ calcd for C23H26N3O5S, 456.1588; found 456.1589. 
1-(tert-Butyl) 2-methyl (2S,4R)-4-((3-ethylquinoxalin-2-yl)oxy)pyrrolidine-1,2-
dicarboxylate (9g). 
 
The same procedure was used as described above for compound 9b. 
Commercially available 3-ethyl-quinoxalin-2(1H)-one 8g (3.0 g, 17.2 mmol) in 
NMP (40 mL) was treated with Cs2CO3 (8.42 g, 25.8 mmol) and proline derivative 
3 (7.80 g, 16.8 mmol) to provide 9g (4.50 g, 65%) as a colorless gummy solid. 1H 
NMR (400 MHz, CDCl3) (mixture of rotamers, major rotamer) δ 7.95 (d, J = 7.5 
Hz, 1 H), 7.76 (d, J = 8.0 Hz, 1 H), 7.62–7.52 (m, 2 H), 5.76 (br s, 1 H), 4.47 (t, J 
= 8.0 Hz, 1 H), 3.95–3.88 (m, 2 H), 3.78 (s, 3 H), 2.95 (q, J = 7.6 Hz, 2 H), 2.67–
2.60 (m, 1 H), 2.42–2.37 (m, 1 H), 1.43 (m, 9 H), 1.33 (t, J = 7.6 Hz, 3 H) ppm; 
13C NMR (100 MHz, CDCl3) δ 173.31, 154.69, 153.80, 152.08, 139.40, 138.79, 
128.97, 128.28, 126.87, 126.69, 80.51, 73.63, 58.25, 52.52, 52.19, 36.69, 28.25, 
26.91, 11.50 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C21H28N3O5, 402.2023; 
found 402.2026. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)non-8-enoyl)-4-((7-
methoxy-3-methylquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (12b).  
 
A solution of ester 9b (3.50 g, 8.4 mmol) in anhydrous CH2Cl2 (25 mL) was 
treated with a solution of 4 N HCl in 1,4-dioxane (25 mL). After stirring the 
reaction mixture at room temperature for 3 h, solvents were evaporated under 
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reduced pressure, and the residue was dried under high vacuum. The pale 
yellow solid was triturated with diethyl ether (3 × 25 mL) and dried under high 
vacuum to yield the amine salt 10b (3.0 g, 100%) as an off-white powder. 
A mixture of amine salt 10b (3.0 g, 8.4 mmol) and (S)-2-((tert-
butoxycarbonyl)amino)non-8-enoic acid 11 (2.50 g, 9.2 mmol) in anhydrous DMF 
(45 mL) was treated with DIEA (6.10 mL, 36.8 mmol) and HATU (5.25 g, 13.8 
mmol). The resulting reaction mixture was stirred at room temperature for 4 h, 
then diluted with EtOAc (400 mL), and washed successively with aqueous 0.5 N 
HCl, saturated aqueous NaHCO3, and saturated aqueous NaCl (250 mL each). 
The organic portion was dried (Na2SO4), filtered, and evaporated under reduced 
pressure. The residue was purified by flash chromatography using 20–30% 
EtOAc/hexanes as the eluent to provide 12b (4.0 g, 83%) as a white foamy solid. 
1H NMR (500 MHz, CDCl3) (mixture of rotamers, major rotamer) δ 7.81 (d, J = 
9.0 Hz, 1 H), 7.18 (dd, J = 9.0, 2.5 Hz, 1 H), 7.12 (d, J = 2.5 Hz, 1 H), 5.84–5.75 
(m, 2 H), 5.21 (d, J = 8.5 Hz, 1 H), 5.01–4.92 (m, 2 H), 4.75 (t, J = 8.0 Hz, 1 H), 
4.38 (q, J = 7.5 Hz, 1 H), 4.18 (d, J = 11.5 Hz, 1 H), 4.06 (dd, J = 12.0, 4.5 Hz, 1 
H), 3.94 (s, 3 H), 3.77 (s, 3 H), 2.69–2.64 (m, 1 H), 2.54 (s, 3 H), 2.41–2.35 (m, 1 
H), 2.04 (app q, J = 7.0 Hz, 2 H), 1.80–1.75 (m, 1 H), 1.63–1.55 (m, 1 H), 1.46–
1.24 (m, 15 H) ppm; 13C NMR (125 MHz, CDCl3) δ 172.13, 171.78, 160.27, 
155.40, 155.27, 144.62, 140.89, 138.96, 134.39, 129.03, 118.73, 114.35, 105.99, 
79.61, 74.30, 57.97, 55.66, 52.67, 52.43, 51.83, 34.94, 33.65, 32.66, 28.91, 
28.74, 28.25, 24.68, 19.87 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C30H43N4O7, 
571.3126; found 571.3128. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)non-8-enoyl)-4-((3-
chloro-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (12c). 
 
The same procedure was used as described above for compound 12b. 
Compound 9c (3.25 g, 7.4 mmol) was treated with 4 N HCl (20 mL) to afford 
amine salt 10c (2.77 g, 7.4 mmol), which was coupled with acid 11 (2.0 g, 7.4 
mmol) using DIEA (4.90 mL, 29.6 mmol) and HATU (4.20 g, 11.0 mmol) to 
provide 12c (3.30 g, 75%) as a white foamy solid. 1H NMR (400 MHz, CDCl3) 
(mixture of rotamers, major rotamer) δ 7.82 (d, J = 9.2 Hz, 1 H), 7.23 (dd, J = 9.2, 
2.8 Hz, 1 H), 7.15 (d, J = 2.8 Hz, 1 H), 5.85–5.75 (m, 2 H), 5.21 (d, J = 8.4 Hz, 1 
H), 5.02–4.91 (m, 2 H), 4.79 (t, J = 8.4 Hz, 1 H), 4.37 (q, J = 8.0 Hz, 1 H), 4.24 
(d, J = 11.6 Hz, 1 H), 4.07 (dd, J = 11.6, 4.4 Hz, 1 H), 3.95 (s, 3 H), 3.78 (s, 3 H), 
O
N CO2Me
O
H
NO
O
N
N
Cl
OMe
 262 
2.74–2.68 (m, 1 H), 2.42–2.36 (m, 1 H), 2.04 (app q, J = 6.8 Hz, 2 H), 1.82–1.76  
(m, 1 H), 1.63–1.55 (m, 1 H), 1.43–1.27 (m, 15 H) ppm; 13C NMR (400 MHz, 
CDCl3) δ 172.33, 171.87, 161.52, 155.59, 152.46, 141.06, 139.19, 136.28, 
134.36, 129.17, 120.25, 114.58, 106.03, 79.88, 75.92, 58.16, 56.02, 52.70, 
52.58, 52.00, 34.99, 33.88, 32.90, 29.14, 28.96, 28.46, 24.89 ppm; HRMS (ESI) 
m/z: [M + H]+ calcd for C29H40ClN4O7, 591.2580; found 591.2582. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)non-8-enoyl)-4-((3-
isopropyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (12e). 
 
The same procedure was used as described above for compound 12b. 
Compound 9e (3.25 g, 7.3 mmol) was treated with 4 N HCl (25 mL) to afford 
amine salt 10e (2.80 g, 7.3 mmol), which was coupled with acid 11 (2.20 g, 8.1 
mmol) using DIEA (5.36 mL, 32.4 mmol) and HATU (4.64 g, 12.2 mmol) to 
provide 12e (4.10 g, 93%) as a white foamy solid. 1H NMR (500 MHz, CDCl3) 
(mixture of rotamers, major rotamer) δ 7.84 (d, J = 8.5 Hz, 1 H), 7.18 (d, J = 9.0 
Hz, 1 H), 7.11 (s, 1 H), 5.87 (br s, 1 H), 5.84–5.76 (m, 1 H), 5.20 (d, J = 8.5 Hz, 1 
H), 4.99 (d, J = 17.5 Hz, 1 H), 4.93 (d, J = 10.0 Hz, 1 H), 4.72 (t, J = 8.0 Hz, 1 H), 
4.39 (q, J = 7.0 Hz, 1 H), 4.15 (d, J = 12.0 Hz, 1 H), 4.06 (dd, J = 12.0, 4.0 Hz, 1 
H) 3.94 (s, 3 H), 3.78 (s, 3 H), 3.40–3.34 (m, 1 H), 2.69–2.64 (m, 1 H), 2.40–2.34 
(m, 1 H), 2.04 (app q, J = 6.5 Hz, 2 H), 1.82–1.75 (m, 1 H), 1.63–1.56 (m, 1 H), 
1.45–1.20 (m, 21 H) ppm; 13C NMR (125 MHz, CDCl3) δ 172.13, 171.69, 160.24, 
155.38, 154.36, 152.00, 140.52, 138.96, 134.50, 129.46, 118.53, 114.35, 105.82, 
79.59, 74.03, 58.01, 55.66, 52.71, 52.43, 51.85, 34.95, 33.66, 32.68, 30.59, 
28.92, 28.75, 28.23, 24.69, 20.55, 20.43 ppm; HRMS (ESI) m/z: [M + H]+ calcd 
for C32H47N4O7, 599.3439; found 599.3440. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)non-8-enoyl)-4-((3-
(thiophen-2-yl)quinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (12f). 
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The same procedure was used as described above for compound 12b. 
Compound 9f (3.0 g, 6.6 mmol) was treated with 4 N HCl (20 mL) to afford amine 
salt 10f (2.60 g, 6.6 mmol), which was coupled with acid 11 (1.80 g, 6.6 mmol) 
using DIEA (4.35 mL, 26.3 mmol) and HATU (3.75 g, 9.9 mmol) to provide 12f 
(3.0 g, 75%) as an off-white foamy solid. 1H NMR (500 MHz, CDCl3) (mixture of 
rotamers, major rotamer) δ 8.09 (dd, J = 4.0, 1.2 Hz, 1 H), 8.02 (dd, J = 8.0, 1.6 
Hz, 1 H), 7.79 (dd, J = 8.8, 1.6 Hz, 1 H), 7.65–7.56 (m, 2 H), 7.53 (dd, J = 4.8, 
0.8 Hz, 1 H), 7.17 (dd, J = 5.2, 4.0 Hz, 1 H), 6.03 (br s, 1 H), 5.85–5.77 (m, 1 H), 
5.19 (d, J = 8.4 Hz, 1 H), 5.03–4.92 (m, 2 H), 4.83 (t, J = 8.0 Hz, 1 H), 4.43 (q, J 
= 7.2 Hz, 1 H), 4.32 (d, J = 12.0 Hz, 1 H), 4.12 (dd, J = 12.0, 4.4 Hz, 1 H), 3.79 
(s, 3 H), 2.83–2.77 (m, 1 H), 2.48–2.41 (m, 1 H), 2.05 (app q, J = 6.8, 2 H), 1.83–
1.77 (m, 1 H), 1.65–1.57 (m, 1 H), 1.46–1.20 (m, 15 H) ppm; 13C NMR (125 MHz, 
CDCl3) δ 172.11, 171.64, 155.38, 152.25, 140.51, 139.45, 138.97, 138.76, 
130.46, 130.34, 129.46, 128.60, 128.19, 127.45, 126.71, 114.36, 79.59, 75.08, 
58.01, 52.72, 52.46, 51.92, 34.91, 33.66, 32.62, 28.92, 28.75, 28.22, 24.76 ppm; 
HRMS (ESI) m/z: [M + H]+ calcd for C32H41N4O6S, 609.2741; found 609.2739. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)non-8-enoyl)-4-((3-
ethylquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (12g).  
 
The same procedure was used as described above for compound 12b. 
Compound 9g (3.50 g, 8.4 mmol) was treated with 4 N HCl (25 mL) to afford 
amine salt 10g (3.0 g, 17.2 mmol), which was coupled with acid 11 (2.50 g, 9.2 
mmol) using DIEA (6.10 mL, 36.8 mmol) and HATU (5.25 g, 13.8 mmol) to 
provide 12g (4.0 g, 83%) as a white foamy solid. 1H NMR (400 MHz, CDCl3) 
(mixture of rotamers, major rotamer) δ 7.97 (dd, J = 8.0, 1.6 Hz, 1 H), 7.77 (d, J = 
8.0, 1.6 Hz, 1 H), 7.63–7.53 (m, 2 H), 5.88 (br s, 1H), 8.84–5.75 (m, 1 H), 5.21 (d, 
J = 9.2 Hz, 1 H), 5.02–4.91 (m, 2 H), 4.74 (t, J = 8.4 Hz, 1 H), 4.37 (q, J = 8.0 Hz, 
1 H), 4.18 (d, J = 11.6 Hz, 1 H), 4.07 (dd, J = 11.6, 4.4 Hz, 1 H), 3.78 (s, 3 H), 
2.93 (q, J = 7.6 Hz, 2 H), 2.71–2.63 (m, 1 H), 2.42–2.35 (m, 1 H), 2.05 (app q, J = 
6.8 Hz, 2 H), 1.82–1.74 (m, 1 H), 1.62–1.55 (m, 1 H), 1.45–1.29 (m, 18 H) ppm; 
13C NMR (100 MHz, CDCl3) δ 172.05, 171.85, 155.39, 154.42, 152.0, 139.20, 
138.94, 138.84, 129.02, 128.27, 126.81, 114.34, 79.55, 74.23, 57.93, 52.62, 
52.44, 51.81, 34.85, 33.64, 32.57, 28.87, 28.70, 28.20, 26.69, 24.70, 11.40 ppm; 
HRMS (ESI) m/z: [M + H]+ calcd for C30H43N4O6, 555.3177; found 555.3177. 
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tert-Butyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)-4-((7-methoxy-3-methylquinoxalin-2-
yl)oxy)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate (16b). 
 
A solution of ester 12b (3.25 g, 5.7 mmol) in THF-H2O mixture (1:1, 100 mL) was 
treated with LiOH.H2O (0.72 g, 17.2 mmol). The resulting reaction mixture was 
stirred at room temperature for 24 h. The reaction mixture was cooled to ~5 °C, 
acidified to a pH of 2.0 by slow addition of aqueous 0.25 N HCl (~ 200 mL), and 
extracted with EtOAc (2 × 400 mL). The organic portions were washed 
separately with saturated aqueous NaCl (200 ml), dried (Na2SO4), filtered, and 
evaporated under reduced pressure. The gummy residue was dissolved in CHCl3 
(50 mL), concentrated under reduced pressure, and the residue was dried under 
high vacuum overnight to yield the acid 13b (3.17 g, 100%) as a white foamy 
solid. 
A mixture of acid 13b (1.60 g, 2.9 mmol) and amine salt 14 (0.93 g, 3.5 mmol) in 
anhydrous DMF (35 mL) was treated with DIEA (2.0 mL, 11.5 mmol) and HATU 
(1.75 g, 4.6 mmol). The resulting reaction mixture was stirred at room 
temperature for 2.5 h, then diluted with EtOAc (250 mL) and washed 
successively with aqueous 0.5 N HCl, saturated aqueous NaHCO3, and 
saturated aqueous NaCl (150 mL each). The organic portion was dried (Na2SO4), 
filtered, and evaporated under reduced pressure. The residue was purified by 
flash chromatography using 50–70% EtOAc/hexanes as the eluent to provide the 
bis-olefin compound 16b (1.57 g, 70%) as a white solid. 1H NMR (400 MHz, 
CDCl3) δ 10.24 (s, 1 H), 7.81 (d, J = 8.8 Hz, 1 H), 7.20 (dd, J = 8.8, 2.8 Hz, 1 H), 
7.13 (d, J = 2.8 Hz, 1 H), 7.07 (s, 1 H), 5.89 (br s, 1 H), 5.85–5.72 (m, 2 H), 5.39 
(d, J = 8.4 Hz, 1 H), 5.26 (d, J = 17.2 Hz, 1 H), 5.14 (d, J = 11.6 Hz, 1 H), 5.01–
4.90 (m, 2 H), 4.45 (t, J = 8.4 Hz, 1 H), 4.38–4.32 (m, 1 H), 4.21 (d, J = 12.0 Hz, 
1 H), 4.02 (dd, J = 11.6, 4.0 Hz, 1 H), 3.93 (s, 3 H), 2.95–2.89 (m, 1 H), 2.56–
2.48 (m, 5 H), 2.13 (q, J = 8.4 Hz, 1 H), 2.05–1.99 (m, 3 H), 1.74–1.66 (m, 1 H), 
1.62–1.54 (m, 1 H), 1.46–1.22 (m, 18 H), 1.07–1.02 (m, 2 H); 13C NMR (100 
MHz, CDCl3) δ 173.70, 172.41, 168.53, 160.32, 155.63, 155.17, 144.38, 140.88, 
138.83, 134.23, 132.47, 128.89, 118.92, 118.57, 114.44, 105.94, 79.76, 74.63, 
60.33, 55.69, 53.16, 52.29, 41.56, 35.18, 34.26, 33.66, 32.20, 31.13, 28.76, 
28.66, 28.25, 25.19, 23.59, 19.84, 6.48, 6.00 ppm; HRMS (ESI) m/z: [M + H]+ 
calcd for C38H53N6O9S, 769.3589; found 769.3579. 
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tert-Butyl ((S)-1-((2S,4R)-4-((7-methoxy-3-methylquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate 
(17b). 
 
The same procedure was used as described above for compound 16b. Acid 13b 
(1.60 g, 2.9 mmol) was coupled with amine salt 15 (0.98 g, 3.5 mmol) using DIEA 
(2.0 mL, 11.5 mmol) and HATU (1.75 g, 4.6 mmol) to provide the bis-olefin 
compound 17b (1.50 g, 66%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 
10.02 (s, 1 H), 7.81 (d, J = 8.8 Hz, 1 H), 7.18 (dd, J = 8.8, 2.8 Hz, 1 H), 7.13 (d, J 
= 2.8 Hz, 1 H), 7.11 (s, 1 H), 5.88 (br s, 1 H), 5.82–5.72 (m, 2 H), 5.42 (d, J = 9.2 
Hz, 1 H), 5.26 (d, J = 17.2 Hz, 1 H), 5.14 (d, J = 11.6 Hz, 1 H), 5.00–4.90 (m, 2 
H), 4.50 (t, J = 8.4 Hz, 1 H), 4.39–4.33 (m, 1 H), 4.18 (d, J = 11.6 Hz, 1 H), 4.02 
(dd, J = 11.6, 4.0 Hz, 1 H), 3.93 (s, 3 H), 2.58–2.50 (m, 5 H), 2.10 (q, J = 8.4 Hz, 
1 H), 2.05–1.98 (m, 3 H), 1.73–1.58 (m, 4 H), 1.49 (s, 3 H), 1.44–1.24 (m, 16 H), 
0.92–0.86 (m, 1 H), 0.84–0.78 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 173.65, 
172.52, 167.55, 160.31, 155.70, 155.16, 144.41, 140.87, 138.83, 134.33, 132.61, 
128.96, 118.87, 118.54, 114.41, 105.96, 79.73, 74.59, 60.30, 55.67, 53.15, 
52.37, 41.73, 36.56, 35.16, 34.25, 33.62, 32.24, 28.71, 28.67, 28.26, 25.31, 
23.42, 19.84, 18.37, 14.27, 13.26 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C39H55N6O9S, 783.3746; found 783.3734. 
tert-Butyl ((S)-1-((2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate 
(16c). 
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The same procedure was used as described above for compound 16b. Ester 12c 
(1.80 g, 3.0 mmol) was treated with LiOH.H2O to afford acid 13c, which was 
coupled with amine salt 14 (0.96 g, 3.6 mmol) using DIEA (2.0 mL, 12.1 mmol) 
and HATU (1.70 g, 4.5 mmol) to provide the bis-olefin compound 16c (1.75 g, 
74%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 10.25 (s, 1 H), 7.82 (d, J = 
8.8 Hz, 1 H), 7.26–7.23 (m, 1 H), 7.17 (d, J = 2.8 Hz, 1 H), 6.99 (s, 1 H), 5.88–
5.74 (m, 3 H), 5.33 (d, J = 8.8 Hz, 1 H), 5.28 (d, J = 17.2 Hz, 1 H), 5.16 (d, J = 
10.4 Hz, 1 H), 5.01–4.90 (m, 2 H), 4.53 (t, J = 8.4 Hz, 1 H), 4.37–4.32 (m, 1 H), 
4.28 (d, J = 11.6 Hz, 1 H), 4.03 (dd, J = 12, 4.0 Hz, 1 H), 3.96 (s, 3 H), 2.96–2.90 
(m, 1 H), 2.60–2.54 (m, 2 H), 2.14 (q, J = 8.8 Hz, 1 H), 2.07–2.00 (m, 3 H), 1.76–
1.54 (m, 2 H), 1.47–1.23 (m, 18 H), 1.08–1.02 (m, 2 H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 174.01, 172.48, 168.59, 161.61, 155.84, 152.31, 141.06, 139.09, 
136.14, 134.39, 132.66, 129.16, 120.43, 118.81, 114.66, 106.03, 80.05, 76.19, 
60.64, 56.05, 53.09, 52.56, 41.86, 35.44, 34.41, 33.90, 32.46, 31.39, 28.99, 
28.89, 28.46, 25.44, 23.80, 6.67, 6.27 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C37H50ClN6O9S, 789.3043; found 789.3030. 
tert-Butyl ((S)-1-((2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate 
(17c). 
 
The same procedure was used as described above for compound 16b. Ester 12c 
(1.80 g, 3.0 mmol) was treated with LiOH.H2O to afford acid 13c, which was 
coupled with amine salt 15 (1.0 g, 3.6 mmol) using DIEA (2.0 mL, 12.1 mmol) 
and HATU (1.70 g, 4.5 mmol) to provide the bis-olefin compound 17c (1.85 g, 
77%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 10.01 (s, 1 H), 7.82 (d, J = 
9.0 Hz, 1 H), 7.26–7.23 (m, 1 H), 7.17 (d, J = 2.5 Hz, 1 H), 7.02 (s, 1 H), 5.87 (br 
s, 1 H), 5.82–5.74 (m 2 H), 5.36 (d, J = 8.8 Hz, 1 H), 5.28 (d, J = 17.0 Hz, 1 H), 
5.15 (d, J = 11.2 Hz, 1 H), 5.00–4.96 (m, 1 H), 4.94–4.91 (m, 1 H), 4.53 (t, J = 8.4 
Hz, 1 H), 4.37–4.32 (m, 1 H), 4.24 (d, J = 11.5 Hz, 1 H), 4.03 (dd, J = 12.0, 4.0 
Hz, 1 H), 3.96 (s, 3 H), 2.61–2.53 (m, 2 H), 2.12 (q, J = 8.8 Hz, 1 H), 2.05–2.00 
(m, 3 H), 1.74–1.58 (m, 4 H), 1.50 (s, 3 H), 1.47–1.24 (m, 16 H), 0.92–0.86 (m, 1 
H), 0.85–0.80 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 173.74, 172.32, 167.42, 
161.39, 155.68, 152.09, 140.85, 138.88, 135.93, 134.20, 132.59, 128.95, 120.19, 
118.57, 114.41, 105.83, 79.79, 75.95, 60.39, 55.83, 52.86, 52.40, 41.79, 36.59, 
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35.21, 34.16, 33.65, 32.30, 28.73, 28.69, 28.27, 25.34, 23.44, 18.41, 14.24, 
13.39 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C38H52ClN6O9S, 803.3200; found 
803.3194. 
tert-Butyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)-4-((3-isopropyl-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate (16e). 
 
The same procedure was used as described above for compound 16b. Ester 12e 
(2.0 g, 3.3 mmol) was treated with LiOH.H2O to afford acid 13e, which was 
coupled with amine salt 14 (1.20 g, 4.5 mmol) using DIEA (2.25 mL, 13.6 mmol) 
and HATU (1.90 g, 5.0 mmol) to provide the bis-olefin compound 16e (1.85 g, 
70%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 10.25 (s, 1 H), 7.85 (d, J = 
8.8 Hz, 1 H), 7.19 (dd, J = 8.8, 2.8 Hz, 1 H), 7.12 (d, J = 2.8 Hz, 1 H), 7.01 (s, 1 
H), 5.92 (br s, 1 H), 5.84–5.73 (m, 2 H), 5.34 (d, J = 8.8 Hz, 1 H), 5.27 (d, J = 
17.2 Hz, 1 H), 5.14 (d, J = 11.6 Hz, 1 H), 5.01–4.89 (m, 2 H), 4.48 (t, J = 8.4 Hz, 
1 H), 4.40–4.33 (m, 1 H), 4.18 (d, J = 11.6 Hz, 1 H), 4.02 (dd, J = 11.6, 7.2 Hz, 1 
H), 3.93 (s, 3 H), 3.40–3.33 (m, 1 H), 2.96–2.90 (m, 1 H), 2.56–2.52 (m, 2 H), 
2.12 (q, J = 8.8 Hz, 1 H), 2.06–1.99 (m, 3 H), 1.75–1.54 (m, 2 H), 1.46–1.23 (m, 
24 H), 1.07–1.02 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 173.80, 172.33, 
168.47, 160.28, 155.64, 154.23, 151.76, 140.49, 138.84, 134.43, 132.48, 129.41, 
118.68, 118.54, 114.43, 105.76, 79.75, 74.33, 60.39, 55.67, 53.21, 52.38, 41.58, 
35.22, 34.24, 33.65, 32.17, 31.15, 30.63, 28.75, 28.65, 28.23, 25.22, 23.59, 
20.61, 20.41, 6.45, 6.02 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C40H57N6O9S, 
797.3902; found 797.3906. 
tert-Butyl ((S)-1-((2S,4R)-4-((3-isopropyl-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate 
(17e). 
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The same procedure was used as described above for compound 16b. Ester 12e 
(2.0 g, 3.3 mmol) was treated with LiOH.H2O to afford acid 13e, which was 
coupled with amine salt 15 (1.27 g, 4.5 mmol) using DIEA (2.25 mL, 13.6 mmol) 
and HATU (1.90 g, 5.0 mmol) to provide the bis-olefin compound 17e (2.0 g, 
75%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 10.03 (s, 1 H), 7.85 (d, J = 
9.2 Hz, 1 H), 7.19 (dd, J = 9.2, 2.8 Hz, 1 H), 7.12 (d, J = 2.8 Hz, 1 H), 7.03 (s, 1 
H), 5.92 (br s, 1 H), 5.84–5.73 (m, 2 H), 5.36 (d, J = 8.8 Hz, 1 H), 5.27 (d, J = 
17.2 Hz, 1 H), 5.14 (d, J = 10.8 Hz, 1 H), 5.01–4.89 (m, 2 H), 4.47 (t, J = 7.6 Hz, 
1 H), 4.40–4.33 (m, 1 H), 4.15 (d, J = 11.6 Hz, 1 H), 4.02 (dd, J = 11.6, 4.0 Hz, 1 
H), 3.94 (s, 3 H), 3.40–3.33 (m, 1 H), 2.57–2.52 (m, 2 H), 2.12 (q, J = 8.4 Hz, 1 
H), 2.05–1.99 (m, 3 H), 1.76–1.58 (m, 4 H), 1.49 (s, 3 H), 1.45–1.20 (m, 22 H), 
0.92–0.87 (m, 1H), 0.85–0.79 (m, 1 H) ppm; 13C NMR (100 MHz, CDCl3) δ 173 
.79, 172.38, 167.50, 160.28, 155.71, 154.23, 151.76, 140.49, 138.85, 134.43, 
132.61, 129.42, 118.69, 118.54, 114.41, 105.76, 79.72, 74.32, 60.40, 55.68, 
53.19, 52.47, 41.71, 36.56, 35.24, 34.22, 33.64, 32.18, 30.61, 28.70, 28.67, 
28.25, 25.35, 23.51, 20.63, 20.42, 18.38, 14.26, 13.31; HRMS (ESI) m/z: [M + 
H]+ calcd for C41H59N6O9S, 811.4059; found 811.4043. 
tert-Butyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)-4-((3-(thiophen-2-yl)quinoxalin-2-
yl)oxy)pyrrolidin-1-yl)-1-oxonon-8-en-2-yl)carbamate (16f). 
 
The same procedure was used as described above for compound 16b. Ester 12f 
(1.85 g, 3.0 mmol) was treated with LiOH.H2O to afford acid 13f, which was 
coupled with amine salt 14 (0.96 g, 3.6 mmol) using DIEA (2.0 mL, 12.1 mmol) 
and HATU (1.70 g, 4.5 mmol) to provide the bis-olefin compound 16f (1.60 g, 
66%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 10.23 (s, 1 H), 8.10 (d, J = 
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3.2 Hz, 1 H), 8.01 (dd, J = 8.0, 1.2 Hz, 1 H), 7.79 (dd, J = 8.8, 1.6 Hz, 1 H), 7.65–
7.56 (m, 2H), 7.53 (d, J = 5.2 Hz, 1 H), 7.17 (dd, J = 4.8, 4.0 Hz, 1 H), 7.11 (s, 1 
H), 6.08 (br s, 1 H), 5.83–5.73 (m, 2 H), 5.35 (d, J = 8.8 Hz, 1 H), 5.26 (dd, J = 
16.8, 1.2 Hz, 1 H), 5.13 (dd, J = 10.4, 1.2 Hz, 1 H), 5.01–4.90 (m, 2 H), 4.54 (t, J 
= 8.8 Hz, 1 H), 4.46–4.39 (m, 1 H), 4.34 (d, J = 12.4 Hz, 1 H), 4.07 (dd, J = 12.0, 
3.6 Hz, 1 H), 2.95–2.87 (m, 1 H),  2.68–2.56 (m, 2 H), 2.10 (q , J = 8.8 Hz, 1 H), 
2.05–1.98 (m, 3 H), 1.75–1.55 (m, 2 H), 1.45–1.16 (m, 18 H), 1.06–0.99  (m, 2 H) 
ppm; 13C NMR (100 MHz, CDCl3) δ 173.83, 172.34, 168.51, 155.70, 152.05, 
140.39, 139.17, 138.93, 138.86, 138.72, 132.47, 130.46, 130.35, 129.56, 128.57, 
128.13, 127.54, 126.72, 118.54, 114.44, 79.73, 75.39, 60.32, 53.23, 52.51, 
41.57, 35.14, 34.10, 33.66, 31.99, 31.14, 28.75, 28.67, 28.26, 25.34, 23.56, 6.46, 
6.03 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C40H51N6O8S2, 807.3204; found 
807.3214. 
tert-Butyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)-4-((3-ethylquinoxalin-2-yl)oxy)pyrrolidin-1-yl)-
1-oxonon-8-en-2-yl)carbamate (16g).  
 
The same procedure was used as described above for compound 16b. Ester 12g 
(1.95 g, 3.5 mmol) was treated with LiOH.H2O to afford acid 13g, which was 
coupled with amine salt 14 (1.10 g, 4.1 mmol) using DIEA (2.30 mL, 14.0 mmol) 
and HATU (2.0 g, 5.3 mmol) to provide the bis-olefin compound 16g (2.0 g, 76%) 
as a white solid. 1H NMR (400 MHz, CDCl3) δ 10.24 (s, 1 H), 7.96 (d, J = 8.4 Hz, 
1 H), 7.78 (d, J = 8.0 Hz, 1 H), 7.63–7.53 (m, 2 H), 7.05 (s, 1 H), 5.93 (br s, 1H), 
5.85–5.73 (m, 2 H), 5.35 (d, J = 8.4 Hz, 1 H), 5.27 (d, J = 17.2 Hz, 1 H), 5.14 (d, 
J = 10.8 Hz, 1 H), 5.00–4.90 (m, 2 H), 4.48 (t, J = 8.0 Hz, 1 H), 4.37–4.32 (m, 1 
H), 4.20 (d, J = 12.0 Hz, 1 H), 4.03 (dd, J = 12.0, 4.0 Hz, 1 H), 2.96–2.89 (m, 3 
H), 2.57–2.52 (m, 2 H), 2.12 (q, J = 8.8 Hz, 1 H), 2.05–1.99 (m, 2 H), 1.75–1.54 
(m, 2 H), 1.46–1.17 (m, 22 H), 1.08–1.02 (m, 2 H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 173.81, 172.33, 168.51, 155.64, 154.33, 151.84, 139.16, 138.91, 
138.84, 132.48, 129.11, 128.31, 126.92, 126.86, 118.54, 114.44, 79.74, 74.56, 
60.33, 53.16, 52.35, 41.56, 35.22, 34.18, 33.65, 32.14, 31.13, 28.74, 28.65, 
28.23, 26.73, 25.24, 23.62, 11.42, 6.47, 6.00 ppm; HRMS (ESI) m/z: [M + H]+ 
calcd for C38H53N6O8S, 753.3640; found 753.3636. 
N
O
H
NO
O
O
HN
O
N
H
O
S
O O
N
N
 270 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-14a-((cyclopropylsulfonyl)carbamoyl)-
2-((7-methoxy-3-methylquinoxalin-2-yl)oxy)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (18b).  
 
A degassed solution of bis-olefin 16b (1.57 g, 2.0 mmol) in 1,2-DCE (310 mL) 
was heated to 50 °C under argon, then Zhan 1b catalyst (0.150 g, 0.20 mmol) 
was added in two portions over 10 min. The resulting reaction mixture was 
heated to 70 °C and stirred for 6 h. The reaction mixture was cooled to room 
temperature and solvents were evaporated under reduced pressure. The residue 
was purified by flash chromatography using 50–90% EtOAc/hexanes as the 
eluent to yield the P1–P3 macrocyclic product 18b (0.67 g, 45%) as an off-white 
solid. 1H NMR (400 MHz, CDCl3) δ 10.28 (s, 1 H), 7.80 (d, J = 9.6 Hz, 1 H), 7.19–
7.16 (m, 2 H), 6.88 (s, 1 H), 5.89 (br s, 1 H), 5.69 (q, J = 9.2 Hz, 1 H), 5.12 (d, J = 
8.0 Hz, 1 H), 4.97 (t, J = 9.2 Hz, 1 H), 4.61 (t, J = 8.0 Hz, 1 H), 4.51 (d, J = 12.0 
Hz, 1 H), 4.28–4.22 (m, 1 H), 4.01 (dd, J = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.94–
2.86 (m, 1 H), 2.70–2.48 (m, 6 H), 2.31 (q, J = 8.4 Hz, 1 H), 1.94–1.68 (m, 2 H), 
1.60–1.22 (m, 19 H), 1.16–1.06 (m, 2 H), 0.95–0.89 (m, 1 H) ppm; 13C NMR (100 
MHz, CDCl3) δ 177.14, 173.33, 168.0, 160.31, 155.32, 155.03, 144.49, 141.01, 
136.30, 134.24, 128.68, 124.47, 118.90, 105.97, 79.85, 74.84, 59.44, 55.72, 
53.06, 51.96, 44.57, 34.58, 32.72, 31.02, 29.73, 28.15, 27.10, 27.05, 26.01, 
22.18, 20.96, 19.73, 6.67, 6.12 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C36H49N6O9S, 741.3276; found 741.3255. Anal. RP-HPLC: tR 12.71 min, purity 
99%. 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-2-((7-methoxy-3-methylquinoxalin-2-
yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (19b). 
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The same procedure was used as described above for compound 18b. Bis-olefin 
17b (1.50 g, 1.9 mmol) was treated with Zhan 1b catalyst (0.150 g, 0.20 mmol) in 
1,2-DCE (300 mL) to provide the P1–P3 macrocyclic compound 19b (1.0 g, 70%) 
as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 10.16 (s, 1 H), 7.82 (d, J = 9.2 
Hz, 1 H), 7.19–7.16 (m, 2 H), 6.92 (s, 1 H), 5.88 (br s, 1 H), 5.69 (q, J = 9.2 Hz, 1 
H), 5.12 (d, J = 7.6 Hz, 1 H), 4.99 (t, J = 8.8 Hz, 1 H), 4.61 (t, J = 8.0 Hz, 1 H), 
4.51 (d, J = 11.2 Hz, 1 H), 4.28–4.22 (m, 1 H), 4.03 (dd, J = 11.2, 4.0 Hz, 1 H), 
3.95 (s, 3 H), 2.70–2.50 (m, 6 H), 2.31 (q, J = 8.8 Hz, 1 H), 1.92–1.66 (m, 4 H), 
1.60–1.20 (m, 21 H), 0.85–0.78 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 
177.16, 173.33, 166.94, 160.33, 155.32, 155.04, 144.46, 141.03, 134.20, 136.25, 
128.66, 124.89, 118.93, 105.98, 79.85, 74.88, 59.46, 55.72, 53.08, 51.97, 44.73, 
36.43, 34.61, 32.72, 29.65, 28.15, 27.06, 26.07, 22.21, 20.96, 19.71, 18.17, 
14.51, 12.51 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C37H51N6O9S, 755.3433; 
found 755.3404. Anal. HPLC: tR 13.57 min, purity 99%. 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-2-((3-chloro-7-methoxyquinoxalin-2-
yl)oxy)-14a-((cyclopropylsulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (18c). 
 
The same procedure was used as described above for compound 18b. Bis-olefin 
16c (1.50 g, 1.9 mmol) was treated with Zhan 1b catalyst (0.150 g, 0.20 mmol) in 
1,2-DCE (300 mL) to provide the P1–P3 macrocyclic compound 18c (0.73 g, 
50%) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 10.30 (s, 1 H), 7.78 (d, J 
= 9.6 Hz, 1 H), 7.25–7.20 (m, 2 H), 7.00 (s, 1 H), 5.86 (s, 1 H), 5.68 (q, J = 9.2 
Hz, 1 H), 5.19 (d, J = 7.6 Hz, 1 H), 4.95 (t, J = 9.2 Hz, 1 H), 4.65 (t, J = 8.0 Hz, 1 
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H), 4.59 (d, J = 11.6 Hz, 1 H), 4.26–4.22 (m, 1 H), 4.03 (dd, J = 11.6, 4.0 Hz, 1 
H), 3.95 (s, 3 H), 2.94–2.87 (m, 1 H), 2.68–2.51 (m, 3 H), 2.31 (q, J = 8.8 Hz, 1 
H), 1.94–1.74 (m, 2 H), 1.60–1.20 (m, 19 H), 1.17–1.04 (m, 2 H), 0.96–0.89 (m, 1 
H) ppm; 13C NMR (100 MHz, CDCl3) δ 177.32, 173.48, 168.24, 161.52, 155.30, 
152.45, 141.15, 136.53, 136.25, 134.26, 129.02, 124.71, 120.31, 106.06, 80.14, 
76.38, 59.71, 56.08, 52.90, 52.15, 44.80, 34.73, 32.85, 31.28, 29.88, 28.38, 
27.36, 27.31, 26.29, 22.46, 21.13, 6.90, 6.35 ppm. HRMS (ESI) m/z: [M + H]+ 
calcd for C35H46ClN6O9S, 761.2730; found 761.2706. Anal. HPLC: tR 14.28 min, 
purity 96%. 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-2-((3-chloro-7-methoxyquinoxalin-2-
yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (19c). 
 
The same procedure was used as described above for compound 18b. Bis-olefin 
17c (1.20 g, 1.5 mmol) was treated with Zhan 1b catalyst (0.150 g, 0.20 mmol) in 
1,2-DCE (300 mL) to provide the P1–P3 macrocyclic compound 19c (1.0 g, 86%) 
as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 10.20 (s, 1 H), 7.78 (d, J = 
10.0 Hz, 1 H), 7.23–7.20 (m, 2 H), 7.07 (s, 1 H), 5.85 (br s, 1 H), 5.67 (q, J = 8.4 
Hz, 1 H), 5.25 (d, J = 7.2 Hz, 1 H), 4.96 (t, J = 9.2 Hz, 1 H), 4.67–4.58 (m, 2 H), 
4.28–4.22 (m, 1 H), 4.04 (dd, J = 11.2, 3.2 Hz, 1 H), 3.96 (s, 3 H), 2.68–2.62 (m, 
2 H), 2.60–2.50 (m, 1 H), 2.33 (q, J = 8.0 Hz, 1 H), 1.91–1.72 (m, 4 H), 1.60–1.20 
(m, 21 H), 0.84–0.78 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 177.18, 
173.18, 167.07, 161.27, 155.06, 152.21, 140.92, 136.27, 135.99, 134.0, 128.76, 
124.88, 120.09, 105.81, 79.90, 76.21, 59.51, 55.85, 52.69, 51.89, 44.70, 36.41, 
34.54, 32.57, 29.48, 28.25, 28.15, 27.11, 26.15, 22.22, 20.83, 18.17, 14.51, 
12.50 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C36H48ClN6O9S, 775.2887; found 
775.2870. Anal. HPLC: tR 14.69 min, purity 97%. 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-14a-((cyclopropylsulfonyl)carbamoyl)-
2-((3-isopropyl-7-methoxyquinoxalin-2-yl)oxy)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (18e).  
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The same procedure was used as described above for compound 18b. Bis-olefin 
16e (1.80 g, 2.3 mmol) was treated with Zhan 1b catalyst (0.150 g, 0.20 mmol) in 
1,2-DCE (350 mL) to provide the P1–P3 macrocyclic compound 18e (0.95 g, 
58%) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 10.28 (s, 1 H), 7.83 (d, J 
= 9.6 Hz 1 H), 7.20–7.15 (m, 2 H), 6.94 (s, 1 H), 5.91 (s, 1 H), 5.70 (q, J = 8.4 Hz, 
1 H), 5.20 (d, J = 8.0 Hz, 1 H), 4.97 (t, J = 8.8 Hz, 1 H), 4.58 (t, J = 8.0 Hz, 1 H), 
4.46 (d, J = 12.0 Hz, 1 H), 4.33–4.26 (m, 1 H), 4.03 (dd, J = 12.0, 4.4 Hz, 1 H), 
3.94 (s, 3 H), 3.41–3.33 (m, 1 H), 2.93–2.86 (m, 1 H), 2.66–2.50 (m, 3 H), 2.34 
(q, J = 8.8 Hz, 1 H), 1.93–1.74 (m, 2 H), 1.60–1.05, m, 27 H), 0.95–0.88 (m, 1 H) 
ppm; 13C NMR (100 MHz, CDCl3) δ 177.22, 173.13, 168.13, 160.22, 154.96, 
154.36, 151.82, 140.61, 136.32, 134.31, 129.28, 124.45, 118.61, 105.79, 79.81, 
74.55, 59.47, 55.71, 53.12, 51.86, 44.52, 34.74, 32.91, 31.00, 30.58, 29.65, 
28.18, 27.16, 27.11, 26.12, 22.14, 20.89, 20.51, 20.42, 6.67, 6.10 ppm; HRMS 
(ESI) m/z: [M + H]+ calcd for C38H53N6O9S, 769.3589; found 769.3565. Anal. 
HPLC: tR 15.82 min, purity 98%. 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-2-((3-isopropyl-7-methoxyquinoxalin-
2-yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (19e). 
 
The same procedure was used as described above for compound 18b. Bis-olefin 
17e (1.90 g, 2.3 mmol) was treated with Zhan 1b catalyst (0.20 g, 0.27 mmol) in 
1,2-DCE (350 mL) to provide the P1–P3 macrocyclic compound 19e (1.1 g, 60%) 
as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 10.15 (s, 1 H), 7.83 (d, J = 9.6 
Hz, 1 H), 7.19–7.15 (m, 2 H), 6.95 (s, 1 H), 5.91 (s, 1 H), 5.70 (q, J = 8.4 Hz, 1 
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H), 5.19 (d, J = 8.0 Hz, 1 H), 4.99 (t, J = 9.6 Hz, 1 H), 4.57 (t, J = 8.0 Hz, 1 H), 
4.47 (d, J = 11.6 Hz, 1 H), 4.34–4.27 (m, 1 H), 4.06 (dd, J = 11.2, 4.0 Hz, 1 H), 
3.94 (s, 3 H), 3.41–3.34 (m, 1 H), 2.68–2.48 (m, 3 H), 2.34 (q, J = 8.4 Hz, 1 H), 
1.93–1.70 (m, 4 H), 1.62–1.17 (m, 27 H), 0.84–0.78 (m, 2 H) ppm; 13C NMR (100 
MHz, CDCl3) δ 177.19, 173.14, 167.04, 160.24, 154.96, 154.36, 151.79, 140.62, 
136.25, 134.28, 129.25, 124.88, 118.64, 105.81, 79.81, 74.61, 59.49, 55.71, 
53.15, 51.87, 44.68, 36.43, 34.75, 32.91, 30.59, 29.59, 28.17, 27.14, 26.17, 
22.18, 20.91, 20.50, 20.42, 18.17, 14.50, 12.49 ppm; HRMS (ESI) m/z: [M + H]+ 
calcd for C39H55N6O9S, 783.3746; found 783.3722. Anal. HPLC: tR 16.46 min, 
purity 98%. 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-14a-((cyclopropylsulfonyl)carbamoyl)-
5,16-dioxo-2-((3-(thiophen-2-yl)quinoxalin-2-yl)oxy)-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (18f). 
 
The same procedure was used as described above for compound 18b. Bis-olefin 
16f (0.60 g, 0.7 mmol) was treated with Zhan 1b catalyst (0.10 g, 0.13 mmol) in 
1,2-DCE (200 mL) to provide the P1–P3 macrocyclic compound 18f (0.35 g, 
61%) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 10.28 (s, 1 H), 8.08 (d, J 
= 3.2 Hz, 1 H), 7.99 (d, J = 7.2 Hz, 1 H), 7.83 (dd, J = 8.4, 1.2 Hz, 1 H), 7.65–
7.55 (m, 2 H), 7.49 (d, J = 4.4 Hz, 1 H), 7.14 (t, J = 4.0 Hz, 1 H), 6.96 (s, 1 H), 
6.08 (br s, 1 H), 5.66 (q, J = 9.2 Hz, 1 H), 5.16 (d, J = 8.4 Hz, 1 H), 4.95 (t, J = 
10.0 Hz, 1 H), 4.69 (t, J = 8.0 Hz, 1 H), 4.63 (d, J = 12.4 Hz, 1 H), 4.34–4.27 (m, 
1 H), 4.08 (dd, J = 12.0, 4.0 Hz, 1 H), 2.94–2.86 (m, 1 H), 2.76–2.69 (m, 2 H), 
2.58–2.48 (m, 1 H), 2.29 (q, J = 8.4 Hz, 1 H), 1.92–1.74 (m, 2 H), 1.64–1.04 (m, 
20 H), 0.96–0.88 (m, 1 H) ppm; 13C NMR (100 MHz, CDCl3) δ 177.19, 173.43, 
168.20, 155.16, 152.45, 140.65, 139.81, 139.10, 139.07, 136.53, 130.53, 130.33, 
129.72, 128.72, 128.30, 127.60, 127.07, 124.72, 80.06, 75.73, 59.75, 53.41, 
52.21, 44.79, 34.84, 33.13, 31.27, 29.96, 28.30, 27.41, 27.23, 26.21, 22.54, 
21.17, 6.93, 6.37 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C38H47N6O8S2, 
779.2891; found 779.2873. Anal. HPLC: tR 15.96 min, purity 97%. 
tert-Butyl ((2R,6S,13aS,14aR,16aS,Z)-14a-((cyclopropylsulfonyl)carbamoyl)-
2-((3-ethylquinoxalin-2-yl)oxy)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
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hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (18g).  
 
The same procedure was used as described above for compound 18b. Bis-olefin 
16g (1.80 g, 2.4 mmol) was treated with Zhan 1b catalyst (0.20 g, 0.30 mmol) in 
1,2-DCE (350 mL) to provide the P1–P3 macrocyclic compound 18g (1.05 g, 
60%) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 10.32 (s, 1 H), 7.94 (d, J 
= 8.0 Hz, 1 H), 7.80 (dd, J = 8.0. 1.2 Hz 1 H), 7.62–7.51 (m, 2 H), 7.02 (s, 1 H), 
5.91 (br s, 1 H), 5.67 (q, J = 8.4 Hz, 1 H), 5.19 (d, J = 7.6 Hz, 1 H), 4.95 (t, J = 
9.2 Hz, 1 H), 4.61 (t, J = 8.0 Hz, 1 H), 4.51 (d, J = 11.6 Hz, 1 H), 4.27–22 (m, 1 
H), 4.03 (dd, J = 11.2, 3.6 Hz, 1 H), 2.94–2.85 (m, 3 H), 2.65–2.52 (m, 3 H), 2.32 
(q, J = 8.4 Hz, 1 H), 1.91–1.76 (m, 2 H), 1.56–1.20 (m, 20 H), 1.15–1.04 (m, 4 H), 
0.93–0.87 (m, 1 H) ppm; 13C NMR (400 MHz, CDCl3) δ 177.23, 173.20, 168.17, 
154.96, 154.48, 152.00, 139.29, 138.81, 136.32, 128.98, 128.20, 126.95, 126.68, 
124.50, 79.77, 74.79, 59.46, 53.16, 51.91, 44.57, 34.64, 32.81, 30.99, 29.66, 
28.13, 27.09, 26.68, 26.06, 22.14, 20.94, 11.31, 6.66, 6.10 ppm; HRMS (ESI) 
m/z: [M + H]+ calcd for C36H49N6O8S, 725.3327; found 725.3301. Anal. HPLC: tR 
14.40 min, purity 99%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-14a-
((cyclopropylsulfonyl)carbamoyl)-2-((7-methoxy-3-methylquinoxalin-2-
yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (22b). 
 
Compound 18b (0.32 g, 0.43 mmol) was treated with a solution of 4 N HCl in 1,4-
dioxane (10 mL). The reaction mixture was stirred at room temperature for 3 h, 
and then concentrated under reduced pressure, and the residue was dried under 
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high vacuum. The off-white solid was triturated with diethyl ether (3 × 10 mL) and 
dried under high vacuum to yield the amine salt 20b (0.29 g, 100%) as a white 
powder. 
A solution of the above amine salt 20b (0.29 g, 0.43 mmol) in anhydrous CH3CN 
(13 mL) was treated with DIEA (0.28 mL, 1.7 mmol) and N-
(cyclopentyloxycarbonyloxy)-succinimide (0.108 g, 0.48 mmol). The reaction 
mixture was stirred at room temperature for 36 h, then concentrated under 
reduced pressure and dried under high vacuum. The residue was purified by 
flash chromatography using 50–90% EtOAc/hexanes as the eluent to provide the 
target compound 22b (0.29 g, 90%) as a white solid. 1H NMR (400 MHz, CDCl3) 
δ 10.29 (s, 1 H), 7.79 (d, J = 9.6 Hz, 1 H), 7.20–7.16 (m, 2 H), 6.98 (s, 1 H), 5.91 
(br s, 1 H), 5.68 (q, J = 8.8 Hz, 1 H), 5.24 (d, J = 8.0 Hz, 1 H), 4.96 (t, J = 8.8 Hz, 
1 H), 4.88–4.84 (br s, 1 H), 4.62 (t, J = 7.6 Hz, 1 H), 4.42 (d, J = 11.6 Hz, 1 H), 
4.33–4.27 (m, 1 H), 4.04 (dd, J = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.94–2.86 (m, 
1 H), 2.69–2.48 (m, 5 H), 2.29 (q, J = 8.4 Hz, 1 H), 1.93–1.23 (m, 21 H), 1.17–
1.05 (m, 2 H), 0.96–0.87 (m, 1 H) ppm; 13C NMR (100 MHz, CDCl3) δ 177.18, 
173.03, 168.05, 160.22, 155.69, 155.32, 144.67, 140.95, 136.25, 134.26, 128.85, 
124.44, 118.79, 105.97, 77.89, 74.63, 59.45, 55.72, 53.02, 52.20, 44.51, 34.55, 
32.72, 32.65, 32.59, 31.02, 29.74, 27.21, 27.03, 26.04, 23.60, 23.57, 22.15, 
20.90, 19.86, 6.67, 6.12 ppm; HRMS (ESI) m/z: calcd for C37H49N6O9S [M + H]+ 
753.3276; found 753.3252. Anal. HPLC: tR 13.05 min, purity 99%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-2-((7-methoxy-3-methylquinoxalin-
2-yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (23b).  
 
The same procedure was used as described above for compound 22b. 
Compound 19b (0.44 g, 0.58 mmol) was treated 4 N HCl in 1,4-dioxane (10 mL) 
to yield the amine salt 21b, which was treated with DIEA (0.38 mL, 2.3 mmol) 
and N-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol) to provide 
the target compound 23b (0.32 g, 72%) as a white solid. 1H NMR (400 MHz, 
CDCl3) δ 10.17 (s, 1 H), 7.79 (d, J = 10.0 Hz, 1 H), 7.20–7.16 (m, 2 H), 6.96 (s, 1 
H), 5.91 (br s, 1 H), 5.69 (q, J = 8.8 Hz, 1 H), 5.25 (d, J = 8.0 Hz, 1 H), 4.98 (t, J = 
9.6 Hz, 1 H), 4.88–4.83 (m, 1 H), 4.61 (t, J = 8.0 Hz, 1 H), 4.43 (d, J = 11.2 Hz, 1 
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H), 4.34–4.27 (m, 1 H), 4.05 (dd, J = 10.8, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.70–2.48 
(m, 5 H), 2.30 (q, J = 8.8 Hz, 1 H), 1.93–1.23 (m, 25 H), 0.85–0.78 (m, 2 H) ppm; 
13C NMR (100 MHz, CDCl3) δ 177.20, 173.01, 167.0, 160.22, 155.68, 155.31, 
144.67, 140.96, 136.21, 134.27, 128.85, 124.86, 118.79, 105.98, 77.89, 74.67, 
59.48, 55.72, 53.05, 52.20, 44.67, 36.43, 34.58, 32.72, 32.65, 32.57, 29.64, 
27.17, 27.04, 26.09, 23.59, 23.57, 22.18, 20.91, 19.85, 18.17, 14.49, 12.51 ppm; 
HRMS (ESI) m/z: calcd for C38H51N6O9S [M + H]+ 767.3433; found 767.3408. 
Anal. HPLC: tR 13.88 min, purity 98%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-2-((3-chloro-7-methoxyquinoxalin-2-
yl)oxy)-14a-((cyclopropylsulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (22c). 
 
The same procedure was used as described above for compound 22b. 
Compound 18c (0.40 g, 0.53 mmol) was treated 4 N HCl in 1,4-dioxane (10 mL) 
to yield the amine salt 20c, which was treated with DIEA (0.35 mL, 2.1 mmol) 
and N-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol) to provide 
the target compound 22c (0.34 g, 83%) as a white solid. 1H NMR (500 MHz, 
CDCl3) δ 10.30 (s, 1 H), 7.79 (d, J = 9.0 Hz, 1 H), 7.23–7.20 (m, 2 H), 7.11 (s, 1 
H), 5.89 (br s, 1 H), 5.68 (q, J = 9.0 Hz, 1 H), 5.30 (d, J = 8.0 Hz, 1 H), 4.96 (t, J = 
9.0 Hz, 1 H), 4.84–4.80 (m, 1 H), 4.67 (t, J = 7.6 Hz, 1 H), 4.51 (d, J = 11.4 Hz, 1 
H), 4.29 (t, J = 7.6 Hz, 1 H), 4.04 (dd, J = 11.0, 3.5 Hz, 1 H), 3.95 (s, 3 H), 2.93–
2.87 (m, 1 H), 2.71–2.47 (m, 3 H), 2.30 (q, J = 8.5 Hz, 1 H), 1.95–1.20 (m, 20 H), 
1.16–1.04 (m, 2 H), 0.95–0.87 (m, 1 H) ppm; 13C NMR (125 MHz, CDCl3) δ 
177.11, 173.01, 168.06, 161.31, 155.75, 152.29, 140.95, 136.22, 136.18, 134.08, 
128.77, 124.49, 120.08, 105.88, 77.98, 76.05, 59.48, 55.86, 52.62, 52.19, 44.53, 
34.43, 32.70, 32.62, 32.47, 31.07, 29.70, 27.23, 27.06, 26.06, 23.59, 23.57, 
22.25, 20.85, 6.67, 6.12 ppm; HRMS (ESI) m/z: calcd for C36H46ClN6O9S [M + 
H]+ 773.2730; found 773.2714. Anal. HPLC: tR 14.35 min, purity 96%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-2-((3-chloro-7-methoxyquinoxalin-2-
yl)oxy)-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (23c). 
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The same procedure was used as described above for compound 22b. 
Compound 19c (0.50 g, 0.64 mmol) was treated 4 N HCl in 1,4-dioxane (10 mL) 
to yield the amine salt 21c, which was treated with DIEA (0.43 mL, 2.6 mmol) 
and N-(cyclopentyloxycarbonyloxy)-succinimide (0.20 g, 0.88 mmol) to provide 
the target compound 23c (0.46 g, 91%) as a white solid.1H NMR (400 MHz, 
CDCl3) δ 10.22 (s, 1 H), 7.78 (d, J = 10.0 Hz, 1 H), 7.23–7.20 (m, 2 H), 7.16 (s, 1 
H), 5.87 (br s, 1 H), 5.66 (q, J = 8.4 Hz, 1 H), 5.39 (d, J = 7.2 Hz, 1 H), 4.95 (t, J = 
9.6 Hz, 1 H), 4.84–4.80 (m, 1 H), 4.65 (t, J = 8.0 Hz, 1 H), 4.53 (d, J = 8.4 Hz, 1 
H), 4.32–4.26 (m, 1 H), 4.04 (dd, J = 12.0, 4.0 Hz, 1 H), 3.95 (s, 3 H), 2.67–2.46 
(m, 3 H), 2.30 (q, J = 8.4 Hz, 1 H), 1.90–1.23 (m, 24 H), 0.84–0.78 (m, 2 H) ppm; 
13C NMR (100 MHz, CDCl3) δ 177.18, 172.93, 167.03, 161.26, 155.73, 152.26, 
140.93, 136.22, 136.16, 134.04, 128.73, 124.86, 120.08, 105.84, 77.96, 76.06, 
59.52, 55.85, 52.61, 52.14, 44.68, 36.42, 34.45, 32.69, 32.60, 32.40, 29.54, 
27.14, 27.07, 26.12, 23.58, 23.55, 22.23, 20.85, 18.17, 14.50, 12.52 ppm; HRMS 
(ESI) m/z: calcd for C37H48ClN6O9S [M + H]+ 787.2887; found 787.2872. Anal. 
HPLC: tR 15.11 min, purity 99%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-14a-
((cyclopropylsulfonyl)carbamoyl)-2-((3-isopropyl-7-methoxyquinoxalin-2-
yl)oxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (22e). 
 
The same procedure was used as described above for compound 22b. 
Compound 18e (0.45 g, 0.58 mmol) was treated 4 N HCl in 1,4-dioxane (10 mL) 
to yield the amine salt 20e, which was treated with DIEA (0.40 mL, 2.4 mmol) 
and N-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol) to provide 
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the target compound 22e (0.40 g, 88%) as a white solid. 1H NMR (400 MHz, 
CDCl3) δ 10.29 (s, 1 H), 7.84 (d, J = 8.8 Hz 1 H), 7.20–7.16 (m, 2 H), 6.94 (s, 1 
H), 5.93 (br s, 1 H), 5.70 (q, J = 8.4 Hz, 1 H), 5.28 (d, J = 8.0 Hz 1 H), 4.97 (t, J = 
8.8 Hz, 1 H), 4.87–4.82 (m, 1 H), 4.59 (t, J = 7.2 Hz, 1 H), 4.44 (d, J = 11.2 Hz, 1 
H), 4.36–4.30 (m, 1 H), 4.04 (dd, J = 11.6, 7.6 Hz, 1 H), 3.94 (s, 3 H), 3.42–3.34 
(m, 1 H), 2.93–2.86 (m, 1 H), 2.70–2.48 (m, 3 H), 2.32 (q, J = 8.4 Hz, 1 H), 1.94–
1.21 (m, 26 H), 1.16–1.05 (m, 2 H), 0.96–0.88 (m, 1 H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 177.20, 172.97, 168.08, 160.25, 155.60, 154.40, 151.82, 140.65, 
136.27, 134.23, 129.18, 124.47, 118.65, 105.81, 77.81, 74.46, 59.49, 55.70, 
53.06, 52.13, 44.52, 34.63, 32.73, 32.57, 31.01, 30.63, 29.68, 27.17, 27.06, 
26.08, 23.56, 22.17, 20.91, 20.48, 20.43, 6.65, 6.10 ppm; HRMS (ESI) m/z: calcd 
for C39H53N6O9S [M + H]+ 781.3589; found 781.3569. Anal. HPLC: tR 16.03 min, 
purity 98%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-2-((3-isopropyl-7-
methoxyquinoxalin-2-yl)oxy)-14a-(((1-
methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (23e). 
 
The same procedure was used as described above for compound 22b. 
Compound 19e (0.45 g, 0.57 mmol) was treated 4 N HCl in 1,4-dioxane (10 mL) 
to yield the amine salt 21e, which was treated with DIEA (0.40 mL, 2.4 mmol) 
and N-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol) to provide 
the target compound 23e (0.40 g, 88%) as a white solid. 1H NMR (400 MHz, 
CDCl3) δ 10.16 (s, 1 H), 7.85 (d, J = 8.8 Hz, 1 H), 7.21–7.16 (m, 2 H), 6.90 (s, 1 
H), 5.93 (br s, 1 H), 5.71 (q, J = 8.4 Hz, 1 H), 5.25 (d, J = 8.0 Hz 1 H), 4.99 (t, J = 
8.8 Hz, 1 H), 4.86–4.82 (m, 1 H), 4.58 (t, J = 8.0 Hz, 1 H), 4.46 (d, J = 11.2 Hz, 1 
H), 4.36–4.29 (m, 1 H), 4.05 (dd, J = 11.2, 3.6 Hz, 1 H), 3.94 (s, 3 H), 3.42–3.34 
(m, 1 H), 2.72–2.48 (m, 3 H), 2.32 (q, J = 8.4 Hz, 1 H), 1.94–1.21 (m, 30 H), 
0.86–0.78 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 177.24, 172.94, 167.04, 
160.25, 155.60, 154.40, 151.81, 140.67, 136.23, 134.21, 129.17, 124.89, 118.66, 
105.83, 77.80, 74.52, 59.53, 55.71, 53.08, 52.13, 44.68, 36.43, 34.65, 32.72, 
32.56, 30.63, 29.59, 27.14, 27.08, 26.14, 23.55, 22.19, 20.92, 20.47, 20.44, 
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18.17, 14.49, 12.47 ppm; HRMS (ESI) m/z: calcd for C40H55N6O9S [M + H]+ 
795.3746; found 795.3723. Anal. HPLC: tR 16.71 min, purity 99%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-14a-
((cyclopropylsulfonyl)carbamoyl)-5,16-dioxo-2-((3-(thiophen-2-
yl)quinoxalin-2-yl)oxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (22f). 
 
The same procedure was used as described above for compound 22b. 
Compound 18f (0.40 g, 0.51 mmol) was treated 4 N HCl in 1,4-dioxane (10 mL) 
to yield the amine salt 20f, which was treated with DIEA (0.35 mL, 2.1 mmol) and 
N-(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol) to provide the 
target compound 22f (0.38 g, 94%) as an off-white solid. 1H NMR (500 MHz, 
CDCl3) δ 10.25 (s, 1 H), 8.08 (s, 1 H), 8.00 (d, J = 8.0 Hz, 1 H), 7.83 (d, J = 8.0 
Hz, 1 H) 7.65–7.56 (m, 2 H), 7.47 (d, J = 4.0 Hz, 1 H), 7.12 (t, J = 4.0 Hz, 1 H), 
6.93 (s, 1 H), 6.11 (br s, 1 H), 5.66 (q, J = 8.8 Hz, 1 H), 5.25 (d, J = 8.0 Hz, 1 H), 
4.95 (t, J = 9.0 Hz, 1 H), 4.80–4.75 (m, 1 H), 4.68–4.61 (m, 2 H), 4.37 (t, J = 9.0 
Hz, 1 H), 4.08 (d, J = 11.2 Hz, 1 H), 2.92–2.85 (m, 1 H), 2.75–2.69 (m, 2 H), 
2.57–2.49 (m, 1 H), 2.29 (q, J = 8.6 Hz, 1 H), 1.88–1.22 (m, 23 H), 1.17–1.05 (m, 
2 H), 0.94–0.87 (m, 1 H) ppm; 13C NMR (125 MHz, CDCl3) δ 176.98, 173.11, 
167.92, 155.68, 152.27, 139.71, 138.90, 138.85, 136.28, 130.44, 130.04, 129.51, 
128.48, 128.08, 127.40, 126.84, 124.47, 77.90, 75.50, 59.51, 53.24, 52.26, 
44.57, 34.61, 32.89, 32.78, 32.48, 31.06, 29.74, 27.19, 27.01, 26.01, 23.58, 
22.29, 20.94, 6.68, 6.14 ppm; HRMS (ESI) m/z: calcd for C39H47N6O8S2 [M + H]+ 
791.2891; found 791.2872. Anal. HPLC: tR 16.39 min, purity 99%. 
Cyclopentyl ((2R,6S,13aS,14aR,16aS,Z)-14a-
((cyclopropylsulfonyl)carbamoyl)-2-((3-ethylquinoxalin-2-yl)oxy)-5,16-dioxo-
1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-
hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-
yl)carbamate (22g). 
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The same procedure was used as described above for compound 22b. 
Compound 18g (0.50 g, 0.69 mmol) was treated 4 N HCl in 1,4-dioxane (10 mL) 
to yield the amine salt 20g, which was treated with DIEA (0.46 mL, 2.8 mmol) 
and N-(cyclopentyloxycarbonyloxy)-succinimide (0.18 g, 0.79 mmol) to provide 
the target compound 22g (0.42 g, 83%) as a white solid. 1H NMR (400 MHz, 
CDCl3) δ 10.31 (s, 1 H), 7.95 (d, J = 8.0 Hz, 1 H), 7.81 (d, J = 8.0 Hz, 1 H), 7.63–
7.52 (m, 2 H), 7.00 (s, 1 H), 5.94 (br s, 1 H), 5.69 (q, J = 8.4 Hz, 1 H), 5.26 (d, J = 
8.0 Hz, 1 H), 4.96 (t, J = 9.6 Hz, 1 H), 4.83–4.78 (m, 1 H), 4.62 (t, J = 8.0 Hz, 1 
H), 4.46 (d, J = 12.0 Hz, 1 H), 4.32–4.25 (m, 1 H), 4.04 (dd, J = 11.6, 3.6 Hz, 1 
H), 2.95–2.85 (m, 3 H), 2.66–2.50 (m, 3 H), 2.30 (q, J = 8.8 Hz, 1 H), 1.93–1.05 
(m, 25 H), 0.95–0.88 (m, 1 H) ppm; 13C NMR (400 MHz, CDCl3) δ 177.18, 
173.05, 168.10, 155.62, 154.51, 152.11, 139.30, 138.85, 136.29, 128.99, 128.18, 
126.96, 126.72, 124.50, 77.82, 74.68, 59.46, 53.12, 52.20, 44.55, 34.56, 32.69, 
32.57, 31.00, 29.70, 27.12, 27.03, 26.74, 26.02, 23.55, 22.17, 20.94, 11.37, 6.66, 
6.11 ppm; HRMS (ESI) m/z: calcd for C37H49N6O8S [M + H]+ 737.3327; found 
737.3306. Anal. HPLC: tR 14.64 min, purity 99%. 
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Synthesis of Intermediates and Linear Final Compounds 
1-(tert-Butyl) 2-methyl (2S,4R)-4-((3-ethyl-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidine-1,2-dicarboxylate (4a).  
 
A solution of 3-ethyl-7-methoxyquinoxalin-2(1H)-one (3.0 g, 14.7 mmol) in 
anhydrous NMP (45 mL) was treated with Cs2CO3 (7.40 g, 22.7 mmol). After 
stirring the reaction mixture at room temperature for 15 min, brosylated cis-
hydroxyproline derivative 1-(tert-butyl) 2-methyl (2S,4S)-4-(((4-
bromophenyl)sulfonyl)oxy)pyrrolidine-1,2-dicarboxylate (6.20 g, 13.3 mmol) was 
added in one portion. The reaction mixture was heated to 55 °C, stirred for 4 h, 
and then another portion of brosylated cis-hydroxyproline derivative (0.48 g, 1.0 
mmol) was added. The resulting reaction mixture was stirred at 55 °C for 
additional 2 h, cooled to room temperature, quenched with aqueous 1 N HCl 
solution (150 mL), and extracted with EtOAc (300 mL). The organic fraction was 
washed successively with saturated aqueous NaHCO3 and NaCl (150 mL each), 
dried (Na2SO4), filtered, and evaporated under reduced pressure. The residue 
was purified by flash column chromatography using 15–30% EtOAc/hexanes as 
the eluent to provide 4a (5.50 g, 87%) as a white foamy solid. 1H NMR (400 MHz, 
CDCl3) (mixture of rotamers, major rotamer) δ 7.85 (d, J = 9.0 Hz, 1 H), 7.18 (m, 
1H), 7.11 (d, J = 2.8 Hz, 1 H), 5.73 (br s, 1 H), 4.47 (t, J = 8.0 Hz, 1 H), 3.98–3.86 
(m, 5 H), 3.78 (s, 3 H), 2.92 (q, J = 7.2 Hz, 2 H), 2.68–2.60 (m, 1 H), 2.43–2.36 
(m, 1 H), 1.43 (s, 9 H), 1.31 (t, J = 7.2 Hz, 3 H) ppm; 13C NMR (100 MHz, CDCl3) 
δ 173.56, 160.59, 155.38, 154.02, 148.95, 141.26, 134.12, 129.07, 119.02, 
106.11, 80.76, 73.81, 58.43, 55.93, 52.73, 52.40, 36.88, 28.47, 26.68, 11.97 
ppm; HRMS (ESI) m/z: [M + H]+ calcd for C22H30N3O6, 432.2129; found 
432.2135. 
1-(tert-Butyl) 2-methyl (2S,4R)-4-((7-methoxy-3-methylquinoxalin-2-
yl)oxy)pyrrolidine-1,2-dicarboxylate (4b). 
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The same procedure was used as described above for compound 4a. 7-
Methoxy-3-methylquinoxalin-2(1H)-one (6.2 g, 32.6 mmol) in NMP (100 mL) was 
treated with Cs2CO3 (16.0 g, 49.0 mmol) and activated cis-hydroxyproline 
derivative (15.0 g, 32.3 mmol) to provide 4b (10.0 g, 74%) as a white foamy 
solid. 1H NMR (500 MHz, CDCl3) (mixture of rotamers, major rotamer) δ 7.80 (d, 
J = 9.0 Hz, 1 H), 7.17 (dd, J = 9.0, 3.0 Hz, 1 H), 7.11 (d, J = 2.5 Hz, 1 H), 5.71 (br 
s, 1 H), 4.48 (t, J = 8.0 Hz, 1 H), 3.99–3.91 (m, 4 H), 3.87 (d, J = 12.5 Hz, 1H), 
3.78 (s, 3 H), 2.67–2.58 (m, 1 H), 2.56 (s, 3 H), 2.43–2.37 (m, 1 H), 1.43 (s, 9 H) 
ppm; 13C NMR (125 MHz, CDCl3) δ 173.36, 160.24, 155.51, 153.81, 144.60, 
141.04, 134.22, 128.95, 118.63, 105.95, 80.54, 73.59, 58.20, 55.68, 52.48, 
52.20, 36.70, 28.26, 19.93 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C21H28N3O6, 
418.1973; found 418.1976. 
1-(tert-Butyl) 2-methyl (2S,4R)-4-((3-isopropyl-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidine-1,2-dicarboxylate (4c). 
 
The same procedure was used as described above for compound 4a. 3-
Isopropyl-7-methoxyquinoxalin-2(1H)-one (4.0 g, 18.3 mmol) in NMP (65 mL) 
was treated with Cs2CO3 (9.0 g, 27.6 mmol) and activated cis-hydroxyproline 
derivative (8.30 g, 17.9 mmol) to provide 4c (7.30 g, 90%) as a colorless gummy 
solid. 1H NMR (500 MHz, CDCl3) (mixture of rotamers, major rotamer) δ 7.83 (d, 
J = 8.0 Hz, 1 H), 7.16 (d, J = 8.4 Hz, 1 H), 7.10 (s, 1 H) 5.74 (br s, 1 H), 4.48 (t, J 
= 7.5 Hz, 1 H), 3.92–3.87 (m, 5 H), 3.78 (s, 3 H), 3.41–3.36 (m, 1 H), 2.68–2.59 
(m, 1 H), 2.42–2.35 (m, 1 H), 1.43 (s, 9 H), 1.31 (t, J = 7.0 Hz, 6 H) ppm; 13C 
NMR (125 MHz, CDCl3) δ 173.37, 160.19, 154.62, 153.82, 152.00, 140.68, 
134.31, 129.39, 118.41, 105.80, 80.49, 73.36, 58.28, 55.67, 52.58, 52.19, 36.68, 
30.81, 28.25, 20.43, 20.38 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C23H32N3O6, 
446.2286; found 446.2287. 
1-(tert-butyl) 2-methyl (2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidine-1,2-dicarboxylate (4d). 
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The same procedure was used as described above for compound 4a. 3-Chloro-
7-methoxyquinoxalin-2(1H)-one (4.0 g, 19.0 mmol) in NMP (60 mL) was treated 
with Cs2CO3 (9.30 g, 28.6 mmol) and activated cis-hydroxyproline derivative 
(8.40 g, 18.1 mmol) to provide 4d (6.30 g, 76%) as an off-white foamy solid. 1H 
NMR (400 MHz, CDCl3) (mixture of rotamers, major rotamer) δ 7.80 (d, J = 8.8 
Hz, 1 H), 7.21 (dd, J = 8.8, 2.8 Hz, 1 H), 7.12 (d, J = 2.8 Hz, 1 H), 5.69 (br s, 1 
H), 4.52 (t, J = 7.6 Hz, 1 H), 4.0–3.94 (s, 4 H), 3.88 (d, J = 12.8 Hz, 1 H), 3.78 (s, 
3 H), 2.72–2.62 (m, 1 H), 2.45–2.37 (m, 1 H), 1.43 (s, 9 H) ppm; 13C NMR (400 
MHz, CDCl3) δ 173.32, 162.35, 153.84, 152.48, 141.03, 136.11, 134.06, 129.97, 
119.95, 105.83, 80.60, 75.02, 58.10, 55.81, 52.36 , 52.10, 36.64, 28.27 ppm; 
HRMS (ESI) m/z: [M + H]+ calcd for C20H25ClN3O6, 438.1426; found 438.1438. 
1-(tert-Butyl) 2-methyl (2S,4R)-4-((7-methoxy-3-(trifluoromethyl)quinoxalin-
2-yl)oxy)pyrrolidine-1,2-dicarboxylate (4e). 
 
The same procedure was used as described above for compound 4a. 7-
Methoxy-3-(trifluoromethyl)quinoxalin-2(1H)-one (4.76 g, 19.5 mmol) in 
anhydrous NMP (65 mL) was treated with Cs2CO3 (9.80 g, 30.0 mmol) and 
activated cis-hydroxyproline derivative (9.0 g, 19.4 mmol) to provide 4e (6.50 g, 
71%) as a pale yellow foamy solid. 1H NMR (500 MHz, CDCl3) (mixture of 
rotamers, major rotamer) δ 7.77 (d, J = 9.0 Hz, 1 H), 7.48–7.43 (m, 2 H), 5.76 (br 
s, 1 H), 4.50 (t, J = 8.0 Hz, 1 H), 3.97–3.91 (m, 5 H), 3.78 (s, 3 H), 2.69–2.64 (m, 
1 H), 2.41–2.34 (m, 1 H), 1.42 (s, 9 H) ppm; 13C NMR (125 MHz, CDCl3) δ 
173.43, 159.58, 153.98, 152.11, 138.39, 137.22, 127.99, 125.73, 120.70 (q, J = 
273.4 Hz), 107.64, 80.69, 74.62, 58.27, 56.02, 52.32, 52.11, 36.70, 28.34 ppm; 
19F NMR (470 MHz, CDCl3); −67.73 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C21H25F3N3O6, 472.1690; found 472.1689. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-
4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (6a).  
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A solution of P2 intermediate 4a (2.75 g, 6.4 mmol) in anhydrous CH2Cl2 (20 mL) 
was treated with a solution of 4 N HCl in 1,4-dioxane (20 mL). After stirring the 
reaction mixture at room temperature for 3 h, solvents were evaporated under 
reduced pressure, and the residue was dried under high vacuum. The pale 
yellow solid was triturated with diethyl ether (20 mL), filtered and washed with 
diethyl ether diethyl ether (3 × 5 mL) to yield the amine salt 5a (2.30 g, 98%) as 
an off-white powder. 
A mixture of amine salt 5a (1.15 g, 3.1 mmol) and Boc-Tle-OH (0.88 g, 3.8 mmol) 
in anhydrous DMF (20 mL) was treated with DIEA (2.52 mL, 15.2 mmol) and 
HATU (2.17 g, 5.7 mmol). The resulting reaction mixture was stirred at room 
temperature for 4 h, then diluted with EtOAc (150 mL), and washed successively 
with aqueous 0.5 N HCl, saturated aqueous NaHCO3, and saturated aqueous 
NaCl (75 mL each). The organic portion was dried (Na2SO4), filtered, and 
evaporated under reduced pressure. The residue was purified by flash 
chromatography using 25–30% EtOAc/hexanes as the eluent to provide 6a (1.45 
g, 85%) as a white foamy solid. 1H NMR (400 MHz, CDCl3) (mixture of rotamers, 
major rotamer) δ 7.87 (d, J = 9.2 Hz, 1 H), 7.19 (dd, J = 8.8, 2.8 Hz, 1 H), 7.13 (d, 
J = 2.8 Hz, 1 H), 5.86 (br s, 1 H), 5.18 (d, J = 9.2 Hz, 1 H), 4.73 (t, J = 8.4 Hz, 1 
H), 4.27–4.22 (m, 2 H), 4.11–4.04 (m, 1 H), 3.94 (s, 3 H), 3.78 (s, 3 H), 2.87 (q, J 
= 7.2 Hz, 2 H), 2.71–2.65 (m, 1 H), 2.39–2.31 (m, 1 H), 1.33 (s, 9 H), 1.27 (t, J = 
7.2 Hz, 3 H), 1.05 (s, 9 H) ppm; 13C NMR (100 MHz, CDCl3) δ 172.50, 171.60, 
160.57, 155.92, 155.11, 149.02, 141.11, 134.13, 129.13, 118.99, 106.20, 79.79, 
74.37, 58.76, 58.19, 55.92, 53.92, 52.57, 35.85, 35.23, 28.43, 26.50, 11.85 ppm; 
HRMS (ESI) m/z: [M + Na]+ calcd for C28H41N4O7, 545.2970; found 545.2973. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-
4-((7-methoxy-3-methylquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (6b).  
 
The same procedure was used as described above for compound 6a. Compound 
4b (3.60 g, 8.6 mmol) was treated with 4 N HCl (25 mL) to afford the amine salt 
5b (3.0 g, 8.5 mmol), which was coupled with Boc-Tle-OH (2.40 g, 10.4 mmol) 
using DIEA (7.0 mL, 42.4 mmol) and HATU (5.65 g, 14.8 mmol) to provide 6b 
(3.50 g, 78%) as a white foamy solid. 1H NMR (500 MHz, CDCl3) (mixture of 
rotamers, major rotamer) δ 7.80 (d, J = 9.0 Hz, 1 H), 7.18 (dd, J = 9.0, 2.5 Hz, 1 
H), 7.12 (d, J = 3.0 Hz, 1 H), 5.84 (br s, 1 H), 5.18 (d, J = 9.5 Hz, 1 H), 4.75 (t, J = 
8.5 Hz, 1 H), 4.27–4.22 (m, 2 H), 4.07 (dd, J = 11.5, 4.5 Hz, 1 H), 3.94 (s, 3 H), 
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3.77 (s, 3 H), 2.70–2.65 (m, 1 H), 2.52 (s, 3 H), 2.38–2.32 (m, 1 H), 1.34 (s, 9 H), 
1.05 (s, 9 H) ppm; 13C NMR (125 MHz, CDCl3) δ 172.42, 171.57, 160.36, 155.87, 
155.39, 144.86, 141.05, 134.51, 129.15, 118.76, 106.19, 79.71, 74.30, 58.70, 
58.03, 55.79, 53.81, 52.48, 35.70, 35.15, 28.36, 26.42, 19.97 ppm; HRMS (ESI) 
m/z: [M + H]+ calcd for C27H39N4O7, 531.2813; found 531.2807. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-
4-((3-isopropyl-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate 
(6c).  
 
The same procedure was used as described above for compound 6a. Compound 
4c (1.30 g, 2.92 mmol) was treated with 4 N HCl (12 mL) to afford the amine salt 
5c (1.05 g, 2.75 mmol), which was coupled with Boc-Tle-OH (0.83 g, 3.60 mmol) 
using DIEA (2.38 mL, 14.4 mmol) and HATU (1.85 g, 4.86 mmol) to provide 6c 
(1.30 g, 85%) as a white foamy solid. 1H NMR (500 MHz, CDCl3) (mixture of 
rotamers, major rotamer) δ 7.83 (d, J = 9.0 Hz, 1 H), 7.17 (dd, J = 9.0, 3.0 Hz, 1 
H), 7.11 (d, J = 3.0 Hz, 1 H), 5.88 (br s, 1 H), 5.20 (d, J = 9.5 Hz, 1 H), 4.72 (t, J = 
8.5 Hz, 1 H), 4.26–4.21 (m, 2 H), 4.07 (dd, J = 11.5, 4.0 Hz, 1 H), 3.94 (s, 3 H), 
3.77 (s, 3 H), 3.39–3.33 (m, 1 H), 2.71–2.65 (m, 1 H), 2.38–2.32 (m, 1 H), 1.33 
(s, 9 H), 1.28 (t, J = 7.0 Hz, 6 H), 1.05 (s, 9 H) ppm; 13C NMR (125 MHz, CDCl3) 
δ 172.41, 171.45, 160.33, 155.77, 154.47, 152.19, 140.67, 134.59, 129.56, 
118.57, 106.01, 79.64, 74.04, 58.66, 58.14, 55.78, 53.91, 52.46, 35.88, 35.16, 
30.80, 28.36, 26.40, 20.61, 20.52 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C29H43N4O7, 559.3126; found 559.3112. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-
4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-2-carboxylate (6d).  
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The same procedure was used as described above for compound 6a. Compound 
4d (1.05 g, 2.40 mmol) was treated with 4 N HCl (10 mL) to afford the amine salt 
5d (0.89 g, 2.40 mmol), which was coupled with Boc-Tle-OH (0.66 g, 2.86 mmol) 
using DIEA (1.90 mL, 11.5 mmol) and HATU (1.41 g, 3.72 mmol) to provide 6d 
(1.0 g, 76%) as an off-white foamy solid. 1H NMR (500 MHz, CDCl3) (mixture of 
rotamers, major rotamer) δ 7.81 (d, J = 9.0 Hz, 1 H), 7.22 (dd, J = 9.0, 2.5 Hz, 1 
H), 7.15 (d, J = 3.0 Hz, 1 H), 5.81 (br s, 1 H), 5.21 (d, J = 10.0 Hz, 1 H), 4.79 (t, J 
= 8.5 Hz, 1 H), 4.31 (d, J = 12.0 Hz, 1 H), 4.21 (d, J = 10.0 Hz, 1 H), 4.09 (dd, J = 
11.5, 4.0 Hz, 1 H), 3.96 (s, 3 H), 3.78 (s, 3 H), 2.74–2.68 (m, 1 H), 2.40–2.34 (m, 
1 H), 1.32 (s, 9 H), 1.04 (s, 9 H) ppm; 13C NMR (125 MHz, CDCl3) δ 172.36, 
171.54, 161.40, 155.87, 152.36, 140.99, 136.27, 134.26, 129.05, 120.05, 106.05, 
79.77, 75.69, 58.63, 58.02, 55.92, 53.43, 52.50, 35.74, 34.98, 28.36, 26.40 ppm; 
HRMS (ESI) m/z: [M + H]+ calcd for C26H36ClN4O7, 551.2267; found 551.2257. 
Methyl (2S,4R)-1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-
4-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-yl)oxy)pyrrolidine-2-
carboxylate (6e).  
 
The same procedure was used as described above for compound 6a. Compound 
4e (1.30 g, 2.76 mmol) was treated with 4 N HCl (10 mL) to afford the amine salt 
5e (1.10 g, 2.70 mmol), which was coupled with Boc-Tle-OH (0.81 g, 3.50 mmol) 
using DIEA (2.30 mL, 14.0 mmol) and HATU (2.0 g, 5.25 mmol) to provide 6e 
(1.50 g, 95%) as a pale yellow foamy solid. 1H NMR (500 MHz, CDCl3) (mixture 
of rotamers, major rotamer) δ 7.78 (d, J = 9.0 Hz, 1 H), 7.47 (dd, J = 9.5, 3.0 Hz, 
1 H), 7.43 (d, J = 2.5 Hz, 1 H), 5.87 (br s, 1 H), 5.22 (d, J = 9.5 Hz, 1 H), 4.74 (t, J 
= 8.5 Hz, 1 H), 4.27 (d, J = 12.0 Hz, 1 H), 4.20 (d, J = 9.5 Hz, 1 H), 4.11–4.07 (m, 
1 H), 3.94 (s, 3 H), 3.77 (s, 3 H), 2.71–2.66 (m, 1 H), 2.38–2.32 (m, 1 H), 1.30 (s, 
9 H), 1.03 (s, 9 H) ppm; 13C NMR (125 MHz, CDCl3) δ 172.36, 171.47, 159.64, 
155.84, 151.89, 138.51, 137.09, 134.59 (q, J = 35.9 Hz), 128.04, 125.73, 120.69 
(d, J = 273.8 Hz), 107.65, 79.69, 75.05, 58.58, 57.92, 56.03, 53.47, 52.49, 35.75, 
34.97, 28.26, 26.37 ppm; 19F NMR (470 MHz, CDCl3); −67.84 ppm; HRMS (ESI) 
m/z: [M + H]+ calcd for C27H36F3N4O7Na, 585.2531; found 585.2516. 
tert-Butyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)-4-((3-ethyl-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (3). Et-tBu-H 
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A solution of P2–P3 intermediate 6a (1.80 g, 3.31 mmol) in THF-H2O mixture 
(1:1, 50 mL) was treated with LiOH.H2O (0.46 g, 11.0 mmol). The resulting 
reaction mixture was stirred at room temperature for 24 h. The reaction mixture 
was cooled to ~5 °C, acidified to a pH of 2.0 by slow addition of aqueous 0.50 N 
HCl (~ 75 mL), and extracted with EtOAc (2 × 150 mL). The organic portions 
were washed separately with saturated aqueous NaCl (75 ml), dried (Na2SO4), 
filtered, and evaporated under reduced pressure. The gummy residue was 
dissolved in CHCl3 (20 mL), concentrated under reduced pressure, and the 
residue was dried under high vacuum overnight to yield the acid 7a (1.75 g, 
100%) as a white foamy solid. 
A mixture of acid 7a (0.88 g, 1.64 mmol) and P1–P1’ amine salt 8 (0.48 g, 1.80 
mmol) in anhydrous DMF (15 mL) was treated with DIEA (1.10 mL, 6.60 mmol) 
and HATU (0.94 g, 2.46 mmol). The resulting reaction mixture was stirred at 
room temperature for 2 h, then diluted with EtOAc (100 mL) and washed 
successively with aqueous 0.5 N HCl, saturated aqueous NaHCO3, and 
saturated aqueous NaCl (50 mL each). The organic portion was dried (Na2SO4), 
filtered, and evaporated under reduced pressure. The residue was purified by 
flash chromatography using 50–80% EtOAc/hexanes as the eluent to provide 
compound 3 (0.95 g, 78%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 10.08 
(s, 1 H), 7.84 (d, J = 9.2 Hz, 1 H), 7.20–7.14 (m, 2 H), 7.07 (s, 1 H), 5.90 (br s, 1 
H), 5.79–5.72 (m, 1 H), 5.28–5.22 (m, 2 H), 5.15 (d, J = 10.4 Hz, 1 H), 4.48 (t, J = 
8.4 Hz, 1 H), 4.30 (d, J = 12.0 Hz, 1 H), 4.24 (d, J = 9.6 Hz, 1 H), 4.03 (dd, J = 
11.6, 3.2 Hz, 1 H), 3.94 (s, 3 H), 2.94–2.83 (m, 3 H), 2.56–2.52 (m, 2 H), 2.12 (q, 
J = 8.4 Hz, 1 H), 1.97 (dd, J = 8.0, 6.0 Hz, 1 H), 1.48 (dd, J = 9.2, 5.6 Hz, 1 H), 
1.40–1.22 (m, 13 H), 1.10–0.96 (m, 12 H) ppm; 13C NMR (100 MHz, CDCl3) δ 
173.05, 172.77, 168.64, 160.56, 155.87, 154.99, 148.86, 141.05, 134.51, 132.76, 
129.32, 119.01, 118.85, 106.19, 80.06, 74.37, 60.09, 58.96, 55.92, 54.51, 42.05, 
38.85, 35.81, 35.75, 34.51, 31.49, 28.43, 26.71, 22.63, 11.84, 6.50, 6.45 ppm; 
HRMS (ESI) m/z: [M + H]+ calcd for C36H51N6O9S, 743.3433; found 743.3431. 
tert-Butyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)-4-((7-methoxy-3-methylquinoxalin-2-
yl)oxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (10b). Me-
tBu-H 
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The same procedure was used as described above for compound 3. Ester 6b 
(1.30 g, 2.45 mmol) was treated with LiOH.H2O (0.36 g, 8.60 mmol) to afford acid 
7b (1.25 g, 2.42 mmol). A portion of acid 7b (0.62 g, 1.20 mmol) was reacted 
with amine salt 8 (0.40 g, 1.50 mmol) using DIEA (0.80 mL, 4.84 mmol) and 
HATU (0.70 g, 1.84 mmol) to provide compound 10b (0.64 g, 74%) as a white 
solid. 1H NMR (400 MHz, CDCl3) δ 10.08 (s, 1 H), 7.79 (d, J = 9.2 Hz, 1 H), 7.18 
(dd, J = 8.8, 2.4 Hz, 1 H), 7.13 (d, J = 2.8 Hz, 2 H), 5.86 (br s, 1 H), 5.80–5.71 
(m, 1 H), 5.28–5.23 (m, 2 H), 5.13 (d, J = 10.8 Hz, 1 H), 4.51 (t, J = 8.4 Hz, 1 H), 
4.30 (d, J = 11.6 Hz, 1 H), 4.24 (d, J = 9.2 Hz, 1 H), 4.03 (dd, J = 12.0, 4.0 Hz, 1 
H), 3.94 (s, 3 H), 2.93–2.86 (m, 1 H), 2.56–2.50 (m, 5 H), 2.11 (q, J = 9.2 Hz, 1 
H), 1.95 (dd, J = 8.0, 6.0 Hz, 1 H), 1.49–1.43 (m, 2 H), 1.33 (s, 9 H), 1.07–0.97 
(m, 12 H) ppm; 13C NMR (100 MHz, CDCl3) δ 172.89, 172.49, 168.48, 160.25, 
155.67, 155.12, 144.48, 140.89, 134.31, 132.51, 128.94, 118.78, 118.64, 106.0, 
79.84, 74.25, 59.79, 58.72, 55.68, 54.23, 41.83, 35.55, 35.42, 34.21, 31.23, 
28.22, 26.48, 22.32, 19.81, 6.27, 6.22 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C35H49N6O9S, 729.3276; found 729.3283. 
tert-Butyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)-4-((3-isopropyl-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (10c). i-Pr-
tBu-H 
 
The same procedure was used as described above for compound 3. Ester 6c 
(2.25 g, 4.03 mmol) was treated with LiOH.H2O (0.68 g, 16.1 mmol) to afford acid 
7c (2.15 g, 3.95 mmol). A portion of acid 7c (1.0 g, 1.84 mmol) was coupled with 
amine salt 8 (0.60 g, 2.25 mmol) using DIEA (1.25 mL, 7.40 mmol) and HATU 
(1.0 g, 2.63 mmol) to provide compound 10c (1.25 g, 90%) as a white solid. 1H 
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NMR (400 MHz, CDCl3) δ 10.11 (s, 1 H), 7.83 (d, J = 9.2 Hz, 1 H), 7.18 (dd, J = 
8.8, 2.4 Hz, 1 H), 7.12 (d, J = 2.8 Hz, 1 H), 7.02 (s, 1 H), 5.91 (br s, 1 H), 5.82–
5.73 (m, 1 H), 5.28–5.23 (m, 2 H), 5.14 (d, J = 10.4 Hz, 1 H), 4.46 (t, J = 8.4 Hz, 
1 H), 4.29–4.22 (m, 2 H), 4.06 (dd, J = 11.6, 4.0 Hz, 1 H), 3.94 (s, 3 H), 3.37–
3.30 (m, 1 H), 2.94–2.87 (m, 1 H), 2.57–2.49 (m, 2 H), 2.12 (q, J = 8.4 Hz, 1 H), 
1.96 (dd, J = 8.4, 6.0 Hz, 1 H), 1.48 (dd, J = 9.6, 6.0 Hz, 1 H), 1.40–1.20 (m, 15 
H), 1.05–0.95 (m, 12 H) ppm; 13C NMR (100 MHz, CDCl3) δ 172.79, 172.42, 
168.52, 160.23, 155.60, 154.19, 151.78, 140.52, 134.42, 132.55, 129.37, 118.61, 
105.81, 79.78, 74.02, 59.97, 58.68, 55.68, 54.34, 41.75, 35.70, 35.57, 34.37, 
31.25, 30.67, 28.21, 26.47, 22.57, 20.51, 20.44, 6.29, 6.21 ppm; HRMS (ESI) 
m/z: [M + H]+ calcd for C37H53N6O9S, 757.3589; found 757.3588. 
tert-Butyl ((S)-1-((2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (10d). Cl-tBu-H 
 
The same procedure was used as described above for compound 3. Ester 6d 
(2.0 g, 3.63 mmol) was treated with LiOH.H2O (0.60 g, 14.3 mmol) to afford acid 
7d (1.90 g, 3.54 mmol). A portion of acid 7d (0.92 g, 1.71 mmol) was coupled 
with amine salt 8 (0.50 g, 1.88 mmol) using DIEA (1.15 mL, 6.96 mmol) and 
HATU (0.95 g, 2.50 mmol) to provide compound 10d (1.0 g, 78%) as a white 
solid. 1H NMR (400 MHz, CDCl3) δ 10.07 (s, 1 H), 7.81 (d, J = 8.8 Hz, 1 H), 7.26–
7.22 (1 H), 7.18 (d, J = 2.4 Hz, 1 H), 7.04 (s, 1 H), 5.87 (br s, 1 H), 5.81–5.74 (m, 
1 H), 5.29–5.20 (m, 2 H), 5.14 (d, J = 10.4 Hz, 1 H), 4.55 (t, J = 8.4 Hz, 1 H), 4.37 
(d, J = 11.6 Hz, 1 H), 4.21 (d, J = 9.6 Hz, 1 H), 4.05 (dd, J = 12.0, 3.6 Hz, 1 H), 
3.96 (s, 3 H), 2.93–2.88 (m, 1 H), 2.57 (dd, J = 7.6, 2.8 Hz, 2 H), 2.12 (q, J = 8.8 
Hz, 1 H), 1.98 (dd, J = 7.6, 6.0 Hz, 1 H), 1.48 (dd, J = 9.6, 6.0, 1 H), 1.38–1.34 
(m, 2 H), 1.31 (s, 9 H), 1.09–0.98 (m, 11 H) ppm; 13C NMR (100 MHz, CDCl3) δ 
172.94, 172.63, 168.57, 161.46, 155.82, 152.21, 141.01, 136.09, 134.25, 132.65, 
129.00, 120.22, 118.77, 106.05, 80.04, 75.77, 60.55, 59.97, 58.85, 54.01, 42.01, 
35.69, 35.53, 34.36, 31.39, 28.34, 26.60, 22.46, 6.40, 6.35 ppm; HRMS (ESI) 
m/z: [M + H]+ calcd for C34H46ClN6O9S, 749.2730; found 749.2736. 
tert-Butyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)-4-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-
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yl)oxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (10e). CF3-
tBu-H 
 
The same procedure was used as described above for compound 3. Ester 6e 
(1.60 g, 2.74 mmol) was treated with LiOH.H2O (0.40 g, 9.53 mmol) to afford acid 
7e (1.56 g, 2.74 mmol). A portion of acid 7e (0.78 g, 1.37 mmol) was coupled 
with amine salt 8 (0.45 g, 1.69 mmol) using DIEA (0.95 mL, 5.75 mmol) and 
HATU (0.85 g, 2.24 mmol) to provide compound 10e (0.80 g, 75%) as an off-
white solid. 1H NMR (400 MHz, CDCl3) δ 10.09 (s, 1 H), 7.80 (d, J = 8.8 Hz, 1 H), 
7.48 (dd, J = 8.8, 2.8 Hz, 1 H), 7.42 (d, J = 2.8 Hz, 1 H), 7.15 (s, 1 H), 5.92 (br s, 
1 H), 5.81–5.72 (m, 1 H), 5.29–5.23 (m, 2 H), 5.14 (d, J = 11.2 Hz, 1 H), 4.50 (t, J 
= 8.8 Hz, 1 H), 4.32 (d, J = 12.0 Hz, 1 H), 4.19 (d, J = 9.6 Hz, 1 H), 4.04 (dd, J = 
12.4, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.93–2.87 (m, 1 H), 2.53 (dd, J = 8.8, 2.8 Hz, 2 
H), 2.13 (q, J = 8.4 Hz, 1 H), 1.96 (dd, J = 8.4, 6.0 Hz, 1 H), 1.48 (dd, J = 9.6, 6.0 
Hz, 1 H), 1.36–1.32 (m, 2 H), 1.28 (s, 9 H), 1.05–0.96 (m, 11 H) ppm; 13C NMR 
(100 MHz, CDCl3) δ 172.74, 172.37, 168.52, 159.38, 155.61, 151.59, 138.37, 
136.95, 134.24 (q, J = 35.8 Hz), 132.54, 127.97, 125.70, 120.57 (d, J = 273.6 
Hz), 118.60, 106.42, 79.76, 75.0, 59.79, 58.60, 55.90, 53.93, 41.79, 35.57, 
35.45, 34.27, 31.24, 28.11, 26.43, 22.45, 6.26, 6.19 ppm; HRMS (ESI) m/z: [M + 
H]+ calcd for C35H46F3N6O9S, 783.2994; found 783.3000. 
tert-Butyl ((S)-1-((2S,4R)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (11a). Et-tBu-Me 
 
The same procedure was used as described above for compound 3. Acid 7a 
(0.73 g, 1.38 mmol) was coupled with amine salt 9 (0.45 g, 1.60 mmol) using 
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DIEA (0.95 mL, 5.75 mmol) and HATU (0.85 g, 2.24 mmol) to provide compound 
11a (0.80 g, 77%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 9.80 (s, 1 H), 
7.83 (d, J = 9.0 Hz, 1 H), 7.20–7.15 (m, 3 H), 5.89 (br s, 1 H), 5.72–5.64 (m, 1 H), 
5.28 (d, J = 17.0 Hz, 1 H), 5.21 (d, J = 9.5 Hz, 1 H), 5.15 (d, J = 10.0 Hz, 1 H), 
4.57 (t, J = 8.0 Hz, 1 H), 4.31 (d, J = 12.0 Hz, 1 H), 4.24 (d, J = 9.5 Hz, 1 H), 4.02 
(dd, J = 12.0, 4.0 Hz, 1 H), 3.95 (s, 3 H), 2.86 (q, J = 7.5 Hz, 2 H), 2.67–2.61 (m, 
1 H), 2.57–2.52 (m, 1 H), 2.11 (q, J = 8.5 Hz, 1 H), 1.94 (dd, J = 8.0, 6.0 Hz, 1 H), 
1.73–1.68 (m, 1 H), 1.64–1.60 (m, 1 H), 1.50 (s, 3 H), 1.39 (dd, J = 9.0, 6.5 Hz, 1 
H), 1.33 (s, 9 H), 1.27 (t, J = 7.5 Hz, 3 H), 1.03 (s, 9 H), 0.90–0.81 (m, 2 H) ppm; 
13C NMR (125 MHz, CDCl3) δ 173.56, 172.86, 167.24, 160.42, 155.77, 154.92, 
148.85, 140.95, 134.54, 132.74, 129.28, 118.89, 118.84, 106.14, 79.98, 74.18, 
59.64, 58.95, 55.83, 54.36, 42.55, 36.69, 35.58, 35.06, 34.16, 28.34, 26.60, 
21.42, 18.54, 14.17, 13.66, 11.70 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C37H53N6O9S, 757.3589; found 757.3587. 
tert-Butyl ((S)-1-((2S,4R)-4-((7-methoxy-3-methylquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (11b). Me-tBu-Me 
 
The same procedure was used as described above for compound 3. Acid 7b 
(0.62 g, 1.20 mmol) was coupled with amine salt 9 (0.40 g, 1.43 mmol) using 
DIEA (0.80 mL, 4.84 mmol) and HATU (0.70 g, 1.84 mmol) to provide compound 
11b (0.70 g, 79%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 9.80 (s, 1 H), 
7.80 (d, J = 9.2 Hz, 1 H), 7.23 (s, 1 H), 7.20–7.14 (m, 2 H), 5.86 (br s, 1 H), 5.72–
5.63 (m, 1 H), 5.29–5.21 (m, 2 H), 5.15 (d, J = 10.0 Hz, 1 H), 4.60 (t, J = 8.4 Hz, 
1 H), 4.32 (d, J = 11.2 Hz, 1 H), 4.23 (d, J = 9.2 Hz, 1 H), 4.01 (dd, J = 11.6, 3.6 
Hz, 1 H), 3.94 (s, 3 H), 2.69–2.61 (m, 1 H), 2.57–2.50 (m, 4 H), 2.10 (q, J = 8.4 
Hz, 1 H), 1.93 (dd, J = 8.0, 5.6 Hz, 1 H), 1.73–1.67 (m, 1 H), 1.63–1.59 (m, 1 H), 
1.50 (s, 3 H), 1.37 (dd, J = 9.6, 6.0 Hz, 1 H), 1.33 (s, 9 H), 1.02 (s, 9 H), 0.88–
0.81 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 173.67, 172.99, 167.35, 
160.48, 155.89, 155.39, 144.74, 141.14, 134.57, 132.82, 129.19, 119.0, 106.25, 
80.10, 74.40, 59.69, 59.04, 55.92, 54.41, 42.64, 36.74, 35.61, 35.12, 34.14, 
28.45, 26.71, 21.44, 20.08, 18.62, 14.26, 13.72 ppm; HRMS (ESI) m/z: [M + H]+ 
calcd for C36H51N6O9S, 743.3433; found 743.3428. 
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tert-Butyl ((S)-1-((2S,4R)-4-((3-isopropyl-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (11c). i-Pr-tBu-Me 
 
The same procedure was used as described above for compound 3. Acid 7c (1.0 
g, 1.84 mmol) was coupled with amine salt 9 (0.67 g, 2.39 mmol) using DIEA 
(1.25 mL, 7.56 mmol) and HATU (1.0 g, 2.63 mmol) to provide compound 11c 
(1.20 g, 85%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 9.85 (s, 1 H), 7.83 
(d, J = 9.2 Hz, 1 H), 7.18–7.12 (m, 3 H), 5.89 (br s, 1 H), 5.73–5.64 (m, 1 H), 
5.30–5.24 (m, 2 H), 5.15 (d, J = 10.4 Hz, 1 H), 4.53 (t, J = 8.4 Hz, 1 H), 4.30–
4.21 (m, 2 H), 4.04 (dd, J = 12.0, 4.0 Hz, 1 H), 3.94 (s, 3 H), 3.38–3.29 (m, 1 H), 
2.60–2.50 (m, 2 H), 2.13 (q, J = 8.4 Hz, 1 H), 1.93 (dd, J = 8.0, 6.0 Hz, 1 H), 
1.73–1.53 (m, 2 H), 1.50 (s, 3 H), 1.44–1.17 (m, 16 H), 1.02 (s, 9 H), 0.90–0.80 
(m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 173.45, 172.52, 167.27, 160.22, 
155.58, 154.23, 151.78, 140.54, 134.40, 132.63, 129.36, 118.73, 118.59, 105.83, 
79.78, 73.98, 59.60, 58.75, 55.68, 54.28, 42.32, 36.52, 35.59, 34.96, 34.20, 
30.65, 28.21, 26.45, 21.47, 20.49, 20.45, 18.39, 13.97, 13.56 ppm; HRMS (ESI) 
m/z: [M + H]+ calcd for C38H55N6O9S, 771.3746; found 771.3735. 
tert-Butyl ((S)-1-((2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (11d). Cl-tBu-Me 
 
The same procedure was used as described above for compound 3. Acid 7d 
(0.92 g, 1.71 mmol) was coupled with amine salt 9 (0.53 g, 1.88 mmol) using 
DIEA (1.15 mL, 6.96 mmol) and HATU (0.95 g, 2.50 mmol) to provide compound 
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11d (1.0 g, 77%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 9.83 (s, 1 H), 
7.80 (d, J = 8.8 Hz, 1 H), 7.23 (dd, J = 8.8, 2.8 Hz, 1 H), 7.18 (d, J = 2.4 Hz, 1 H), 
5.84 (br s, 1 H), 5.72–5.63 (m, 1 H), 5.27 (d, J = 16.4 Hz, 1 H), 5.23 (d, J = 9.2 
Hz, 1 H), 5.15 (d, J = 10.4 Hz, 1 H), 4.62 (t, J = 8.0 Hz, 1 H), 4.38 (d, J = 12.0 Hz, 
1 H), 4.21 (d, J = 9.6 Hz, 1 H), 4.03 (dd, J = 11.6, 4.4 Hz, 1 H), 3.96 (s, 3 H), 
2.64–2.54 (m, 2 H), 2.13 (q, J = 8.8 Hz, 1 H), 1.94 (dd, J = 8.0, 6.0 Hz, 1 H), 
1.75–1.58 (m, 2 H), 1.50 (s, 3 H), 1.44–1.38 (m, 1 H), 1.31 (s, 9 H), 1.02 (s, 9 H), 
0.88–0.80 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 173.35, 172.64, 167.17, 
161.29, 155.66, 152.08, 140.87, 135.95, 134.08, 132.60, 128.85, 120.08, 118.75, 
105.89, 79.91, 75.56, 59.53, 58.73, 55.82, 53.80, 42.38, 36.50, 35.43, 34.89, 
33.98, 28.21, 26.44, 21.32, 18.40, 13.99, 13.52 ppm; HRMS (ESI) m/z: [M + H]+ 
calcd for C35H48ClN6O9S, 763.2887; found 763.2878. 
tert-Butyl ((S)-1-((2S,4R)-4-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-
yl)oxy)-2-(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (11e). CF3-tBu-Me 
 
The same procedure was used as described above for compound 3. Acid 7e 
(0.78 g, 1.37 mmol) was coupled with amine salt 9 (0.48 g, 1.71 mmol) using 
DIEA (0.95 mL, 5.75 mmol) and HATU (0.85 g, 2.24 mmol) to provide compound 
11e (0.82 g, 75%) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 9.80 (s, 1 
H), 7.81 (d, J = 8.8 Hz, 1 H), 7.48 (dd, J = 8.8, 2.8 Hz, 1 H), 7.43 (d, J = 2.8 Hz, 1 
H), 7.25 (s, 1 H), 5.92 (br s, 1 H), 5.73–5.64 (m, 1 H), 5.28 (d, J = 17.2 Hz, 1 H), 
5.20 (d, J = 9.6 Hz, 1 H), 5.15 (d, J = 10.8 Hz, 1 H), 4.56 (t, J = 8.4 Hz, 1 H), 4.34 
(d, J = 12.0 Hz, 1 H), 4.18 (d, J = 9.6 Hz, 1 H), 4.0 (dd, J = 11.6, 3.6 Hz, 1 H), 
3.94 (s, 3 H), 2.64–2.51 (m, 2 H), 2.13 (q, J = 8.4 Hz, 1 H), 1.95 (dd, J = 8.0, 6.0 
Hz, 1 H), 1.73–1.60 (m, 2 H), 1.59 (s, 3 H), 1.43–1.38 (m, 11 H), 1.28 (s, 9 H), 
0.89–0.80 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 173.53, 172.82, 167.41, 
159.76, 155.80, 151.85, 138.61, 137.20, 134.48 (q, J = 35.9 Hz), 132.86, 128.21, 
125.90, 120.81 (d, J = 274.0 Hz), 118.96, 107.68, 80.0, 75.16, 59.69, 58.90, 
56.13, 54.12, 42.60, 36.75, 35.69, 35.17, 34.28, 28.34, 26.65, 21.66, 18.65, 
13.79, 13.44 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C36H48F3N6O9S, 
797.3150; found 797.3146. 
Cyclopentyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-
2-vinylcyclopropyl)carbamoyl)-4-((3-ethyl-7-methoxyquinoxalin-2-
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yl)oxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (14a). Et-
Cyp-H 
 
Compound 3 (0.40 g, 0.54 mmol) was treated with a solution of 4 N HCl in 1,4-
dioxane (10 mL). After stirring the reaction mixture at room temperature for 3 h, 
solvents were evaporated under reduced pressure. The residue was triturated 
with diethyl ether (3 × 10 mL) and dried to yield the amine salt 12a (0.37 g, 
100%) as a white powder. 
A solution of the above amine salt 12a (0.37 g, 0.54 mmol) in anhydrous CH3CN 
(15 mL) was treated with DIEA (0.37 mL, 2.24 mmol) and N-
(cyclopentyloxycarbonyloxy)-succinimide (0.15 g, 0.66 mmol). The reaction 
mixture was stirred at room temperature for 36 h, then concentrated under 
reduced pressure and dried under high vacuum. The residue was purified by 
flash chromatography using 50–90% EtOAc/hexanes as the eluent to provide the 
target compound 14a (0.36 g, 88%) as a white solid. 1H NMR (400 MHz, CDCl3) 
δ 10.03 (s, 1 H), 7.83 (d, J = 9.0 Hz, 1 H), 7.19 (dd, J = 9.0, 2.8 Hz, 1 H), 7.14 (d, 
J = 2.5 Hz, 2 H), 5.90 (br s, 1 H), 5.80–5.73 (m, 1 H), 5.33–5.24 (m, 2 H), 5.15 (d, 
J = 10.6 Hz, 1 H), 4.90–4.86 (m, 1 H), 4.51 (t, J = 8.6 Hz, 1 H), 4.32–4.26 (m, 2 
H), 4.05 (dd, J = 11.6, 3.6 Hz, 1 H), 3.94 (s, 3 H), 2.93–2.84 (m, 3 H), 2.57–2.53 
(m, 1 H), 2.12 (q, J = 8.4 Hz, 1 H), 1.96 (dd, J = 8.0, 6.0 Hz, 1 H), 1.76–1.45 (m, 
8 H), 1.30–1.14 (m, 5 H), 1.08–0.98 (m, 11 H) ppm; 13C NMR (100 MHz, CDCl3) 
δ 172.93, 172.61, 168.54, 160.41, 156.49, 154.92, 148.91, 140.92, 134.60, 
132.66, 129.31, 118.81, 106.13, 78.06, 74.17, 60.02, 59.22, 55.82, 54.40, 41.96, 
35.68, 35.61, 34.38, 32.92, 32.71, 32.53, 31.41, 26.61, 23.80, 22.53, 11.72, 6.40, 
6.17 ppm; HRMS (ESI) m/z: [M + H]+ calcd for C37H51N6O9S, 755.3433; found 
755.3429. 
Cyclopentyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-
2-vinylcyclopropyl)carbamoyl)-4-((7-methoxy-3-methylquinoxalin-2-
yl)oxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (14b). Me-
Cyp-H 
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The same procedure was used as described above for compound 14a. 
Compound 10b (0.31 g, 0.42 mmol) was treated with 4 N HCl in 1,4-dioxane (10 
mL) to yield the amine salt 12b, which was treated with DIEA (0.30 mL, 1.82 
mmol) and N-(cyclopentyloxycarbonyloxy)-succinimide (0.12 g, 0.53 mmol) to 
provide the target compound 14b (0.26 g, 84%) as a white solid. 1H NMR (400 
MHz, CDCl3) δ 10.05 (s, 1 H), 7.80 (d, J = 8.8 Hz, 1 H), 7.19 (dd, J = 9.2, 2.8 Hz, 
1 H), 7.14 (d, J = 2.8 Hz, 1 H), 7.08 (s, 1 H), 5.88 (br s, 1 H), 5.81–5.72 (m, 1 H), 
5.34 (d, J = 9.6 Hz, 1 H), 5.26 (d, J = 17.2 Hz, 1 H), 5.15 (d, J = 10.0 Hz, 1 H), 
4.92–4.87 (m, 1 H), 4.52 (t, J = 8.0 Hz, 1 H), 4.32–4.25 (m, 2 H), 4.05 (dd, J = 
11.2, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.94–2.87 (m, 1 H), 2.57–2.51 (m, 5 H), 2.11 (q, 
J = 8.4 Hz, 1 H), 1.97 (dd, J = 7.6, 5.6 Hz, 1 H), 1.78–1.45 (m, 8 H), 1.38–1.32 
(m, 2 H), 1.08–0.98 (s, 11 H) ppm; 13C NMR (100 MHz, CDCl3) δ 172.73, 172.46, 
168.40, 160.26, 156.40, 155.16, 144.55, 140.89, 134.35, 132.48, 128.95, 118.80, 
118.69, 106.0, 77.94, 74.16, 59.87, 59.05, 55.69, 54.20, 41.79, 35.57, 35.50, 
34.17, 32.78, 32.60, 31.24, 26.47, 23.68, 22.41, 19.84, 6.28, 6.22 ppm; HRMS 
(ESI) m/z: [M + H]+ calcd for C36H49N6O9S, 741.3276; found 741.3275. 
Cyclopentyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-
2-vinylcyclopropyl)carbamoyl)-4-((3-isopropyl-7-methoxyquinoxalin-2-
yl)oxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (14c). i-Pr-
Cyp-H 
 
The same procedure was used as described above for compound 14a. 
Compound 10c (0.50 g, 0.66 mmol) was treated with 4 N HCl in 1,4-dioxane (10 
mL) to yield the amine salt 12c, which was treated with DIEA (0.44 mL, 2.66 
mmol) and N-(cyclopentyloxycarbonyloxy)-succinimide (0.16 g, 0.70 mmol) to 
provide the target compound 14c (0.48 g, 95%) as a white solid. 1H NMR (400 
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MHz, CDCl3) δ 10.07 (s, 1 H), 7.83 (d, J = 9.2 Hz, 1 H), 7.19–7.12 (m, 3 H), 5.91 
(br s, 1 H), 5.80–5.72 (m, 1 H), 5.38 (d, J = 9.6 Hz, 1 H), 5.26 (d, J = 17.2 Hz, 1 
H), 5.13 (d, J = 10.4 Hz, 1 H), 4.90–4.86 (m, 1 H), 4.48 (t, J = 8.8 Hz, 1 H), 4.32–
4.27 (m, 2 H), 4.06 (dd, J = 12.0, 4.0 Hz, 1 H), 3.94 (s, 3 H), 3.38–3.32 (m, 1 H), 
2.93–2.87 (m, 1 H), 2.55–2.51 (m, 2 H), 2.12 (q, J = 8.8 Hz, 1 H), 1.96 (dd, J = 
8.4, 6.0 Hz, 1 H), 1.78–1.47 (m, 7 H), 1.40–1.23 (m, 9 H), 1.07–0.97 (m, 11 H) 
ppm; 13C NMR (100 MHz, CDCl3) δ 172.81, 172.34, 168.52, 160.22, 156.33, 
154.23, 151.80, 140.53, 134.43, 132.54, 129.36, 118.59, 105.82, 77.86, 73.99, 
59.92, 59.02, 55.67, 54.31, 41.77, 35.64, 35.51, 34.33, 32.78, 32.56, 31.24, 
30.65, 26.48, 26.18, 23.66, 22.50, 20.50, 20.46, 6.29, 6.20 ppm; HRMS (ESI) 
m/z: [M + H]+ calcd for C38H53N6O9S, 769.3589; found 769.3587. 
Cyclopentyl ((S)-1-((2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (14d). Cl-Cyp-H 
 
The same procedure was used as described above for compound 14a. 
Compound 10d (0.50 g, 0.67 mmol) was treated with 4 N HCl in 1,4-dioxane (10 
mL) to yield the amine salt 12d, which was treated with DIEA (0.45 mL, 2.72 
mmol) and N-(cyclopentyloxycarbonyloxy)-succinimide (0.16 g, 0.70 mmol) to 
provide the target compound 14d (0.46 g, 90%) as a white solid. 1H NMR (400 
MHz, CDCl3) δ 10.03 (s, 1 H), 7.81 (d, J = 9.0 Hz, 1 H), 7.23 (dd, J = 9.0, 3.0 Hz, 
1 H), 7.18 (d, J = 3.0 Hz, 1 H), 7.14 (br s, 1 H), 5.86 (br s, 1 H), 5.78–5.72 (m, 1 
H), 5.33 (d, J = 8.4 Hz, 1 H), 5.27 (d, J = 17.0 Hz, 1 H), 5.15 (d, J = 10.6 Hz, 1 
H), 4.88–4.85 (m, 1 H), 4.58 (t, J = 8.4 Hz, 1 H), 4.38 (d, J = 12.0 Hz, 1 H), 4.23 
(d, J = 10.0 Hz, 1 H), 4.04 (dd, J = 11.6, 3.6 Hz, 1 H), 3.96 (s, 3 H), 2.92–2.88 
(m, 1 H), 2.57 (dd, J = 8.0, 2.4 Hz, 2 H), 2.12 (q, J = 8.6 Hz, 1 H), 1.97 (dd, J = 
7.6, 6.0 Hz, 1 H), 1.75–1.43 (m, 8 H), 1.37–1.30 (m, 2 H), 1.08–0.96 (m, 11 H) 
ppm; 13C NMR (100 MHz, CDCl3) δ 172.86, 172.61, 168.53, 161.47, 156.58, 
152.27, 141.03, 136.25, 134.30, 132.63, 129.01, 120.21, 118.81, 106.07, 78.16, 
75.68, 59.99, 59.17, 55.95, 53.93, 42.04, 35.64, 35.50, 34.26, 32.92, 32.72, 
31.40, 26.60, 23.82, 22.40, 6.40, 6.35 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C35H46ClN6O9S, 761.2730; found 761.2730. 
Cyclopentyl ((S)-1-((2S,4R)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-
2-vinylcyclopropyl)carbamoyl)-4-((7-methoxy-3-(trifluoromethyl)quinoxalin-
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2-yl)oxy)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (14e). CF3-
Cyp-H 
 
The same procedure was used as described above for compound 14a. 
Compound 10e (0.40 g, 0.51 mmol) was treated with 4 N HCl in 1,4-dioxane (10 
mL) to yield the amine salt 12e, which was treated with DIEA (0.35 mL, 2.10 
mmol) and N-(cyclopentyloxycarbonyloxy)-succinimide (0.13 g, 0.57 mmol) to 
provide the target compound 14e (0.35 g, 86%) as an off-white solid. 1H NMR 
(400 MHz, CDCl3) δ 10.05 (s, 1 H), 7.81 (d, J = 9.2 Hz, 1 H), 7.48 (dd, J = 9.2, 
2.8 Hz, 1 H), 7.43 (d, J = 2.8 Hz, 1 H), 7.18 (s, 1 H), 5.93 (br s, 1 H), 5.81–5.72 
(m, 1 H), 5.32–5.25 (m, 2 H), 5.15 (d, J = 11.2 Hz, 1 H), 4.81–4.77 (m, 1 H), 4.53 
(t, J = 8.4 Hz, 1 H), 4.35 (d, J = 12.0 Hz, 1 H), 4.19 (d, J = 9.6 Hz, 1 H), 4.02 (dd, 
J = 12.0, 4.0 Hz, 1 H), 3.94 (s, 3 H), 2.94–2.88 (m, 1 H), 2.56–2.52 (m, 2 H), 2.13 
(q, J = 8.4 Hz, 1 H), 1.97 (dd, J = 7.6, 5.6 Hz, 1 H), 1.74–1.33 (m, 11 H), 1.25–
1.0 (m, 11 H) ppm; 13C NMR (100 MHz, CDCl3) δ 172.69, 172.39, 168.42, 
159.54, 156.34, 151.65, 138.40, 136.96, 134.34 (q, J = 35.8 Hz), 132.50, 127.96, 
125.67, 120.60 (d, J = 273.6 Hz), 118.66, 107.42, 77.82, 74.94, 59.77, 58.92, 
55.90, 53.87, 41.82, 35.47, 35.43, 34.16, 32.75, 32.42, 31.24, 26.41, 23.67, 
23.62, 22.37, 6.26, 6.20 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C36H46F3N6O9S, 795.2994; found 795.2996. 
Cyclopentyl ((S)-1-((2S,4R)-4-((3-ethyl-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (15a). Et-Cyp-Me 
 
The same procedure was used as described above for compound 14a. 
Compound 11a (0.35 g, 0.46 mmol) was treated with 4 N HCl in 1,4-dioxane (10 
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mL) to yield the amine salt 13a, which was treated with DIEA (0.31 mL, 1.94 
mmol) and N-(cyclopentyloxycarbonyloxy)-succinimide (0.13 g, 0.57 mmol) to 
provide the target compound 15a (0.34 g, 96%) as a white solid. 1H NMR (500 
MHz, CDCl3) δ 9.77 (s, 1 H), 7.83 (d, J = 9.0 Hz, 1 H), 7.19 (dd, J = 9.0, 2.5 Hz, 1 
H), 7.15 (d, J = 2.5 Hz, 1 H), 5.89 (br s, 1 H), 5.72–5.64 (m, 1 H), 5.33–5.25 (m, 2 
H), 5.15 (d, J = 10.5 Hz, 1 H), 4.87 (m, 1 H), 4.58 (t, J = 8.0 Hz, 1 H), 4.33 (d, J = 
12.0 Hz, 1 H), 4.27 (d, J = 10.0 Hz, 1 H), 4.02 (dd, J = 12.0, 4.0 Hz, 1 H), 3.95 (s, 
3 H), 2.86 (q, J = 7.5 Hz, 2 H), 2.67–2.62 (m, 1 H), 2.56–2.51 (m, 1 H), 2.11 (q, J 
= 8.5 Hz, 1 H), 1.93 (dd, J = 8.0, 6.5 Hz, 1 H), 1.77–1.05 (m, 13 H), 1.38 (dd, J = 
9.0, 6.0 Hz, 1 H), 1.27 (t, J = 7.5 Hz, 3 H), 1.03 (s, 9 H), 0.90–0.80 (m, 2 H) ppm; 
13C NMR (125 MHz, CDCl3) δ 173.55, 172.78, 167.25, 160.40, 156.48, 154.95, 
148.92, 140.95, 134.60, 132.73, 129.30, 118.90, 118.79, 106.15, 78.07, 74.10, 
59.64, 59.25, 55.82, 54.31, 42.55, 36.68, 35.54, 35.01, 34.10, 32.93, 32.71, 
26.59, 23.80, 18.54, 14.15, 11.70 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C38H53N6O9S, 769.3589; found 769.3584. 
Cyclopentyl ((S)-1-((2S,4R)-4-((7-methoxy-3-methylquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (15b). Me-Cyp-Me 
 
The same procedure was used as described above for compound 14a. 
Compound 11b (0.40 g, 0.54 mmol) was treated with 4 N HCl in 1,4-dioxane (10 
mL) to yield the amine salt 13b, which was treated with DIEA (0.36 mL, 2.18 
mmol) and N-(cyclopentyloxycarbonyloxy)-succinimide (0.14 g, 0.62 mmol) to 
provide the target compound 15b (0.34 g, 96%) as a white solid. 1H NMR (400 
MHz, CDCl3) δ 9.77 (s, 1 H), 7.80 (d, J = 9.0 Hz, 1 H), 7.32 (s, 1 H), 7.19–7.14 
(m, 2 H), 5.87 (br s, 1 H), 5.71–5.64 (m, 1 H), 5.38 (d, J = 9.6 Hz, 1 H), 5.27 (d, J 
= 17.0 Hz, 1 H), 5.15 (d, J = 10.6 Hz, 1 H), 4.94–4.87 (m, 1 H), 4.61 (t, J = 8.0 
Hz, 1 H), 4.32 (d, J = 11.6 Hz, 1 H), 4.27 (d, J = 9.6 Hz, 1 H), 4.03 (dd, J = 11.6, 
4.0 Hz, 1 H), 3.94 (s, 3 H), 2.70–2.60 (m, 1 H), 2.56–2.50 (m, 4 H), 2.11 (q, J = 
8.4 Hz, 1 H), 1.92 (dd, J = 8.0, 6.0 Hz, 1 H), 1.80–1.49 (m, 12 H), 1.37 (dd, J = 
9.2, 6.0 Hz, 1 H), 1.02 (s, 9 H), 0.88–0.79 (m, 2 H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 172.57, 172.73, 167.33, 160.40, 156.55, 155.34, 144.74, 141.06, 
134.50, 132.74, 129.08, 118.86, 106.20, 78.07, 74.25, 59.61, 59.26, 55.81, 
54.28, 42.50, 36.68, 35.50, 34.97, 34.11, 32.92, 32.75, 26.60, 23.81, 21.41, 
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19.96, 18.52, 14.05, 13.71 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C37H51N6O9S, 755.3433; found 755.3433. 
Cyclopentyl ((S)-1-((2S,4R)-4-((3-isopropyl-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (15c). i-Pr-Cyp-Me 
 
The same procedure was used as described above for compound 14a. 
Compound 11c (0.62 g, 0.80 mmol) was treated with 4 N HCl in 1,4-dioxane (12 
mL) to yield the amine salt 13c, which was treated with DIEA (0.53 mL, 3.20 
mmol) and N-(cyclopentyloxycarbonyloxy)-succinimide (0.20 g, 0.88 mmol) to 
provide the target compound 15c (0.58 g, 93%) as a white solid. 1H NMR (400 
MHz, CDCl3) δ 9.83 (s, 1 H), 7.84 (d, J = 9.2 Hz, 1 H), 7.23 (m, 1 H), 7.20–7.13 
(m, 2 H), 5.89 (br s, 1 H), 5.73–5.64 (m, 1 H), 5.35 (d, J = 9.2 Hz, 1 H), 5.27 (d, J 
= 16.4 Hz, 1 H), 5.14 (d, J = 10.4 Hz, 1 H), 4.90–4.84 (m, 1 H), 4.56 (t, J = 8.0 
Hz, 1 H), 4.33–4.24 (m, 2 H), 4.04 (dd, J = 12.0, 4.4 Hz, 1 H), 3.94 (s, 3 H), 3.38–
3.31 (m, 1 H), 2.67–2.52 (m, 2 H), 2.12 (q, J = 8.0 Hz, 1 H), 1.93 (dd, J = 8.0, 6.0 
Hz, 1 H), 1.77–1.50 (m, 12 H), 1.41–1.25 (m, 8 H), 1.02 (s, 9 H), 0.89–0.80 (m, 2 
H) ppm; 13C NMR (100 MHz, CDCl3) δ 173.37, 172.52, 167.22, 160.22, 156.29, 
154.26, 151.81, 140.55, 134.42, 132.59, 129.35, 118.76, 118.57, 105.84, 77.86, 
73.89, 59.55, 59.06, 55.67, 54.22, 42.32, 36.51, 35.51, 34.96, 34.10, 32.80, 
32.56, 30.65, 26.44, 23.66, 21.43, 20.50, 20.42, 18.40, 13.95, 13.57 ppm; HRMS 
(ESI) m/z: [M + H]+ calcd for C39H55N6O9S, 783.3746; found 783.3745. 
Cyclopentyl ((S)-1-((2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)-2-
(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (15d). Cl-Cyp-Me 
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The same procedure was used as described above for compound 14a. 
Compound 11d (0.50 g, 0.65 mmol) was treated with 4 N HCl in 1,4-dioxane (10 
mL) to yield the amine salt 13d, which was treated with DIEA (0.43 mL, 2.60 
mmol) and N-(cyclopentyloxycarbonyloxy)-succinimide (0.16 g, 0.70 mmol) to 
provide the target compound 15d (0.45 g, 89%) as a white solid. 1H NMR (400 
MHz, CDCl3) δ 9.79 (s, 1 H), 7.80 (d, J = 8.8 Hz, 1 H), 7.30 (s, 1 H), 7.26–7.21 
(m, 2 H), 7.18 (d, J = 2.0 Hz, 1 H), 5.85 (br s, 1 H), 5.73–5.64 (m, 1 H), 5.35 (d, J 
= 9.2 Hz, 1 H), 5.27 (d, J = 16.8 Hz, 1 H), 5.15 (d, J = 10.8 Hz, 1 H), 4.87–4.84 
(m, 1 H), 4.64 (t, J = 7.6 Hz, 1 H), 4.40 (d, J = 11.6 Hz, 1 H), 4.23 (d, J = 10.0 Hz, 
1 H), 4.02 (dd, J = 11.6, 4.0 Hz, 1 H), 3.96 (s, 3 H), 2.66–2.54 (m, 2 H), 2.12 (q, J 
= 8.4 Hz, 1 H), 1.94 (dd, J = 7.6, 6.0 Hz, 1 H), 1.76–1.48 (m, 12 H), 1.39 (dd, J = 
9.2, 5.6 Hz, 1 H), 1.01 (s, 9 H), 0.88–0.80 (m, 2 H) ppm; 13C NMR (100 MHz, 
CDCl3) δ 173.30, 172.60, 167.17, 161.27, 156.42, 152.14, 140.88, 136.12, 
134.10, 132.57, 128.82, 120.05, 118.80, 105.89, 78.01, 75.48, 59.53, 59.02, 
55.82, 53.74, 42.36, 36.50, 35.34, 34.86, 33.90, 32.78, 32.58, 26.43, 23.70, 
21.32, 18.40, 13.95, 13.56 ppm; HRMS (ESI) m/z: [M + H]+ calcd for 
C36H48ClN6O9S, 775.2887; found 775.2890. 
Cyclopentyl ((S)-1-((2S,4R)-4-((7-methoxy-3-(trifluoromethyl)quinoxalin-2-
yl)oxy)-2-(((1R,2S)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-2-
vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-
yl)carbamate (15e). CF3-Cyp-Me 
 
The same procedure was used as described above for compound 14a. 
Compound 11e (0.40 g, 0.50 mmol) was treated with 4 N HCl in 1,4-dioxane (10 
mL) to yield the amine salt 13e, which was treated with DIEA (0.35 mL, 2.10 
mmol) and N-(cyclopentyloxycarbonyloxy)-succinimide (0.13 g, 0.57 mmol) to 
provide the target compound 15e (0.38 g, 94%) as an off-white solid. 1H NMR 
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(400 MHz, CDCl3) δ 9.79 (s, 1 H), 7.81 (d, J = 9.2 Hz, 1 H), 7.48 (dd, J = 8.8, 2.8 
Hz, 1 H), 7.43 (d, J = 2.8 Hz, 1 H), 7.32 (s, 1 H), 5.91 (br s, 1 H), 5.73–5.63 (m, 1 
H), 5.30–5.25 (m, 2 H), 5.16 (d, J = 10.8 Hz, 1 H), 4.80–4.75 (m, 1 H), 4.60 (t, J = 
7.6 Hz, 1 H), 4.37 (d, J = 12.0 Hz, 1 H), 4.19 (d, J = 9.6 Hz, 1 H), 3.98 (dd, J = 
11.6, 3.6 Hz, 1 H), 3.94 (s, 3 H), 2.67–2.51 (m, 2 H), 2.12 (q, J = 8.0 Hz, 1 H), 
1.94 (dd, J = 8.0, 6.0 Hz, 1 H), 1.73–1.48 (m, 13 H), 1.38 (dd, J = 9.2, 1.6 Hz, 1 
H), 0.99 (s, 9 H), 0.89–0.81 (m, 2 H) ppm; 13C NMR (100 MHz, CDCl3) δ 173.26, 
172.60, 167.14, 159.51, 156.31, 151.68, 138.39, 136.96, 134.38 (q, J = 36.0 Hz), 
132.58, 127.98, 125.62, 120.60 (d, J = 274.4 Hz), 118.76, 107.42, 77.82, 74.86, 
59.41, 58.95, 55.89, 53.79, 42.36, 36.50, 35.30, 34.91, 33.89, 32.76, 32.40, 
26.38, 23.66, 23.62, 21.34, 18.40, 13.95, 13.56 ppm; HRMS (ESI) m/z: [M + H]+ 
calcd for C37H48F3N6O9S, 809.3150; found 809.3157. 
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